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Short abstract
Viruses are of considerable interest for several fields of life science
research. The genomic richness of these entities, their environmen-
tal abundance, as well as their high adaptability and, potentially,
pathogenicity make treatment of viral diseases challenging. This
thesis proposes three novel contributions to antiviral research that
each concern analysis procedures of high-throughput experimen-
tal genomics data. First, a sensitive approach for detecting viral
genomes and transcripts in sequencing data of human cancers is
presented that improves upon prior approaches by allowing de-
tection of viral nucleotide sequences that consist of human-viral
homologs or are diverged from known reference sequences. Sec-
ond, a computational method for inferring physical protein contacts
from experimental protein complex purification assays is put for-
ward that allows statistically meaningful integration of multiple
data sets and is able to infer protein contacts of transiently binding
protein classes such as kinases and molecular chaperones. Third, an
investigation of minute changes in viral genomic populations upon
treatment of patients with the mutagen ribavirin is presented that
first characterizes the mutagenic effect of this drug on the hepatitis
C virus based on deep sequencing data.
Kurzzusammenfassung
Viren sind von beträchtlichem Interesse für die biowissenschaft-
liche Forschung. Der genetische Reichtum, die hohe Vielfalt, wie
auch die Anpassungsfähigkeit und mögliche Pathogenität dieser
Organismen erschwert die Behandlung von viralen Erkrankun-
gen. Diese Promotionsschrift enthält drei neuartige Beiträge zur
antiviralen Forschung welche die Analyse von experimentellen
Hochdurchsatzdaten der Genomik betreffen: erstens, ein sensitiver
Ansatz zur Entdeckung viraler Genome und Transkripte in Se-
quenzdaten humaner Karzinome, der die Identifikation von viralen
Nukleotidsequenzen ermöglicht, die von Referenzgenomen ab-
weichen oder homolog zu humanen Faktoren sind. Zweitens, eine
computergestützte Methode um physische Proteinkontakte von ex-
perimentellen Proteinkomplex-Purifikationsdaten abzuleiten welche
die statistische Integration von mehreren Datensätzen erlaubt um
insbesondere Proteinkontakte von flüchtig interagierenden Protein-
klassen wie etwa Kinasen und Chaperonen aus den Daten ableiten
zu können. Drittens, eine Untersuchung von kleinsten Änderungen
viraler Genompopulationen während der Behandlung von Patien-
ten mit dem Mutagen ribavirin die zum ersten Mal die mutagene
Wirkung dieses Medikaments auf das Hepatitis C Virus mittels
Tiefensequenzdaten nachweist.
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Think of the small as large
and the few as many.
Confront the difficult
while it is still easy;
accomplish the great task
by a series of small acts.
Daodejing Chapter 63 (excerpt).
Laozi, probably 6th century BC.

Abstract
Viruses are of considerable interest for several fields of bioscience
research. The genomic richness of these entities, their environmen-
tal abundance, as well as their high adaptability and, potentially,
pathogenicity make treatment of viral diseases challenging and an-
tiviral research medically relevant. Especially if seen in a context
of clinical reality that is dominated by chronic disease, drug resis-
tance, and side effects, it becomes clear that an integrated view on
virological data analysis spanning aspects from basic research to
drug development and clinical applications is required in order to
facilitate medical progress.
Such an integrated view should, at the least, encompass early
detection of emergent human pathogenic viruses (virus discovery),
support antiviral drug discovery (drug target identification), and aid
in developing and optimizing clinical treatment of infectious dis-
eases in order to to curb viral drug resistance and increase therapy
success (treatment optimization). This treatise aims to provide contri-
butions to all three of these areas.
Specifically, the thesis proposes three novel contributions to
antiviral research that each concern analysis procedures of high-
throughput experimental genomics data. First, a sensitive approach
for detecting viral genomes and transcripts in sequencing data of
human cancers is presented that improves upon prior approaches
by allowing detection of viral nucleotide sequences that consist
of human-viral homologs or are diverged from known reference
sequences.
Second, a computational method for inferring physical protein
contacts from experimental protein complex purification assays
is put forward that allows statistically meaningful integration of
multiple data sets and is able to infer protein contacts of transiently
binding protein classes such as kinases and molecular chaperones.
Third, an investigation of minute changes in viral genomic pop-
ulations upon treatment of patients with the mutagen ribavirin is
presented that first characterizes the mutagenic effect of this drug
on the hepatitis C virus based on deep sequencing data.
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Introduction

1 Preface
Viruses are of considerable interest for several fields of bioscience
research such as genomics, epidemiology, medicine, bioinformatics, as well
as, naturally, virology. The genomic richness of these entities, their envi-
ronmental abundance, as well as their high adaptability and, potentially,
pathogenicity make viral research both relevant and diverse. In addition,
and unbeknownst to many, viruses are not only subjects of research but
also essential tools of microbiology; indeed, viral proteins such as poly-
merases are now standard components in molecular laboratories and the
study of viruses resulted in serendipitous moments such as the discovery
of cellular oncogenes, a concept of crucial importance for oncology. In a
similar manner, many viral innovations found their way into genomes of
cellular organisms, including human: so are important factors of placenta
formation of viral origin, and viruses may even have been instrumental to
the emergence of cellular life as we know it.
Last, and most obviously, viruses are important pathogens that, while
representing the minority of microbial organisms infecting humans, are
the major source of newly emerging pathogens. Both the SARS and the
swine flu outbreaks may serve as current examples. The genomic diversity
as well as the astonishingly high adaptability of viruses make treatment
of both known and emergent viral diseases challenging. Especially if seen
in a context of clinical reality that is dominated by chronic disease, drug
resistance, and side effects, it becomes clear that an integrated view on
virological data analysis spanning aspects from basic research to drug
development and clinical applications is required in order to facilitate
medical progress. It is the opinion of the author that such an integrated
view should, at the least, (1) encompass early detection of emergent human
pathogenic viruses, (2) support antiviral drug target discovery, and (3) aid
in developing and optimizing clinical treatment of infectious diseases. This
treatise aims to provide contributions to all three of these areas.
24 from basic research to clinical applications
(1) Even the experimental protein purifica-
tion data that is analyzed in the second
contribution is, in its essence, of genetic
origin since open reading frames of the
investigated proteins form the principle
input data.
Contributions
This thesis is organized along three major themes that may
aid the reader in connecting the diverse research results presented
herein into a coherent whole. First among these themes is the afore-
mentioned integrated view on virological data analysis consisting
of (1) virus discovery to support sensitive detection of novel human
pathogens, (2) drug target identification to facilitate development of
novel antivirals, and last, (3), treatment optimization to curb emer-
gence of viral resistance and increase therapy success. Besides this
main theme, a second recurring leitmotif is the use of particularly
sensitive statistical methods that aid in separating faint biological
signals from technical noise; such methods are critical components
of all novel approaches introduced in this thesis. Last, the third and
most speculative theme of this treatise concerns the subtle similari-
ties of viral infection disease to another class of heterogeneous and
adaptive disorders: heterogeneous human cancers. While we will
revisit this last theme only at the very end, the reader is encouraged
to keep it in mind as an ulterior motive, a Hintergedanken.
Apart from these overarching themes, this thesis proposes three
novel and specific contributions to antiviral research that each
concern analysis procedures of high-throughput experimental
genomics data.(1) First, a sensitive approach for detecting viral
genomes and transcripts in mixed sequencing data of human
cancers (presented at the end of Chapter II). Second, a statistical
method for inferring physical protein contacts from experimen-
tal protein purification assays (presented at the end of Chapter
III). Third, an investigation of minute changes in viral population
structures upon treatment of patients with mutagenic drugs (pre-
sented at the end of Chapter IV). All these contributions represent
published, first-author works of the author as referenced in the
introduction of each manuscript as well as in the list of List of pub-
lications.
While the chapters of this thesis quite naturally fall into place
when considered from the proposed, integrated viewpoint of viro-
logical data analysis, this orderly view is not how the manuscripts
that compose the core of this work have been originally conceived.
Instead, the chronology of these manuscripts follows the order
(and, perhaps, the scientific development) of the author as he ven-
tured from systems biology (Chapter III) to clinical virology (Chap-
ter IV) and further towards high-throughput genomics and oncology
(Chapter II).
It is only in hindsight that the three aforementioned themes
connect these manuscripts in a favorable manner. The reader is
therefore kindly asked to indulge the author at his attempts to form
a coherent whole of the disparate parts. If this works seems to de-
lude the reader into thinking that basic research were a predictable
process, it is to convey the material in a more concise manner rather
than to belie its less structured origins.
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(2) Assenov et al. (2008), Blankenburg et al.
(2009), Schelhorn et al. (2008)
(3) The web service geno2pheno[hcv]
provides decision support for clinicians
and virologist in the context of anti-
HCV precision medicine. It has been
developed by Sven-Eric Schelhorn and
Michael Zeidler and is now continued
by Bastian Beggel. It is widely used by
the HCV community and more than
20,000 genotype samples have been
analyzed by the service since May 2011.
See http://hcv.bioinf.mpi-inf.mpg.de/
Limitations
There are several topics of research that would be a natural fit
to the aforementioned integrated view on virological data analysis
but that are intentionally omitted from this thesis either for the sake
of increased focus, or because the author does not feel sufficiently
competent in discussing them here.
Among the prior group of topics are presentations of the various
software systems that the author developed for conducting the
analyses presented in this thesis. One such system in particular,
Virana, has been used extensively for preparation and analysis of
viral next-generation sequencing data and can be considered the
major technical contribution of the author. Nevertheless, since a
detailed discussion of this software system does not significantly
advance the main aim of this thesis, i.e., the understanding and
treatment of viral disease, it is left out of this treatise.
Similarly, prior work of the author regarding the estimation of
interacting protein regions and investigation of protein interaction
networks(2) is omitted here. In particular, an unpublished pilot
study conducted in cooperation with Elena Zotenko that proposed
a novel optimization procedure for deducing physical protein con-
tacts based on protein interaction networks is left out: although
biologically insightful and methodologically interesting, the pub-
lication at the end of Chapter III seemed to be more concise and
the method less easily confounded by incomplete protein domain
annotations.
Last, although Chapter IV presents approaches to modeling viral
evolution and treatment response in patients in vivo, these results
predominantly relate to basic rather than to applied research. Ap-
plications of these results, for example within rational approaches
to therapy optimization as brought forward by Altmann et al. 2009,
Beerenwinkel et al. 2003, Roomp et al. 2006, Sing et al. 2005 and
others are not explicitly treated here. While the author gained ex-
pertise in this field during his PhD studies as demonstrated by the
development of geno2pheno[hcv],(3) he felt that further consider-
ation of this vast and interesting subject would extend this thesis
even further. Instead, the interested reader is encouraged to con-
sider rational therapy optimization as a continuation of Chapter IV
of this thesis and review the aforementioned citations in order to
obtain an overview of this field.
Among the second group of topics that are left out due to lim-
ited competence of the author are the large fields of target valida-
tion, combinatorial drug discovery, and rational drug design. It is
quite obvious from the structure of this thesis that, while antivi-
ral drug targets relating to both viral and host factors are among
the potential results of the protein interaction analysis featured in
Chapter III, these targets are neither validated nor further utilized
here in order to propose novel antivirals. Instead, the existence
26 from basic research to clinical applications
(4) Lengauer (2007), Lengauer et al. (2002)
(5) de Clercq (2011), Hopkins and Bick-
erton (2010), Jhoti and Leach (2007),
Kirchmair et al. (2011), Kuntz (1992),
Lengauer et al. (2004), Menéndez-Arias
and Gago (2012), Real et al. (2004)
(6) Burton (2002), Fox (2007), Marasco and
Sui (2007), Sawyer (2000), Tan et al. (2007)
(7) de Clercq (2007), Flexner (2007), Wain-
berg (2008)
of safe and effective compounds with antiviral activity is already
taken as a given in Chapter IV where the clinical effects of such
drugs on the viral population are discussed.
Nevertheless, in order to supplement the interested reader with
additional material in this regard, a short list of references may be
of use. A bird’s eye view on the antiviral drug development process
is given in two multi-volume works edited by Thomas Lengauer.(4)
For introductions to principles of drug discovery the reader may
wish to review Hughes et al. 2011, Pauwels 2006. Several works
discuss virtual and experimental screening approaches for lead dis-
covery and optimization.(5) A special focus of future antivirals will
likely be put on biologicals, e.g., protein-like compounds such as
antibodies, vaccines, as well as on drugs targeting host factors.(6)
These and related future directions of antiviral research are exten-
sively discussed by Erik de Clercq and others.(7)
Outline
This thesis is divided into five chapters. While the the middle
three chapters from the core of the treatise and discuss research of
the author, the leading and closing chapters feature introductions to
viruses and and concluding remarks, respectively.
The introductory Chapter I reviews general concepts of viruses
such as their physical and genomic characteristics before aiming
to familiarize the reader with theories on the evolutionary origin
of viruses and their relation to the three domains of cellular life.
The tight relation of cellular and viral life is further supported by
recent results on ancient proviral integration events in the human
germline. Subsequently, estimated trends of global disease burdens
of viral infections will be discussed before concluding this chap-
ter with an investigation of worldwide viral abundance and the
zoonotic emergence of viral disease.
Chapter II features the first contribution of the author to the
field of viral research. After an introduction to metagenomics and
the burgeoning field of next-generation sequencing, aspects of
computational analyses of mixed sequencing data are discussed.
Subsequently, a conceptual interlude provides a review on the
history, virology, and epidemiology of tumor viruses. The chapter
concludes with an investigation of low-frequency viral factors in
metagenomes and -transcriptomes of human tumors, a study that
contributes to both viral surveillance and the identification of novel
causes of cancer.
Chapter III shifts the focus from genomics to systems biology
and presents the second major contribution of this thesis. The chap-
ter sets out by introducing the concept of protein interactions and
reviews experimental and computational assays to measure these
interactions. Subsequently, the biology of viral host factors is dis-
cussed and approaches for their determination are explicated. The
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importance of these host factors is further highlighted by a descrip-
tion of antiviral drugs that are in current use or in development,
as well as a first introduction to the concept of antiviral drug re-
sistance. The chapter concludes with a contribution for statistical
inference of physical protein contacts, an approach that may aid in
the identification of novel antiviral drug targets.
The last core section of this thesis, Chapter IV, deals with clinical
applications concerning the determination of effects of antiviral
drug treatment. After introducing concepts of viral population
structures and intra-host viral adaptation, current approaches for
treating infections with highly divergent viruses are discussed.
These concepts are applied to the therapeutic context of one partic-
ular virus, Hepatitis C (HCV), for which current as well as future
treatment options are reviewed. Last, the modes of action of a class
of antivirals, mutagens, are introduced before the chapter concludes
with an experimental investigation of the effects of a specific muta-
genic drug, ribavirin, on the HCV population structure.
Finally, in Chapter V, this thesis is brought to a conclusion in
the context of the aforementioned integrated view on virological
data analysis. In addition, and by way of expanding on thoughts
presented earlier, a wider view on subclonal diseases is offered that
encompasses heterogeneous human cancers. The thesis finishes
with predictions concerning the future development of the field
from which specific recommendations for further research may be
derived.
The core chapters of this thesis are relatively independent from
each other. While each of the research items presented can be ar-
ranged into the aforementioned integrated view on virological data
analysis, these items relate to diverse fields of bioinformatics (i.e.,
metagenomics, systems biology, and viral population genomics) that have
only low methodological overlap. It is due to this diversity that the
thesis, while cumulative in nature, is relatively explicative in order
to best introduce and relate each of the research items. The author
hopes that the reader finds the breadth of the material pleasantly
extensive rather than tedious.
Last, it is the modest hope of the author that this work may con-
vey some of the fascination he feels for viruses in their twofold
role as both pathogens and explanatory devices of Nature. By way
of extending a related quote printed in the forematter of this the-
sis: "If you cannot do great things, do small things in a great way." –
Napoleon Hill.
Despite its volume, the author aimed at making this thesis such a
small thing.
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guages where the term virus is defined
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smallest microorganisms or extremely complex
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protein coat surrounding an RNA or DNA
core of genetic material, that are capable of
growth and multiplication only in living cells,
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man, animals, or plants (...)" from: Web-
ster’s Third New International Dictionary,
Unabridged (Merriam-Webster, 2002).
(5) Bruinsma et al. (2003), Grayson et al.
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2 Viral genomes and structures
This thesis begins with a presentation of the historic and current
conceptualizations of its main protagonists, viruses. After reviewing their
physical characteristics, we focus on the question if viruses should be
considered living entities. Based on these insights, this section presents
on overview of modes of viral replication before concluding with a review
of viral taxonomic classification. While this chapter may, in principle, be
skipped by readers with a background in virology, the sections on viral
taxonomy and modes of replications have some bearing on Chapter II.
Physical characteristics
At the end of the 19th century, discoveries by Dmitri Ivanovsky,
Martinus Beijerinck, and Friedrich Loeffler of non-bacterial pathogens
heralded the beginning of a new biological science, virology.(1)
Viruses, later shown to depend on living tissue for replication, were
soon recognized as important complements of the germ theory of
disease as promoted by Louis Pasteur and others. Historic defini-
tions of viruses define these entities as
"strictly intracellular and potentially pathogenic entities with an infectious
phase, and (1) possessing only one type of nucleic acid, (2) multiplying in
the form of their genetic material, (3) unable to grow and to undergo binary
fission, (4) devoid of a Lipmann [energy and carbon metabolic] system."(2)
Today, viruses are predominantly seen as a class of obligate
intracellular parasites, invasive biological agents that infect and
reproduce inside the cells of every known organism. In addition,
viruses function as important scientific discovery tools for various
disciplines of biology,(3) thereby further emphasizing the ancient
Latin meaning of the term virus that incorporates aspects of both
destruction and creation.(4)
Physically, known viruses are often conceptualized as virions ,
minuscule containers with physical dimensions of 20–200nm (about
1/100th of the size of a bacterium) that consist of RNA or DNA
genomic material, supplementary proteins, and a protein shell (the
capsid ) that may additionally be surrounded by a lipid membrane,
the envelope. Capsids come in a variety of shapes that reflect the
particular selective pressure the virus is subjected to(5); apart from
the usual icosahedral configurations, some of these shapes are
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bewildering and resemble spindles, lemons, contain terminal hooks
or claws, and are bottle-shaped or fully linear.(6)
After successful entry into a susceptible host cell (see Section
14), viruses set up complex replication machinery (the ’virus fac-
tory’) that employs host components to replicate viral genomes and
produce new viral progeny. Due to their obligate parasitic nature,
viruses cannot procreate without the host cell. Viral replication
usually terminates lytically by bursting the cell after large numbers
of viral progeny have been created. This process usually kills the
cell by exocytosis or generation of a large number of viral antigens
that lead to activation of innate and adaptive arms of the immune
system and thus induce immune-mediated cell death (see Section
14). Alternatively, infection can occur chronically by limited pro-
duction and budding of viral progeny that does not lyse the cell, or
by a process denoted as lysogeny or latency where the viral genome
becomes part of the hosts genetic material by either episomal or
proviral mechanisms (see Section 10). In the latter case, lytic repro-
duction is entered at a later time of the viral life cycle.
While traditionally the nucleotide-containing virion is considered
to be the definitive viral entity, it was recently proposed that the
virus is not the infective viral particle but the established virus
factory within the infected cell.(7) This contested(8) definition seems
to put viral behavior, arguably a more specific and comprehensive
view of this entity, into the limelight while demoting structural
aspects of the capsid to a mere storage form, very much like a
bacterial or fungal spore. This view puts the virus on equal footing
with intracellular bacterial parasites which exhibit life styles that
are at least in some regards comparable with that of viruses.
However, even the more general definition of viruses as small,
protein-containing obligate intracellular parasites does not seem
to cover well all observed viral entities. The recent identification
of giant viruses, as well as non-viral sub-cellular pathogens like
viroids, RNA satellites, protein-based prions, and retro-elements,
all of which exhibit virus-like behavior but are missing many vi-
ral attributes blur the lines between viral and non-viral entities.(9)
While non-viral ’selfish’ genetic elements have recently been de-
noted as ’orphan replicons’ and were suggested to be part of an
universal tree of life together with viruses,(10) a well-defined notion
of viruses remains controversial and viruses are now considered to
be an intrinsically ill-defined taxonomic group.(11)
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Viruses as living systems
The definition of life has long been the subject of both biological
and philosophical discussions.(12) Several notions of life have been
proposed taking thermodynamic, computational, evolutionary, bio-
chemical, and network-centric views.(13) The status of viruses in
this regard has been argued since their discovery; indeed, viruses
were first considered living entities and present-day successors of
primitive genes in the primordial world, possibly predating cellular
life.(14) Viruses are near in complexity to the single gene, arguably
the simplest entity that ever has been suspected to be living based
on scientific arguments.(15) As a consequence of their simplicity,
neither "nucleocentric" (the genetic material was first) nor "cyto-
plasmist" (the metabolism was first) theories on the origin of life are
unequivocally applicable to viruses and a "virocentric" synthesis of
these theories was therefore proposed.(16) Historically, the notion
of viruses as living entities was most prominently represented by
J. B. S. Haldane who besides pursuing influential medical genetic
research and terming the modern word ’clone’, was one of the first
who stated that
"life may have remained in the virus stage for many millions of years before
a suitable assemblage of elementary units was brought together in the first
cell."(17)
(before revoking this opinion later).(18) Later arguments state that
viruses miss life-like properties such as self-organization, self-
maintenance, common ancestry, energy metabolism, or evolution
independent of cells; thus, viruses are now considered non-living
entities by the majority of experts in the field.(19)
However, new arguments regarding the structural similarity of
viral capsids, theories on viral invention of the DNA replication
machinery, and the discovery of giant viruses containing cellu-
lar genes, have recently renewed the debate about the status of
viruses as living beings.(20) In particular, initial arguments stating
that viruses miss important features of living systems such as self-
maintenance, self-replication, common ancestry (or, at least no de-
tectable common ancestry due to extensive gene transfer), structural
continuity across generations, as well as metabolic and protein-
synthesis related genes have sparked lively debates.(21) Some of the
opinions thus expressed judge the discussion as so useless as to
"propose an eleventh reason to exclude viruses from the tree of life: there is
no such thing as a tree of life"(22)
– at least if applied to species instead of single genes. Indeed, al-
ternative notions of a forest of life connected by extensive gene
transfer (cf. Section 3 of this chapter) should be well considered.(23)
In conclusion, the controversy about the definition of life may
well be termed unscientific from the beginning (as quoted by K.
R. Popper)(24) and thus the question of the status of viruses in this
regard should perhaps be pursued with a certain lightheartedness
rather than in a strictly scientific manner.
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Viral taxonomy and classification
Viruses are commonly named in semi-structured fashion, either
for the disease of which they are causative (e.g., polio virus), the
organ or tissue they are affecting (e.g., Hepatitis viruses from Greek
hepar, liver, or Rhino viruses, from the Greek word for nose), their
physical characteristics (e.g., rota virus, Latin for wheel), the place
of their first isolation (e.g., Marburg virus, Coxsackie virus), the re-
searcher who discovered them (e.g., Ebstein-Barr virus), or names
associated with folklore (e.g., Influenza, Dengue). As discussed
previously, from a structural point of view viral particles consist
of a membrane-enveloped or naked protein capsid that surrounds
the viral genome and often displays a variety of protein receptors.
Viral capsids have a variety of functions, most of them concerning
protection of the viral genome from external influence, while others
are regarding viral entry into the host cell, genome packaging, and
assembly of new virions.(25) Capsids commonly consist of tens to
many thousands of protein subunits that form macromolecular as-
semblies predominantly spherical (more specifically, icosahedral) or
helical symmetry.(26)
Group Genome Orientation Viruses
I DNA +/- double stranded Bacteriophages, Adenoviruses, Herpesviruses, Polyomavirus
II DNA + single stranded Parvoviruses, Torque teno virus
III RNA +/- double stranded, seg-
mented
Rotavirus
IV RNA - single stranded Coronavirus, Rubellavirus, Rhinovirus, Poliovirus, Hepatitic C virus
V RNA + single stranded Coronavirus, Influenzavirus A/B, Rabies virus, Ebola virus, Hanta virus
VI RNA + singe stranded, RT HIV-1/2, HTLV-1
VII DNA +/- partially double stranded Hepadnavirus
Table 2.1: Baltimore classification of
viruses. Classes I–VI were originally
proposed by David Baltimore
(Baltimore, 1971) and later extended
to also include Hepadnaviruses.
Examples for specific viruses were
added by the author.
After determination of the first protein structure, the capsid of
the tobacco mosaic virus,(27) and followed by visualizations of viral
particles by electron microscopy in the 1960s, a hierarchical system
consisting of phylum, class, order, family, genus and species was
proposed to classify viruses based mostly on structural aspect of
their capsid. Classification was undertaken based on size, symme-
try, presence of an envelope, and number of capsomers, and only
secondary by the nature of the nucleic acid the capsid contains
(namely, type of acid, segmentation, linearity, ploidy, strandedness,
and coding orientation).(28)
However, these taxonomical classification based primarily on
structural aspects of viral capsid proteins were soon shown to be
flawed; as these proteins have evolved independently at multiple
occasions during evolutionary history,(29) viruses may utilize very
different life cycles even if sharing a capsid protein.(30) Following
advances in nucleotide sequencing in 1970s it became clear that
viruses are polyphyletic(31),(32) and thus cannot be taxonomically
organized based on their genetic divergence from a single common
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ancestor.(33) Additionally, and in contrast to organisms within the
three accepted domains of life, viruses in general do not possess
a common nucleic acid such as rRNA based on which genetic di-
vergence can be estimated. In addition, newly originating viruses
are often a result of considerable horizontal gene transfer between
viruses or between viruses and their hosts, thus further complicat-
ing the determination of evolutionary descent.(34)
Due to the lack of common evolutionary descent, viruses are
therefore often not classified based on intrinsic attributes of their
genes but rather by mechanistic properties pertaining to their mode
of nucleic acid replication. Even though viruses are obligate cellular
parasites and do not contain or encode for a complete replication
machinery, they follow the general paradigm of microbiology (DNA
makes RNA makes protein) in the sense that all viruses have to
produce mRNA from their genome on order to exploit the cellular
machinery for viral protein synthesis. Following the highly influen-
tial Baltimore scheme of viral classification,(35) all viruses are thus
grouped into originally six (later extended to seven, designated as
I-VII) classes based on the general microbiological pathway that
produces mRNA from the viral genome (see Tables 2.1 and 2.2).
Regardless of their exact mode of replication, critical aspects of vi-
ral life cycles become readily apparent once their mode of mRNA
synthesis has been identified. As a consequence of the usefulness
of this manner of classification, today both structural aspects and
the Baltimore scheme are employed for assigning viruses to unified
taxonomies by the International Committee on the Taxonomy of
Viruses(36) and the National Center for Biotechnology Information,
NCBI.(37)
Group Replication
I DNA-dependent DNA polymerase copy both strands to produce a dsDNA viral genome. DNA-dependent
RNA polymerase copies the - strand into a + strand mRNA for translation.
II DNA-dependent DNA polymerase copies the + strand to produce a dsDNA intermediate. DNA-dependent
DNA polymerase copy the - DNA strand into ss + strand DNA genome. DNA-dependent RNA polymerase
enzymes copy the - strand DNA into + strand mRNA.
III RNA-dependent RNA polymerase copies both strands to generate a viral genome copy. RNA-dependent RNA
polymerase copies the - RNA strand into + viral mRNA.
IV RNA-dependent RNA polymerase enzymes copy the - RNA genome to a - strand RNA genome via a + strand
RNA intermediary. This genome copy also functions as mRNA.
V RNA polymerase enzymes copy the + RNA genome to a + strand RNA genome via a - strand RNA intermedi-
ary. RNA-dependent RNA polymerase enzymes copy the (-) RNA strand into (+) viral mRNA
VI RNA-dependent DNA polymerases copies the + RNA genome into - DNA strand. DNA-dependent DNA poly-
merase copies the - DNA strand into a dsDNA intermediate. DNA-dependent RNA polymerase copies the -
DNA strand to produce the + RNA genome. DNA-dependent RNA polymerase copies the - DNA strand into
+ viral mRNA.
VII Partially double stranded DNA is completed by DNA-dependent DNA polymerase and circularized. DNA-
dependent RNA polymerase produced + mRNA from the circularized DNA. The partially double stranded
genome is produced by RNA-dependent DNA polymerase and DNA-dependent DNA polymerase from the +
mRNA.
Table 2.2: Viral replication strategies.
Process of viral replication
depending on Baltimore groups
(Roman numerals, cf. Table 2.1).
By 2012, the ICTV (International Committee on Taxonomy of
Viruses) , the institution tasked to develop, refine, and maintain a
universal virus taxonomy, recognized 96 viral taxonomic families,
34 from basic research to clinical applications
(38) King et al. (2011)
(39) Sayers et al. (2012)
(40) Fauquet and Fargette (2005)
(41) Fauquet and Stanley (2005)
(42) Van Regenmortel (2003)
(43) Van Regenmortel (1989)
(44) Van Regenmortel et al. (1996)
i.e., the major taxonomic category employed for differentiating and
categorizing viral life cycles.(38) These families encompass 2,618
viral species which, in turn, are subdivided into additional strains
and genotypes. Many of the latter are represented in the NCBI
viral RefSeq sequence database which currently contains more than
3,000 entries.(39) In contrast to the three established domains of life
that usually have a well-defined notion of the term ’species’, the
definition of this term is not straightforward for viruses.(40) This
is a result of the fact that viruses are often divergent and only few
exemplars, termed ’isolates’,(41) of any closely related ensemble of
viruses (as, for example, genomes of viruses infecting a single host)
are usually known. Critically, isolates are not directly transferable
to the species concept; rather, multiple related isolates are usually
assigned to a single species.(42) The ICTV proposal of
"A virus species is a polythetic class of viruses that constitutes a replicating
lineage and occupies a particular ecological niche"(43)
is highly flexible and transfers the responsibility for correctly ap-
plying the term to virologists who are experts for a specific viral
family.(44)
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3 The origins of viruses
After discussing the difficulties of defining the concept of a virus,
its status as living organism, and its taxonomic classification, we next
look in more detail at viral evolution in order to establish from where these
difficulties originate. In particular, we will review the relationship between
viruses and the three domains of cellular life and highlight the importance
of viruses as gene transfer vehicles; last, a bold theory on the origin of
cellular life is introduced that features viruses as protagonists.
Viruses and the three domains of life
All cellular life present today, as categorized into the three domains
Bacteria, Archaea, and Eukarya, has descended from a single ances-
tor (LUCA: last universal cellular ancestor),(1) a complex life form
with complete, protein-based ribosomal machinery(2) that already
used the universal genetic code.(3) Based on sequence similarity of
ribosomal proteins and rRNA-components, it is possible to assign
to each cellular organisms a position within a single tree of life, a
common representation of ancestry and speciation.(4),(5)
As briefly touched upon before, families of giant viruses such as
mimiviruses, marseilleviruses, and mamaviruses(6) were identified that
possess genomes and physical dimensions rivaling that of bacteria.
The genomes of these and other viral families contain genes for
carbon-, energy-, and cellular metabolism(7) – functions that are
more characteristic for cellular than of viral life(8). These findings
have lead to the proposition of an additional, fourth domain of life
consisting of giant viruses,(9) a notion that was later found to be
invalid due to erroneous phylogenetic assumptions.(10)
Since novel genes cannot appear in viral particles de novo, it is
very likely that genes of giant viruses are homologs of cellular
genes from either current or long extinct cellular lines, possibly
reaching back before the LUCA. These genes may then have been
manipulated by gene duplication, recombination, and frameshift
mutations and thus repurposed by selection and divergent evolu-
tion while also being subject to frequent horizontal gene transfer
between viruses and their hosts. The latter may have occurred to an
extent resulting in more novel genes having been transferred from
viruses to cellular life than vice versa(11) (a notion that is, however,
contested).(12)
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Established and novel theories on the origin of viruses
Several conflicting hypotheses for the origin of viruses have been
proposed; these include notions that viruses are remnants of pre-
cellular life forms (virus-first hypothesis), that viruses are reduced
forms from cellular life that either escaped the cellular environ-
ment and adapted to a parasitic style of life (escape hypothesis), or
that viruses are parasites of evolutionary more competent rivals
(one of whose descendants developed to be the LUCA instead of
becoming extinct (reduction hypothesis ). Newer investigations have
re-evaluated these hypotheses based on the current data and con-
firm an ancient origin of viruses(13) that probably goes back to a
primordial environment, termed the RNA-world, in which viruses
either preceded cellular life(14) or existed concurrently with it.(15)
These arguments pertaining to the origin of viruses are based
on the observation that viral genes originally involved in DNA
and RNA replication are structurally more similar between viruses
infecting all three domains of life than between viruses and cellu-
lar organisms.(16) Similarly, specific protein folds of viral capsids
are also present in RNA and DNA viruses and in viruses infect-
ing the three domains of life, thus strongly suggesting that these
viruses predate the LUCA and may have significantly shaped the
emergence of cellular life.(17) Further insights derived from the
comparison of protein structures suggest that the world of viruses
may have been split from the beginning: while RNA viruses origi-
nated by escape or reduction, DNA viruses may have evolved only
later from RNA viruses, possibly due to an evolutionary arms race
between RNA-based viral and RNA-based cellular life in which
viruses changed the chemical implementation of their genomes in
order to protect themselves against host nucleases.(18)
Virus-like gene transfer agents (GTAs) are hypothesized to be
major drivers in the development of complexity in early evolu-
tion.(19) While prokaryotes are under constant selective pressure to
maintain small genomes,(20) many viruses are less constrained in
this regard due to the need for a certain minimal genome size in or-
der to ensure high-pressure capsid-packing required for successful
infection.(21) Horizontal gene transfer events are a common mode
of genomic exchange between viruses and prokaryotes:(22) more
than 60% of the sequenced bacterial genomes contain at least one
integrated viral genome (a provirus) and up to 3% of the nucleotide
content of all bacterial genomes may consist of such proviruses.(23)
The widespread use of horizontal transfer may confer selective ad-
vantages to the host and thus increase metabolic resources for the
virus: this case is illustrated by marine phages that infect Prochloro-
coccus and Synechococcus, the most abundant photosynthetic organ-
isms in oceanic ecosystems, and supplement the host repertoire of
photosynthesis genes, thereby increasing host fitness.(24)
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Viruses as midwifes of the tree of life
Due to the high abundance of viruses and other virus-like gene
transfer agents, the virosphere forms a gigantic reservoir of genes
that can be transferred to cellular organisms, in principle.(25) In-
terestingly, it is therefore at least conceivable that DNA replication
may have originated first in the virosphere, for example as a re-
sult of gene duplication of existing RNA polymerases, followed
by divergent evolution. More daring hypotheses even suggest that
components of the cellular DNA replication machinery could have
been transported by horizontal gene transfer from the first DNA
viruses to cellular life, thereby aiding in the emergence of the first
DNA cellular life forms.(26) Indeed, there is strong evidence for the
fact that while DNA was invented before the LUCA,(27) it was not
yet replicated by that time. Instead, data suggest that replication
mechanisms were invented by Bacteria and Archaea independently
after the divergence of these domains.(28)
This hypothesis is compatible with the proposed introduction
of DNA replication systems into RNA-based cellular life by DNA
viruses.(29) While certainly a provocative theory, a similar event
also demonstrates large-scale intercellular innovation originating
from viruses at later evolutionary times: it is now well established
by comparative genomics data that eukaryotic mitochondria orig-
inated from a free-living a-Proteobacterium.(30) However, it is less
commonly known that the bacterial RNA and DNA polymerases of
the proto-mitochondria have been replaced by more efficient viral
homologs of T-odd bacteriophages at the time of endosymbiosis, an
event that is conceptually similar to the proposed introduction of
DNA replication in bacteria.(31)
Interestingly, viral invention and the proposed transfer of viral
DNA replication mechanisms into cellular organisms solves an ap-
parent evolutionary paradox: DNA is more stable than RNA and
protects genetic information against oxidization and cytosine-uracil
mutations, thus providing a necessary precondition for the evolu-
tion towards larger genome sizes.(32) However, it is unclear what a
viable RNA-DNA intermediate that is required for evolving such
a transition may look like, or how the future potential for encod-
ing a larger genome may confer an immediate selective advantage
to a cell that has just transitioned to a DNA-based genome. The
proposed stepwise origin of DNA replication that makes use of an
RNA template(33) may explain the diversity of proteins replicat-
ing DNA in the three domains of life,(34) provides an immediate
benefit to DNA viruses due to the protection of their genome from
host RNA nucleases,(35) and is further supported by evidence for
a potential RNA-DNA intermediary that has been identified in
phages.(36)
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(44) Forterre (2011)
(45) Which are of viral origin (Coronaviridae)
and are about 32 kbp long; cf. Lauber
et al. (2013) for a recent discussion on the
relation of replication fidelity, genome
size, and genetic complexity of RNA
genomes in general and Coronaviridae in
particular.
(46) Forterre (2006a)
(47) Forterre (2006a)
(48) Woese (2000)
By way of extending these provocative assumptions, an elegant
theory of the origin of DNA-based life proposes that the three do-
mains of life are the results of three independent fusion-events
between viral DNA replication machinery and RNA-based cellu-
lar life.(37) Depending on the phylogenetic data used for analysis,
multiple conflicting scenarios for the evolutionary relation between
the three domains of life are proposed, each of which fails to ex-
plain all of the observed data(38): either two lineages diverged from
the LUCA, giving rise to Bacteria and the common ancestor of Ar-
chaea and Eukarya, respectively,(39) or two primordial lineages gave
rise to Eukarya and the common ancestor of Archaea and Bacte-
ria.(40) While the identity of the LUCA is argued to be either an
RNA-based cellular life form,(41) or a bacterium giving rise to the
Archaea,(42) the popular chimeric theory of eukaryotic evolution
suggests that eukaryotes are a product of extensive genome fusion
event between archaeal and bacterial lineages.(43)
The ’three viruses, three domains’ theory, in contrast, suggests
that the LUCA was RNA-based cellular life that gave rise to Bac-
teria and the common ancestor of Archaea and Eukarya, the latter
of which might have arisen by divergence or by fusion of Bacteria
and Archaea,(44) resulting in the three accepted domains of life.
Three independent fusions of a founder cell of each domains with
a different DNA virus, respectively, may then have lead to a trans-
formation of the RNA genomes into DNA genomes. As a result, the
transformed cells and their descendants may have been able to sta-
bilize their genomes with regard to mutations and afford genome
sizes larger than the largest currently known RNA genomes.(45)
Due to the higher genetic stability and functional versatility, these
cells may have then been in a position to quickly outcompete other
RNA-based life forms, which were consequently lost from evolu-
tionary records.
This theory, while not falsifiable by available data, has consider-
able explanatory power. First, it explains why there are only three
domains of life: viral fusion is a rare event and RNA-based cells
were outcompeted and removed from the biosphere, thus elimi-
nating the basis for further fusion events. The three domains of life
that originated before loss of RNA-based life specialized in differ-
ent life styles (fast replicating Bacteria versus predatory Eukarya)
or invaded environmental niches (Archaea).(46) Second, the theory
justifies why there are three different canonical versions of riboso-
mal proteins, as well as extensive differences between components
of the DNA replication machinery in the three domains of life.(47)
Third, the hypothesis provides arguments for mutation rates in
the time period between the LUCA and the origin of the three do-
mains of life being in accordance with RNA-based life, while later
evolutionary rates are suggestive of DNA-based life.(48) In sum-
mary, these hypotheses suggest that viruses may play an influential
role in the evolution of the three kingdoms of life. Whether viruses
should be considered to be part of the tree of life or only act as
mediators between its branches is open to debate.
(1) Rice et al. (2004)
(2) Levin and Moran (2011)
(3) cf. Vasileva and Jessberger (2005)
for a recent overview on the latter two
processes.
(4) Feschotte and Gilbert (2012)
4 The virus within
As briefly discussed in the previous sections viruses do
not only exists as infectious virions that produce acute or chronic infec-
tions, but may also integrate their genomes directly into the host genome,
thus effectively becoming part of the host and, in specific cases, of the host
germline. As this section will discuss, such proviral integration events lit-
ter the genomes of most or all vertebrates, including human, and the study
of these integrated genomes by sequencing offers new insights into the evo-
lution of viruses and their hosts. This integration proves to be a two-edged
sword: at least some human diseases are expected to be related to ancient
integration events, human physiology critically depends on factors of viral
origin. While this section will offer some information in this regard, a de-
tailed discussion of the pathogenic effects of proviral integration is deferred
until later in the next chapter.
Proviral integration
Viruses are environmentally ubiquitous and able to infect all
three domains of life(1) as well as other viruses.(2) While human
pathogenic viruses dominate our understanding of and the research
on viruses, most of these entities have a host range not overlap-
ping with primates, are highly adapted to the human host, or have
achieved germ-line symbiosis with it. The latter viruses are achieve
achieve vertical transmission in the offspring of the host by a pro-
cess termed proviral integration that inserts viral genomes either by
a complex, integrase-mediated process that protects the integrity
of the insert (Retroviridae), or by homologous recombination/non-
homologous end joining(3) that often produces defective (i.e., repli-
cation incompetent) inserts (some Adenoviridae and Herpesviridae
as well as viral families listed in Table 4.1). Such integration events
may be permanently fixated into a species if the integration oc-
curs in germ-line cells and is either evolutionary neutral or confers
selective advantages to the host.
The human genome, for example, contains about half a mil-
lion fixations of endogenous viral elements (EVEs),(4) originating
from both historical reinfections and intracellular transpositions
of retrotransposons, mobile genetic elements that can move within
genomes via an RNA intermediate and who may have been the
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(7) Bill and Summers (2004), Geuking et al.
(2009), Gilbert and Feschotte (2010), Horie
et al. (2010)
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Viral family Host
Baculovirus Insects
Herpesviridae Humans
Nudivirus Parasitic wasps
Phycodnaviridae Brown algae
Circoviridae Mammals
Geminiviridae Tomentosae
(tobacco and
three other
species)
Parvoviridae Mammals;
shrimp
Partitiviridae Plants; arthro-
pods; Protozoa
Reovirus Aedes spp.
mosquitoes
Totiviridae Fungi; plants;
ticks
Dicistroviridae Honeybees
Flaviviridae Medaka fish;
mosquitoes
Potyviridae Grapes
Bornaviridae Vertebrates
Bunyaviridae Ticks
Filoviridae Mammals
Nyavirus Zebrafish
Orthomyxoviridae Ticks
Rhabdoviridae Insects
Retroviridae Vertebrates
Hepadnavirus Passerine birds,
Humans
Pararetrovirus Plants
Table 4.1: Retroviruses and
non-retroviruses that integrate into
eukaryotic genomes. See Feschotte and
Gilbert (2012) for a list of references
supporting these findings.
(9) Awadalla (2003), Drake et al. (1998),
Duffy et al. (2008)
(10) Gilbert and Feschotte (2010)
(11) Katzourakis et al. (2009)
(12) Maksakova et al. (2006), Yalcin et al.
(2011)
(13) Coffin et al. (1997a), Stoye et al. (1991)
(14) Kearney et al. (2011)
(15) Jha et al. (2011)
ancestors of modern retroviruses.(5) While integration of EVEs has
long been supposed to be an exclusive property if retroviruses,
recent studies have demonstrated that all seven major groups of
eukaryotic viruses have the propensity for subgenomic integration
in a wide range of hosts, sometimes even crossing biological king-
doms.(6) Insertion site duplications and poly-A tails have indicated
that retro-transmission by retrotransposons or retroviruses as well
as by non-homologous end joining may be instrumental in forma-
tion of most non-retroviral EVEs.(7) Several of these non-retroviral
ERVs demonstrate host ranges of previously unknown extent (see
Figure 4.1), thereby suggesting that these viral families may form
viral reservoirs in animal hosts and may thus provide the basis for
potential zoonotic pandemic events affecting human society (cf.
Section 6 of this chapter).(8)
Ancestral viruses in the human genome
Evolutionary dating of current viral strains is complicated due to
the frequent incidence of mutations and recombinations among
viruses at rates several orders of magnitude higher than those of
their host.(9) These circumstances have considerably confounded
previous phylogenetic analyses of viruses. The study of EVEs fix-
ated in host genomes gave rise to the field of paleovirology, i.e., the
analysis of integrated proviruses, and firstly enabled the investiga-
tion of viral evolution across hundreds of million of years. These
analyses recently revealed that long term viral substitution rates are
significantly slower than expected from the short-term data, a fact
relevant for current research on human pathogenic viruses.(10) At
the same time, some viral families appear to be much older than
originally expected and infected mammals more than a hundred
million years ago, thus highlighting aspects of virus-host coevolu-
tion and potentially informing theories on viral emergence.(11)
Several mammals such as mice and Koalas currently express in-
fectious ERVs and are under constant epidemic pressure by these
elements. These organisms are heavily influenced by EVE activ-
ity, both genotypically and phenotypically(12) More dramatically,
recombination of EVEs may results in fully replication-competent
viruses that cause spontaneous lymphomas and mammary tumors
in mice.(13) Notably, these mechanisms are reminiscent of the ori-
gin of XMRV, a putative murine retrovirus that has falsely been
associated with human prostate cancer.(14)
No fully infectious endogenous element seems to remain in
the human germline as of today. This is most probably due to
losses of genetic material on the one hand and purifying selec-
tion on the other hand. In evolutionary terms, however, the last
infectious activity of such elements in human is still recent: approx-
imately 150,000 years ago, well after the emergence of the modern
human.(15) As a result of this relatively recent activity, about 105
fragments of vial origin remain in the human germline, constituting
over 8% of the human genome.
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Gene transfer and pathogenicity
In contrast to the more common transposable elements in eukary-
otic genomes that increase species diversity and have dominantly
deleterious impact,(16) EVEs have introduced aspects of biological
innovations advantageous to their hosts. These innovations pri-
marily consist of domesticated viral factors that were originally
introduced to subvert the host immune system,(17) or that add new
protein-coding genes to the host repertoire.(18) Such beneficial gene
transfers seem to have occurred multiple times in invertebrates at
formative moments of their evolution. For instance, totipotent stem
cells during the first cell divisions of the ovum are controlled by
a master switch promoter of viral origin.(19) This promoter is re-
peatedly silenced and reactivated during embryonal development,
resulting in cycles of pluripotency and totipotency of the affected
cells that serve important regulatory purposes.
These findings are in line with earlier research that identified the
viral origin of the synctin gene family – essential factors for both
placenta-uteral membrane fusion during placenta formation and for
modulation of the maternal immune system during pregnancy that
prevents abortion of the foreign embryonal tissue.(20) Interestingly,
synctins modulate trophoblast cell fusion through mechanisms sim-
ilar to env-mediated retroviral entry and have been incorporated
in the mammal germ-line independently on at least six occasions
in rodents, primates, rabbits, and other species, notably excluding
pig and horse which have other, and potentially less efficient, mech-
anisms of placenta formation.(21) This domesticated viral DNA
has been established in the population by positive selection and
may have been crucial for the rise of placental mammals a hundred
million years ago.
There is currently no strong evidence for de novo EVE integration
associated with any human disease and known human EVEs seem
to lack the ability for autonomous retro-transposition and construc-
tion of infectious particles either due genomic losses or epigenetic
deactivation.(22) However, loss of replication competence does not
exclude the possibility of genomic rearrangements based on non-
allelic homologous recombination. Such recombination events are
likely to have significantly shaped human genomic architecture
across evolutionary time(23) and are currently implicated in diseases
such as male infertility and malign neoplasms.(24) In combination
with the ability of EVEs to disseminate transcription factor binding
sites and control p53 binding motifs,(25) these facts highlight the
potential impact of EVEs on tumor development. Indeed, break-
down of epigenetic maintenance of EVE integration sites has the
potential of malignantly affecting gene expression at up to 7% of
all transcription start sites in the human genome.(26) This finding
is implicated as contributing factor not only to cancer but also to
autoimmune and neurological diseases, such as multiple sclerosis,
type I diabetes, rheumatoid arthritis, and schizophrenia.(27)

(1) Murray and Lopez (1997a,b,c)
(2) Mathers and Loncar (2006)
(3) Arnesen and Kapiriri (2004)
5 Global burden of viral disease
By way of continuing the theme of the role of viral infections in
human disease, the following section aims to summarize existing statistics
on the influence of different public health factors on human well-being.
These data are based on WHO studies that aim to quantify relative risks
originating from infectious and other diseases and predict their develop-
ment into the near future. For viral infections, these predictions may serve
as rough landmarks for the relative importance of future treatment and
preventive efforts.
Quantifying human suffering
A large scale study by the World Health Organization (WHO)
termed Global Burden of Disease(1) (GBD) undertook the task of
globally estimating the influence of diseases on health. In this
first-of-a-kind study on quantification of human suffering, the
disability-adjusted life year (DALY) is used as an epidemiological
unit of disease burden and firstly quantified the global impact non-
fatal diseases in a transparent and reproducible manner. DALYs are
defined as the absolute number of human life years lost due to pre-
mature mortality and years lived with disability, and thus serve as
a time-based health-outcome measures, similar to quality-adjusted
life years (QALY). In contrast to the latter, DALYs allow quantifying
premature mortality with non-fatal health outcomes. DALYs are
modified based both on the severity of the disability and on the
period of life being lost to the individual, with suffering and dis-
ability at younger ages being weighted higher than disease at old
age. Although later studies criticized the GBD approach based on
unquantified uncertainties in low-income regions(2) and missing ro-
bustness of parameter choices for computing DALYs.(3) Regardless
of these confounds, the GBD remains to the most comprehensive
series of studies on the subject.
In the original WHO study, DALYs for three causal groups
(group I–III, see Table 5.1) were computed by regression models
based on death registry data and supplemental epidemiological
information from 1950 to 1990. The data contained 107 causes of
death tabulated by age, sex, and geographic region. In addition,
incidence rates prevalence, duration, and case-fatality rates for 483
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Groups Disorders
I Communicable dis-
eases, maternal, peri-
natal, and nutritional
disorders
II Non-communicable
diseases such as ma-
lignant neoplasms
and cardiovascular
and neuropsychiatric
disorders
III Intentional or un-
intentional injuries,
including accidents and
war-like conflict
Table 5.1: Burden of disease incident
groups. The ratio of group II deaths
to group I deaths aids as a crude
indicator for the epidemiological
transition of low-income countries
dominated by preventable diseases to
higher-income countries dominated
by an aging population. Source:
WHO burden of disease report.
(7) the latter numbers are based on the
UNAIDS World AIDS Day Report,
http://www.unaids.org/en/resources/
publications/2012/name,76120,en.asp
disabling sequelae(4) of the causes of death were considered. The
original study by Murray et al.(5) was later significantly refined by
Mathers et al. to correct for additional risk factors such as the pre-
viously underestimated severity of the AIDS pandemic, increasing
tobacco use, as well as by adapting the estimates to projections for
the increase of world population.(6) These refinements were applied
on WHO GBD 2004 data and published in 2008, yielding updated
estimates from 2008 to 2030.
Estimating global mortality rates
In general, the 2006 study predicts large declines in mortality
in the next decades for all principal Group I diseases, includ-
ing HIV/AIDS, tuberculosis, and malaria. In particular, global
HIV/AIDS deaths are predicted to decline after the year 2012 and
result in 1.2 million deaths in 2030 (compared to 1.7 million deaths
in 2011).(7) While age-specific death probabilities for most Group
II conditions are also estimated to decline, the increasingly aging
population of most countries will likely result in significantly more
deaths due to Group II conditions in general, culminating in 70%
of all deaths by 2030. In particular, global cancer deaths and global
cardiovascular deaths are projected based on the 2006 estimates
to increase by 61% and 72% in 2030, respectively. Last, group III
deaths are estimated to rise by 28% by 2030, predominantly due al-
most twice the number of road traffic incidents in 2030 than in 2004
as a result of increasing motorization of low-income countries.
If ranked by single causes of death, ischemic heart disease
(atherosclerosis of the coronary arteries, mostly due to lifestyle
choices such as smoking), cerebrovascular disease (stroke), chronic
obstructive pulmonary disease (chronic bronchitis due to smok-
ing, infections, and environmental toxins), and lower respiratory
infections (pneumonia) are predicted to be the leading causes of
death by 2030. Cumulatively, tobacco-related deaths, including lung
cancer, will represent near 10% of global mortality by 2030. While
HIV/AIDS deaths are projected to decrease, they will remain a
major factor of mortality for the next decades.
Expected development of disease burden
In contrast to death rates, DALYs also incorporate people living
with disabilities and are projected to decline by 10% by 2030 in
comparison to 2004. These estimates already take into account the
estimated population increase of 25% in the same period, thereby
highlighting the significant reduction in relative disease burden of
about 30% per capita. Driven by economic growth, global DALYs
are predicted to decrease at a rate faster than the overall death rate
due to the aging population that will encounter death at a later
point in life. In particular, Group I causes of DALYs are predicted
to halve by 2030 – then accounting for only 20% of all global DALYs
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2004 · Incident DALYs
Lower respiratory infections 6.2
Diarrhoeal diseases 4.8
Unipolar depressive disorders 4.3
Ischaemic heart disease 4.1
HIV/AIDS 3.8
Cerebrovascular disease 3.1
Prematurity and low birth weight 2.9
Birth asphyxia and birth trauma 2.7
Road accidents 2.7
Neonatal infections 2.7
2030 (projected) · Incident DALYs
Unipolar depressive disorders 6.2
Ischaemic heart disease 5.5
Road accidents 4.9
Cerebrovascular disease 4.3
COPD 3.8
Lower respiratory infections 3.2
Hearing loss, adult onset 2.9
Refractive errors 2.7
HIV/AIDS 2.5
Diabetes mellitus 2.3
Table 5.2: Relative DALYs 2004 and
2030 (projected). DALYs are expressed
as percent of total DALYs. Source:
WHO burden of disease report.
– while the Group II disease burden is projected to increase to two
thirds of all global DALYs. Interestingly, cancers with viral risk
factors are not considered within Group I DALYs in these projec-
tions. Although cancer incidents with viral cofactors such as liver
cancer (HBV and HCV) and cervical cancer (HPV) will continue
to increase due to long time periods between initial infection and
development of cancer, these DALYs do not contribute to the Group
I burden in 2030.
Leading causes of DALYs in 2030 are predicted to be unipolar
depressive disorders, ischemic heart disease, and road traffic acci-
dents. In particular lower respiratory infections and HIV/AIDS, the
dominant infectious causes of DALYs in previous decades, are pro-
jected to decline significantly. This development is predominantly a
result of great successes in antiviral research, such as antiretroviral
drugs effective against HIV and the wide use vaccines, as for exam-
ple against polio. On the other hand, diseases associated with old
age or increasing wealth such as diabetes mellitus, road traffic ac-
cidents, hearing loss and tobacco-associated diseases are predicted
to increase substantially, resulting from increases in income and
longevity especially in low-income countries.
In general, the next years will probably show a shift in the dis-
tributions of deaths and DALYs from younger to older ages and
from Group I causes (communicable diseases such as viral in-
fections) to Group II causes (non-communicable diseases such as
most cancers). This phenomenon likely is an indicator for the epi-
demiological transition from low-income countries dominated by
preventable diseases to higher-income countries dominated by an
aging population. While epidemiological changes resulting from
better clinical care will particularly mitigate the negative effects of
non-communicable as well as cardiovascular and infectious dis-
eases, such factors may be overpowered by population growth and
aging. The latter will especially amplify non-communicable disease
such cancers as well as maladies associated with tobacco smoking
as, for example, cardiovascular and chronic obstructive pulmonary
diseases.
While therefore infectious diseases will probably take a back-
seat in the next decades compared to other diseases due to the
successes of antiviral research and increasing standard of living in
low-income countries, the latter phenomenon also has detrimen-
tal consequences. As the next section will demonstrate, sequela
of rising incomes such as increased urbanization and air travel
may facilitate the emergence of novel viral diseases as for example
swine flu and SARS, in principle. Antiviral research will therefore
be of continuing importance especially with respect to worldwide
surveillance of viral disease.
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(4) This is considering the whole mass or
fresh biomass of an organism and includes
intracellular water. In contrast, ecological
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mass of all organically bound carbon
contained in an organism, which usually
is 30% of the fresh weight and sometimes
considerably lower.
(5) Whitman et al. (1998)
(6) Atkinson et al. (2009), Garcia-Pichel
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6 Viral abundance and emergence
Viruses are highly abundant and diverse entities that per-
meate both the external world as well as our bodies and germlines. The
present section introduces recent estimates of the copiousness and global
environmental effects of viral particles and argues for a great genetic rich-
ness of viral genomes and proteomes. Apart from their significance as a
reservoir for genetic innovations, the diversity of viruses also has impli-
cations for public health: since viruses are able to switch host species, in
principle, many or most new human pathogenic viruses emerge from a
background of zoonosis, i.e., transmission from animal life to human. This
fact has been exemplified several times in the last years and surveillance of
viral factors is therefore of growing importance for public health.
Environmental abundance of viruses
Prokaryotes are highly numerous entities that represent 90% of
the ocean biomass, feature abundances in excess of 40 million en-
tities in a gram of soil, and differ drastically in their composition
between geographical locations.(1) Overall, there are an estimated 5
⇥ 1030 prokaryotes present in the worldwide ecosystem, the most
abundant single species of which being photosynthetic marine
cyanobacteria which consists of approximately 1027 individuals.(2)
For comparison, the number of cyanobacteria therefore is about a
million-fold higher than the number of stars in the universe, esti-
mated as 5 ⇥ 921 entities based on stellar density and the observ-
able volume of the universe(3).
In addition, the combined mass of prokaryotic biomass(4) of
350,000–550,000 megatons (Mt) equals or exceeds the total biomass
of plant life.(5) In contrast, the biomass of high-mass animal species
like human (an estimated 350 Mt given seven billion individuals
with an average weight of 50kg) or antarctic krill (500 Mt) is easily
surpassed by cyanobacteria alone (1,000 Mt).(6)
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Sequence-independent experimental methods such as direct-
count epifluorescence and transmission electron microscopy were
first to indicate that, similar to Bacteria and Archaea, viruses and
virus-like particles are also highly abundant in the environment.
Given the copiousness of bacteria within both seawater and soil,
it is not surprising that phages, i.e., bacteria-infecting viruses, are
at least as bountiful. Indeed, since viral abundance seems to be
highly correlated with the occurrence of prokaryotes, the prior may
exceed the latter by one to two orders of magnitude,(7) a number
that is also supported by experimentally measured phage burst
sizes(8) Indeed, the resulting estimates for the number of virus-like
particles in the biosphere are ranging from 1031 to 1033, depending
on the biome under investigation.(9),(10) The approximately 1013
human cells are outnumbered 10-fold by prokaryotes and 100-fold
by viruses and up to 94% of all existing nucleic acid containing
particles may be of viral origin.(11)
While many viral strains pathogenic for human are known to-
day, it is estimated that less than 1% of the global viral diversity
has been sampled scientifically, leading to the designation of the
virome as "dark matter" of ecology.(12) However, pathogenic effects
of viruses are not limited to single hosts: although constituting only
5% of the oceans’ biomass, viruses are generating approximately
1023 infections per second, thereby lysing in excess of 18% of the
oceans’ biomass per day and mediating 25% of the oceans’ primary
production of nutrients.(13) The dissolved organic matter set free
by this process of "viral priming" constitutes a major geochemical
forces in the oceans, heavily influencing large-scale carbon cycles
and green-house gas emissions.(14) In addition, these processes
also substantially influence the global food web by controlling the
amount of iron available for photosynthesis and limiting the prop-
agation of dominant prokaryotic species such as phytoplankton
populations during bloom, thus increasing biological variety in the
oceans.(15)
Based on techniques such as micropore filtration that allow in-
vestigation of the nucleotide content of viral particles, studies were
conducted on viral abundance in external environments such as
fresh and salt water as well as within terranean samples(16) (see
Fancello et al. (2012) for a review). These investigations further
demonstrated the vast diversity of the virome, especially regarding
bacteriophages.(17) Indeed, recent results indicate that between 500
and 129,000 viral genotypes are present in a liter of seawater (the
term genotype is roughly equivalent to a species in the context of
metagenomics but is usually employed to denote viral subspecies
in clinical virology). These numbers can be extrapolated to 1030
unique viral genotypes present in the oceans, indicating that the
marine virome may be the most diverse ecological community on
earth.(18) Given this high diversity, it is not surprising that the great
majority of genotypes found by recent studies in oceanic samples
do not have identifiable homology to known genes.(19)
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Extrapolating these numbers to global estimates is problem-
atic(20) and extensive gene transfer between viruses may mask the
underlying diversity of unique genetic and proteomic components.
However, the proposed vast richness of the virome is also sup-
ported by proteomics. Indeed, the total viral proteome space is esti-
mated to encompass up to a billion virally encoded ORFs.(21) Even
though more comprehensive and recent studies based on a wider
range of data and using more stringent analysis approaches(22)
drastically reduced these estimates to between 3.9 million protein
clusters derived from metagenomics studies and at least 0.6 billion
proteins clusters based on known phage-host systems,(23) viruses
may still represent the largest genetic reservoir on the planet.
These studies are paralleled by related results stating that most
viral proteins have no homologs in modern cells, a fact seemingly
in contradiction with the traditional concept of viruses as "gene
robbers", i.e., recruiters of and shuttle vectors for genes of cellu-
lar origin.(24) It has recently become clear that this abundance of
viral genes without cellular homologs is not a consequence of the
large number of yet unknown cellular genes or an artifact resulting
from distant divergence of the homologous sequences. Instead, it
is now accepted that at least 63 protein domain superfamilies (of
the about 2,000 superfamilies known to SCOP(25)) have no struc-
tural relatives among cellular life and thus represent uniquely viral
innovations.(26)
Due to the large abundance of viruses, the fact that all known
forms of cellular life are subject to infection and consequently, in
principle, to horizontal gene transfer by viruses,(27) and the high
rates viral mutation of up to 5–6 orders of magnitude higher than
the mutation rates of their hosts,(28) the uniquely viral superfam-
ilies may be considered a core mechanism of protein evolution.
Effectively, the virome may thus act as a continuous source of
novel, stable protein folds that supply cellular organisms with
structural innovations. If stable cellular protein conformations rep-
resent islands in theoretical structure space that are embedded in
a ’ocean’ of structurally unstable conformations, these stable but
yet-unobserved viral structures may act as land bridges between
cellular protein folds.(29) These metaphorical bridges may thus am-
plify development of new protein functions by pre-selecting and
importing stable protein folds into cellular organisms, thus poten-
tially facilitating evolution of cellular organisms(30)
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Emerging human pathogenic viruses
The majority of newly identified or emerging human viral diseases
such as severe acute respiratory syndrome (SARS) and the Nipah
virus arise from a background of zoonosis, i.e., originate from non-
human hosts, most of them mammal wildlife.(31) Although the
trajectory of viral emergence is currently contested (both increas-
ing and mildly decreasing rates are reported in the literature),(32)
these numbers are still sufficiently high to cause alarm: indeed,
while viruses make up a comparably small part of known human
pathogenic vectors, the majority of all newly identified pathogens
are viruses.(33) Recent estimates based on only one species of bats,
a notoriously super-infected mammal here employed as a represen-
tative for the approximately 5,500 mammals known, revealed more
than 50 previously unknown viral species in only nine viral families
assayed.(34) Based on statistical estimates about the completeness
of sampling and the number of known mammals, the total richness
of unknown mammalian viruses may thus exceed 300,000 species
within the nine assayed viral families alone.(35)
Viruses have evolved towards broad host ranges that may even
encompass multiple domains of life: some Nodaviridae, for instance,
infect insects, plants, as well as fungi.(36) Interestingly, host change
may evolve quickly especially in highly divergent viruses such as
avian influenza that may require only few mutations in order to
acquire airborne transmission capabilities between mammals.(37)
At the same time, host specificity in itself is very diverse and phy-
logenetic analyses have determined that even closely related viral
species may have distinct host ranges.(38)
It is therefore not surprising that up to a third of the viral fam-
ilies known to infect eukaryotes are also infecting humans, and
more than two thirds of viruses infecting humans also infect other
vertebrates.(39) Most of the hosts susceptible and permissive to
infection by human viruses are mammals, in particular rodents,
hoofed animals, primates, and bats; less than 20% of these hosts
are birds. Emerging from this reservoir of zoonotic viruses, new
human viruses are discovered at rates of about three a year.(40) As
a consequence, over two thirds of all new human pathogens consist
of viruses.(41)
Thankfully, although an estimated one third of the viruses infect-
ing livestock may also infect humans, transmission of these viruses
between humans is limited: only about half of all viruses infecting
humans can also be transmitted within the human species, and
only 25% are considered sufficiently infective to spread efficiently
in a susceptible population.(42) Still, examples for past zoonotic
viruses originating from mammals and birds that have established
themselves in the human population exist, as for example IV-1 and
HIV-2 (chimpanzees and mangabeys, respectively), SARS (bats),
HTLV, dengue, and yellow fever (primates), measles and smallpox
(livestock), as well as Influenza A (wild birds).(43)
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Viral epidemiology and surveillance
As a result of significant increases in global trade and air travel that
accompany globalization, travelers infected with human pathogenic
agents are now more prone to transmitting pathogens to new hosts
around the globe in a fashion that is both rapid and unforesee-
able. Mass migrations of human populations in general create ideal
conditions for the transmission of infectious diseases(44) and air
travel in particular has been associated with the global spread of
the initial waves of infections with HIV, SARS coronavirus, West
Nile virus, and tuberculosis.(45) The increased global transportation
of food produce occasionally contaminated with pathogenic animal
faeces(46) and intensive farming accompanied with heavy use of
antibiotics(47) provide ideal conditions for the evolution of viruses
with broad host ranges. These animal pathogens are considered
important sources for emerging human diseases, a fact that is illus-
trated by the recent transmissions of Influenza H7N7 from poultry
and H1N1 from pigs.(48)
In addition to agricultural sources of novel pathogens, climate
change modifies the geographical distribution of viral hosts, result-
ing in the occurrence of tropical infectious diseases in new locations
as exemplified by the recent outbreak of West Nile encephalitis in
the United States.(49) Deforestation of high-diversity biotopes, and
illegal trafficking of animal wildlife allows pathogens to reach new
environments, thereby increasing the likelihood of zoonotic events
originating from invaded biotopes(50) that have already been im-
plicated in the origin of HIV, Nipah virus, and filoviruses and may
be responsible for up to 75% of all emerging infectious diseases in
humans.(51)
Last, both idiopathic pathologies suspected to involve unknown
viruses and medical conditions such as organ transplantation, HIV-
mediated T-cell depletion, and some forms of cancers that involve
host immunosuppression, favor emergence of human pathogenic
viruses from the background of usually non-pathogenic latent in-
fections with viral commensals. Indeed, several such diseases as for
example respiratory diseases, diarrhea, multiple sclerosis, Kawasaki
disease, as well as rheumatoid arthritis and inflammatory bowel
disease have been associated with known and unknown viral fac-
tors, some of which may have zoonotic origins (see Delwart (2013),
Wylie et al. (2013) for a list of current publications concerning these
associations).
Similarly, highly prevalent commensals and chronically infecting
human viruses such as TTV, one of the newest emergent viruses
for which there is currently no clear disease association, may reveal
pathogenic potential in contexts of immunodeficiency or within
specific patient populations.(52) Other zoonotic commensals exist
which can cause human diseases in rare cases: for example the lym-
phocytic choriomeningitis virus, a zoonotic pathogen originating
from mice and hamsters for which up to 3% of the German popu-
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lation carries antibodies and that may cause deadly meningitis in
about 1% of the infected patients.(53)
In combination with studies demonstrating that divergent
viruses may quickly adapt to new hosts (see arguments in the
previous section), these results suggests that additional human
diseases with yet unknown etiology may be caused by emergent vi-
ral agents, thus highlighting the need for ongoing global pathogen
surveillance.
Global response to viral epidemics is heavily depending on early
and fast identification of the causative pathogens. For instance, the
1918 pandemic of H1H1 Influenza that infected approximately half
a billion people is estimated to have killed 3% of the global popula-
tion.(54) However, the causative factor of the disease was only later
shown to be a virus rather than, as first suspected, the bacterium
Haemophilus influenza, both of which have significantly different dis-
ease mechanisms, epidemiological behavior, and, at least nowadays,
treatment options. In contrast, the 2002 pandemic associated with
the severe respiratory syndrome (SARS) was linked to a novel coro-
navirus by Sanger (dideoxy) sequencing within weeks of the initial
outbreak.(55) Both increased global communications and better un-
derstanding of disease mechanisms enabled dramatically improved
medical and preventive response in the 2002 pandemic, resulting in
significantly lower numbers of infected people (~8000) and fatalities
despite comparable transmissibility (R0=2–5) and case fatality rates
(~10%) of the H1H1 and SARS infections.(56)
In order to detect emergent human pathogens as early as pos-
sible, basic research initiatives investigating the environmental vi-
rome are currently supplemented with applied studies on human-
proximal viral communities. These studies focus on the develop-
ment and spread of human pathogenic viruses in the context of
preemptive epidemiology and public health and employ systematic
screening in order to support rapid detection of known and novel
viral pathogens.
The speed of identification of causative viral agents is currently
further accelerating due to advances in sample preparation and
next-generation sequencing techniques that allow identification of
uncultured pathogens in clinical samples with unprecedented ve-
locity. Recent examples employing this technology that indicate the
future of rapid-response epidemiology include the identification
and genomic characterization of the Lujo virus in South Africa in
2008(57), the cattle Schmallenberg virus in Germany and the Nether-
lands in 2011,(58) and the toxic Escheria coli bacterium O102:H4 in
Hamburg in 2011 within days of receiving the first clinical sam-
ple.(59)
In addition, there is rising public awareness of early detection of
novel and known human pathogens as exemplified by scenarios of
general public health and surveillance,(60) and discussions about
the possible use of weaponized organisms employed by terrorist
organizations.(61)
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The present chapter forms the vanguard of the three core chapters of
this thesis. It discusses the concept of viral metagenomics, i.e., the system-
atic search for viral nucleotide signatures in mixed samples, in the context
of both surveillance of emerging pathogens and the search for previously
unknown causes of human cancers.
After briefly introducing the concept of metagenomics, this chapter
presents an introduction to sequencing approaches in virology in order to
provide sufficient background for later sections. Subsequently, an outline
is presented of both founding studies and recent developments in metage-
nomics, with a special focus on the detection and characterization of viral
pathogens. In a conceptual interlude, the biomedical notion of oncogenic
viruses and their multifaceted modes of interaction with cellular sys-
tems are surveyed. The bioinformatics paradigm of metagenomics and the
virological paradigm of oncogenic viruses are then synthesized into a com-
putational method for detecting low-abundance transcripts of known and
novel viruses in human tissues. The chapter concludes with an application
and validation of the aforementioned method on deep sequencing data from
neuroblastoma, a human pediatric tumor.
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7 Introduction to metagenomics
Due to their high genetic diversity, their possible role as gene
transfer vehicles between species, and the selective pressure they exert on
many cellular populations, viruses are critical regulators of global biodi-
versity.(1) Investigation of viral environmental diversity is now considered
to be a fruitful area for basic research initiatives that aim to classify novel
functional genetic elements in the virome, gain insight into the origin and
evolution of viruses, or attempt to understand patterns of interactions
between viral, bacterial, and eukaryotic components of marine and ter-
ranean ecosystems. While often applied to a wide range of bioinformatics
approaches and technologies, the term metagenomics foremost denotes
the application of sequencing methodologies for the investigation of an
entire, uncultured community of microbial(2) organisms directly sampled
from their natural environment.(3)Although first based on clonal sequenc-
ing data,(4) subsequent systematic metagenomics studies employed high
sensitivity deep sequencing technology in order to systematically analyze
microbial communities. Since metagenomics is highly dependent on nu-
cleotide sequencing, the following section will provide a brief introduction
to this bourgeoning subfield of genomics.
Viral next-generation sequencing
Besides cell cultures, polymerase chain reaction (PCR), and electron
microscopy, sequencing has become one of the major experimental
technologies of virology. As of September 2013, GenBank contained
1,619,495 sequence entries assigned to viral taxonomies (NCBI
taxon identifier 10239), the majority of which originate from HIV-1,
Influenza A, and hepatitis viruses. Based on historical data, these
entries represent an annual growth of more than 20%(5) and almost
entirely reflect sequences of high clinical significance: indeed, 18
of the 20 most frequently sequenced viruses are pathogenic in hu-
mans. Based on these sequences, more than 4,000 full viral genomes
have been determined as of today. Scientific insights derived from
these genomes had large impact on various subfields of virology
and sequencing of viral factors is now considered one of the most
important experimental technologies employed in virology.
Nucleotide sequencing is based on two breakthrough microbi-
ological technologies, namely DNA amplification by PCR(6) and
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the first generation of DNA sequencers using chain-terminating
nucleotides.(7) While these technologies provide an affordable way
to sequence templates up to 1000 bp, their low scalability as well as
their reliance on prior template amplification using specific primers
restrict their use on samples containing large or highly diverse se-
quence content. In addition, PCR amplification followed by direct
Sanger sequencing exhibits only limited sensitivity at resolving mi-
nority variants, i.e., low-frequency sequence fragments in mixed
samples; indeed, these variants can only be detected by Sanger se-
quencing if represented at more than 10-20% frequency.(8) While
this sensitivity can be increased by sequencing multiple individ-
ual DNA molecules from each sample, a process termed limiting-
dilution PCR, this procedure is costly and displays only low scala-
bility.(9) As a consequence of these confounds, Sanger sequencing
is not suited for investigating metagenomics samples that contain
samples with large volumes of unknown species with highly vary-
ing abundances and that are expected to include large fractions of
minority variants.
Next-generation sequencing. By building on prior breakthroughs
in semiconductor technology and microfluidics, novel sequencing
technologies have been developed that afford both dramatically
increased throughput and high sensitivity. These technologies,
commonly termed next-generation sequencing(10) firstly provided
researchers with the ability to generate millions or billions of se-
quence bases over night, thus empowering even single labs to se-
quence a human genome or hundreds of viral genomes in a short
time frame and at acceptable costs. In contrast to Sanger technol-
ogy, NGS platforms can detect minority variants with high sensitiv-
ity even at low frequencies of 1-2%.(11)
As a result of the high acceptance of next-generation sequencing
by academic and industrial research centers and the ever increas-
ing capacities of sequencing platforms, the available sequencing
capacity is now significantly higher than abilities for analyzing the
generated sequencing data. The resulting large volumes of sequenc-
ing data, also denoted as ’data deluge’, are exemplified by the large
numbers of sequences deposited in specialized data archives such
as ENA and SRA,(12) and pose significant challenges concerning
storage, transfer, and analysis of these data.
While differing in their exact implementation, current second
generation sequencing technologies have in common that they op-
erate on pre-amplified DNA pools of large ensembles of cells that
are processed in complex library preparation steps, sequenced in a
massively parallel fashion, and read out by high-throughput imag-
ing technology that deduce the actual base content (base calling) of
the sample. While deep sequencing allows for determination of
millions or billions of sequence fragments within a single run of
the sequencing instrument, the length of each sequence fragment
(read) is limited, depending on platform specifics, to about 150–800
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ALEXA-Seq
Apopto-Seq
AutoMeDip-Seq
Bind-n-Seq
Bisulfite-Seq
ChIA-PET
ChIP-Seq
ChIRP-Seq
ChiRP-Seq
ClIP-Seq
CNV-Seq
Degradome-Seq
DGE-Seq
DNA-Seq
DNase-Seq
dRNA-Seq
F-Seq
FAIRE-Seq
FRT-Seq
Frag-Seq
HITS-CLIP
Immune-Seq
indel-Seq
MBD-Seq
MeDIP-Seq
MethylCap-Seq
microRNA-Seq
mRNA-Seq
NA-Seq
NET-Seq
NOMe-Seq
NSR-Seq
PARE
PAS-Seq
Peak-Seq
PhIP-Seq
Protein-Seq
ReChIP-Seq
RIP-Seq
RIT-Seq
RNA-Seq
RNASeq
rSW-Seq
SAGE-Seq
Shape-Seq
Seq-Array
Sono-Seq
Sort-Seq
Tn-Seq
Table 7.1: Library formulations for deep
sequencing. Incomplete list. From:
http://core-genomics.blogspot.
de/2011/09/
next-generation-sequencing-acronyms.
html
bp due to biochemical and biophysical constrains of the sequencing
process. As a consequence, these technologies are also often termed
’short read’ technologies and are contrasted with third generation
(’long read’) sequencing technologies that allow for dramatically
longer reads lengths in the kilobase range, albeit at lower overall
throughput and, currently, accuracy.(13)
Specific formulations for the library preparation process exist
that influence the sequencing process; for example, reads can be
sequenced from the opposite ends of a single DNA molecule, a pro-
cess that provides additional linkage information and is denoted
as paired end or mate pair sequencing. In addition, sequence frag-
ments can be annealed to additional adapters that allow for mixing
of sequencing libraries, a process termed multiplexing. In addition,
a wealth of library formulations exist that aim to measure different
biological entities or relations using sequencing; an incomplete list
of these approaches is provided in Table 7.1.
Sequencing platforms. In the context of this work, two second-
generation sequencing platforms are of prime importance: the first
technology, Roche/454 pyrosequencing, relies on internal ampli-
fication of the pre-amplified library product using micro-droplet
emulsion PCR. Each droplet contains a single bead, i.e. a nanotech-
nological entity that fixates a single DNA molecule. This molecule
is amplified to several thousand copies that remain attached to the
bead. Beads are located on a picotiter plate consisting of millions of
wells. These wells are organized into flowcells that allow for adding
of nucleotides and washing reagents in all wells in parallel. DNA
molecules on loaded beads within the flowcell are simultaneously
sequenced by sequentially adding one of four deoxy-nucleotides
(dNTPs) nucleotides to the flowcell. These nucleotides are polymer-
ized by enzymatic synthesis of complementary DNA strands within
each well (thus the term sequencing by synthesis).
Apart from employing emulsion PCR for amplification, a notable
technical innovation of the Roche/454 platform is the pyrosequenc-
ing detection process by which each nucleotide incorporation re-
sults in the release of pyrophosphate. Pyrohosphate is converted by
the ATP sulfurylase into ATP, which in turn activates luciferase and
results in emission of a light signal whose intensensity is propor-
tional to the number of bases incorporated. Since nucleotides are
added to the flowcells with precise timing at each sequencing cycle,
peaks of photonic signals can be translated into base calls for each
well, which are concatenated into sequencing reads.
In contrast to Roche/454 technology, the Illumina HiSeq and
MiSeq platforms employ different approaches that allow for signif-
icantly higher throughput, although at lower read length. Illumina
instruments rely on high-density amplification of clonal colonies
of DNA strand that are fixed onto a glass surface. Amplification
occurs on this surface in a process termed bridge amplification and
results in clusters of clonaly amplified molecules. Sequencing is
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performed by simultaneously flushing all four nucleotides over
all colonies of a sequencing lane, a specified compartment of the
flowcell. Since nucleotides are fluorescently labeled with distinct
fluorophores, and nucleotide synthesis is self-terminating (reversible
chain termination), laser illumination of the sequencing lane can be
employed in order to detect the last incorporated nucleotides in all
colonies using an imaging instrument. After enzymatic cleaving
of the fluorescent dye and 3’ terminators of the last nucleotide, the
procedure can be repeated for a limited number of cycles.
By employing pyrophosphate-based chemistry, the 454 plat-
form avoids using reversible chain termination chemistries used by
other sequencing platforms that afford only shorter read lengths.
However, the Roche/454 platform gains this advantage at the cost
of increased difficulties in separating homopolymer runs which
tend to produce a continuous light signal across multiple base in-
corporations, thus increasing the error rate of the 454 sequencing
process to about 1% (compared to about 0.1% for Illumina plat-
form).(14) A second, and perhaps more important advantage of
the Illumina technology is sequencing throughput: since sequence
clusters amplified by Illumina bridge amplification can be attached
to the flowcell at higher densities compared to wells employed by
the 454 technology, Illumina devices typically afford significantly
higher numbers of sequenced bases per instrument run.(15)
Additional sequencing platforms of note are "2.5"th generation
and third generation technologies such as the Ion Torrent Per-
sonal Genome Machine and the Pacific Biosciences RS, respectively.
While the Ion Torrent can be viewed as a low-cost relative to 454
machines, affording significantly simpler library preparation and
cheaper machines by using pH change upon base incorporation
as signal and electrical signals for detection, the PacBio platform
employs dramatically different technologies that do not require am-
plification of molecules. Instead, the RS employs single-molecule se-
quencing by observing synthesis activity of individual polymerases
trapped in one of 150,000 wells that use phospho-linked fluorescent
nucleotides as substrates. While featuring only low signal-to-noise
ratios due to its reliance on non-amplified molecules, this technol-
ogy affords very long read lengths of more than 3 kbp and avoids
biases associated with DNA amplification.
Sequencing errors. For the second generation sequencing pro-
cess, image analysis results in reconstructed sequencing reads that
represent noisy measurements of large numbers of overlapping
fragments that originate from an ensemble of genomes. Due to
oversampling (i.e., each genome position is sequenced multiple
times, typically 30–200-fold for DNA sequencing), and the usage of
pre-amplified DNA, each sequencing experiment is able to generate
more base pairs than the original sample contained. This high av-
erage coverage is generally required in order to ascertain sufficient
minimal coverage of high-fidelity reads at each genome position.
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In order to compare the accuracies of sequencing platforms, error
rates of the sequencing process can be determined by amplifying
clonal samples (which have been obtained by limited dilution, for
example) within bacterial plasmids that display significantly re-
duced error rates compared to PCR amplification.(16) Variation
from the consensus sequence of the sequenced reads can thus be
associated with the sequencing process rather than with amplifica-
tion. These analyses have resulted in specific error profiles for the
454 and Illumina sequencing platforms that predominantly consist
of erroneous base substitutions that depend on the sequence con-
text(17) as well of base under-/overcalls in homopolymeric regions
that result in artifactual indels.(18)
Other technical errors are frequently introduced prior to se-
quencing by the library preparation process: as already touched
upon, current second-generation sequencing platforms require
sufficient DNA material in order to operate at high accuracy. There-
fore, the sample DNA (or reverse-transcribed RNA) has to be am-
plified prior to sequencing using PCR technologies. Amplification
can be confounded by several types of technical errors, such as
primer mismatches and selective amplification which may increase
the frequency of certain DNA molecules. In addition, nucleotide
substitutions due to errors of the DNA polymerase, as well as ar-
tifactual recombinations resulting from template switching and
unspecific hybridizations may occur.(19)
Finally, sequencing of RNA poses additional sources for errors.
RNA or transcriptome sequencing requires additional steps prior
to sequencing; first, RNA has to be isolated from genomic DNA
in the sample. Subsequently, contaminating rRNA is removed by
antisense oligos or selection of polyadenylated RNA. Finally, com-
plementary DNA synthesis by reverse transcriptase is primed by
oligo(dT) or random hexamer primers. These primers as well as
gene length, GC content and dinucleotide frequencies may intro-
duce additional biases.(20) Since RNA has to be reverse-transcribed
for sequencing by the reverse transcriptase, an enzyme that usually
lacks proof-reading ability, additional nucleotide substitutions may
be introduced at this level.(21)
Reads generated by sequencing platforms are commonly anno-
tated with quality scores that quantify the uncertainty of each par-
ticular base call.(22) However, the interpretation and calibration of
these scores is often difficult and may not sufficiently reflect biases
resulting from the sequence content.(23) In addition, quality scores
cannot capture well errors associated with the placement of dele-
tions read alignments commonly have to be post-processed.(24) In
spite of these shortcomings, quality values are regularly employed
in a first step in order to trim or remove unreliable sequence reads,
thereby significantly reducing error rates of downstream analy-
ses.(25) More involved quality control procedures are available, as
for example removal of rare (and thus more likely to be erroneous)
sequence fragments based on k-mer analysis.(26)
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Read analysis. Subsequent to error correction, quality-controlled
reads are either aligned (mapped) to a reference genome or assem-
bled de novo if no such reference is available. For each of these
purposes, a variety of specialized software implementations are
available that consider various phenomena such as transcriptome
splicing, viral diversity, or different library types.(27) Based on com-
paring several alignments or assemblies as well as by incorporation
of reference sequence information, genomic and transcriptomic
variants such as SNVs, short indels, splice variants, and larger
structural variations can be extracted from the alignment, in princi-
ple. These data can be further functionally annotated using protein
structures and disease gene and pathway information in public
databases, thus yielding clinically actionable results.(28)
Determination of genomic and transcriptomic variants poses
unique challenges, many of them facilitated by mapping ambigui-
ties, highly diverse genomes, or inaccuracies of reference sequences.
With regard to viruses, identification of SNVs at individual posi-
tions (SNV calling) or multiple correlated positions on the same
genome (haplotype estimation) are of foremost importance due to
their clinical relevance for viral phenotypic traits. SNVs are usu-
ally identified based on the sequence alignment by counting base
calls of multiple overlapping reads at a individual genome posi-
tion. However, due to high viral diversity and considerable error
rates of the sequencing process, true minority variants are often
difficult to discern from technical artefacts, even at high sequence
coverage. This difficulty has lead to the development of statistical
models by the virology and oncology communities, both of which
regularly deal with low-frequency SNVs and heterogeneous sam-
ples (cf. Chapter IV of this thesis and Beerenwinkel et al. 2012 for
an overview of such models that are frequently used in virology).
Deep sequencing approaches in virology
Next-generation sequencing has been employed in various appli-
cations of basic and clinical virology, such as determining popu-
lation diversity of viral species,(29) viral transmission of resistance
variants,(30) and whole-genome sequencing of medically relevant
viruses.(31) Chapter IV of this thesis is dedicated to exploring some
of these medical applications in greater detail.
In addition to sequencing viral DNA genomes, gene expres-
sion patterns of viral RNA genomes, viral mRNA, and of viral
microRNA are often determined to provide a more complete pic-
ture of the virome. In particular, large DNA viruses with many
genes employ a complex array of coding and non-coding transcripts
that are of medical interest.(32) Complementary to determining the
genome and transcriptome of viruses, analyses of genomes and
transcriptomes of infected hosts are currently also being pursued
using deep sequencing technologies.(33)
As touched upon previously in Chapter I, the discovery of novel
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emergent viruses by metagenomics approaches plays a key role
in preventive surveillance and timely reaction to viral outbreaks.
For the latter, deep sequencing in addition to electron microscopy
and non-specific PCR are especially versatile tools since they do
not rely on prior knowledge about the pathogen being sought. As
mentioned in Chapter I, recent outbreaks of haemorrhagic fever
and epidemic infection of cattle with the Schmallenberg virus have
been traced to their causative factors within days, thus allowing
for rapid responses to the epidemic.(34) In a related manner, as
will be expanded upon later in this chapter, analysis of host-viral
metagenomes and metatranscriptomes comprise a current field
of research that aims to identify clinically relevant viruses within
patients with unknown disease etiology.(35)
In accordance with the specific aim of a given metagenomic
study, two classes of metagenomics sequencing approaches are
often distinguished: targeted, or amplicon, sequencing and shotgun
sequencing.(36)
Metagenomics sequencing approaches. Targeted sequencing is based
on selected amplification of known, evolutionarily conserved ge-
netic marker sequences in a metagenomic sample. In order to afford
a systematic and comprehensive view of a microbial community,
this approach requires that each member species of the community
is covered by at least one known genetic marker sequence known to
the researcher. Individual marker genes conserved across all three
domains of life such as 16S and 18S rRNA genes and factors re-
quired for nucleotide metabolism and protein processing are widely
used for identification and taxonomic characterization of prokary-
otic lineages.(37)
However, as discussed earlier, marker gene approaches are not
amenable to characterizing viral populations which lack common
genetic markers due to their polyphyletic evolutionary origin (cf.
Chapter I). In addition, targeted approaches are limited to char-
acterizing very limited sequence regions by design, confounding
hindering functional investigation of complete microbial genomes.
Therefore, while being relatively cost effective due to both the lower
amount of genetic material required and the limited amount of
involved computational processing, reliance on marker genes is
prone to underestimating microbial diversity.(38) Consequently, tar-
geted approaches are currently used for determining the taxonomic
composition of metagenomic samples or for specialized clinical
applications but not for more comprehensive functional studies of
microbial communities.
As an alternative to targeted approaches, current metagenomics
investigations usually employ shotgun sequencing that are not lim-
ited to specific marker regions but sequence the full nucleotide
content of a given sample. While being more cost intensive than tar-
geted approaches, shotgun sequencing is more generally applicable
to investigating a broad range of taxonomic, genomic, and func-
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Year Discovery
2002 Marine viral metagenome
2003 Gut microbiome
2004 Marine sediment metagenome
2005 Novel human viruses detected in
blood, plasma, and nasopharyngeal
aspirates
2006 RNA viruses detected in seawater and
human feces
2007 New polyomavirus discovered. First
metagenome of virioplankton and soil
published. First use of next-generation
sequencing for detecting viruses in
honey bees.
2008 Several metagenomes of fecal and
water biomes, widespread use of next-
generation sequencing
2009 Numerous viruses in potable water,
human liver, pants, wild animals, and
insects detected
2010 Metagenomes of chimpanzee and
mosquito
2011 Viral metagenomes of pigs, simian
monkeys, and turkeys
Table 7.2: Major milestones in viral
metagenomics. Major milestones in
environmental and animal viral
metagenomics. From: Mokili et al.
(2012)
tional properties of microbial communities. Additionally, it is also
amenable to the reconstruction of entire microbial (draft) genomes
by de novo metagenomic sequence assembly. Due to the increased
availability of deep sequencing and bioinformatics methodologies
as well as resulting from the shifting aim of metagenomics ap-
proaches toward more detailed functional investigations, shotgun
sequencing has become the method of choice of current investiga-
tions.
Human and viral metagenomics
The main advantage of the metagenomics approach over traditional
mechanisms of culturing and analyzing individual organisms is
the access to the vast majority of microbes that cannot be cultured
given the current biological knowledge;(39) indeed, only about half
of the known phyla of bacteria have at least one member species
that can be cultured in the laboratory(40) and an estimated 99% of
all microbial species cannot be grown in-vitro at all.(41) In addi-
tion to providing a more complete picture of the microbial world,
metagenomics also allows for the investigation of both the taxo-
nomic structure and mutual functional interdependence of whole
microbial communities. As a consequence, metagenomics offers
a relatively unbiased(42) view on the microbial world that is both
wider and deeper than was previously possible.
Early metagenomics studies have focused on characterizing
uncultured microorganisms in environmental samples in a con-
text of basic research independently of the pathogenicity of these
agents.(43) Metagenomics has since then been recognized as a crit-
ical component of the applied human health sciences, in particu-
lar epidemiology and medicine. Availability of deep sequencing
methods has enabled targeted investigations of microbial diversity
associated with human health(44) that revealed a large abundance of
microorganisms as well as an intricate interplay between bacterial
communities and their human host(45) (see Table 7.2 for a chronol-
ogy of viral metagenomics studies).
While these interactions are usually non-pathogenic for individ-
uals with an intact immune response,(46) the characterization of
microbial communities of healthy humans is now actively pursued
in order to define baseline communities whose deviations may be
indicative of a variety of pathological disorders.(47) Such baselines
have been measured within several human biomes(48) and first in-
sights derived from such studies are currently being employed for
designing human fecal transplants that are able to restore produc-
tive bacterial populations in diseased patients.(49)
Viral metagenomics. Throughout the history of medicine, the
discovery of microbial agents, in general, and viral agents, in par-
ticular, followed (rather than preceded) the identification of the
pathogenic condition itself. AIDS, poliomyelitis, liver cancer, and
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cervical cancers were all described in the literature prior to detect-
ing the causative viral agent. Traditionally, virologists depended
on methods like inoculation (anno 1796), filtration and reinfection
(1892), cell cultures (1909), and electron microscopy (1933) to infer
the presence of pathogens, all of which exhibit considerable exper-
imental biases. These traditional approaches were later succeeded
by sequence-dependent methods such as PCR and microarrays(50)
that relied on prior knowledge of a specific marker sequence of the
pathogen and resulted in the discovery of several new HIV geno-
types and the SARS coronavirus, respectively.
Epidemiological studies support the conjecture that many human
pathogenic viruses remain to be discovered(51) and viral commu-
nities have received renewed attention as cofactors of cancer, as
well as of autoimmune and degenerative disorders,(52) and causes
of idiopathic diseases such as infantile diarrhea, influenza-like ill-
nesses, and chronic fatigue syndrome.(53) Similar to prior studies
of the human bacterial baseline microbiome, investigations aiming
to characterize the human baseline virome of diverse human tissue
samples as for example originating from blood, oral cavity, sputum,
gut, and fecal matter were undertaken.(54) These investigations re-
sulted in large proportions of 66% of sequence reads that had not
been characterized before in public nucleotide archives.(55)
Disease Nucleotide Virus discovered Technology Reference
Lower respiratory tract infection Both Parvovirus, coronavirus Sanger Allander et al. (2005)
Human merkel cell carcinoma RNA Polyomavirus 454 Feng et al. (2008)
Diarrhea RNA Astrovirus, torque teno virus,
norovirus, picobirnavirus,
enterovirus, nodavirus
Sanger Finkbeiner et al. (2008)
Fatal transplant-associated disease RNA Arenavirus 454 Palacios et al. (2008)
Hemorragic fever RNA Arenavirus 454 Briese et al. (2009)
Acute flaccid paralysis DNA Bocavirus, picornaviruses,
circovirus, nodavirus, dicistro-
viruses
454 Victoria et al. (2009)
Encephalitis RNA Astrovirus 454 Quan et al. (2010)
Lower respiratory tract infections RNA Rhinovirus C 454 Lysholm et al. (2012)
Tropical febrile illness DNA Circovirus Illumina Yozwiak et al. (2012)
Table 7.3: Recent literature in clinical
metagenomics. Selection of recent
literature in clinical metagenomics
that lead to discovery of a candidate
pathogenic viruses. Derived from
Fancello et al. (2012).
As already discussed in Chapter I, viruses are of polyphyletic
descent and do not possess common genetic marker genes. There-
fore, sequence-dependent approaches that rely on hybridization
of a known marker sequence (e.g., using a primer or hybridization
probe) to DNA or RNA contained in the sample are of only limited
use for detecting novel viruses. While individual viral families can
be identified by amplifying viral hallmark genes (VHG) that en-
code conserved viral proteins such as viral capsids or polymerases
by intentionally unspecific methods as, for example, degenerative
PCR,(56) such approaches are not applicable for sizable fractions
of to the virome.(57) Additionally, the use of VHGs is confounded
by horizontal gene transfer and viral variability that may delete or
modify the selected VHGs and thus hindering detection.(58)
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These restrictions on the use of early sequence-dependent meth-
ods for detecting novel viruses have led to the development of
non-targeted methods(59) that do not presuppose knowledge about
the pathogen being sought. These methods rely on extensions or
innovations of existing microbiological protocols and are either
suited for amplifying purified viral DNA without the need for
specific primers (sequence-independent single-primer amplifica-
tion and random PCR) or applicable to differentially analyzing
the sequence content of two samples by comparative hybridiza-
tion (suppression subtractive hybridization and representational
difference analysis).(60) While applications of these methods have
lead to the discovery of HTLV-1, Torque Teno virus, parvoviruses,
coronaviruses, and polyomaviruses in clinical samples,(61) they have
since then been replaced by shotgun metagenomics approaches fea-
turing higher sensitivities and a more comprehensive view on the
microbiome.(62)
Several of these shotgun metagenomics approaches were re-
cently employed for identification of novel viruses in patients
suffering from a range of adverse conditions. The human biomes
under investigation included human feces, blood, and brain(63)
and yielded several new, potentially pathogenic viruses (cf. Table
7.3 and Fancello et al. 2012). As a consequence of these successes,
clinical metagenomics is now considered a premier tool for detect-
ing novel human pathogens in clinical as well as in public health
settings.(64)
(1) Kunin et al. (2008), Raes et al. (2007)
(2) Bhaduri et al. (2012), Kostic et al. (2011)
(3) Contigs: overlapping nucleotide seg-
ments that represent a consensus region
of the genome. The set of all contigs is the
primary output of a sequence assembly.
8 Computational metagenomics
Metagenomic approaches generate large amounts of sequencing
data that have to be processed by computational methods in order to come
to conclusions about the distribution of microorganisms within the sample
under investigation. As detailed earlier, the analysis of viral sequence data
is complicated by high viral mutation rates and resulting divergence of
viral metagenomic sequences from the known viral reference sequences.
In addition, viruses are subject to considerable gene transfer and do not
possess as common marker gene such as the 16S/18S rRNA genes. In
combination, these confounds make the wealth of computational tools that
have been developed for the analysis of bacterial metagenomics data less
suitable for analyzing viral samples.(1)
Read mapping and assembly
The analysis of shotgun metagenomics data falls under the domain
of sequence-based bioinformatics and commonly includes a range of
methods that are organized into computational pipelines. As indi-
cated earlier, samples undergo purification and library preparation.
The resulting library is then sequenced by one of the deep sequenc-
ing platforms discussed earlier.
The processing of the resulting sequencing reads is highly de-
pendent on the specific aim of the metagenomics study. Human
clinical metagenomics approaches usually remove known bacterial
contaminants and and reads homologous to the human reference
genome or transcriptome by means of read mapping or sequence
clustering.(2) In particular, since many human pathogens are al-
ready sequenced, read mapping against these references often
serves as the initial step for analyzing clinical metagenomics data.
In contrast, environmental and human baseline metagenomics
approaches usually refrain from read mapping due to the sparse-
ness of suitable reference sequence for most of the microbiota under
investigation. These approaches instead often rely on taxonomic
binning or on de novo sequence assembly in order to combine the
short reads of current sequencing technologies in into longer se-
quence contigs(3) that allow for more specific taxonomic annotation.
Contigs can then be further processed in order to construct longer
sequence scaffolds that serve as draft genomes for species within
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the metagenomic sample and enable functional analyses and com-
parisons.
Sequence assembly is frequently considered the computationally
hardest problem of sequence-based bioinformatics. It is influenced
by a variety of biases and technical considerations too vast to be
presented here but extensively reviewed in Baker 2012, Myers 2005,
Paszkiewicz and Studholme 2010. In simple terms, assembly is the
problem of reconstructing the whole genome (or transcriptome) of
an organism from sequenced nucleotide fragments. Due to a variety
of biological factors such as large genome size, short read lengths,
genomic repeats, low complexity regions, contaminant organisms,
sequencing errors, heterozygosity, ploidy, and uneven sequence
coverage, an unique or even continuous assembly is currently only
possible for small genomes. These confounding factors of sequence
assembly are further complicated in metagenomic analyses where
complex samples exceed available sequencing capacities, orthologue
regions of different species merge into chimeric contigs, and uneven
sequence coverage is the norm rather than the exception.
In contrast to assembly of metagenomics samples consisting
mainly of bacteria, however, less ambiguous assemblies are pro-
duced from viral genomes due to the compactness and low number
of repeats in the latter. In addition, high viral replication rates at
least in clinical settings allow for sufficient amounts of sample, thus
providing high sequencing coverage and contiguous assemblies of
viral genomes.(4)
Most established assemblers developed for deep sequencing data
are relying on varying formulations of Overlap-Layout-Consensus
graphs and related string graphs on the one hand(5) or k-mer
graphs (i.e., de Bruijn graphs) for assembly of DNA genomes and
RNA transcriptomes,(6) the later of which is subject to additional
confounds such as dynamic intron/exon structure as well as differ-
ential expression of transcripts. While the string graph can utilize
reads of arbitrary length and is less vulnerable to sequencing er-
rors than de Bruijn graphs, in principle, the reliance of string graph
approaches on sequence alignments makes them inherently slower
compared to de Bruijn graph approaches if no algorithmic pre-
processing is undertaken.(7) In contrast, the de Bruijn graph data
structure is not depending on sequence alignments and allows
for the computationally efficient computation of sequence assem-
blies; in return, post-processing (scaffolding) and the use of multiple
sequencing libraries with varying characteristics is required to
make use of longer read lengths and to allow for panning of re-
peat regions(8) However, the memory requirements of de Bruijn
graph approaches are high (up to 512 GB for eukaryotes with large
genomes) since the size of the graph depends on the number of
distinct k-mers in the genome, and read data generally contain
sequencing errors that induce additional, artifactual k-mers. As a
consequence, de Bruijn graph memory requirements tend to in-
crease linearly with the number of sequence reads rather than with
computational metagenomics 69
(9) Brown et al. (2012)
(10) Koren et al. (2011), Lai et al. (2012),
Laserson et al. (2011), Namiki et al. (2012),
Peng et al. (2012), Ye and Tang (2009)
(11) Bankevich et al. (2012), Boisvert et al.
(2010, 2012), Chikhi and Rizk (2012),
Conway et al. (2012), Simpson and Durbin
(2012), Ye et al. (2011)
(12) Rosario and Breitbart (2011)
(13) Angly et al. (2006), Edwards and
Rohwer (2005)
(14) Benson et al. (2006), Breitbart et al.
(2003), Edwards and Rohwer (2005),
Huson et al. (2009), Zhang et al. (2006)
(15) Breitbart and Rohwer (2005),
Finkbeiner et al. (2008), Koonin and Wolf
(2008), Kristensen et al. (2010), Lapierre
and Gogarten (2009), Paul et al. (1993)
(16) Edwards and Rohwer (2005)
(17) Daubin and Ochman (2004), Yin and
Fischer (2008)
(18) Rosario and Breitbart (2011)
the size of the genome if no error correction is applied, thus making
high sequencing coverages as required for assembly of eukaryotic
especially problematic.(9)
The memory problem is especially grievous for metagenomic
assembly, as sufficiently capturing the genomic richness of complex
samples requires extremely high sequencing depth. In order to ac-
commodate confounds of metagenomic assemblies such as uneven
coverage and cross-species chimeras, specialized algorithms have
been developed that explicitly consider species distributions and
uneven coverage(10) or implement novel data structures to decrease
memory consumption.(11) Based on finished assemblies, absolute
and relative species abundances as well as community diversity
and structure of metagenomic samples can be estimated (cf. Fan-
cello et al. 2012) while the taxonomic origin of each contig can be
identified via taxonomic annotation methods.
Taxonomic annotation
Viral metagenomics firstly provided the biomedical sciences with
an opportunity to systematically investigate both environmental
and human biomes in order to identify emerging and established
human pathogenic viruses. However, the identification of such
novel pathogens is significantly impeded by our lack of knowledge
about the virome. The majority of metagenomic sequences with any
homology to GenBank records are assigned to 60 viral families (of
the 96 viral families known according to ICTV), representing about
equal numbers of RNA and DNA viruses.(12) However, these se-
quence hits exhibit only low sequence similarity (<50% amino acid
similarity) and comprise genes associated with central metabolic
functions rather than specifically viral genes.(13)
More critically, 51%–98% of the sequences produced by viral
metagenomics studies that sampled the human biome did not have
apparent homology to any entries in public nucleotide archives.(14)
While a lesser part of these unknown sequences may be part of a
pangenome of poorly conserved genes that occur in both cellular
and viral genomes, many of these sequences are likely to represent
signatures of unknown viruses(15) Interestingly, similar studies on
bacterial habitats found only 10% unknown sequences, indicating
that the extent of diversity and the amount of genes that cannot be
classified might be significantly higher for viruses than for bacte-
ria.(16)
Likewise, analyses on the level of reading frames (ORFs) showed
that 30% of ORFs in the sampled viral genomes are not homolo-
gous to known eukaryotic or prokaryotic factors, thrice as many as
in bacterial metagenomes and cultured bacteria.(17) Cumulatively,
the 24 metagenomic studies published by 2011 have yielded 0.8
Gbp (70%) of ORFs with no homology to GenBank records.(18)
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Means of taxonomic annotation. A prerequisite for the identifica-
tion and detailed functional and metabolic investigation of novel
microbial organisms in metagenomic sequence data is a taxonomic
annotation, or taxonomic binning, of sequence fragments.(19) Bin-
ning is commonly based on local sequence similarity of reads to
entries in protein or nucleotide reference sequence databases such
as NCBI RefSeq, nr, or nt(20) that have a known taxonomic identity.
Additionally, sequence data under investigation are often correlated
with phylogenetic information in order to derive the lowest com-
mon ancestor of taxa corresponding to several related taxonomic
bins.(21)
Technically, the search for locally similar sequences in reference
databases is conducted by either employing hash-based seed-and-
extend methods such as BLAST(22) or methods derived therefrom
and adapted to metagenomics data.(23) Alternatively, abstracted
models of sequence similarity implemented via Hidden Markov
Models that can detect specific marker genes or motifs with high
computational efficiency are employed.(24)
As indicated before, databases of reference sequences capture
only a small fraction of the microbial sequence space sampled by
current metagenomics studies. As a consequence, many sequence
reads cannot be taxonomically categorized using similarity-based
methods that rely on the existence of similar sequences in nu-
cleotide archives. In order to address this confound, composition-
methods (also termed alignment-free methods) have been developed
that categorize sequence reads not by similarity but by more ap-
proximate nucleotide signatures such as GC content and the over-
representation of specific k-mers. These nucleotide signatures are
shaped by biological factors as for example translational codon
selection, context-dependent mutation pressures, and polymerase
nucleotide incorporation biases that are hypothesized to be specific
for microbial species or taxonomic clades.(25)
Composition-based methods for taxonomic annotation are com-
putationally less demanding than similarity-based approaches and
are additionally able to identify highly divergent species as well
as novel clades. On the other hand, composition-based methods
display reduced accuracy and, due their reliance on nucleotide
count statistics that require sufficient read lengths to achieve high
specificity, suffer more from the short read length of current se-
quencing technologies than similarity-based approaches. The major
subclass of composition based methods employ supervised learn-
ing approaches that rely on comparing sequence reads to previ-
ously known genomic signatures; these methods require sufficient
amounts of known reference sequences as training material which
are not always available.(26) Consequently, both similarity-based
and supervised composition-based approaches are affected by the
low coverage of public reference archives.(27)
In practice, metagenomic binning, phylogenetic placement, as
well as in-depth functional and pathway annotations of sequence
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reads are conducted in an integrated fashion by computational
annotation frameworks. These frameworks internally employ local
similarity-based methods (such as BLAST(28) and HMMs(29) or
rely on genomic signatures of nucleotide composition using either
supervised or unsupervised(30) machine learning methods (cf.
Mande et al. 2012 for an exhaustive list of annotation frameworks).
Viral sequence annotation
Among the vast range of computational annotation and binning
methods, only few are directly tailored to viral sequences. Viruses
pose a special problem for taxonomic classification due to their
polyphyletic origin, absence of common markers genes, high se-
quence divergence, extensive gene transfer, short genome, and the
potentially high similarity between host and viral genomes in terms
of both homologous genes and codon usage patterns.
Most similarity-based approaches to taxonomic annotation
rely on hash-based local gapped alignments using variants of
BLAST,(31) including comparisons of query and reference sequences
in nucleotide space (BLASTn), protein space (BLASTp), query nu-
cleotides translated to protein space (BLASTx), and reference and
query nucleotides both translated to protein space (tBLASTx). Pub-
lic BLAST reference databases offered by NCBI and EBI such as
nt (nucleotide database) or nr (protein database) also include sec-
ondary reference sources as, for example, GenBank/RefSeq entries
and Swissprot/PDB entries, respectively. These databases were
recently supplemented by environmental sequence tags (env) re-
sulting from metagenomics studies, making these databases the
most comprehensive source for biological sequence information
currently available.
Due to the ability of BLASTx and tBLASTx methods to bypass
synonymous mutations during codon translation and thus identify
functionally conserved homologs, these approaches are recom-
mended for discovering remote similarities and are particularly
well suited for identification of divergent viral species.(32) Bacterial
metagenomics studies commonly post-process BLASTx results in
order to better reflect taxonomic relations.(33) However, such ap-
proaches, while represented in the literature,(34) are of only limited
applicability to viral data where taxonomic relations do not fol-
low a Linnaean-like taxonomic hierarchy. In addition to directly
comparing query and reference on the sequence level, more remote
homologies or functional annotations of sequence regions can of-
ten be inferred by using abstractions of sequence motifs in terms
of Hidden-Markov Models or position-specific scoring matrices
that have been trained on reference protein sequences. However,
although facilitating functional characterization of highly diver-
gent query sequences, their reliance on the availability of protein
reference sequences makes HMM models by Pfam, InterPro, PHI-
Blast/Psi-Blast, or, more recently, HMM-FRAME(35) less well suited
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for viral taxonomic annotation where protein references may be not
available.
Several similarity-based approaches aim to address some of the
aforementioned confounds of viral taxonomic annotation; however,
these approaches presently are either limited to BLASTN/BLASTP
similarity searches that are unsuited for detecting similarities be-
tween highly diverged viral genomes and their references,(36) or
they employ only a limited range of known reference sequences
without making use of the wealth of the full NCBI nr and nt nu-
cleotide archives,(37) thereby potentially missing known viral genes.
In a similar fashion, composition-based taxonomic classification
methods that are currently in use by the metagenomics commu-
nity(38) may be confounded by viral species that emulate the codon
usage patterns of their hosts(39) or are not specifically trained or
validated on viral genomes.(40)
In summary, therefore, there currently is no golden bullet for
viral taxonomic annotation and the reliance on imperfect reference
archives and incomplete viral taxonomies remains a hindering
factor of viral metagenomics.
(1) The terms oncogenic virus, cancer
virus, and tumor virus are here used
interchangeably. While the concept of
oncovirus has roots in the study of cancer-
causing RNA retroviruses, the term tumor
virus has been predominantly employed
by virologists targeting DNA cancer
viruses. As both DNA and RNA viruses
have later been shown to promote cancer
by manipulating similar cellular pathways
(although usually by different means),
the semantic distinction implied by the
different lexemes is void. An exception is
the word transforming virus as it explicitly
specifies pathogens that change the phe-
notype of a cell in an in-vitro environment
rather than in an in-vivo environment
which is required for true oncogenesis.
(2) Ellerman (1908)
(3) Rous (1973)
(4) Gross (1951), Rous and Beard (1935)
(5) which earned Rous the 1966 Nobel
Prize for Physiology or Medicine
(6) Martin (2004), Temin and Rubin (1958)
9 Introduction to tumor viruses
The following conceptual interlude changes the focus of this
chapter from a bioinformatics topic, metagenomics, to a central theme of
microbiology: oncogenic or tumor viruses.(1) As will be discussed in the
next sections, the origins of the two scientific disciplines virology and
oncology as well as many methods of microbiology are highly related to
investigations of animal tumor viruses. Detection and characterization of
oncogenic pathogens has important practical consequences for medicine
and epidemiology. In addition, basic researchers are interested in tumor
viruses due to the highly effective genetic control elements that these
pathogens employ to modulate core cellular pathways such as replication,
apoptosis, and immune response. These cellular pathways are not only
utilized by viruses but are also frequently aberrant in malignant human
cells, thus providing a conceptual bridge between virology and oncology.
Retroviruses and discovery of cellular oncogenes
Soon after characterization of the first plant viruses, two land-
mark discoveries marked the beginning of both animal and tumor
virology: first the result that avian leukemia, at that time not con-
sidered to be a cancer, can be caused by an unknown filterable agent
of sub-bacterial size(2) that later was identified as the first retrovirus.
Second, the evidence for infectiousness of another cancer, avian
sarcoma, by inoculation of cell-free tumor extracts in healthy ani-
mals with the Rous sarcoma virus (RSV).(3) Subsequent discoveries
revealed infectious oncogenic viruses in malignancies of several an-
imals such as rabbits and mice(4) and indicated that tumor viruses
encompass both RNA and DNA viruses of several viral families.
Fundamental to further research on oncogenic viruses was the
development of quantitative transformation assays(5) which first
facilitated a detailed investigation of several different RSV variants.
These investigations demonstrated the distinctness of cellular trans-
formation and viral replication, thereby suggesting that RSV vari-
ants contain an oncogenic gene dispensable for viral replication.(6)
This gene, src, was later shown to stably integrate into the host
genome and cause cellular transformation; as such, it constitutes
the first identified oncogene. These results gave rise to the provirus
theory of retroviral persistence that was later experimentally proven
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(7) Baltimore (1970), Duesberg and Vogt
(1970), Temin (1964), Temin and Mizutani
(1970)
(8) for instance, by being incorporated
in cellular protein complexes and there
having a dominant-negative effect on the
functioning of the whole complex
(9) Huebner and Todaro (1969), Stehelin
et al. (1976)
(10) Coffin (1997)
(11) Nevins and Vogt (1996)
(12) Interestingly, although replication-
incompetent, acutely transforming tumor
viruses may still retain continued invec-
tiveness if the infected cell is co-infected
with a related and replication competent
virus, such as the Friend virus or wild
type Avian Leukemia virus. These helper
viruses provide critical services such as
capsid assembly and genome packaging
to the damaged tumor virus. Thus, the
presence of helper viruses, while not
having an oncogenic effect itself, may
mask the activity of low-abundance tumor
viruses.
(13) Bishop (1991)
(14) Stehelin et al. (1976)
Class Proto-oncogenes
Growth factor sis
Kinases erbB, fms, kit,
abl, src, raf, akt
G proteins H-ras, K-ras
Transcription factors erbA, ets, myc,
rel
Table 9.1: Proto-oncogenes associated
with retroviruses. Proto-oncogenes
discovered by studying retroviruses.
From: Butel (2000), Javier and Butel
(2008)
(15) Der (1987), Der et al. (1982), Parada
et al. (1982), Sukumar et al. (1983)
(16) Butel (2000)
in two landmark studies by David Baltimore and Howard Temin.(7)
While oncogenes were first believed to be entities of exclusively
viral origin that are activated by somatic mutations or external
carcinogens, it was soon shown that retroviruses such as RSV are
able to capture (i.e., copy) proto-oncogenes from the host cell. These
capturing retroviruses probably originated from non-transforming
retroviruses, for example the Avian Leukemia virus that incorpo-
rated a cellular proto-oncogene into their genome during proviral
integration and subsequent read-through transcription. Upon sub-
sequent infections, the captured proto-oncogene may be integrated
into the chromosomes of the same or other host cells, often either
in a mutationally activated form or integrated into a cell type lack-
ing transcriptional control for this oncogene. As a consequence, the
integrated oncogene is either permanently activated or its prod-
ucts are phenotypically inhibiting its cellular homologues,(8) thus
predisposing the cell for oncogenesis.(9)
Due to their capability to rapidly and efficiently cause cellular
transformation in vitro as well as in vivo,(10) viruses containing cel-
lular oncogenes such as RSV, Murine Leukemia virus and Feline
Leukemia virus(11) were later termed acutely transforming. Impor-
tantly, capture of cellular oncogenes usually leads to deletions of
essential genes within the viral genome, rendering the capturing
virus replication incompetent and thus only able to initiate a single
round of infection(12).
Historically, the investigation of captured cellular genes in trans-
forming viruses was critical for understanding the molecular mech-
anisms of oncogenesis by activation of oncogenes.(13) As mentioned
previously, not only was Rous Sarcoma virus the first discovered
tumor virus but its transformative gene, src, was also the first onco-
gene to be identified.(14) While later studies on virally activated
cellular proto-oncogenes uncovered many central elements of the
cellular regulatory machinery involved in oncogenesis (see Table
9.1), it was shown that RSV is among the few acutely transforming
viruses that retain replication competence after oncogene capture.
Thankfully, however, such replication-competent acutely transform-
ing viruses are extremely rare and no such retrovirus is known to
infect humans.
Subsequent studies on non-viral activation of oncogenes in a
range of tumors demonstrated that activating mutations both in
oncogenes captured by viruses and in somatically mutated cellular
oncogenes often occurred at identical sites, thus indicating com-
mon molecular mechanisms of oncogenesis.(15) Investigations of
insertional mutagenesis of non-acutely transforming retroviruses
affecting cellular oncogenes later substantiated this cellular oncogene
theory of cancer, thus providing the first comprehensive theory on
cancer genesis by combining etiologies associated with viral cofac-
tors, with chemical and environmental carcinogens, as well as with
somatic mutations(16) (cf. Table 9.2).
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(17) Braithwaite and Prives (2006), Knudson
(1971), Lane and Crawford (1979)
1. Cellular origins of oncogenes: acutely
transforming retroviruses carry onco-
genes that are derived from cellular
genes
2. Genetic basis of cancer: cancer may
arise through activated cellular onco-
genes that positively affect the mito-
genic cycle
3. Multistep oncogenesis: multiple ge-
nomic events are necessary for cancer
development and progression
4. Negative regulators of cancer: cancer
may rise through deactivated cellu-
lar tumor suppressors that negatively
affect the mitogenic cycle and may
initiate apoptosis
5. Unification of etiologies: viruses, chem-
ical carcinogens, radiation, and somatic
mutations may cause cancer by affect-
ing the same mitogenic pathway
Table 9.2: Oncological discoveries based
on virology. Oncological discoveries
based on virological experiments.
(18) Finlay et al. (1989), Greenblatt et al.
(1994), Harris (1996), Vogelstein et al.
(1989)
(19) Usually denoted v-onc in contrast to an
activated cellular oncogene, c-onc
(20) Activated: here, this denotes the
change from a proto-oncogenic to an
oncogenic state
DNA tumor viruses and discovery of tumor suppressors
After the discovery of viral capture mechanisms of cellular onco-
genes and the rise of the oncogene theory of cancer, the study of
human tumor viruses rapidly expanded to include DNA viruses
such as polyomaviridae, adenoviridae, and papillomaviridae. It became
soon clear that, in contrast to both rapidly and non-rapidly trans-
forming retroviruses, oncogenes within transforming DNA viruses
had a genuinely viral origin (v-onc), had multiple functional roles
within viral infections, and were essential for viral replication.
In particular, these viral oncogenes affected a newly discovered
class of cellular proteins such p53 and Rb that modulate cellular
transcription factor binding to control cell cycle progression, senes-
cence, apoptosis, and DNA repair.(17)
p53 and Rb possess regulatory and signaling functions that have
suppressive effects on oncogenesis and were later found to be mu-
tated in over half of all cancers.(18) In contrast to cellular oncogenes
that dominantly promote activation of the mitogenic pathways,
tumor suppressor proteins have a recessive effect, inhibit cell cy-
cle progression, and are activated by a range of conditions such
as cellular stress (DNA damage), transformation (as indicated by
aberrant proliferative signaling), or viral replication (as indicated
by activation of innate immune system). DNA tumor viruses as, for
example, adenoviruses, polyomaviruses, and herpes- and papillo-
maviruses counte the cellular antiviral response in a variety of ways
by inhibiting tumor suppressor pathways with viral oncogenes,
thereby increasing the permissiveness of the cell for viral replication
and also predisposing it to oncogenesis.
Direct and indirect mechanisms of oncogenesis
The currently known repertoire of human oncogenic viruses in-
cludes both large and small DNA viruses, as well as retroviral
and non-retroviral RNA viruses that have either acutely or non-
acutely transforming properties. Besides grouping viral pathogens
by nucleic-acid type (RNA or DNA), tumor viruses are often clas-
sified by their direct or indirect oncogenic mechanisms. As will be
discussed later in more detail, tumor viruses may induce cancer by
one or several such oncogenic mechanisms either in parallel or in
succession.
Many human oncogenic viruses such as HPV, MCV, EBV and
KSHV contain a virus-derived oncogene, termed v-onc.(19) v-oncs
are usually activators of cellular proto-oncogenes or deactivators
of cellular tumor suppressors and constant v-onc expression is a
necessary condition for maintaining the transformed cell state.
While the targeted oncogene or tumor suppressor often requires
additional mutations to become activated,(20) v-onc transcripts are
expected to be present in each cancer cell and directly predispose
the cell to oncogenesis. Consequently, viruses encoding a v-onc are
denoted as directly oncogenic.
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(21) Jeang et al. (2004), Seeger and Mason
(2000), Tsai and Chung (2010), Yasunaga
and Matsuoka (2007)
(22) Gallagher et al. (2003)
(23) Aneiploidy: Abnormal number of
chromosomes within a cell.
(24) Duensing et al. (2000), Hein et al.
(2009)
On the other hand, predominantly indirectly acting oncogenic
viruses such as HBV, HCV, and retroviruses achieve transformation
by more distal mechanisms such as insertional mutagenesis, pre-
vention of apoptosis of pre-cancerous cells, opportunistic infections
with other viruses by virus-induced immunosuppression, or oxidiz-
ing DNA damage by chronic inflammation. Indirect tumor viruses
are not depending on the continued expression of a viral oncogene
but influence the viral context in a more circumstantial manner.
While the distinction of directly and indirectly acting tumor
viruses may serve as an useful organizing principle in tumor vi-
rology, several viruses such as human polyomaviruses, HBV, HCV,
and HTLV-1 promote both direct and indirect mechanisms,(21)
thereby indicating a continuum rather than distinct classes of viral
oncogenic mechanisms.
A third order of oncogenic viral cofactors, here loosely denoted
as hit-and-run viruses, also employs indirect oncogenic mecha-
nisms whose exact definition is currently contested.(22) Hit-and-run
viruses are hypothesized to predispose the cell to chromosomal
instability by an array of molecular mechanisms that result in ane-
uploidy(23), large-scale chromosomal rearrangements, and genomic
losses that may promote oncogenesis.(24) In the hit-and-run model
of oncogenesis, oncoviral factors are essential for the initial transfor-
mation but may be lost from progressed tumors due to activation of
additional cellular oncogenes and selection of growth-autonomous
cells that make the original viral factor dispensable.
The following section will expand on these topics and investigate
in more detail the exact molecular mechanisms of tumor virus
transformation.
(1) Matsuoka and Jeang (2007)
(2) Mikkers and Berns (2003)
1. Promotion of genetic instability and
DNA damage, for instance in HPV
(Duensing and Munger, 2003) and EBV
(Liu et al., 2004)
2. Cell immortalization and telomere
lengthening, for example in EBV (Sug-
imoto et al., 2004) and KSHV (Verma
et al., 2004)
3. Control of mitogenic and tumor
suppression pathways, as in HPV
(Scheffner and Whitaker, 2003) and
KSHV (Friborg et al., 1999)
4. Inhibition of intrinsic and extrinsic
apoptosis pathways, in particular cas-
pase activation (EBV Grimm et al.
(2005), KSHV Matta et al. (2003))
5. Modulation of the cell micro-
environment by cytokine and growth
factor production causing inflammation
(EBV Maggio et al. (2002))
6. Evasion of immunological surveillance
by episomal and proviral latency or
inhibition of host immunoregulatory
molecules such as interferones, inter-
leukins, and MHCs Coscoy and Ganem
(2000)
Table 10.1: Molecular pathways
modulated by tumor viruses. Molecular
pathways modulated by tumor
viruses that may lead to oncogenesis.
(3) Coffin (1997)
(4) Esquela-Kerscher and Slack (2006),
Negrini et al. (2007)
10 Molecular mechanisms of tumor virus
transformation
Both cancer cells and oncogenic viruses modulate mito-
genic, apoptotic, and immune pathways in order to influence the cell cycle
and promote rapid replication. Importantly, however, oncogenesis is not
an integral part of the life cycle of tumor viruses. Instead, it is to be con-
sidered as an accidental side effect of long term molecular interactions
of a persistent virus with limited or lost replication competence with the
host cell machinery. As briefly discussed in previous sections, known hu-
man tumor viruses predispose cells to oncogenesis by manipulating host
cellular pathways and the cellular environment by a broad range of mech-
anisms. These mechanisms can be summarized in two broad classes of
molecular events: (1) by direct means and mostly enacted by oncogenes
of viral origin that modulate the host cellular machinery in order to pro-
mote replication and lessen immune surveillance(1) (see Table 10.1), or (2)
by indirect means such as insertional mutagenesis at host genomic loci
near cellular oncogenes, modulation of the cellular inflammatory context,
epigenetic effects, and inducement of chromosomal instabilities.(2) The
oncogenic etiology of tumor viruses is strikingly different between these
two means of oncogenesis as well as between simple retroviruses, com-
plex retroviruses, and DNA viruses, as will be illustrated in the following
section.
Tumor viruses modulate mitogenic and immune pathways
Cellular proto-oncogenes code for gene products that regulate
cell growth and differentiation by modulating mitogenic path-
ways. Known classes of oncogenes include growth factors, tyro-
sine/serine/threonine kinases, GTPases, and transcription fac-
tors.(3) Due to a variety of mutational events such as single nu-
cleotide polymorphisms or indels within the coding sequence,
insertional misregulation in coding or promoter sequences, genomic
aberrations such as translocations, copy number variations, and
gene fusions, as well as modifications of regulatory transcription
factors and miRNAs,(4) these genes can be activated and become
tumor inducing agents. In contrast to the strict definition of cellu-
lar oncogenes as positive regulators of the mitogenic pathway that
may induce cancer if mutated or misexpressed, the concept of vi-
rally derived oncogenes is used in a considerably broader sense and
78 from basic research to clinical applications
(5) Stehelin et al. (1976)
(6) Knudson (1971)
(7) Bishop (1991), Weinberg (1989)
(8) Butel (2000), Temin and Rubin (1958)
(9) Duesberg and Vogt (1970), Martin
(2004)
(10) Der et al. (1982), Parada et al. (1982)
(11) Butel (2000)
(12) Baltimore (1970), Temin and Mizutani
(1970)
Virus Viral oncogene Cellular factor
HBV HBx p53, CBP/p300,
PI3K
HCV Core, NS3,
NS5A
p53, pRb, TNFR,
TBP, PI3K
EBV LMP-1 TRAFs, TRADD,
RIP, vimentin,
JAK3
HPV E5-E7 p53, TNFR, pRb,
p21, CycA, CycE
HTLV-1 Tax pRb, CBP/p300,
p21, CycA, CycE
HIV Tat CycT1, TFIIH,
P-TEFb, PKR,
pCAF, CBP/p300,
TAFII250
KSVH vIRF, vGCR,
Kaposin
CBP/p300
Table 10.2: Frequent cellular targets of
viral oncogenes. Investigation of
frequent targets of viral oncogenes
lead to the identification of cellular
proto-oncogenes. Only selected
cellular factors are shown. From
Boccardo and Villa (2007).
(13) Javier and Butel (2008), McLaughlin-
Drubin and Munger (2008), Teodoro and
Branton (1997)
(14) McLaughlin-Drubin and Munger
(2008)
(15) Smith (1994)
includes all genes that code for protein factors that modulate mi-
togenic, apoptotic or or immune pathways in ways that predispose
the cell to malignant transformation.
Proto-oncogenes are positive regulators of the cell cycle and their
activation usually has a dominant oncogenic effect (that is, in vitro
transformation or in vivo oncogenesis occurs if at least one allele
of the proto-oncogene is activated).(5) In contrast, tumor suppres-
sors such as p53 or rb that are engaged DNA repair, repression of
cell devision, and triggering of apoptosis are negative regulators of
the cell cycle and their deactivation by means similar to oncogene
activation has a recessive effect, requiring at least two transfor-
mative mutations or "hits" in order to trigger oncogenesis.(6) The
realization that multiple genetic events are necessary for cancerous
transformation gave rise the theory of multi-step oncogenesis and it
is now accepted that discrete genetic events cooperatively and suc-
cessively confer survival advantages and thus clinical malignancy
to the cancerous cell.(7)
As mentioned in previous sections, advances in the technol-
ogy of culturing cells that can be infected with viruses lead to the
possibility of employing viruses as biological model systems for
oncology.(8) Based on the identification of the first cellularly derived
oncogene in retroviruses(9) and followed by the realization that mu-
tations in cellular proto-oncogenes are causative for most somatic
cancers,(10) experimental investigations resulted in the discovery of
more then 70 cellular proto-oncogenes(11) (see Table 10.2 for a list
of selected examples). In addition, these studies revealed one of the
major innovations of the viral world: the reverse transcriptase.(12)
Many viral factors modulate core cellular regulatory and defense
mechanisms in order to increase the viral replicative time window,
for example by inhibiting or modulating tumor suppressor proteins
such as p53 and Rb to fixate the cell cycle and prevent apoptosis, or
by inhibiting antiviral defense mechanisms such as cellular endonu-
cleases.(13) While all these events predispose the cell to oncogenesis
by enhancing proliferation of aberrant cells, these events are not
sufficient for oncogenesis and further conditions such as somatic
mutations, environmental risk factors, and immunosuppression are
generally considered to be necessary for cancer formation.(14)
Viral genomes frequently contain cellularly or virally derived
genes that facilitate persistence of the virus by decreasing recog-
nition of viral factors by components of the adaptive and innate
immune system, such as chemokines, cellular proliferation factors,
and inhibitors of apoptosis (cf. Chapter III for a discussion of viral
strategies of immune evasion in a context of viral host factors).(15)
Especially larger DNA viruses, as for example KSHV and Poxvirus,
employ several passive and active strategies to evade the host im-
mune system (see Table 10.3). These strategies induce prolonged
immunosuppression of infected cells and result in cellular stress
as well as in unhindered modulation of mitogenic and apoptotic
pathways, thereby creating an ideal background from which cancer
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(17) Sun et al. (2005), Trivedi et al. (2004)
(18) Engels et al. (2006), Miller et al. (1996)
1. Restriction of viral transcription by
proviral, episomal, or epigenetic la-
tency mechanisms
2. Infection of cellular compartments that
are under lessened immune surveil-
lance such as brain or kidney
3. Variation of the viral genome by error-
prone viral polymerases to decrease
antibody and T-cell recognition of viral
antigens
4. restriction of host major histocompat-
ibility complex expression by viral
inhibitors
5. Inhibition of antigen processing and
presentation
6. Infections of immune cells
Table 10.3: Viral modulation of the host
immune system. Viral strategies to
modulate the host immune system in
order to support viral persistence.
Derived from Butel (2000).
(19) Virimia: Medical condition where viral
particles have access to the bloodstream.
(20) Centurion-Lara et al. (2004)
(21) Johnson and Desrosiers (2013)
(22) An episome is a viral genome or parts
thereof persisting as linear or lariat
(lasso-shaped) structures in the cellular
cytoplasm or nucleus independently and
physically separated from the host genetic
material.
(23) Retroviruses insert their genome into
the host genome as an obligatory part of
their life cycle. After viral entry, the viral
RNA genome is reverse-transcribed into
a double-stranded DNA molecule by a
viral enzyme, reverse transcriptase. The
double-stranded viral DNA is integrated
into the host genome by the viral integrase
enzyme. The integrated copy of the viral
genome is termed a provirus and would
resemble cellular genes if it were not
under transcriptional control of a specific
viral promoter element, the long terminal
repeat (LTR). The integration site of
the integrated genome, the provirus, is
essentially random, although preferences
for specific sequence motifs or chromatin
states have been reported (Deichmann
et al., 2011).
can arise.(16)
Similarly, the replication of some oncogenic viruses is controlled
in healthy patients but increases to pathogenic levels in contexts of
immunosuppression as, for example, induced by HIV infections or
medication after organ transplants. While an intact immune system
can remove rare neoplastic cells, immunosuppressed and persis-
tently infected patients may harbor a critical mass of cells with
virus-induced decreased immune surveillance, thus making suc-
cessful proliferation and immune escape of cancerous cells possible.
In addition, primary infections that favor survival of altered cells
and promote opportunistic infections may act cooperatively with a
subsequent infection of an oncogenic driver virus, as for example
shown for HIV/KSHV and EBV/KSHV:(17) KSHV probably infects
the whole genus homo; however, the cases of Kaposi’s sarcoma his-
torically had only low incidence rates until the onset of the AIDS
epidemic, after which the number of KSHV-associated cancer cases
in immunosuppressed patients rose by several thousand percent(18)
Oncoviral persistence and latency
Most human pathogens trade off between two strategies of replica-
tion: high rates of reproduction and rapid viremia,(19) or long term
persistence in the host and control of the host immune system.
Viral strategies of replication and persistence While most acute hu-
man pathogens such as Influenza, Noroviruses, and Rhinoviruses
rapidly induce viremia and achieve high replication rates in order
to infect other hosts, viruses establishing persistent infections in
a host population have a higher chance of vertical transmission
and require molecular mechanisms in order to constantly evade
host immune clearance. Bacterial and protozoan organisms as well
as many DNA viruses utilize the large protein repertoire of their
comparatively large and complex genomes in order to achieve con-
tinued immune evasion by exploiting regulatory (e.g. by inhibiting
host factors) or immuno-combinatorial (e.g. by changing surface
receptors) mechanisms.(20) In contrast, RNA viruses such as HCV
and HIV have compact genomes that allow for rapid replication.
In combination with high mutation rates and large viral burst sizes
that rapidly create novel genetic variants, these pathogens are able
to evade immune recognition and establish chronic infections.(21)
Finally, both DNA viruses (EBV) and RNA-viruses (HIV, HTLV-
1) often support lysogenic as well as lytic replication cycles and
may employ episomal(22) and proviral(23) latency mechanisms as
part of the lysogenic cycle. These latency mechanisms, augmented
by epigenetic modifications of the viral genomes, may limit viral
transcription or remove viral genomes from the cytoplasmic context
in order to lessen immune surveillance and allow for long-term (or
even permanent) viral persistence.
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(24) Der et al. (1982), Devare et al. (1983),
Stehelin et al. (1976)
(25) Maeda et al. (2008), Mikkers and Berns
(2003), Moloney (1960), Neel et al. (1981)
(26) Hayward et al. (1981)
(27) Matsuoka and Jeang (2007)
(28) zur Hausen (2009b)
(29) Levine (2009)
(30) Moore and Chang (2003)
Latency-associated mechanisms of oncogenesis In contrast to animal
retroviruses as for example Rous sarcoma virus, Harvey’s murine
sarcoma virus, and simian sarcoma virus that induce cancer by
integrating cellularly derived oncogenes such as src, H-ras, and
sis into the cellular context,(24) transforming retroviruses that lack
cellularly derived oncogenes are typically replication competent
and undergo polyclonal integration into the host genome as part of
the viral life cycle.
Occasionally, proviral integration may occur in or near a cellular
proto-oncogene or tumor suppressor, thus modulating expression
of the cellular factor by the integrated viral promoter and enhancer
elements, presumably even over large distances as a consequence
of chromatin looping.(25) Alternatively, viral integration may oc-
cur within a cellular factor, thus creating an activated fusion tran-
script.(26)
In either case, integration can disrupt the genomic organization
and regulation of the proto-oncogene or tumor suppressor locus,
thus predisposing the host cell to oncogenesis. Such mechanisms
of oncogenic activation that are a direct consequence of proviral
integration are termed cis activation of the cellular oncogene. They
are contrasted with oncogenic mechanisms depending not on the
integration event itself (although integration may be part of the
viral life cycle) but on expressed viral factors that modulate cellular
pathways in a manner similar to viral oncogenes of DNA tumor
viruses. The latter mechanism is termed trans activation and is
predominantly employed by complex retroviruses such as HIV and
HTLV-1.(27)
Oncogenesis is circumstantial. The ability for prolonged persis-
tence, either by active immune evasion, chronic infection, or viral
latency is a critical characteristic of all human tumor viruses as it
provides a necessary precondition for inducing an oncogenic state
in the host cell.(28) Viral persistence may be further enforced by
infections of cell types not permissive to viral replication, cross-
species infections (zoonosis), viral genomic deletions (acutely
transforming retroviruses), and infections of immunocompromised
hosts, all of which may prevent cell lysis and thus successful pro-
duction of new viral particles.
This self-limiting replicative behavior of tumor viruses is one of
the hallmarks of tumor virology and strongly suggests that trans-
formative behavior is not part of the normal viral life cycle. Instead,
inducing malignant transformation is a detrimental biological acci-
dent for tumor viruses, either as a side effect of viral manipulation
of mitogenic and apoptotic pathways aimed at facilitating viral
replication,(29) or as a consequence of long-term proviral, episomal,
or chronic persistence.(30)
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(32) Frenkel and Roizman (1972), Lilley
et al. (2007), Moore and Chang (2003)
(33) McLaughlin-Drubin and Munger
(2008), Si and Robertson (2006)
(34) Duensing et al. (2000), Duensing and
Munger (2002), Elgui de Oliveira (2007),
Gruhne et al. (2009), Hein et al. (2009),
Kamranvar et al. (2007)
(35) Gallagher et al. (2003), Levrero (2006),
Machida et al. (2006)
(36)
; and Staal, F. J. F., Ela, S. W. S., Roed-
erer, M. M., Anderson, M. T. M., Herzen-
berg, L. A. L., and Herzenberg, L. A. L.
(1992). Glutathione deficiency and human
immunodeficiency virus infection. Lancet,
339(8798):909–912
(37) Nabirochkin et al. (1998), Sung et al.
(2012)
(38) Esteller (2008), Jones and Baylin (2002)
Tumor viruses promote oncogenesis by indirect mechanism
In addition to directly oncogenic mechanisms enacted by viral
oncogenes and indirect activation of cellular oncogenic factors by
proviral integration, many tumor viruses also influence the cellular
context, DNA damage response, or epigenetic pathways and thus
predispose the cell to cancer in a more distal manner. The indirect-
ness of these molecular mechanisms combined with the temporal
delay and stochastic nature of oncogenesis results in considerable
uncertainties regarding their characterization. Lytic viral activity is
generally not observed in progressed cancer cells due to changes
in replicative permissiveness or damages to the viral genome.(31)
Instead, viral genomes either continue to latently persist in the
transformed cell, thus further evading immune detection and repli-
cating whenever the cancer cell divides(32) or are fully lost from
progressed tumor cells. The latter event, termed ’hit-and-run’ sig-
nature of viral activity,(33) is conceptually related to virally induced
oncogenesis that does not require continued maintenance of nu-
cleotide signatures in the transformed cell and thus is especially
hard to trace by molecular methods.
DNA damage and genomic instability. Most tumor viruses such
as adenoviruses, EBV, Hepatitis B and C viruses, herpesviruses,
papillomaviruses, HTLV-1, KSHV, and polyomaviruses manipu-
late cellular DNA damage response pathways in a variety of ways
in order to increase replicative capacities, support viral latency, or
protect viral genomes from degradation (reviewed inWeitzman
et al. (2010)). As a side effect, these manipulations may result in
chromosomal instability, aneuploidy, large-scale chromosomal re-
arrangements, and genomic losses that promote oncogenesis.(34)
Additionally, oncogenic viruses such as HBV and HCV that cause
chronic infection implicitly modulate the cellular context by virus-
specific T cells mediated inflammation or chronic immune response,
resulting in mitochondrial damage and DNA double strand breaks
due to production of oxidative chemical agents,(35) for instance as a
result of viral inhibition or metabolic depletion of cellular antioxi-
dants such as glutathione that also exhibit antiviral activity.(36) Last,
retroviruses may induce mobilization of endogenous transposons or
produce genomic breakpoints by polyclonal viral integration, both
of which may also result in chromosomal instabilities.(37)
Epigenetic modifications. In additional to promoting genomic in-
stabilities, virally mediated epigenetic modifications of the viral and
human genomes may also directly promote oncogenesis: several
epigenetic markers such as DNA methylation and acytelation, his-
tone modification, and miRNA signatures are important factors of
oncogenesis.(38) DNA methylation of CpG islands, for instance, is
a common cellular mechanism for regulation of expression and is
employed in genomic imprinting, X-chromosome inactivation, and
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(41) Colot and Rossignol (1999), Doerfler
(1991), Yoder et al. (1997)
(42) Ferrari et al. (2009), Flanagan (2007),
Javier and Butel (2008)
(43) Fernandez et al. (2009), Knipe and
Cliffe (2008), Pantry and Medveczky
(2009), Robertson and Ambinder (1997)
(44) Ferrari et al. (2008), Nyborg et al.
(2010)
(45) Di Bartolo et al. (2008), Shamay et al.
(2006)
(46) Richman et al. (2009)
silencing of foreign genomic elements.(39) As discussed previously,
human tumor viruses frequently establish latent infections and thus
have to evade immune surveillance. DNA methylation has been
proposed as a viral regulatory mechanisms that restricts expression
of viral elements associated with an immune response(40) (see Ta-
ble 10.4 for a list of known and suspected tumor viruses that show
evidence for employing epigenetic regulation).
Epigenetic mechanisms for silencing viral genomes are also
employed by the host cell in order to limit expression of endoge-
nous virus-like elements such as retrotransposons as well as for
constraining proviruses that may negatively impact genomic sta-
bility.(41) Several viruses are able to specifically recruit or inhibit
these cellular epigenetic mechanisms for their own purposes.(42)
Tumor viruses such as HSV1, EBV, KSHV and adenoviruses, for
instance, employ epigenetic mechanisms to regulate expression of
viral latency proteins that are recognized by cytotoxic T cells(43) or
more generally influence histone acetyltransferase activity,(44) while
herpesviruses such as KSHV specifically methylate promoters of
host genes involved in immune surveillance.(45)
As a consequence of these early insights in viral epigenetic
processes, antiviral therapy that nonspecifically removes genome
methylation in order to unmask HIV proviruses in latent reservoirs
has been proposed.(46)
Name Genome Family kbp Methylation Viral oncogenes Known or suspected cancers
EBV dsDNA Herpesviridae 172 Partial LMP1, BZLF1,
EBNA2,
EBNA3, BRLF1
Burkitt’s lymphoma, nasopharyngeal
primary carcinoma, Hodgkin disease,
gastric carcinoma
KSHV dsDNA Herpesviridae 138 Partial LANA, vIRFs Kaposi’s sarcoma, primary effusion
lymphoma, multicentric Castleman’s
disease
HPV dsDNA Papillomaviridae 8 Complete E2, E6, E7 Cancer of cervix, vulva, vagina, penis,
anus, orial cavity, oropharynx, and
tonsil
HBV partial dsDNA Hepadnaviridae 3 Complete HBx hepatocellular carcinoma
HCV ssRNA Flaviviridae 10 None NS4B hepatocellular carcinoma, non-Hodgkin
lymphoma
HTLV-1 ssRNA (RT) Retroviridae 9 Partial Tax adult T-cell leukemia, lymphoma
HIV ssRNA (RT) Retroviridae 9 partial indirect indirect
HCMV dsDNA Herpesviridae 230 partial IE1-72, IE2-86 colorectal cancer, glioma, prostate
SV40 dsDNA Polyomaviridae 5 None T-Ag Osteosarcoma, mesothelioma, brain
JCV dsDNA Polyomaviridae 5 None T-Ag Brain, colorectal, glioma, medulloblas-
toma
BKV dsDNA Polyomaviridae 5 None T-Ag Prostate, brain
MCV dsDNA Polyomaviridae 5 None ? Merkel cell carcinoma
Table 10.4: Known and suspected cancer
viruses. Known and suspected cancer
viruses and their methylation status.
Derived from Fernandez and Esteller
(2010) and Sarid and Gao (2011).
(1) Parkin et al. (2005), zur Hausen (2006)
(2) Parkin (2006)
(3) Butel (2000)
Viral family Oncogenic Model
Adenoviridae potantial yes
Flaviviridae confirmed no
Hepadnaviridae confirmed yes
Herpesviridae confirmed yes
Papillomaviridae confirmed yes
Polyomaviridae confirmed yes
Retroviridae (simple) potential yes
Retroviridae (complex) confirmed yes
Table 11.1: Viral families associated
with oncoviral activity. Viral families
associated with oncoviral activity and
presence of an animal model system
for the association. From Butel
(2000), Javier and Butel (2008)
.
(4) Epstein et al. (1964)
(5) Boccardo and Villa (2007)
11 Epidemiology of tumor viruses
Today, several infectious agents have been identified as either
cause or contributing factor of human cancers. The four major cancer
viruses HBV, HCV, HPV, and EBV alone are causative for approximately
12% all human cancer cases,(1) with an estimated 26% of all cancer cases
in developing countries being caused by an infectious agent.(2) The known
human oncogenic viruses are distributed throughout complex retroviruses,
Flaviviridae, as well as all known DNA viral families, with exception of
Parvoviridae that may have a too limited genomic architecture to influ-
ence the cell cycle.(3) While epidemiology is frequently employed to detect
novel tumor viruses, the stochastic nature of oncogenesis, temporal de-
lays between oncoviral infection and the diagnosis of cancer, as well as the
commonness of many oncoviral infections (such as with HPV and Her-
pesviruses) make establishing a causal relation between cancer incidence
and viruses challenging. This section will discuss the epidemiological
state of known oncogenic viruses as well as problems with establishing
causal relations based on epidemiological data. In this manner this section
sets a stage for the next section that will introduce molecular methods for
discovery of new tumor viruses.
Known and novel human tumor viruses
The concept of tumor viruses received renewed attention in the
1960s when the first human oncogenic agent, Epstein–Barr virus
(EBV), was discovered by electron microscopy (EM) within Burkitt
lymphomas (BL).(4) Since then, the carcinogenic potential of viruses
from the five taxonomic families Herpesviridae, Retroviridae, Hepad-
naviridae, Flaviviridae, and Papillomaviridae is recognized as suffi-
ciently evident by the International Agency for Research in Cancer
(IARC) to designate these viruses as group I carcinogens. In addi-
tion, HIV-2, MCV, and several additional human papillomaviruses
have been classified as possibly (IARC group 2A/B) carcinogenic to
humans and both adenoviruses and simple retroviruses have been
suspected of potential oncogenic activity (see Table 11.1). Infections
by all these viral vectors are accountable for approximately 15% of
all human cancer cases and constitute the second major preventable
cancer risk factor after tobacco use(5) (see Table 11.2 for relative
cancer incidence rates of cancers with known oncoviral cofactors).
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Virus Fractions Number of cases (in thousand)
HPV 3% (Mouth)-100% (Cervix) 6.3 (Oropharynx) - 492.8
(Cervix)
HBV Liver 54% 340
HCV Liver 31% 195
EBV 46% (Hodgkin’s lymphoma)
- 98% (Nasopharyngeal carci-
noma)
6.7 (Burkitt’s lymphoma) - 78.1
(Nasopharyngeal carcinoma)
KSHV Kaposi’s sarcoma 100% 66.2
HTLV Adult T cell
leukaemia/lymphoma 2%
3.3
.
Table 11.2: Prevalence and number of
cases of virally induced cancers.
Prevalence and number of cases of
virally induced cancers. From
Schiller and Lowy (2010)
(6) zur Hausen (2009b)
(7) zur Hausen (2009a,b)
Virus Cancers Reference
JSRV lung cancer Felini et al.
(2012), Sun
et al. (2007)
TTV Colon cancer,
pancreatic can-
cer, liver cancer,
lung cancer,
cervical cancer
zur Hausen
(2012), zur
Hausen and
de Villiers
(2009)
MMTV Breast cancer
JCV Colon cancer,
anal cancer
Table 11.3: Suspected cancer-virus
associations currently being investigated.
Suspected cancer-virus associations
currently being investigated. From
Sarid and Gao (2011)
(8) Callahan (1996)
(9) Etkind et al. (2000), Ford et al. (2004a,b),
Moore et al. (1969), Schlom et al. (1971)
(10) Lawson et al. (2001), Mant and Cason
(2004, 2005), Mant et al. (2004a,b), Stewart
et al. (2000), Szabo et al. (2005)
(11) zur Hausen (2009b)
(12) Gardner et al. (1971), Padgett et al.
(1971), Shah et al. (1973), Weber and
Major (1997)
(13) Eash et al. (2006)
Importantly, the recent detection of several polyomaviruses with
suspected oncogenic potential indicates that there still are human
cancer-causing viruses to be identified.(6) Notably, lung cancers
in never smokers, neuroblastoma, diffuse large B-cell lymphoma,
childhood acute lymphocytic leukemias, as well as some instances
of breast cancer and genital cancers are suggestive of viral cofac-
tors.(7) Additionally, viruses such as the Mouse Mammary Tumor
Virus (MMTV), Polyomaviruses, Adenoviruses, and the Torque-
Teno virus (TTV) are currently being investigated for their potential
of inducing human oncogenesis (see Table 11.3). The following
paragraphs will discuss some of these potentially oncogenic viral
families in more detail.
MMTV. MMTV is a retrovirus that induces breast cancer by
insertional mutagenesis in mice and is often transmitted to the
offspring through breast milk.(8) Viral particles similar to MMTV
identified in high-risk human breast cancer patients were shown to
exhibit reverse transcriptase activity and MMTV sequences could be
identified in over half of breast cancer biopsies according to several
studies.(9) However, the exact identity of the possible MMTV ho-
mologue is still debated and it is presently unclear if it constitutes
evidence for a zoonotic event, a human MMTV homologue, or lab
contamination.(10)
Polyomaviruses. Human polyomaviruses are particular interest
for studies that aim to identify possible new oncogenic cofactors.
It has been suggested that replication-competent polyomaviruses
that procreate at high multiplicities and are transmitted during
consumption of red beef produce replication-incompetent, carcino-
genic variants at a low rates that may be a cofactor of childhood
leukemias and colon cancer.(11) Similar to EBV, the human poly-
omaviruses Jamestown Canyon virus (JCV) and BK virus (BKV)
are very common in humans and may infect up to 90% of the adult
human population, thus constituting a viral commensal.(12) While
infections with polyomaviruses usually remain asymptomatic, both
JCV and BKV contain an oncogenic T (tumor) antigen and have
been associated with triggering disease in immunocompromised
patients,(13) the latter fact being a general indicator for potential
oncogenic activity of viruses. In spite of ongoing research on more
specific associations of these viruses with human tumors, only JCV
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(14) Enam et al. (2002), Imperiale (2001),
Krynska et al. (1999)
(15) Butel and Lednicky (2000), Vilchez and
Butel (2004)
(16) Gazdar et al. (2002)
(17) Rizzo et al. (1999), Shah (2007), Shiva-
purkar et al. (1999)
(18) Berk (2005), Elgui de Oliveira (2007)
(19) Dewannieux et al. (2006), Ruprecht
et al. (2008)
(20) Wang-Johanning et al. (2008)
(21) Contreras-Galindo et al. (2008)
(22) Chen et al. (1991), Grulich et al. (2007)
(23) Beral et al. (1990), Engels et al. (2002),
Schulz (2009), Vajdic and van Leeuwen
(2009), zur Hausen (2012)
(24) Roulston et al. (1999)
could yet be loosely associated with brain and gastric tumors.(14)
A third human polyomavirus, simian virus 40 (SV40), infects
up to 20% of the human population and encodes a known viral
oncogene, the large T antigen that initiates viral DNA synthesis
and inactivates the tumor suppressor proteins p53 and pRb in order
to promote DNA synthesis.(15) Most human tissues are permis-
sive to SV40 replication and undergo lysis, thereby preempting
transformation. An exception is presented by human mesothelial
cells that may be non-permissive to efficient viral replication and
lysis and are therefore prone to virally induced oncogenesis as a
result of chronic, low-level infection.(16) However, while SV40 is
indeed found in many malignant mesothelioma tumors and in-vitro
models, the evidence for the oncogenic activity of the virus is con-
flicting(17) and the role of SV40 as a human carcinogen remains
controversial.
Adenoviruses and HERV-Ks. Human adenoviruses are viral com-
mensals that may cause respiratory illnesses in children as well
as conjunctivitis and gastroenteritis. While these viruses harbor
two known viral oncogenes and are associated with malignant
tumors in rodents, no human cancers are currently known to be
caused by adenoviruses.(18) Notably, also endogenous retroviral
elements of the HERV-K family have characteristics that are sug-
gestive of oncoviral activity. These viruses are still able to code
for complete if non-infectious viral particles that can rendered
infectious by removal of stop-codons.(19) Increased HERV-K expres-
sion was observed in breast cancer,(20) HIV-associated lymphomas,
non-HIV-associated lymphomas, and HIV-associated Hodgkin’s
lymphomas,(21) possibly indicating a role for these viruses in onco-
genesis.
Role of epidemiology in detecting tumor viruses
The search for novel cancer viruses is primarily guided by priori-
tizing relatives to known tumor viruses or cancers with certain epi-
demiological characteristics for detailed investigation. In particular,
cancers that are related to immunosuppression or that are localized
in specific geographic regions as in the case of HBV may point to an
infectious carcinogen.(22) These kinds of investigations have charac-
terized the epidemiological profile of both KSHV and MCV ahead
of the detection of the infectious agent and are currently persued to
identify novel cancer viruses in immunosuppression-related tumors
and cancers related to red meat consumption.(23)
Identification of tumor viruses by means of epidemiology is con-
founded by the fact that interactions between oncoviral and host
factors can result in a variety of outcomes, from no apparent effects
to viral lysis, apoptosis, or cancer.(24) In addition to this stochastic
nature of oncogenesis, several factors significantly hamper the iden-
tification by epidemiological means; among these factors are the
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(25) zur Hausen (2009b)
(26) zur Hausen (2009b)
(27) Bernardin et al. (2010), Willner et al.
(2009)
(28) Sarid et al. (1999), Yasunaga and
Matsuoka (2007)
(29) Nevins and Vogt (1996)
long clinical latency of cancer, low viral replication in progressed
tumors, the ubiquity of infections with viral commensals, the re-
quirement for further mutations in the host and viral genomes,
as well as the influence of other external mutagens that may act
synergistically with infections to cause cancer.(25)
Due to these difficulties, epidemiological insights are primar-
ily used for prioritizing suspected tumor viruses for experimental
research. In this manner, several oncogenic viruses have been iden-
tified by observing epidemiological indicators such as geographic
coincidence of viral infections and specific cancers (HBV), regional
clustering of cancer cases that may suggest an infectious cause
(EBV), dependency on sexual contacts or blood transfusion (HPV,
HCV), or cancers arising under immunosuppression (EBV, KSHV,
HPV).(26)
Viral commensals. The high abundance of viruses in the human
microbiome suggests that, contrary to both the common concept
of viral infections and the focus of medical research on pathogens,
most viruses inhabiting humans are not pathogenic. Indeed, many
viruses initially suspected to be transfusion contaminants such as
Torque Teno virus (TTV) and Hepatitis G virus (HGV) were later
shown to be highly abundant in several human organs and are now
considered to be viral commensals that may provide advantages to
the host by restricting prokaryotic replication.(27) While uncommon
viruses such as KSHV and HTLV-1 are specifically present in a
particular cancer and are thus comparatively simple to identify
as oncogenic cofactors,(28) viral commensals are non-specifically
present in afflicted as well as healthy populations and are therefore
notoriously difficult to causally relate to any disease state.
Stochasticity and clinical latency of oncoviral transformation. As dis-
cussed in previous sections, oncogenic retroviruses are classified
into acutely and non-acutely transforming viruses. Acutely trans-
forming retroviruses contain an oncogene derived from a captured
cellular proto-oncogene, are typically replication defective, and
rapidly induce tumors. Non-acutely transforming retroviruses, on
the other hand, do not encode a cellular-derived oncogene but may
activate cellular proto-oncogenes through insertional mutagene-
sis, inducing tumors with long clinical latency due to the inherent
stochasticity of the integration process. RNA and DNA viruses
that lead to cancer due to chronic infection are also associated with
similarly long clinical latency until cancer onset.
As touched upon earlier in this chapter, the long clinical latency
and the low rate of transformation of virally induced human can-
cers indicate that virally caused oncogenesis in human is not part of
the replication strategy of tumor viruses. Instead, viral oncogenesis
is a consequence of either rare events (such as insertional mutagen-
esis) or long-term exposure to weakly viral oncogenic factors, both
of which result in comparatively slow carcinogenic kinetics.(29)
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(30) Relman (1999a)
(31) "(i) The parasite occurs in every case of the
disease in question and under circumstances
which can account for the pathological
changes and clinical course of the disease.
(ii) The parasite occurs in no other disease as
a fortuitous and non-pathogenic parasite. (iii)
After being fully isolated from the body and
repeatedly grown in pure culture, the parasite
can induce the disease anew.", original in
Rivers (1937), quotation from Fredericks
and Relman (1996)
(32) Kuo et al. (1989)
(33) Moore and Chang (1995)
(34) Amann et al. (1995)
In addition, oncogenesis is a stochastic multi-step process that
requires additional somatic mutations or genomic aberrations for
the cell to transform and evade immune control; while viral infec-
tion may be essential for the first steps of oncogenesis mainly by
providing the cell with growth advantages, immortality, or lessened
immune surveillance, these viral factors are not sufficient for fully
malignant transformation. However, the initial advantages con-
ferred by the tumor viruses may provide the basis for additional
transforming events which cumulatively and auto-catalytically
enhance oncogenesis.
Given the raw number of commensal viruses and the number of
infections they cause in large portions of the population, persistent
viral commensals are interesting candidates for triggering such
low-probability transforming events. Similarly, viruses that arise
in a context of immunosuppression may transform cells that are
not under immune surveillance, thereby increasing the chance
of oncogenesis even at low rates of infection. Indeed, all known
human cancer viruses are either ubiquitous viral commensals or
are targeting immunocompromised subgroups such as patients
suffering from AIDS or having received organ transplants.
Tumor viruses and causal inference. In addition to the ubiquitous-
ness of viral commensals, the stochastic nature of oncogenesis,
and the long clinical latency of cancer, causal reasoning regarding
viral-cancer associations is confounded by three further factors that
generally apply to all pathogens. First, any causal inference pertain-
ing to disease-pathogen relationships is usually based on inductive
reasoning, i.e., generalizations based on particular observables that
might be misleading or incomplete in specific cases. Second, hu-
man diseases often are multi-factorial and include many variables
such as length and type of pathogenic exposure, state of the host
immune system, infected cell type, and particularities of the ge-
netic variation in host and pathogen.(30) The interactions of these
variables are difficult to assess in any scheme of causal reasoning.
Finally, prospective studies based on pathogen exposure are often
impossible due to ethical or practical limitations, thereby hamper-
ing systematic approaches of causal inference (i.e., experimental
testing).
Traditionally, the causal relationship between a pathogen and
a disease is considered proven beyond reasonable doubt by ad-
hering to Koch’s postulates(31). For instance, the causal links be-
tween several viruses and human pathogenic conditions such as
HCV with hepatitis,(32) and HTLV-1 with Kaposi’s sarcoma(33)
have been successfully established using this scheme. More re-
cently, advances in microbiological techniques, the realization that
many pathogens cannot be cultured(34) or may be present at lower
abundances in healthy subjects, and the fact that pathogens may
cause the pathogenic condition after considerable temporal delay
led to several reformulations of Koch’s postulates that emphasize
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(35) Evans (1976), Falkow (1988), Fredericks
and Relman (1996), Hill (1965)
(36) (i) The diseased metagenome is re-
quired to be significantly different from
the metagenome constructed with the
same sample type obtained from a
healthy matched control subject. (ii)
The suspected metagenomic traits must
be present and more abundant in the
diseased subject compared to matched
control. (iii) Inoculating a healthy indi-
vidual with a sample from a diseased
subject must result in disease state. (iv)
Differential metagenomic traits in step
(i) recovered in the newly induced dis-
eased subject may be the biomarker of the
candidate etiological agent. (v) Selective
inoculation of samples from the disease
subject (ii) must induce disease in another
healthy control subject if the metagenomic
contains the trait associated with the etio-
logical agent of the disease, or phenotype
under investigation. Adapted from Mokili
et al. (2012)
(37) Pagano et al. (2004), zur Hausen (2002)
(38) This epidemiological challenge has
been encountered before when smoking
was investigated as a possible risk factor
for lung cancer. Since smoking was
widespread in the population at the time
of the study and lung cancer is commonly
diagnosed well after exposure to smoking,
large cohorts and prospective studies
where required to obtain the necessary
statistical power for proving increased
cancer risk in smokers (Doll and Hill,
1956)
(39) Bexfield and Kellam (2011)
(40) Münz et al. (2009)
(41) Paprotka et al. (2011)
(42) cf. Lipkin (2013); this parallels the well
known mathematical fact that existence
proofs are much easier to provide than
non-existence proofs.
(43) Whose scientific work or names will
not be mentioned here so as to not per-
petuate the ghost of false association and
scientific wrongdoing.
(44) Kao and Chen (2002), Taira et al. (2004)
(45) Moore and Chang (2010)
biomolecular methodology and relaxed criteria for the consistency
of pathogen-disease association.(35) The reformulations presently
culminated in the Metagenomic Koch’s postulates.(36)
Disproving virus-cancer associations. In spite of these reformu-
lations of Koch’s postulates, causally relating tumor viruses to a
cancer remains a task that is both conceptually and methodolog-
ically challenging.(37) The causal relation between infection and
disease state is especially hard to prove in cases where several vi-
ral commensals are infecting the same disease tissue, or the virus
is only a contributing factor for the disease, as it is the case for
many human tumor viruses.(38) Although many novel viruses have
been identified in animals or humans afflicted with a specific dis-
ease, most of these viruses were not causally related to the disease
but constituted viral commensals or chance associations.(39) For
instance, although several viruses were associated with multiple
sclerosis, none of these infections could be conclusively proven to
be causally related to the disease.(40) In a similar manner, XMRV
was long thought to be causative for chronic fatigue syndrome and
some instances of prostrate cancer until this association was shown
to be based on experimental confounds.(41) It is therefore notable
that falsifying spurious and false associations of diseases with spe-
cific pathogens can be significantly more difficult than proving true
associations.(42) This is especially the case in contexts of limited
treatment options where possible viral infections constitute a straw
of hope for patients that they cannot let go of; this may be exempli-
fied by amyotrophic lateral sclerosis that has wrongly been linked
to enteroviruses, or the temporal pattern of age of onset (or diag-
nosis) of autism that coincides with measles, mumps and rubella
(MMR) vaccine administration, events that have been falsely associ-
ated and later economically exploited by certain individuals.(43)
Treatment of oncoviral infections
Global prophylactic vaccination against viral infections such as po-
lio, measles, and smallpox are among the most successful medical
endeavors ever undertaken. Currently, infections of only two hu-
man tumor viruses, HPV and HBV, can effectively be prevented
by vaccination. These vaccinations lead to long-term reductions
in cancer incidents in the immunized populations that constitute
conclusive proof for the oncogenic effect of these viruses.(44)
As discussed previously, virus-mediated oncogenesis is a rare
event and most cancer viruses act as co-carcinogens rather than
deterministically triggering cancer at each infection; indeed, only
KSHV and HPV are now considered to be necessary causes for
Kaposi’s sarcoma and cervical cancer, respectively, while other on-
coviral infections mostly remain asymptomatic and contribute only
slightly to the total cancer risk.(45) In the vast majority of cases,
tumor viruses within cancer cells have neither increased transmis-
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Yarchoan (2003)
sibility nor higher replication fitness than viruses infecting healthy
tissues. Instead, cancer is a ’dead end’ for cancer-causing viruses
that are often replication incompetent due to mutations in their
genomes. As a result of this propensity of tumor viruses against
producing large numbers of new viral particles, long-term viral
persistence is often asymptomatic, i.e., it elicits only transient or
limited immune response and very limited viremia. It is primar-
ily due to this asymptomatic behavior that oncoviral infections are
difficult to diagnose and patients are often clinically presented af-
ter onset of cancer. Also, as a consequence of their resilient nature
and limited interaction with the host, persistent viral infections
are inherently hard to treat with antivirals; consequently, medical
treatment is often limited to preventive measures in susceptible
populations.(46)
Sadly, identifying new cancer viruses does not necessarily lead
to increased prevention of oncoviral infection or to vaccine devel-
opment: in spite of the past successes of HBV vaccination, the de-
velopment of the recently approved HPV vaccines was hindered by
significant political and economical pressures. Due to limited prof-
itability, vaccines against the first known human cancer virus, EBV,
and against the leading cofactor to adult cancer in Africa, KSHV,
are not expected to be developed anytime soon. Since vaccination
is by far the best means to fight infectious diseases and chemo- and
radiation therapies are not available in many regions of the world,
oncogenic viruses will prove to be significant burdens to public
health for years to come at least in low-income nations.

(1) Breitbart et al. (2002)
(2) Angly et al. (2006), Breitbart et al. (2004,
2002), Desnues et al. (2008), Dinsdale et al.
(2008), Rice et al. (2001), Williamson et al.
(2008)
(3) Briese et al. (2009), Finkbeiner et al.
(2008), McMullan et al. (2012), Quan et al.
(2007), Sullivan et al. (2011), Victoria et al.
(2009)
(4) Weber et al. (2002)
(5) Subtractive approaches to sequence-
based pathogen discovery identify and
discard human sequence homologs from
the sequenced data and consider the
remaining transcripts as potential viral
signatures. They stand in contrast to de
novo sequence assembly approaches that
aim to reconstruct whole viral genomes
from overlapping reads
(6) Zhang et al. (2000)
(7) Li and Durbin (2009), Li et al. (2008)
(8) Kostic et al. (2011), Moore et al. (2011)
(9) Hamilton (1999)
12 Tumor viruses and viral
metagenomics
As discussed previously, identification of tumor viruses and their
causal relation to cancers faces several methodological and conceptual dif-
ficulties. This section reviews metagenomics approaches for identification
of these elusive pathogens in deep sequencing data and provides the back-
ground for the last section of this chapter that introduces a novel approach
for detecting signatures of tumor viruses in human cancers.
Pathogen-focused viral metagenomics
At the same time as the first studies on environmental viral metage-
nomics(1) that characterized viral diversity of ecological domains
such as sea water, soil,(2) and a variety of human environments(3)
were carried out, (see earlier sections of this chapter) investiga-
tions of animal and plant metagenomes were undertaken with
the expressed aim to systematically identify known and novel vi-
ral pathogens (see Bexfield and Kellam 2011 or Table 12.1 for an
overview).
One of the first of these sequence-based studies(4) introduced
the subtractive approach(5) to pathogens discovery in human EST
data by aligning sequence fragments to reference entries in pub-
lic databases.(6) Several other subtractive approaches expanded
on this strategy and used suffix-tree (or related Burrows-Wheeler
transform) short-read mapping technologies,(7) or hash-based read
mappers to sequentially align query reads to human and micro-
bial reference sequences in order to detect signatures of known
pathogens.(8)
Assembly-based apporaches. An interesting alternative approach
to sequence-based detection of viral factors employs small inter-
fering RNA (siRNA),(9) a species of host RNA that is used as part
of the host innate immune system to post-transcriptionally silence
genes of intracellular pathogens. Since by virtue of their mode of
molecular action siRNA are highly enriched in sequences homol-
ogous to microbial genomes, the sequencing of siRNA provides a
high signal-to-noise ratio for identifying new viruses. Using either
mapping-based approaches to detect previously known pathogens
or assembly-based approaches to reconstruct novel viruses from the
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sequenced siRNA, studies successfully recovered RNA and DNA
viruses from disease vectors such as mosquito, as well as from
several model organisms, honey bees, and crop plants.(10) Based
on these successes, more detailed investigations of RNA samples
of patient populations with idiopathic syndromes of acute viral
infections(11) as well as of immunosuppressed patients suffering
from AIDS and organ transplants(12) were undertaken, the latter of
which resulted in the identification of a novel human pathogenic
arenavirus. However, the use of siRNA-based approaches requires
specialized sequencing libraries and is thus not amenable to analy-
ses based on general RNA-Seq libraries.
Confounds of oncoviral metagenomics
The search for human tumor viruses poses particular challenges
to sequence-based viral discovery pipelines. As discussed in pre-
vious sections, virological confounds such as latent viral replica-
tion strategies, viral replication incompetence, and loss of viral
genetic material from the cell often result in limited or selective
transcription of oncoviral genomes.(13) Low concentration and ex-
tratumoral location of viral producer cells(14) or selection of growth-
autonomous cells in progressed tumors(15) can significantly dilute
the number of viral transcripts in a sample. Additionally, tran-
scription of human oncogenic factors modulated by viral(16) or
endogenous(17) retroviral promoters as well as ‘hit-and-run‘ mecha-
nisms of viral oncogenesis that imply loss of viral material(18) may
predispose cells to transformation without requiring maintenance
of viral transcripts. Known tumor viruses such as high-risk HPV
strains, EBV, and MCPyV, which selectively transcribe their genome
during viral latency(19) (HPV: E6/7, EBV: EBNA1/2, MCPyV: large
T antigen) and generate low abundances of tens (MCPyV) to hun-
dreds (KSHV, EBV)(20) of transcripts per cell that require especially
sensitive methods of detection.
In addition to virological confounds affecting detection sensitiv-
ity, sequence-based approaches to pathogen detection are also ham-
pered by varying degrees of sequence similarity between sequence
reads and human and viral references sequences. Specifically, viral
oncogenes homologous to human factors and chimeric transcripts
originating from proviral insertion sites may share significant se-
quence similarity with human transcripts,(21) thus making unequiv-
ocal identification of viral factors difficult. In addition, high rates
of viral sequence divergence from 10-5 to 10-8 (dsDNA viruses)
up to 10-4 (ssRNA viruses) substitutions per site and year(22) may
mask true similarities between sequence reads and viral references,
thereby further hindering recognition of known viruses.
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Systematic approaches to oncoviral metagenomics
In the last years, several systematic viral metagenomics studies have
investigated human cancers or cancer-related diseases in order to
detect putative viral cofactors. These systematic approaches are
primarily based on shotgun deep sequencing technologies(23) and
identified several cancer-virus associations. Among the viruses
thus identified are MCPyV, a human polyomavirus, as a cofactor of
Merkel cell carcinoma.(24) In addition, analysis of transcriptomes
of Lymphoproliferative disorders(25) resulted in identification of
EBV, expressed sequence tag (EST) libraries of body cavity-based
lymphoma cells yielded the detection of KSHV fragments,(26) and
comparison of human-derived EST tag sequences with samples
obtained from several human tumors found Human Herpesvirus 6
signatures.(27)
Finally, investigations of several idiopathic human cancers that
were likely to involve a viral cofactor but did not result in iden-
tification of any human pathogens provided important negative
proofs of cancer-virus associations. Among these studies are the
the analysis of cutaneous squamous cell carcinoma and metastatic
melanoma that were based on physiological or epidemiological ev-
idence for a viral cofactor but yielded negative results(28) as well
as high-throughput investigations of thousands of tumors (not in-
cluding human neuroblastoma) from the Cancer Genome Atlas that
involved near a trillion RNA-Seq reads and also did not result in
novel cancer-virus associations.(29)
Currently, the three published pipelines PathSeq, RINS, and
CaPSID(30) undertake to automatically identify known and, to a
limited extend, novel human pathogens in human deep-sequencing
samples.
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Preliminary conclusion
In conclusion, this chapter has presented a novel field of research,
metagenomics, and a class of experimental technologies, deep se-
quencing, the combination of which allows for the first time to
elucidate the complete genomic content of natural habitats. One
of these habitats, the human body, is of particular importance
for identifying a highly elusive type of pathogens: human tumor
viruses. These entities have a unique biology and their manifold
interactions with human factors as well as their potential to explain
the genesis of several types of cancers with unknown etiology make
these entities highly interesting for biomedical research.

(1) Schelhorn et al. (2013)
13 Detecting tumor viruses in human
cancers
As discussed at length in previous sections, detection of tumor
viruses in cancer tissues is challenging, both due to the high amount of
sequencing data, the low expected abundance of tumor viruses within the
data, and the unknown identity of these viruses. This section presents
work that aims to extend the aforementioned approaches to systematic
viral metagenomics by addressing several perceived shortcomings of the
established methods and to achieve best-in-class sensitivity at detection
of divergent viruses and taxonomic annotation while at the same time
improving on processing speed and the detection of human-viral homologs
such as cellularly derived viral oncogenes.
Apart from formatting changes and few stylistic corrections
such as shifting citation marks to the end of sentences for better
readability, the manuscript presented here is identical to the pub-
lished version.(1) It may be mentioned that since publication of the
manuscript, the analysis of neuroblastoma data has been further
extended by the author to more than 200 transcriptome samples
and 30 whole-genome samples. The propositions made within the
manuscript also hold given the new data.
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Introduction
Abstract. In excess of 12% of human cancer incidents have a viral
cofactor. Epidemiological studies of idiopathic human cancers indi-
cate that additional tumor viruses remain to be discovered. Recent
advances in sequencing technology have enabled systematic screen-
ings of human tumor transcriptomes for viral transcripts. However,
technical problems such as low abundances of viral transcripts in
large volumes of sequencing data, viral sequence divergence, and
homology between viral and human factors significantly confound
identification of tumor viruses.
We have developed a novel computational approach for detecting
viral transcripts in human cancers that takes the aforementioned
confounding factors into account and is applicable to a wide vari-
ety of viruses and tumors. We apply the approach to conducting
the first systematic search for viruses in neuroblastoma, the most
common cancer in infancy. The diverse clinical progression of this
disease as well as related epidemiological and virological findings
are highly suggestive of a pathogenic cofactor. However, a viral
etiology of neuroblastoma is currently contested.
We mapped 14 transcriptomes of neuroblastoma as well as
positive and negative controls to the human and all known viral
genomes in order to detect both known and unknown viruses.
Analysis of controls, comparisons with related methods, and sta-
tistical estimates demonstrate the high sensitivity of our approach.
Detailed investigation of putative viral transcripts within neurob-
lastoma samples did not provide evidence for the existence of any
known human viruses. Likewise, de novo assembly and analysis
of chimeric transcripts did not result in expression signatures as-
sociated with novel human pathogens. While confounding factors
such as sample dilution or viral clearance in progressed tumors
may mask viral cofactors in the data, in principle, this is rendered
less likely by the high sensitivity of our approach and the number
of biological replicates analyzed. Therefore, our results suggest that
frequent viral cofactors of metastatic neuroblastoma are unlikely.
Introduction. To date, pathogenic agents are known to be causally
related to 20% of human cancer cases and significantly affect the
global health burden of this disease.(2) The majority of these agents
comprise oncogenic viruses such as human papilloma virus (HPV),
Epstein-Barr virus (EBV), hepatitis B virus (HBV), and hepatitis
C virus (HCV).(3) Characterizing the oncogenic potential of viral
pathogens has important consequences for prevention, diagnosis,
and treatment of malignant neoplasms.(4) Tumor viruses in partic-
ular have received renewed attention in the context of recent global
efforts to characterize the etiology of cancer.(5) Consequently, viral
cofactors for several idiopathic cancers are currently investigated
and epidemiological indicators suggest that additional human tu-
mor viruses remain to be discovered.(6)
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Neuroblastoma is a heterogeneous embryonal tumor(7) that is
accountable for 15% of deaths caused by malignant conditions in
children.(8) The disease is associated with an exceptionally low me-
dian age of presentation of 17 months(9) and is often diagnosed in
utero. Metastatic neuroblastoma has two biologically divergent sub-
types. Stage 4S is characterized by an age of presentation between
in utero and 18 months, metastases confined to liver, skin, lymph
nodes and bone marrow, and its ability to regress spontaneously;
in contrast, stage 4 tumors are presented at any age, demonstrate
high infiltration rates in bone marrow and bone, and are most of-
ten progressive.(10) While genes related to neuronal differentiation
have been described to be upregulated in stage 4S in comparison to
stage 4 neuroblastoma, thereby indicating distinct levels of neuronal
differentiation,(11) little is currently known about the differences be-
tween molecular etiologies of stage 4 and stage 4S neuroblastoma.
The variation of clinical outcomes between neuroblastoma sub-
types indicates distinct genetic and environmental factors affecting
the development of this malignancy. Interestingly, the early onset
of the disease overlaps with periods of high susceptibility to viral
infections and is reminiscent of acute lymphoblastic leukemia – an-
other pediatric tumor with uncertain etiology for which an infective
cofactor has long been suspected.(12) Furthermore, epidemiological
studies have associated reduced neuroblastoma risk with immuno-
logic indicators such as previous childhood infections, day care
attendance, and breast feeding that are suggestive of an infective
cofactor.(13) While transforming polyomaviruses such as JCV and
BKV were previously identified within neuroblastoma samples and
other pediatric embryonal tumors, newer studies seem to render
these associations inconclusive.(14) Therefore, the role of pathogenic
cofactors of neuroblastoma oncogenesis remains unresolved.
In general, the search for suspected viral cofactors of idiopathic
diseases requires systematic screening of human tissues for viral
biomarkers such as virus-derived nucleotide sequences. Unfortu-
nately, viruses are of polyphyletic origin and thus lack common
universal marker genes as they are frequently exploited in metage-
nomics studies targeting cellular microorganisms. Consequently,
it is not currently possible to specifically PCR-amplify viral nu-
cleotide sequences within a given tissue without prior information
about the infective agent being sought.(15) As a result, several sys-
tematic assays for pathogen detection have been developed that do
not rely on targeted PCR-amplification of viral factors(16) and were
employed to identify Kaposi’s sarcoma-associated herpes virus
(KSHV) as a human tumor virus.(17) These systematic approaches
were recently supplemented by sensitive deep sequencing technolo-
gies and applied to exclude several cancer-virus associations based
on negative evidence and aided in the identification of MCPyV, a
human polyomavirus, as a cofactor of Merkel cell carcinoma.(18)
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Deep sequencing technologies have enabled detection of both
known and novel viruses with unprecedented sensitivity.(19) How-
ever, the large numbers of sequence fragments ("reads") generated
by these methods necessitate data reduction approaches for filter-
ing and condensing the list of putative viral transcripts. Two such
approaches are currently represented in the literature: digital tran-
script subtraction that discards human sequence homologs from the
sequence data and considers the remaining transcripts as poten-
tial viral signatures,(20) and de novo sequence assembly that aims to
reconstruct whole viral genomes from overlapping reads.(21) Re-
cently, variants of these of two approaches have been implemented
in several computational pipelines such as PathSeq, RINS, and CaP-
SID.(22)
Identification of tumor viruses in particular poses several impor-
tant challenges to existing computational pipelines. Confounding
factors such as loss of viral genetic material from progressed tu-
mors as well as limited replication competence or latent replication
strategies often result in low or selective transcription of tumor
viruses.(23) In addition, viral oncogenes homologous to human
factors and chimeric transcripts originating from proviral inser-
tion sites may share significant sequence similarity with human
transcripts,(24) thus making unequivocal identification of viral fac-
tors difficult. Finally, high rates of viral sequence divergence from
10-5-10-8 (dsDNA viruses) up to 10-4 (ssRNA viruses) substitutions
per site and year(25) hinder recognition of known viruses based on
known reference sequences.
We have developed Virana, a novel computational approach
specifically tailored to detecting low-abundance transcripts that
diverge from known viral reference sequences or share significant
sequence homology with human factors. In particular, our method
maps sequence reads to a combined reference database comprising
the human genome and all known viral reference sequences. The
approach is configured to allow for high mismatch rates and map-
pings to multiple reference sequences (’multimaps’). By using this
combined and sensitive mapping strategy, our approach is espe-
cially well suited for detecting human-viral chimeric transcripts and
viruses diverging from known references. In contrast to existing
subtractive approaches for viral transcript discovery, our method
abstains from discarding reads homologous to the human genome
from further analysis. Instead, Virana exploits multimaps to as-
sign sequence reads to a homologous context comprising human
reference transcripts and viral reference genomes. These homol-
ogous regions retain the full, unfiltered information contained in
the raw sequence data while also being amenable to further anal-
yses by multiple sequence alignments, human-viral phylogenies,
and orthogonal taxonomic annotations, thus greatly aiding in the
interpretation of the results.
We applied our novel approach on an overall number of 14 deep
sequencing transcriptomes of stage 4 and stage 4S metastatic neu-
roblastoma in order to identify putative viral cofactors associated
with this idiopathic disease.
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Materials and methods
Clinical samples and experimental deep sequencing data. Primary
neuroblastoma samples from stage 4 (progressive) patients (n=7)
and stage 4S (regressive) patients (n=7) were obtained prior to
treatment from the central neuroblastoma tumor bank at the Uni-
versity Hospital of Cologne, Germany. None of the tumors har-
bored amplification of the MYCN proto-oncogene as determined by
two independent laboratories for each case by fluorescence in situ
hybridization (FISH) and Southern blot.(26) Only neuroblastoma
samples with a tumor cell content of above 60% as assessed by a
pathologist were selected for deep sequencing. Integrity of RNA
was evaluated using the Bioanalyzer 2100 (Agilent Technologies)
and only samples with an RNA integrity number of at least 7.5
were considered for further processing. Quality of all neuroblas-
toma samples and related deep sequencing data was additionally
confirmed by an orthogonal computational analysis focusing on
human gene expression in the context of differential splicing.(27)
All patients were enrolled in the German Neuroblastoma trials
with informed consent. In order to validate our approach we ad-
ditionally employed a positive control panel consisting of tumors
with known viral cofactors. An EBV-positive B-cell-lymphoma
(BCL) was received from the Pediatric Oncology and Hematology
Department of the Hannover Medical School. Deep-sequencing
reads obtained from full transcriptome libraries of two HPV18-
positive HeLa samples (HeLa) and a HPV16-positive primary cer-
vical squamous cell carcinoma (ceSCC) were downloaded from
the Short Read Archive (SRA) and preprocessed as specified in
the original publication.(28) Transcriptome data of a HBV-positive
hepatocellular carcinoma (HCC) HKCI-5a cell line with confirmed
HBV integration events was downloaded from the SRA based on
information in the original publication.(29) A negative control panel
consisting of a normal brain transcriptome generated as part of the
Illumina BodyMap 2.0 project was obtained from the SRA at run
accession number ERR030882.
Library preparation and sequencing. mRNA libraries of the EBV-
positive B-cell lymphoma and 14 neuroblastomas were prepared
following the Illumina RNA Sample Preparation Kit and Guide
(Part #1004898 Rev. A). For each sample, 5 µg high-quality total
RNA was processed for mRNA purification, chemical fragmen-
tation, first strand synthesis, second strand synthesis, end repair,
3‘-end adenylation, adapter ligation, and PCR amplification. Vali-
dated libraries underwent gel size selection and final paired-end se-
quencing with an effective read length of 2⇥ 36 bp on the Illumina
Genome Analyzer IIx following Illumina standard protocols. Ad-
ditionally, libraries for two of the 14 neuroblastoma samples were
generated using the same protocols and sequenced with an effective
paired-end read length of 2⇥ 95 bp on an Illumina HiSeq 2000. All
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libraries had insert size distributions approximating µ = 150 bp,
s = 50 bp as later confirmed by read mapping. The data were fil-
tered according to signal purity by the Illumina Realtime Analysis
(RTA) software.
Simulated sequencing data. In this study we employ simulated
sequencing data from three viral genomes that are homologous to
human factors. Reads originating from the ABL1-homologue of the
Abelson murine leukemia virus (A-MuLV, GI:9626953, positions
1326-2605), from the the gag region of HERVK22I (obtained from
Repbase,(30) positions 1-1452), and from Bo17, a GCNT3-homolog
of the bovine herpesvirus 4 (BoHV-4, GI:13095578, positions 107098-
108748) were generated in silico by dwgsim, a read simulator based
on wgsim.(31) In addition, we produced simulated chimeric tran-
scripts by fusing each of the aforementioned sequence regions to
the human TP53 gene, a known proto-oncogene (UCSC build hg19,
GRCh37, chr17, positions 7572926-7579569). These artificial fusion
transcripts were generated using Fusim(32) based on TP53 exon
models obtained from the UCSC refGene database.(33) Fusion tran-
scripts were then used as templates for generating simulated data
sets with dwgsim. In all cases, dwgsim was applied using the de-
fault empirical error model. Paired-end read lengths and insert
size distributions were chosen according to the neuroblastoma se-
quencing data (see above). Additional simulated sequencing data
generated by a related publication were analyzed as described in
Section "Estimation of read mapping sensitivity".
Sample data notation. Sample panels containing neuroblastoma
transcriptomes sequenced at 2⇥ 36 bp and 2⇥ 95 bp effective read
lengths are denoted as NB1 and NB2, respectively. While the NB1
panel contains seven transcriptomes of neuroblastoma stages 4
and 4S each, the NB2 panel contains one sample of stages 4 and
4S each (see Table 13.1). Positive control panels of human cancer
transcriptomes with known viral cofactors (BCL, HeLa, ceSCC, and
HCC) are denoted as POS. The negative control panel consisting of
a normal human brain transcriptome is denoted as NEG.
Reference genomes. The current assembly of the human reference
genome (UCSC build hg19, GRCh37) as well as corresponding ref-
Gene splice-site annotations were obtained from UCSC. Splice vari-
ant annotations and cDNA sequences for the human genome were
downloaded from Ensembl.(34) A set of all 4,680 available complete
viral reference genomes and their taxonomic lineages were obtained
from NCBI via the E-utilities web service(35) and the database
query: "Viruses[Organism] AND srcdb_refseq[PROP] NOT cellular
organisms [ORGN]". In addition, we obtained consensus reference
sequences for all human endogenous retroviruses (HERV-K/HML-
2) represented in Repbase (Primate HERV, HERVK11DI, HERVK11I,
HERVK13I, HERVK22I, HERVK3I, HERVK9I, HERVKC4)).(36) All
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Panel Source Sample ID Read length Depth (Gbp) Read pairs (M)
POS HeLa 15 2⇥ 54 bp 0.076 0.737
POS ceSCC 16 2⇥ 54 bp 0.157 1.527
POS ceSCC 17 2⇥ 54 bp 0.041 0.400
POS BCL 18 2⇥ 36 bp 3.134 43.527
POS HCC 19 2⇥ 100 bp 11.22 55.547
NEG Brain 20 2⇥ 50 bp 7.351 73.513
NB1 4 1 2⇥ 36 bp 1.184 16.439
NB1 4 2 2⇥ 36 bp 0.770 10.695
NB1 4 3 2⇥ 36 bp 0.881 12.236
NB1 4 4 2⇥ 36 bp 0.744 10.345
NB1 4 5 2⇥ 36 bp 1.207 16.759
NB1 4 6 2⇥ 36 bp 1.050 14.581
NB1 4 7 2⇥ 36 bp 0.829 11.527
NB1 4S 8 2⇥ 36 bp 1.031 14.317
NB1 4S 9 2⇥ 36 bp 1.172 16.282
NB1 4S 10 2⇥ 36 bp 0.868 12.065
NB1 4S 11 2⇥ 36 bp 0.890 12.368
NB1 4S 12 2⇥ 36 bp 0.845 11.737
NB1 4S 13 2⇥ 36 bp 1.174 16.300
NB1 4S 14 2⇥ 36 bp 0.847 11.772
NB2 4 7 2⇥ 95 bp 9.284 48.863
NB2 4S 13 2⇥ 95 bp 8.748 46.041
Table 13.1: Sequencing characteristics of
data sets. Sequencing characteristics
of neuroblastoma (NB), positive
control (POS), and negative control
(NEG) panels. Depths are reported in
basepairs (bp).
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reference genomes were combined into a single human-viral refer-
ence database for Virana. Since RINS and CaPSID cannot use such
a combined database, human and viral reference sequences were
collected within two separate databases for these approaches.
Quality control, mapping, and assembly. Paired-end reads from
the neuroblastoma panels and positive control panels were quality-
controlled with an in-house sequence analysis framework in order
to identify sample contamination, adapter contamination, and batch
effects. After quality control, the sequence data consisted of 13.494
Gbp (NB1), 18.032 Gbp (NB2), 14.63 Gbp (POS), and 7.351 Gbp
(NEG) of sequence reads, respectively (see Table 13.1).
All data were mapped against a combined human-viral refer-
ence database with the splicing-aware and gapped read mapper
STAR(37) in paired-end mode. While Virana considers the read
mapper to be a replaceable component, in principle, we decided to
employ STAR due to its mapping speed, high sensitivity settings,
and its consideration of putative chimeric transcripts. We config-
ured the mapper for high sensitivity by following recommendations
of the author of STAR (personal communication). In particular,
we set the rate of acceptable mismatches to 0.3 times the length of
each read and the seedSearchStartLmax and winAnchorMultimapN-
max parameters to 12 and 50, respectively. The minimum length
of chimeric segments (chimSegmentMin) was reduced to 15 in or-
der to detect fusion transcripts at short read lengths. Known splice
sites from splice annotations of the human reference genome as
well as canonical splice sites were considered in the mapping. For
each read, multiple mapping locations with alignment score dis-
tances of up to 10 ranks relative to the best score were permitted
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(’multimaps’). Read alignments were stored in standardized BAM
files. STAR supports detection of chimeric transcripts by reporting
discordant read pairs whose ends map to different chromosomes.
These discordant read pairs were employed in further analyses as
detailed in the next section.
In order to identify putative new viral transcripts, read pairs
with at least one unmapped read end were extracted from BAM
files by the Samtools suite(38) and assembled into longer contigs by
the de novo transcriptome assemblers Trinity and Oases(39) using
default parameters. Oases was configured for using different k-mer
values in order to facilitate reconstruction of low-abundance viral
transcripts. Contigs of length less than 300 bp were considered to
be spurious assemblies and excluded from further processing.
Detection of chimeric transcripts. Virana supports detection of
human-viral chimeric transcripts in two different manners. First,
the read mapper employed in our study is able to partially align
reads that contain a human-viral chimeric breakpoint to multiple
reference sequences. Consequently, these partially aligned reads
can be detected by Virana within the generic analysis of homolo-
gous regions (see below). The second, more sensitive approach to
detecting chimeric transcripts is based on paired-end read informa-
tion. Since the STAR mapper assigns reads to a combined reference
database comprising both human and viral reference sequences,
ends of paired-end reads whose inserts span the breakpoint of a
chimeric transcript will be aligned to different reference sequences.
These discordant read pairs are reported by STAR during read
mapping (see above) and can further be filtered by mismatch score
or sequence complexity in order to yield a high-confidence list of
chimeric transcripts.
Generation of homologous regions. A distinguishing feature of Vi-
rana is its ability to automatically reconstruct the homologous con-
text of reads that map to both viral and human reference sequences.
This homologous context is constructed in four steps:
(1) First, reads that map to at least one viral reference are ex-
tracted from the mapping together with their primary (highest
alignment score) and secondary (up to ten ranks of alignment
scores below the highest score) mapping positions (see Figure 13.1).
Since viruses of the same taxonomic family often exhibit significant
sequence similarity, reads that map to one family member often
also map to related family members as well as to homologous loci
in the human reference. Based on these primary and secondary
mapping locations, Virana obtains overlapping human reference
transcripts, viral genomic references, and viral taxonomic informa-
tion pertaining to the location. For each sequence read, information
obtained in this manner is collected in a data structure denoted as
HIT. HITs originating from the same analysis panel are pooled for
further analysis.
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(2) Second, pooled HITs originating from the same analysis panel
are assigned to viral taxonomic families based on the viral genomic
references they refer to. Sets of HITs assigned to the same viral
taxonomic family are denoted as the homologous group (HOG) of
that family. The same HIT may, in principle, be assigned to several
HOGs.
(3) Third, since reads and references generally share local rather
than global sequence similarity, sequences in HOGs cannot con-
veniently be aligned in a multiple sequence alignment. This cir-
cumstance considerably complicates interpretation of homologous
relationships between multiple reads and references. Virana there-
fore applies a three-step greedy clustering approach to split HOGs
into manageable and alignable clusters denoted as homologous
regions.
(3a) The set of all reads within a HOG is re-aligned to the set
of all references (human reference transcripts and viral reference
genomes) within the HOG using a highly sensitive BLASTN(40)
alignment (word size 7). Since all possible mapping locations are
required for further processing, BLAST is configured for high per-
missiveness (E-value 10).
(3b) Each HIT is assigned to a singleton cluster. Clusters con-
taining reads that map to the same reference are merged if their
reference mapping locations (as determined by BLASTN) are less
or equal than L=25 basepairs apart (L-gaps). Optimal values for
L are determined empirically, see Section "Estimation of required
sequencing coverage for detection of a homologous region" for a
robustness analysis. Merging continues until the number of clusters
converges. Subsequently, all clusters with fewer than an empiri-
cally chosen cutoff of t=5 reads are discarded in order to remove
spurious hits. After filtering, each remaining cluster represents
a candidate HOR. Since cluster membership is defined by reads
mapping to common references, each pair of references within the
candidate HOR shares one or more regions of high local sequence
similarity (e.g., the loci the read mapped to) connected by L-gaps.
(3c) For each HOR, parts of reference sequences that are neither
covered by a read mapping location nor by an L-gap between read
mapping locations are trimmed.
(4) Last, due to the high mutual similarity of sequences within
trimmed HORs, sequences within each HOR are now amenable to
sequence alignment against the longest reference sequence within
that HOR using LASTZ, the successor of BLASTZ.(41) The resulting
star-shaped multiple sequence alignment is then used for construc-
tion of per-sample (for reads) and per-gene (for human reference
transcripts) consensus sequences. Aligned consensus sequences
retain information on non-consensus nucleotides due to the usage
of IUPAC ambiguous nucleotide codes. Consensus sequences can
then be manually inspected in order to determine single nucleotide
permutations and indels up to length L that distinguish sequence
reads, viral references, and human reference transcripts.
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Consensus sequences can be further processed by phylogenetic
analyses. For generating phylogenies, Virana employs the software
PhyML(42) following the maximum likelihood approach and using
default parameters recommended by the HIV sequence database
(http://hiv.lanl.gov, GTR model of nucleotide substitution, tran-
sition/transversion ratio: 4, gamma shape parameter: 1, number
of substation rate categories: 4, approximate Likelihood Ratio Test
(aLRT) using SH-like supports where applicable). We note that the
topology of the phylogenetic trees constructed in this manner is
stable with regard to the model choice; while more complex model
parameters may yield better likelihoods in some instances, these
differences do not influence interpretation of our results.
Taxonomic annotation. In this study, we additionally compare
consensus sequences of aligned HOGs as well as de novo assem-
bled sequence contigs to nucleotide (NCBI NT) and protein (NCBI
NR) reference archives in order to assign transcripts to a taxonomic
origin. To this end, we employ several BLAST(43) search strategies
(BLASTN, BLASTX, and TBLASTX) with sensitive word sizes (4,
3, and 3, respectively). TBLASTX bypasses synonymous mutations
during similarity search and is particularly suited for detecting
functionally conserved homologs. This approach is therefore rec-
ommended for discovering remote similarities(44) and is widely
used in environmental metagenomics.(45) A permissive E-value
threshold of 0.1 is used for all comparisons in order to reduce the
possibility of missing true viral hits. For each query transcript
and search strategy, the three highest-scoring reference sequences
are extracted from the BLAST results. Subsequently, descriptions,
taxonomic information, and available gene annotations for high-
scoring reference hits are pooled and query transcripts are assigned
a putative viral, human, or ambiguous origin based on the pooled
information. In order to limit the search space of the computa-
tionally intensive TBLASTX procedure, we constrain the allowed
taxonomic origin of reference sequences to only viral (NCBI taxon
ID 10239) or human (NCBI taxon ID 9606) hits while excluding ar-
tificial sequences (NCBI taxon ID 81077) using the NCBI database
query "(((txid10239 [ORGN]) OR (txid9606 [ORGN]) OR (human
[ORGN])) NOT (txid81077 [ORGN]))".
Estimation of read mapping sensitivity. We quantify the ability of
our novel method Virana and the related methods RINS(46) and
CaPSID(47) at detecting diverged viral transcripts among human
sequence data by employing a recently published validation data
set.(48) This data set consists of a negative control background set
of reads simulated from the human reference genome that is spiked
with four sets of 10,000 reads simulated from 10 viral reference
genomes. Nucleotide positions within reads of each of the four
viral spike-in data sets are mutated randomly independently and
uniformly with a set-specific probability q 2 {0, 0.05, 0.1, 0.25} be-
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fore being merged with the background data set. The set of viral
reference sequences represents 10 different viral families that infect
plants (Cherry green ring mottle virus, Cestrum yellow leaf curling
virus, Elm mottle virus, East African cassava mosaic virus), birds
(Gallid herpesvirus 1), insects (Cotesia congregata bracovirus), bac-
teria (Guinea pig Chlamydia phage), amphibians (Frog adenovirus
1), and mammals (Rat coronavirus Parker, Banna virus).
All five data sets (non-spiked human negative control and four
human-viral spike-in sets) are analyzed by Virana, RINS, and CaP-
SID using identical reference sequences as described in Section
"Reference genomes". Sensitivity (fraction of correctly identified
viral reads among all viral reads) and specificity (1 - fraction of
falsely identified human reads among all human reads) of viral
read detection are determined for each method and data set. Anal-
yses are performed with either default parameters (Virana), pa-
rameters published in the original validation data set (CaPSID),
or settings adapted by us in order to maximize sensitivity (RINS:
minimal contig length decreased to 100, read lengths and insert size
distributions according to input data).
Since all methods map to the same complete viral reference set,
reads from a particular viral genome of the validation data set may
be distributed across several closely related reference genomes, all
of which may be considered valid mappings. For this reason, we
added post-processing steps to CaPSID and RINS and performed
this validation on the level of viral taxonomic families rather than
on the level of single viral species. We note, however, that results
of all tested methods including Virana retain information on sin-
gle viral species throughout the analysis. In particular, sensitivity
and specificity of the methods change only minimally if data is
analyzed on the single species level.
Analysis of human-viral homologous and chimeric transcripts. Analy-
sis of the human-viral homologous regions and chimeric transcripts
based on simulated read data (see Section "Simulated sequencing
data") was conducted by configuring CaPSID, RINS, and Virana
analogous to the previous section. For the validation of fusion tran-
script detection, the number of true positives is set to the number
of all reads originating from the human-viral fusion transcript.
Since all detection methods in this validation are configured to
only report reads mapping to the viral part of the fusion transcript,
sensitivity estimates are scaled down equally for all methods in
this particular validation. Analysis of discordant read ends in or-
der to detect the origins of chimeric transcripts was performed as
described before (see Section "Detection of chimeric transcripts").
Estimation of required sequencing depth. Expanding on related
work,(49) we quantify the theoretical sensitivity of Virana by esti-
mating the number of viral transcripts per cell that are required
for achieving a certain minimal sequencing coverage at a probabil-
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ity of at least 95%. Based on human genome annotations obtained
from UCSC, we determined an average length of human coding
sequences (CDS) of l = 1,634 bp. By conservatively assuming that
an idealized cell contains 200,000 mRNAs(50) of average length l
fragmented at f = 500 bp as a result of library preparation, an ex-
pected number of m = 653,600 cDNA fragments are generated per
cell. For a given viral transcript of length r and a viral transcript
abundance x per cell, we expect a number of v = x r/ f viral tran-
script fragments. Assuming a theoretical, unbiased sequencing
process, the probability of sequencing a viral transcript fragment
among the overall m transcript fragments is pviral = v/m. Given a
single-end read length of j, a number k = rc/(2j) reads are required
to achieve a sequence coverage c of that viral transcript. The prob-
ability pkviral of observing at least k reads during sequencing with a
sequencing depth n is specified by the cumulative binomial distri-
bution function with parameters k, n and pviral . Due to numerical
instabilities of computing the cumulative binomial distribution for
large values n, we exploit the Central Limit Theorem and estimate
pviral by the Camp-Paulson normal approximation to the binomial
distribution. This approach has a negligible approximation error of
< 0.007/pn pviral q, where q = 1  pviral .(51)
Our approach further depends on successfully reconstructed
homologous regions, each requiring an empirically determined
minimum number of t = 5 transcripts separated by no more than
L = 25 base pairs. Although the probability pregion of a homolo-
gous region being successfully constructed from viral transcripts
at a given sequence coverage can be derived analytically for a spe-
cial case,(52) this solution neither considers edge effects occurring
for small transcripts nor takes into account the distribution of in-
sert sizes of paired-end reads. We therefore approach the problem
empirically by in silico simulation of paired-end reads that are as-
signed randomly independently and uniformly to transcripts of
different lengths and at varying coverages. This simulation process
addresses the aforementioned confounding factors by consider-
ing transcript boundaries and sampling insert sizes from a normal
distribution parametrized according to neuroblastoma sequence
data employed in this study (see Section "Library preparation and
sequencing"). A mean estimator for pregion and its standard error
SEpregion were derived by averaging the success rates of homologous
region constructions across 1,000 simulations for each transcript
length, read length, region linkage, and read coverage.
Availability. All sequence data generated in this study are
publicly available in the European Nucleotide Archive (ENA) at
study accession number PRJEB4441. Software implementations
of our method and all validation procedures are available from
http://mpii.de/~sven/virana and/or from the authors upon re-
quest.
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Results and discussion
This study presents a novel approach to detecting viral transcripts
in human tumor transcriptomes. In contrast to related approaches
such as RINS and CaPSID that rely on subtracting reads homol-
ogous to human transcripts from the analysis, our novel method
Virana assigns sequence reads to a combined human-viral reference
database without discarding homology information (see Figure
13.1). By employing a particularly fast and sensitive read map-
per, Virana gains sensitivity at discovering highly divergent and
chimeric viral transcripts. In addition, this configuration allows for
exploitation of multimaps (e.g., sequence reads mapping to several
reference genomes with varying mismatch rates) to discover the
homologous context of sequence reads with regard to viral and hu-
man reference sequences. Last, Virana employs chimeric alignments
as well as de novo assembly of unmapped sequence reads followed
by taxonomic annotation in order to discover proviral integration
events and novel viruses, respectively.
Detection of divergent viruses. In order to compare Virana and
the two subtractive approaches CaPSID and RINS in a controlled
environment we rely on a previously published simulated data set
consisting of a negative control data set free of viral reads, here
denoted as background set. The background set is used to con-
struct four additional validation data sets spiked with viral reads
at increasing rates of sequence divergence (0%, 5%, 10%, 25%, see
Materials and Methods). Performance is quantified in terms of sen-
sitivity and specificity (see Materials and Methods). Applying all
three viral detection methods on the validation data sets reveals
comparatively high rates of correctly detected viral reads for CaP-
SID and RINS at low sequence divergences between 0% and 5%.
Specifically, the two subtractive methods achieve 0.99-1.13 fold
higher sensitivities compared to Virana (sensitivities of 0.835-1.0
versus 0.844-0.882 for subtractive approaches and Virana, respec-
tively, see Figure 13.2). In contrast, Virana substantially surpasses
subtractive approaches at higher rates of viral sequence divergence
(10-25%), offering comparatively stable sensitivities up to 7-fold and
182-fold higher than Capsid and RINS, respectively (sensitivities
of 0.0008-0.6578 versus 0.1456-0.7880 for subtractive approaches
and Virana, respectively, see Figure 13.2, left panel). Notably, while
subtractive approaches fail to identify 20-90% of viruses in set-
tings of high sequence divergence, Virana is the only approach
able to reliably detect the full set of viruses in all validation sce-
narios (see Figure 13.2, right panel). As a result of Virana’s ability
to detect human-viral transcript homologs, reads originating from
several human endogenous retroviruses (HERVs) that are part of
the human reference genome but technically also belong to the viral
family Retroviridae are detected in validation data at all levels of
sequence divergence. Since the detected HERV reads originate from
the human rather than from the viral part of the validation data,
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Reads not mappable to any reference are
extracted, assembled de-novo and
taxonomically annotated.
Read pairs are mapped to a combined
set of human and viral reference genomes.
Read pairs whose ends map to different
references and unmapped reads are extracted
for further processing (see above).
The mapping process allows for primary and
secondary (multimaps) mapping locations.
Reads may map to more than one reference.
In these cases, mapping patterns contain information 
about human-viral homologous sequence regions.
If a read maps to at least one viral reference, it is 
transformed into a HIT that is further enriched with 
with viral reference sequences and human cDNAs 
overlapping the mapping location.
All HITs mapping to viral reference sequences of the 
same viral taxonomic family are grouped into a 
common Homologous group (HOG). HITs originating 
from different samples of the same analysis panel 
are pooled to amplify weak viral signals.
HITs within a HOG that share a viral reference 
sequence and have mapping positions that are at 
most L basepairs distant are merged into a 
common Homologous Region (HOR). HORs within 
each HOG are repeatedly merged until no mergable 
pairs of HORs remain. 
Parts of reference sequences within each HOR that 
are neither covered by reads nor part of a L-gap 
are trimmed, resulting in high local sequence 
similarity of all sequences in the HOR. Reads and 
trimmed reference sequences of each HOR are 
aligned in a multiple sequence alignment.
Aligned sequence within each HOR that originate 
from the same sample or the same human cDNA or 
viral genome are summarized into a consensus 
sequence. Aligned consensus sequences are 
taxonomically annotated with BLAST and further 
analyzed within phylogenetic trees.
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Figure 13.1: Virana’s approach to
identifying viral transcripts in human
tumors. a) Transcriptome sequence
samples are first mapped to a
combined set of human and viral
reference sequences in a
splicing-aware fashion. b) Unmapped
or discordantly mapped read pairs
are further processed by assembly
methods to detect novel viruses or
transcript chimeras that may indicate
proviral integration events. c) Reads
mapping to one or more viral
genomes (HITs) are analyzed in an
integrated fashion by considering
human homologous mapping
locations and viral taxonomies. This
process results in a number of
homologous regions (HOR) for each
viral family. HORs are represented as
multiple sequence alignments
incorporating a wealth of sequence
information. Alignments are further
enriched by taxonomic annotations
and phylogenetic analyses.
these reads classified as false positive (FP) hits for the purpose of
this validation. As a result of this artifact, Virana exhibits a slightly
lowered specificity compared to subtractive approaches (0.99985
versus 1.0 for Virana and CaPSID/RINS, respectively). However,
we note that HERV reads are correctly classified by Virana during
homologous region construction and by optional BLAST-based
taxonomic annotation. These reads can therefore be safely and au-
tomatically ignored in subsequent analyses if HERV expression is of
no interest to the researcher.
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In spite of the involved construction process of homologous re-
gions, Virana is fastest among the three viral detection approaches,
requiring only about half an hour per sample analyzed. In con-
trast, RINS and CaPSID require two to 17 times longer per sample,
respectively (see Figure 13.3). Interestingly, the majority of time
spend by CaPSID is lost on subtraction, indicating that this step is
a limiting factor of subtractive approaches. We note than reported
times are based on analyses using a single compute core. Since all
evaluated methods benefit from multithreading, dedicating addi-
tional compute cores to the analysis allows for further reduction in
processing time.
 	

        



















 
















! 
"#
$# "







%

&

'


! 
"#
$# "
! 
"#
$# "
! 
"#
$# "
! 
"#
$# "
(
((
)
*
(((
+
,
()
,
)
(
+
,
()
)

-


-%


-




.


$%%
.%%
Figure 13.3: Time required for data
analysis. Cumulative time in minutes
required for analysis of the
divergence validation set. Times are
reported for the negative control
without viral spike-ins as well as for
four mixed data sets consisting of
negative control background set with
viral spike-ins at different divergence
rates. Segments within bar plots
represent different analysis processes
employed by the three viral detection
methods Virana, CaPSID, and RINS.
All measurements are based on a
single CPU Intel(R) Xeon(R) E5-4640
clocked at 2.40 GHz.
Detection of low-coverage, homologous, and chimeric viral transcripts.
Having established Virana’s ability to detect reads sampled at
comparatively high coverage from viral genomes with low or no
human-viral sequence similarity, we next test the sensitivity of the
viral detection methods in a more challenging scenario involving
gene regions of animal viruses that have close human homologs
and are sampled at low sequencing coverages. Three such human-
viral homologs are used in the analysis: V-ABL of the acutely
transforming retrovirus A-MuLV, Bo17 of herpesvirus BoHV-4 (a
model virus for oncogenic gammaherpesviruses such as EBV and
KSHV and implied in several animal cancers)(53) and gag of HERV-
K(HML2)22I, a class of human endogenous retroviruses associated
with some forms of breast cancer).(54) Validation is based on sim-
ulated sequencing data and split into two scenarios (see Materials
and Methods for details). Within the first scenario, simulated se-
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quencing reads are sampled directly from human-viral homologs
while in the second scenario reads are generated from artificial fu-
sion transcripts that each involve one of the three homologs fused
to the human TP53 proto-oncogene. The resulting human-viral fu-
sion transcripts mimic transcriptional signals indicating retroviral
integration or homologous recombination of viral DNA next to a
human gene which may result in activation of the latter by inser-
tional mutagenesis.
We apply the viral detection methods Virana, CaPSID, and RINS
on these two validation data sets in order to evaluate sensitivity at
detecting viral genes that are similar to human factors either due
to natural sequence homology or due to gene fusions. Performance
is quantified by detection sensitivity, specificity, as well as by the
absolute number of reads correctly detected. While all methods
performed at a perfect specificity of 1.0, only Virana detects viral
transcripts at all coverages and with two to three-fold higher sensi-
tivities compared to competing methods (Figure 13.4). In particular,
sequence reads originating from endogenous retroviruses were al-
most always subtracted from the analysis by RINS and CaPSID.
In addition, RINS seemed to be confounded by low sequencing
coverage, a fact most probably resulting from its heavy reliance on
de novo transcript assembly. Subsequent analysis of discordantly
mapped read pairs by Virana (see Materials and Methods) correctly
identified the TP53 gene as fusion partner of both V-ABL and Bo17,
indicating that detection of human-viral chimeras is reliable even
at low twofold coverage. Due to the repeat nature of the HERV-K
sequence in the human genome and the resulting re-occurrence of
HERV-K homologs at multiple loci in the human reference it was
not possible to unambiguously identify the fusion partner of the
HERV-K gag gene.
Estimation of optimal sequencing depth. Due to a variety of fac-
tors (see Discussion) human tumor viruses often replicate at very
low levels within the infected cell. Determining the required se-
quencing depth for detecting viral transcripts present at specific
cellular abundances is therefore crucial for planning transcrip-
tome experiments designed to identify tumor viruses. Based on
statistical arguments and average mRNA sizes (see Materials and
Methods), we inferred the minimal abundances of viral transcripts
required in an average cell required for detection depending (1) on
the length of the transcript being sought and (2) on the sequencing
depth employed in the experiment. Here we report results for an
average viral cDNA-transcript (795 bp), an average viral transcript
region analyzed in the validation of human-viral homologs (Bo17
and vABL, 1, 465 bp, see previous section), an average length hu-
man CDS (1, 634 bp), and the genome size of a small tumor virus
(A-MuLV, 5, 896 bp). Based on these estimates and given an av-
erage sequencing depth as employed in the NB1 analysis panel,
Virana requires a minimum twofold sequence coverage of an aver-
114 from basic research to clinical applications
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Figure 13.4: Detection of low-coverage,
homologous, and chimeric viral
transcripts. Displayed are
performances of Virana, CaPSID, and
RINS at detecting the three
human-viral homologous gene
regions Bo17, gag, and vABL.
Performance is quantified in terms of
sensitivity (right panel) and absolute
number of reads correctly identified
(left panel) at differing sequencing
coverages (2-60 fold). Methods are
validated at detecting both isolated
gene regions (upper part) as well as
at detecting human-viral fusion
transcripts involving each of the
three gene regions fused to the
human TP53 proto-oncogene (lower
part). Specificity of detection is 1.0
(100%) for all detection methods (not
displayed).
age viral cDNA transcript in order to detect the transcript within a
homologous region with 99.9% probability (Figure 13.5, upper left
quadrant, dashed blue vertical line). This sequence coverage is pro-
duced with 95% probability if at least one viral transcript is present
per cell, on average (Figure 13.6, upper left quadrant, dashed blue
vertical line). The number of viral transcripts per cell required for
detection is inversely related to transcript length and sequencing
depth, in principle: at a transcript length corresponding to a small
viral genome (5, 896 bp) and a per-sample sequencing depth of 1%
of the sequencing depth generated in the NB1 panel, a transcript
coverage of 0.6 and at least 55 viral transcripts per cell are required
for reliable detection (Figure 13.6, upper right panel, dotted black
vertical line).
Analysis of positive and negative experimental controls. In order to
evaluate Virana on experimental data we conducted an analysis of
several positive and negative control samples with a cumulative
size of 21.982 Gbp. The negative control sequencing data originates
from a normal brain transcriptome that is suitable as a control for
neuroblastoma data. Positive controls span a range of cancer tran-
scriptomes that are associated with several viral cofactors such as a
hepatocellular carcinoma (HCC) cell line with proviral integration
detecting tumor viruses in human cancers 115
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Figure 13.6: Estimation of required cellular transcript abundances for achieving a given transcript coverage. Sequencing coverage of viral transcripts is depending on the average
number of transcript copies per cell in the sequenced sample, on the length of the viral transcript being sought, and on characteristics of the sequencing process. In order
to better visualize the optimal sequencing depth required for detection of viral factors, we estimated the required number of transcript copies per cell for different
sequencing depths. These sequencing depths are expressed as factors relative to the depths employed for the NB1/NB2 panel generated in this study (which are here
reported as a relative sequencing depth of = 1).
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(55) http://res.illumina.com/documents/
products/technotes/technote_
phixcontrolv3.pdf
(56) Li et al. (2013)
of Hepatitis B virus, a cervical squamous cell carcinoma (ceSCC)
and two HeLa cell line samples with associated human papillo-
mavirus (HPV), and an Ebstein-Barr virus (EBV) positive B-cell
lymphoma (BCL).
As displayed in Figure 13.7 (upper part), analysis of the brain
negative control sample demonstrates that viral transcription is
ubiquitous even in normal (non-cancerous) samples. Specifically,
several bacteriophages of the taxonomic families Microvirodae, My-
oviridae, Podoviridae, and Siphovoridae indicate sample contamination
with bacteria as well as technical spike-ins.(55) Remarkably, the Col-
iphage phi-X174 genome of the family Microvirodae could be fully
assembled by Virana’s homologous region construction, yielding a
single fragment of 99% sequence identity and 100% coverage com-
pared to the phi-x174 reference genome. In addition, several retro-
viral and flaviviral hits at low abundances of 1-28 reads per million
reads mapped (RPMM) highlight human factors such as HERV-Ks
(endogenous retroviruses) as well as human proto-oncogenes SRC
/ABL and DNAJC14/RP11 that have close homologs in the viral
families Retroviridae and Flaviviridae, respectively. The taxonomic
ambiguity of these regions is automatically identified during Vi-
rana’s homologous region construction and confirmed by optional
BLAST-based annotation compared to NCBI nt and nr databases (as
indicated by thinner bars in Figure 13.7).
Analysis of positive control samples resulted in 41 homologous
regions (HORs)spanning five viral families (see Figure 13.7, lower
part). Viral cofactors associated with each of the cancer samples are
correctly recovered at a high dynamic range of read abundances
between 3 RPMM (HCC with integrated HBV provirus) and 1,628
RPMM (HeLa cell line associated with HPV18). In addition, several
viral fragments were successfully reconstructed within HORs of
the positive control samples, such as a 9,550 bp long EBV segment
containing latency-associated factors EBNA 3b, 3c, and 4a (80% se-
quence identity with the wild type genome) as well as a 1,693 bp
long HBV fragment containing the oncogenic HBV-X gene (98%
sequence identity compared with Hepatitis B virus isolate HK1476).
Similar to results on the negative control brain sample, several
HORs with lower abundances assigned to the taxonomic fami-
lies Retroviridae and Flaviviridae represent human-viral sequence
homologies that are automatically flagged to be of ambiguous taxo-
nomic status by Virana.
Interestingly, the HCC sample was also investigated in recent
work focusing on detecting viral integration events.(56) In this re-
cent study, the authors confirmed one integration event by Sanger
sequencing while alluding to two additional events still awaiting
experimental validation. By analyzing discordantly mapped read
ends, Virana could correctly identify all three HBV fusion events
involving human genes TRRAP (11 read pairs), ZNF48 (11 read
pairs), and PLB1 (6 read pairs) as part of the primary mapping
procedure.
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Panel Source ID Pairs mapped Both ends Uniquely Depth (Gbp)
POS HeLa 15 94.900% 94.900% 68.422% 0.127
POS ceSCC 16 90.803% 90.803% 69.561% 0.264
POS ceSCC 17 96.629% 96.629% 73.921% 0.075
POS BCL 18 91.612% 91.612% 63.528% 6.424
POS HCC 19 94.693% 94.693% 73.500% 14.924
NEG Brain 20 95.481% 95.481% 72.515% 11.234
NB1 4 1 95.878% 95.878% 69.422% 2.275
NB1 4 2 96.062% 96.062% 74.342% 1.43
NB1 4 3 96.385% 96.385% 75.938% 1.641
NB1 4 4 95.749% 95.749% 71.012% 1.503
NB1 4 5 95.057% 95.057% 69.203% 2.652
NB1 4 6 94.819% 94.819% 69.856% 2.39
NB1 4 7 96.597% 96.597% 72.107% 1.635
NB1 4S 8 95.952% 95.952% 70.681% 2.093
NB1 4S 9 95.242% 95.242% 74.009% 2.223
NB1 4S 10 96.854% 96.854% 74.756% 1.651
NB1 4S 11 96.819% 96.819% 75.256% 1.668
NB1 4S 12 96.710% 96.710% 74.899% 1.539
NB1 4S 13 95.344% 95.344% 72.326% 2.35
NB1 4S 14 97.110% 97.110% 74.829% 1.65
NB2 4 7 86.225% 86.225% 69.552% 12.243
NB2 4S 13 86.280% 86.280% 72.538% 11.517
Table 13.2: Mapping rates. Mapping
ratios and depths of neuroblastoma
(NB), positive control (POS), and
negative control (NEG) panels.
Mapped reads are relative to the
number of sequenced read pairs that
have passed quality control. Depths
are reported in basepairs (bp) and
include reads with multiple mapping
locations (‘multimaps’).
Analysis of neuroblastoma samples. Deep-sequencing of 14 neu-
roblastoma samples on two sequencing platforms yielded 26.700
Gbp (NB1) and 23.760 Gbp (NB2) of mapped read pairs (includ-
ing multimaps), respectively (see Table 13.2). While samples were
sequenced independently and marked with unique identifiers to
allow for sample tracking at each step of the analysis, reads from
each sample panel and each tumor stage (4 or 4S) were pooled
for analysis. Processing the pooled sample panels with Virana re-
sulted in 46 homologous regions representing four viral families
(see Figure 13.8). All HORs were associated with low relative read
abundances of 1-67 RPMM compared to confirmed viral signa-
tures of experimental positive controls (3-1,628 RPMM, see Figure
13.7). Several homologous regions assigned to bacteriophage vi-
ral families Baculoviridae and Myoviridae are attributable to sample
contamination.
Reads assigned to viral families Retroviridae and Flaviviridae were
determined to originate from either endogenous elements (HERVs)
or from human proto-oncogenes that have close homologs in pes-
tiviruses and acutely transforming retroviruses. HORs associated
with these viral families were automatically assigned human or am-
biguous taxonomic origin by Virana, as indicated by narrower bars
in Figure 13.8. We undertook manual investigation of homologous
relationships within each ambiguous HOR by analyzing multi-
ple sequence alignments and phylogenetic trees of the respective
regions. These analyses revealed unambiguous clusterings of neu-
roblastoma sequence reads near human or endogenous factors in all
cases (see Figure 13.9 for an example phylogeny).
No significant differences in viral expression signatures be-
tween neuroblastoma 4 and 4S stages could be detected except
detecting tumor viruses in human cancers 119
(57) Grabherr et al. (2011), Schulz et al.
(2012), Zhao et al. (2011a)
for HERV-K endogenous retroviruses which display 36-86% higher
abundances in stage 4S (NB1: 56 RPMM, NB2: 28 RPMM) than
in stage 4 (NB1: 41 RPMM, NB2: 15 RPMM) neuroblastomas. All
reads assigned to homologous regions were further analyzed for
evidence of chimeric transcription (see Materials and Methods).
While several read pairs with putative chimeric mappings could
be identified, all viral chimeric read ends were clustered within
low-complexity regions of the viral genomes. Analyses revealed
that these putative chimeric mappings represent sequencing errors
and low-complexity templates that non-specifically attracted reads
of similarly low sequence complexity. No cluster of chimeric reads
located at a specifically viral genome location and representing a
human-viral breakpoint could be identified.
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Figure 13.7: Overview of identified homologous regions in positive and negative experimental controls. Left panel: cumula-
tive numbers of reads assigned to viral taxonomic families (log-scale). Each bar represents a homologous group
(HOG) colored according to viral taxonomic family. Bars comprise several segments, each representing a homolo-
gous region (HOR). Heights of segments indicate the putative origin of reads assigned to this region (human, viral,
or ambiguous). Viral families of bacteriophages are marked accordingly. Right panel: Analogous to left panel, but
the lengths of bars represent relative rather than absolute abundances quantified in cumulative reads per million
reads mapped (RPMM).
Reconstruction of novel transcripts by de novo assembly. In order
to identify transcripts of novel viruses that do not map to known
references, we generated de novo transcriptome assemblies of all un-
mapped reads. We applied the two de Bruijn graph based assembly
methods Oases and Trinity that demonstrated best-in-class per-
formance in recent evaluations(57) on sequencing data of the NB2
panel. This sequencing data is especially amenable to assembly due
to its long read length (see Table 13.1). Assembly resulted in 14,077
and 21,510 reconstructed neuroblastoma 4S contigs for Oases, and
Trinity, respectively (see Figure 13.10). Assembly of the neurob-
lastoma 4 sample yielded 11,828 and 12,341 contigs from the same
methods. Results of Oases and Trinity assemblies are comparable
in terms of contig length. All contigs were subjected to taxonomic
annotation using high-sensitivity TBLASTX annotation based on
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cording to viral taxonomic family. Bars comprise several segments, each representing a homologous region (HOR).
Heights of segments indicate the putative origin of reads assigned to this region (human, viral, or ambiguous). Viral
families of bacteriophages are marked accordingly. Right panel: Analogous to left panel, but the lengths of bars
represent relative rather than absolute abundances quantified in cumulative reads per million mapped (RPMM).
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Figure 13.9: PHuman-viral phylogeny
based on a HOR. Phylogenetic tree of
HOR #16 of the NB1 stage 4 panel.
Viral reference sequences are
indicated with red branches and
associated tip labels (’Virus’) while
human factors are labeled with green
branches. Blue branches represent
consensus sequences of
neuroblastoma reads (’Sample’). The
tree was generated by the maximum
likelihood approach PhyML using
the multiple sequence alignment of
the HOR as input (see Materials and
Methods). Distances between nodes
are quantified as substitutions per
site. As can be derived from the tree,
neuroblastoma consensus sequences
are tightly clustered in close
proximity to the endogenous
retrovirus HERVK9I and two human
factors, thereby unambiguously
indicating the human origin of these
neuroblastoma reads. Clusters of
other sequences represent well
known sequence homologies, as for
example between human ABL1/SRC
genes and acutely transforming
retroviruses.
human and viral content of the NCBI nt and nr databases (see Ma-
terials and Methods). Overall, 72 contigs (0.1-0.16% of contigs of
any specific assembly) were identified to be of putative viral origin.
26 contigs were assigned to bacteriophage references and excluded
from further analysis. Based on searches against the full NCBI nr
detecting tumor viruses in human cancers 121
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Figure 13.10: Reconstruction of novel
transcripts by de novo assembly.
Histograms display lengths of
reconstructed sequence contigs
assembled from unmapped reads of
NB2 stage 4 and stage 4S samples
(y-axis in log-space). Two
independent assembly methods,
Trinity and Oases, were used in the
reconstruction. The grand total
number of contigs reconstructed
within each assembly is displayed in
the rightmost column. Reconstructed
contigs are annotated with their
putative taxonomic origin as inferred
by comparison with NCBI nucleotide
(nt) and protein (nr) archives using
TBLASTX database searches.
(58) Heck et al. (2009), Menegaux et al.
(2004)
(59) Flaegstad et al. (1999), Jørgensen et al.
(2000), Krynska et al. (1999)
(60) Stolt et al. (2005)
(61) zur Hausen (2001)
(62) Berk (2005), Eash et al. (2006)
(63) Elgui de Oliveira (2007), zur Hausen
(2009b)
and nt databases followed by manual inspection, all remaining 46
contigs were determined to display higher similarities to bacterial
or human sequences than to any viral reference.
Neuroblastoma is a pediatric tumor of the sympathetic nervous
system that represents the most common form of cancer in infancy.
It is characterized by a striking diversity in biology and clinical
behavior of its subtypes. This heterogeneity as well as supporting
epidemiological findings are highly suggestive of infectious cofac-
tors involved in genesis and maintenance of the disease.(58) While
several studies utilizing technologies with lower sensitivity com-
pared to our approach have identified human polyomaviruses in
neuroblastoma and pediatric embryonal tumors,(59) newer investi-
gations seem to render these associations inconclusive.(60) However,
viral commensals of the families polyomaviridae and adenoviridae are
indeed suspected to acquire rare transforming properties as a con-
sequence of viral latency or defective replication(61) and to encode
oncogenes(62) whose carcinogenic potential in human is currently
investigated.(63) We undertook the first systematic search for known
and unknown viruses in transcriptomes of metastatic neuroblas-
toma by analyzing deep sequencing RNA-Seq data of 14 metastatic
neuroblastomas from two tumor stages as well as positive and neg-
ative experimental controls.
Several high-throughput methods for detecting viral sequence
reads among human RNA-Seq data have been developed. Among
these methods, PathSeq, CaPSID and RINS are most prominent due
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(64) Butel (2000)
(65) de Villiers et al. (2004), Karlin et al.
(1990), Simmonds et al. (2005)
to their design as reusable computational pipelines. In this study
we selected CaPSID and RINS due to their high performance and
public availability and compared their detection performance with
that of our novel method Virana. Both CaPSID and RINS follow a
subtractive approach, e.g. they separately map input data to viral
and human reference sequences and subtract viral read mappings
that are similar to the human genome from the analysis. While
CaPSID is conceptualized as a generalized framework that supports
the subtraction process by means of a database and a web server,
RINS features an integrated pipeline that splits input reads into
shorter fragments in order to increase mapping sensitivity, followed
by transcriptome assembly of putative viral reads into full length
transcripts.
Both RNA and DNA viruses may share considerable sequence
homology to human factors due to reasons such as lateral gene
transfer, oncogene capture, ancestral endogenization, or insertional
mutagenesis leading to chimeric transcripts.(64) Such homologous
transcripts may display human-viral sequence similarities of 86%
(Bovine Herpes virus) and up to 92% (acutely transforming retro-
viruses). Subtractive approaches silently discard these transcript
from the analysis due to their similarity to the human reference
genome. In contrast, our novel method Virana follows a radically
different approach. Instead of separate mapping to viral and hu-
man reference database followed by digital subtraction, Virana
undertakes a particularly sensitive read mapping to a combined
set of human and viral references. By allowing for multimaps, this
mapping strategy facilitates discovery of viral transcripts regardless
of their similarity to human factors. Apart from being conceptually
simpler by relying on only one mapping step and discarding the
subtraction procedure that is both possibly erroneous and com-
putationally costly, this approach empowers the mapper to make
informed decisions about relative alignment quality by weighing
different human and viral reference positions against each other. As
a direct consequence of this increased mapping quality, paired-end
reads can be mapped across human and viral references, allowing
for detection of human-viral chimeric transcription and proviral
integration events.
We quantitatively validated Virana’s approach both in settings
involving simulated reads as well as in real-world scenarios in-
volving experimental positive and negative controls. In these val-
idations, Virana displays significantly higher detection sensitiv-
ities than competing approaches especially at high rates of viral
sequence divergence exceeding 5% that are common for tumor
viruses.(65) As a consequence, Virana was the only method able to
detect all viral families independent of sequence divergence in the
validation data set. In spite of the additional processing undertaken
by our method, Virana features between and two and three times
faster execution speeds compared to related methods.
Interestingly, viral reads analyzed in the sequence divergence
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(69) Cornelissen et al. (2003), Feng et al.
(2008), Metzenberg (1990)
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validation originate from a broad array of viral species, only two
of which infect mammalian hosts and none of which display sig-
nificant human-viral sequence homology. As a consequence, this
validation favors subtractive approaches by reducing the dan-
ger of erroneous subtraction of viral reads that are similar to the
human genome. In addition, the sequence divergence validation
contained reads sampled at high coverage. However, transcripts
of tumor viruses are often expressed at only low cellular abun-
dances and are thus expected to have low sequence coverage. We
therefore next validated the ability of viral detection approaches
to detect viral transcripts homologous to human factors at vary-
ing levels of sequence coverage. Virana, by virtue of not relying on
digital subtraction, demonstrated superior sensitivity at this val-
idation both in settings of natural sequence homology as well as
in cases of human-viral chimeric transcription. Specifically, Virana
was the only method able to detect evidence for all viruses even at
low twofold coverages. We observed that both RINS and CaPSID
discarded a substantial amount of human-viral homologous tran-
scripts due to their high similarity to the human reference genome,
a fact that explains the lower performance of these methods in this
validation scenario.
Analysis of positive and negative experimental controls fur-
ther reveals that Virana is able to detect viral transcripts associated
with four types of cancer at a high dynamic range of relative abun-
dances. While Virana displays a slightly reduced specificity in
simulated and experimental evaluations, these false positive hits
are limited to only two viral families (Flaviviridae and Retroviridae)
that display high sequence similarity to human factors. These hits
are additionally annotated with an ambiguous taxonomic origin by
Virana. In addition, Virana provides extensive support for inves-
tigating such ambiguous viral hits by analyzing the homologous
context of putative viral reads in a context of multiple sequence
alignments and phylogenies.
In principle, several biological confounding factors may hinder
detection of viral transcripts by any sequence-based method. Low
concentration and extratumoral location of viral producer cells(66)
or selection of growth-autonomous cells in progressed tumors(67)
can significantly dilute the number of viral transcripts in a sample.
Additionally, known tumor viruses such as high-risk HPV strains,
EBV, and MCPyV selectively transcribe their genome during viral
latency (HPV: E6/7, EBV: EBNA1/2, MCPyV: large T antigen),(68)
thus generating only low abundances of tens (MCPyV) to hundreds
(KSHV, EBV) of transcripts per cell.(69) Last, transcription of hu-
man oncogenic factors modulated by viral or endogenous retroviral
promoters as well as ‘hit-and-run‘ mechanisms of viral oncogenesis
that imply loss of viral material may predispose cells to transforma-
tion without requiring maintenance of viral transcripts.(70)
Our approach aims to counteract these confounding factors by
two strategies: first by sequencing neuroblastoma transcriptomes
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(71) Fang and Cui (2011)
(72) Bexfield and Kellam (2011), Feng et al.
(2007), Moore et al. (2011)
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at comparatively high depth in order to detect rare transcripts and
second by using several biological replicates at different tumor
stages, thus reducing the probability of total loss of viral material
from all analyzed samples. Based on statistical estimations con-
cerning Virana’s homologous region construction process and the
sequencing depth of our experimental data, we can conclude that
our approach requires minimal abundances of only two average-
length viral transcripts per cell even under adverse conditions such
as high viral divergence or extensive human-viral sequence homol-
ogy. While representing a theoretical sensitivity that may be altered
by sequencing biases,(71) these copy numbers compare very favor-
ably with related estimates reporting minimal abundances of one to
several complete viral genomes per cell.(72)
After applying Virana to several positive control panels of hu-
man cancers with known viral cofactors and accurately reconstruct-
ing large fragments of viruses that are causally related to the re-
spective tumors, we analyzed neuroblastoma transcriptomes at high
sequencing depth and using two different sequencing platforms.
Analyses of neuroblastoma transcriptomes resulted in the detection
of putative viral transcripts with high local sequence similarity to
several viral families. However, automatic taxonomic annotation as
well as detailed manual inspection of homologous regions pertain-
ing to these families revealed the human or bacteriophage origin of
all transcripts. While we could find differences in the abundance
of HERV-K transcripts between neuroblastoma stages 4 and 4S, the
causative role of HERV transcription with regard to oncogenesis is
currently unclear(73) and, as to our knowledge, only tentative asso-
ciations with specific cancers have been made as to date.(74) Apart
from these tentative differences in HERV-K abundances, no quan-
titative difference between neuroblastoma stages 4 and 4S could be
identified with regard to viral transcription.
In conclusion, our observations provide negative evidence
regarding the contested question of putative viral cofactors of
metastatic neuroblastoma by suggesting that viruses are unlikely
to be frequent cofactors in the maintenance of metastatic neuroblas-
toma.
III
Host-pathogen protein interactions
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This third chapter outlines the current state of the art in de-
tecting protein interactions in a wider context of inferring host-
pathogen interactions, i.e., protein interactions between two pro-
teins of pathogenic and human origin, respectively. These protein
interactions are especially relevant in light of antiviral therapy
since drugs targeting viral host factors are promising candidates
for future generations of highly effective antivirals. Apart from
presenting the current state of virology with respect to viral-host
interactions, this chapter additionally focuses on methods for de-
tecting and interpreting physical protein contacts from affinity
purifications, a specific class of experimental protein interaction
assays.
At its beginning in Section 14, the chapter introduces the con-
cept of viral host factors, i.e., proteins that are essential for viral
infection, replication, and persistence. After detailing viral use of
such factors for several purposes, the current state of development
of antiviral agents such as vaccines and specifically targeted drugs
is presented in Section 15 and medicines targeting or employing
human host factors are highlighted. Subsequently in Section 16, an
introduction to experimental and computational methods for mea-
suring protein interactions is presented and further illustrated with
current approaches for detecting viral host factors in Section 17.
This chapter closes with Section 18 where a study is presented that
proposes a new statistical method for inferring protein interactions
from protein purification data and an application of this method on
host-pathogen (HP) interactions of HIV is presented.

(1) Tortorella et al. (2000)
(2) Baranowski (2001), Marsh and Helenius
(2006), Schneider-Schaulies (2000)
(3) Boyd et al. (1993); the term tropism here
denotes the the specificity of a virus for
either a particular host cell type (cellular
tropism), a host tissue (tissue tropism),
or a host species (host tropism, often also
denoted as host range), cf. McFadden
et al. (2009). Viral tropism is determined
by both susceptibility (allowing viral
entry) and permisseness (allowing viral
replication) of the infected cells, tissues, or
species.
14 Virally targeted host factors
While viruses may, in principle, exhibit highly virulent and thus
pathogenic phenotypes that kill the host, such a strategy is not in the
evolutionary interest of the virus since it requires a host reservoir for pro-
longed survival. Viral strains that co-exist with rather than overwhelm the
host are therefore more likely to have epidemiologically and thus evolution-
arily favorable characteristics. If regarded from an evolutionary viewpoint,
this long-term coexistence of viruses and their hosts displays a "precar-
ious balance"(1) and persistent viruses are required to develop intricate
interactions with their host. Among these factors are entry factors, a range
of macromolecular entities such as protein receptors, lipids, saccharides,
as well as their combinations that are located in the cell membrane and
promote viral entry.(2)
Due to their large genomes, correspondingly slow rate of sequence
variation, and large coding potential, DNA viruses exhibit strategies
for immune evasion that are distinct from strategies of divergent RNA
viruses; while the latter predominantly rely on antigenic variation of
envelope proteins in order to evade immune detection, DNA viruses utilize
both passive as well as active means of escaping the host immune system.
In particular, poxviruses, herpesviruses, and adenoviruses utilize their
large protein repertoire to actively suppress the host immune system,
disable apoptosis, and thus persist in the host indefinitely.
This section introduces crucial host factors that either are utilized by
viruses to gain access to the cell (entry factors) or that represent compo-
nents of the host immune system which are subverted by viral factors in
order to achieve persistence. These interactions are almost exclusively me-
diated by proteins, and the resulting virus-host protein interactions serve
as important discovery tools for basic research aiming to highlight key host
immune pathways. In addition, and more relevant for this thesis, such
protein interactions are interesting antiviral drug targets, a topic that is
explored in more detail in subsequent sections of this chapter.
Viral entry factors and coreceptors
The use of and adaption to cellular entry factors is a major de-
terminant for infectiousness, cellular tropism, and host range of
viruses.(3) Host range in itself is a highly variable characteristic
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(2012), Woolhouse (2001)
(6) Antia et al. (2003), Bae and Son (2010),
Haagmans et al. (2009), Parrish and
Kawaoka (2005)
(7) Baranowski (2001), Iorio et al. (1989),
Zhang et al. (2007)
(8) Woolhouse et al. (2002)
among viruses (cf. Chapter I). Often, multiple entry factors are
required for efficient entry and secondary factors (often termed
coreceptors) are employed by viruses in order to increase the effi-
ciency of the process. Of the about 90 human viruses with known
cellular entry factors (representing 21 of 23 known viral families
that infect humans), approximately 75% use protein receptors while
the remainder specializes on linear polysaccharides for entry.(4)
The choice of host factors has important consequences for host
specificity: this is demonstrated in the case of HIV-1 where small
changes to viral proteins are sufficient to result in functional amino
acid changes that determine CCR5 or CXCR4 coreceptor usage,
thus altering cellular tropism of the virus. This propensity to adapt
to host factors is varying between viruses and may result in cross-
species infectivity. Pathogens as for instance HBV or Mumps virus
(MuV) are viral specialists that probably have co-evolved with the
human species and exclusively infect humans; on the other hand,
viruses such as rabies virus are able to infect a wide range of hosts
by utilizing cellular receptors that are highly conserved (more than
90% amino acid identity) between host species.(5)
As will be discussed later in Chapter IV, divergent viral species
that contain highly variable minority variants rapidly evolve to
novel phenotypes if selection pressure is sufficiently strong; these
phenotypes frequently also include novel binding interfaces that
promote both host tropism as well as immune escape by anti-
genic variation. Importantly, sufficient changes in cellular tropism
may also result in modified host ranges (host tropism). This phe-
nomenon of a pathogen adapting to a novel species is closely as-
sociated with disease emergence and viral zoonosis (cf. Chapter
I) and may be a contributing factor to the current AIDS pandemic
as well as for up to one novel human disease each year, many of
whose are originating from bats, primates, and rodents.(6)
Due to the particular structural (and therefore, by extension, also
sequence-based) characteristics that determine tropism of a virus,
interfaces between viral and host proteins are often associated
with antigenicity, i.e. host immune response. Indeed, receptor and
antibody binding sites (epitopes) of viral proteins have been shown
to frequently overlap.(7) As a consequence, immune evasion and
host cell tropism seem to be intricately linked and changes of host
cell tropism in order to evade immune recognition may thus be an
important part of the virus-host evolutionary arms race.(8)
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Viral subversion of the innate immune system
Due to their high abundance, diversity, and adaptivity,
viruses pose particular challenges to the host immune system.
The mammalian immune system consists of two large components.
The innate immune system acts as a first line of defense against vi-
ral infection, has only limited specificity, and does not provide an
immunological memory. The adaptive or acquired immune system,
on the other hand, is mostly relevant in later phases of infection.
It is driven by lymphocytes that evolve to high specificity by gene
rearrangement and clonal selection and are retained for years after
initial infection, thereby enabling quicker responses to subsequent
infections with the same pathogen.
In the following, we will first discuss viral strategies for modu-
lation and subversion of the host innate immune system in order
to motivate and inform the search for viral host factors involved in
these pathways. Subsequent sections will introduce similar inter-
actions of viruses with the adaptive immune system. In addition,
knowledge of these core immune components is relevant for the
next chapter of this thesis where mechanisms of viral immune es-
cape and the immunomodulatory activity of certain drugs will be
discussed (cf. Chapter IV).
The majority of the human population is chronically or latently
infected with one or several viruses such as herpes simplex viruses
types 1/2 (HSV-1/2), human cytomegalovirus (HCMV), varicella-
zoster virus (VZV), or human herpesviruses 6 and 7 (HHV-6 and
HHV-7).(9) Indeed, there is paleovirological evidence that her-
pesviruses co-evolved with the human species for at least 400
million years.(10) While these viruses are usually causing asymp-
tomatic infections, their long-time persistence within the host and
within the human population as a whole well illustrates the abil-
ity of these pathogens to control the human immune response
indefinitely. These viruses employ their long genomes and corre-
spondingly large reservoir of proteins in order to inhibit multiple
components of the innate immune system such as cytokine and
chemokine signaling,(11) as well as pathways of the adaptive im-
mune system such as the complement cascade, antibody-mediated
effector mechanisms, and MHC I/II antigen processing and presen-
tation.(12)
Recognition of viral factors by the host as well as proper activa-
tion of innate host defense pathways such as the interferon system
are essential for mounting an effective immune response. Congenial
failure in these components may often result in higher susceptibility
to viral diseases in general; this is particularly true for highly ag-
gressive viruses such as Lassa that may not leave the host sufficient
time for mounting an adaptive immune response.(13)
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(2008)
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Since successful activation of innate immune pathways may
hinder initial infection of the cell, these pathways are regularly
antagonized by both acutely and latently infecting viruses. In the
following, we will concentrate on the two major components of
the innate immune response: pattern-recognition receptors and
inflammatory cytokines.
Pattern-recognition receptors. Pattern-recognition receptors (PRRs)
are of particular importance in the context of virus-host protein
interactions. These host proteins detect molecular patterns of
pathogenic infection and can elicit signaling cascades that acti-
vate other actors of the innate immune system such as the type I
interferons IFNa/IFNb and pro-inflammatory cytokines which in
turn direct T helper cells and cytotoxic T cells of the adaptive im-
mune system.(14) In particular, PRR response activates transcription
factors interferon (IFN)-regulatory factor 3 (IRF3), IRF7 and/or
nuclear factor-kB (NFkB), resulting in the expression of IFNb and,
subsequently, of IFN-stimulated genes (ISGs) that collectively avert
or limit viral infection.(15)
Of the known families of PRRs, the Toll-like receptors (TLRs) and
the retinoic-acid-inducible gene I (RIG-I)-like receptors (here de-
noted as RLRs and comprising retinoic-acid-inducible gene I (RIG-I)
and the melanoma differentiation-associated gene 5 (MDA5)) have
been investigated in detail.(16) Both of these protein families detect
pathogen-associated molecular patterns (PAMPs), in particular viral
RNA and DNA, but also lipids, lipopolysaccharides, as well as heat
shock proteins and glycoproteins that are specific for broad classes
of pathogens.(17) TLRs are expressed both intra- and extracellularly
by antigen-presenting cells (APCs) such as macrophages which
ingest and degrade pathogens.(18)
In general, PRRs are specialized towards detecting viruses with
specific genomic features; while double-stranded viral DNA (ds-
DNA) genomes are detected by Toll-like receptor 9 (TLR9), viruses
with dsRNA genomes are detected by TLR3 and MDA5, the lat-
ter of which can also detect positive-sense single-stranded RNA
genomes. Other single-stranded RNA genomes with retroviral and
negative-sense characteristics are detected by TLR7/TLR8 and RIG-
I, respectively.(19) Viral factors inhibiting PRRs often manipulate
Toll/IL-1 receptor (TIR) domains that are highly conserved across
TLRs and have been shown to be essential for signaling.(20)
By interacting with these cellular components, for example by
protease-mediated cleavage (HCV), transcriptional down-regulation
(HTLV-1) or antagonistic binding (Influenza A), viruses may inhibit
downstream activation of NFkB and IRFs.(21) By contrast, and as an
important feature of cellular self-recognition, endogenous host nu-
cleotides do not activate PRRs due to their single-stranded nature
(in case of RNA), reduction of immuno-stimulatory CpG-DNA (in
case of DNA), extensive base modifications (pseudouridine), as well
as the 5’ capping with methylguanosine and monophosphates.(22)
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These characteristics of host nucleotides are often mimicked by
viruses in order to evade immune detection; in particular, viruses
may employ either viral or host factors to cap viral mRNAs or
shield their genomes from host proteins.(23) Conversely, viruses
may also trigger PRRs to modulate host pathways for their own
purposes and identical PRRs may be triggered by different viruses
with either negative or positive results on virulence and disease
progression.(24)
In addition, and similar to the modulation of TLR signaling path-
ways, viruses also directly inhibit RLR signaling by binding and
cleavage of TLRs and downstream effectors.(25) Many viruses target
later stages of innate immune signaling; indeed it has recently been
shown that most TLR receptor signals converge at TRADD (tumor-
necrosis factor receptor (TNFR)-associated via death domain)(26),
an adaptor molecule that can shuttle between cytoplasm and nu-
cleus and activate apoptosis. Similarly, all known PRRs signaling
converge at the IKK family of proteins. Such bottlenecks within the
human innate immune system are attractive targets for viral inhibi-
tion and subversion (see later Sections of this chapter for a detailed
investigation of the importance of bottleneck proteins). Indeed, IKK
proteins and the transcription factors they activate are targeted by
viral factors of HCV, hantaviruses, and coronavirus.(27) Also, both
HCV and HIV employ viral factors to subvert the human DEAD-
box protein 3 (DDX3), a protein co-complexing with IKK factors, for
replication and transcript transport, respectively.(28)
Inflammatory cytokines. Natural killer (NK) cells are important
components of the innate immune system that produce inflamma-
tory cytokines. Cytokines are polypeptides secreted by NK cells
and cytolytic T cells that are essential for organizing a wide array of
cellular processes such as inflammation, proliferation, and differen-
tiation and may induce cell death or directly mediate cytotoxicity. It
is assumed that activation of cytokines and the associated immune
responses regularly clears less severe infections from the host, of-
ten in pre-symptomatic stages of viral disease. Interestingly, it is
the effects of cytokines and not viral activity that produces the flu-
like symptoms of many viral diseases such as fever, headache, and
drowsiness.(29)
Due to their various protective effects on the host cell, several
classes of cytokines such as interleukins, interferons, tumor necrosis
factors, and chemokines (pro-inflammatory cytokines that direct
other immune cells to infected tissues by chemical gradients) are
prime targets for viral subversion. Many viral strategies for in-
hibiting cytokines focus on blocking interferon and chemokine
production by blocking transcription factors,(30) by inhibiting cy-
tokine maturation,(31) or by down-regulation through activation of
cellular receptors.(32)
Another ingenious viral strategy for cytokine subversion con-
sists of antagonistic binding (or "scavenging") of cytokines and
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chemokines by soluble viral receptors. These bait proteins are ho-
mologous to cellular cytokine receptors and are expressed mainly
by large DNA viruses such as herpesviruses and poxviruses in or-
der to interfere with TNF and IFN signaling.(33)Other herpesviruses
are known to express chemokine receptors that continuously ac-
tivate signaling cascades, thus modulating the cell cycle and con-
tributing to tumor formation.(34) Similarly, KSHV and MCV, a
poxvirus, are associated with tumor formation and secrete broad-
spectrum chemokine receptor antagonists.(35)
Finally, cytokine system subversion by viruses can also serve
more nefarious purposes. By expressing viral cytokine receptor
homologs on the cell surface that have subtly altered signaling
functions, HCMV, for instance, selectively depletes chemokines in
the cellular environment and thus inhibits leukocyte activation.
Other viruses employ the chemokine system for their own use and
specifically activate chemokine receptors in order to attract immune
cells for infection(36) or for guiding Th1/Th2 T-cell differentiation
by selectively activating chemokine receptors in a manner beneficial
to viral immune escape.(37)
Viral subversion of the adaptive immune system
Following the initial innate immune response to viral infec-
tion, a second layer of host defense, the adaptive immune system, is
activated. In contrast to the innate immune response, the adaptive
immune system coordinates more specific and longer lasting an-
tiviral activities. The adaptive immune system consists of two large
components, termed cellular and humoral arms that provide immu-
nity for intracellular and extracellular spaces, respectively. Both
arms are triggered by cytokine and chemokine signaling of the in-
nate immune system and natural killer cells and are interconnected
and coordinated by interleukins and other messenger molecules.
The humoral arm consists mainly of B cells that produce an-
tibodies, highly diverse protein complexes that bind to antigens
on viral particles or infected cells. Antibody binding marks these
antigen-bearing entities for destruction by natural killer cells, com-
ponents of the complement cascade, and cytotoxic T lymphocytes
(CTLs or T-cells). T-cells are the most important actors of the cellu-
lar arm of adaptive immunity. These cells are able to detect foreign
peptides displayed by the major histocompatibility complex (MHC)
on the surface of antigen-presenting cells. Both arms of the adap-
tive immune system are prime targets for viral subversion as the
following paragraphs will illustrate.
Major Histocompatibility Complexes Host cells present peptides
that have been expressed within the cell and subsequently de-
graded by the proteasome in specialized protein receptors located
on the cell surface. These receptors, most prominently the Major
virally targeted host factors 135
(38) Braciale et al. (1987), Brodsky et al.
(1999), Guidotti and Chisari (1996)
(39) Pieters (1997)
(40) Jonjic´ et al. (1989)
(41) Marsh (2013)
(42) The remaining component not encoded
by HLAs is a protein of comparably low
molecular weight, b2 microglobulin
(43) In addition, they may be an important
factor influencing human mate selection,
a process that may be evolutionarily
selected to increase immune diversity
in the human population Brennan and
Kendrick (2006), Parham and Ohta (1996).
(44) Horst et al. (2011)
Histocompatibility Complexes (MHC), enable lymphocytes of the im-
mune system such as cytotoxic T Lymphocytes to detect invading
pathogens by binding to characteristic antigenic peptides, termed
epitopes. Cytotoxic T Lymphocytes implement the cellular arms of
the adaptive immune system while also providing important signal-
ing services for humoral, or antibody-mediated, immunity.
MHC complexes play an essential role in the detection of foreign
peptides and come in two varieties: MHC-I molecules are expressed
by most vertebrate cells and display epitopes that originate from
the cytosolic compartment and have been degraded by the protea-
some. Upon binding to T-cell receptors and CD8 coreceptors on
CD8+ T-cells, CTLs may activate immune pathways that allow for a
targeted immune responses and eliminate virus-infected cells.(38)
In contrast to MHC-I molecules that primarily display peptides
of intracellular origin to CD8+ T cells, MHC-II molecules present
antigenic peptides also from the extracellular space that underwent
phagocytosis or endocytosis to T-cells employing the CD4 corecep-
tor, thus termed CD4+ T cells (T-helper cells).(39) MHC-II molecules
are usually expressed on "professional" antigen-presenting cells
(professional APCs or PAPCs) such as B cells, dendritic cells, and
macrophages. Upon recognition of antigenic epitopes, CD4+ T cells
also induce antiviral response as well as T cell proliferation.(40)
Human MHC-I isoforms are predominantly constituted of prod-
ucts of human leukocyte antigens (HLA), a genetically highly vari-
able family of genes distributed over at least 9 loci in the human
genome that encode several thousand known alleles in the human
population(41),(42) These HLA genotypes display varying MHC
binding properties to peptides and are major determinants of suc-
cessful human immune response to foreign as well as to autoim-
mune factors.(43)
Peptide transport and MHC maturation MHC-I molecules in par-
ticular undergo a process of maturation that is completed by pep-
tide loading and translocation of the loaded complex onto the cell
surface. Mature MHC-I complexes exist as a trimer comprising of
a heavy chain (43-kDa membrane glycoprotein featuring a peptide
groove), a light chain (12-kDa soluble protein b-microglobulin),
and the ligand of the complex, a 8-10 residues peptide fragment
encoding the antigenic epitope.
Antigenic peptides are generated by digestion of polyubiqui-
tylated proteins by the proteasome, a large intracellular protein
complex that functions as a multicatalytic protease. The digested
peptide fragments are transported from the cytoplasm to the en-
doplasmic reticulum (ER) by the hetero-dimeric Transporter complex
associated with Antigen Processing (TAP).(44) where MHC-I complexes
mature and are loaded with peptides. Specifically, preparation and
peptide loading of MHC-I molecules requires a macromolecular
assembly termed the peptide-loading complex (PLC). This complex
transiently interact with the MHC-I complex and are required for
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stable expression of the receptor on the cell surface.(45)
Since MHC-I molecules are constructed from a highly variable
set of HLA gene products that display large differences in assembly
kinetics, MHC-I complexes are not fully stable after initial assembly.
In addition, peptides may display varying binding efficiency and
peptide loading may be deferred. For these reasons, chaperone
supervision is required to facilitate correct assembly(46) One of
these chaperones is tapasin, a transmembrane glycoprotein that is
essential for MHC-I maturation by stabilizing the groove of the
MHC complex until peptide loading has occurred.(47) As part of
its stabilizing function, tapasin selectively chooses peptides for
loading that kinetically stabilize the MHC complex, a process that
is denoted as peptide editing. In addition, tapasin also performs
recruitment functions of other proteins such as TAP to the peptide
loading complex.(48)
Viral subversion of MHC pathways Viruses have evolved a range
of strategies to subverting host MHC pathways. Among these
strategies are inhibition of degradation of viral proteins by the
proteasome, modulation of MHC-I transport by TAP, hindrance of
tapasin-mediated localization of MHC-I complexes on the cell sur-
face, and retainment or degradation of matured MHC molecules.
Herpesviruses in particular inhibit each known step of the MHC-I
presentation pathway by interfering with the degradation of viral
proteins, by blocking synthesis of MHC-I molecules, by specifically
inhibiting components of the MHC-I complex, or by promoting se-
lective degradation or intracellular detention of these molecules.(49)
Degradation of ubiquitylated proteins into short peptides by
the proteasome is blocked by several herpesviruses. Among the
targeted host systems are the ubiquitin system that is crucial for
degradation of viral proteins into epitopes,(50) as well the protea-
somal degradation machinery that is inhibited by glycine-alanine
and serine-proline repeat repeat motifs encoded in viral genomes,
thus preventing processing of viral proteins.(51) Interestingly, these
repeat motifs probably evolved independently(52) and are hypoth-
esized to interfere with protein unfolding or recognition by the
proteasome 19S subunit.(53)
Other cellular subsystems are also specifically targeted by her-
pesviral factors. At least eight different herpesviruses are known
to degrade, induce confirmation alterations of, or interfere with
peptide binding or ATP binding of the TAP complex in ways that
are surprisingly unrelated in their mechanisms of action.(54) Her-
pesviruses such as HSV, EBV, and HCMV are known to block TAP-
transport by different mechanisms such as antagonistic binding to
peptide or ATP binding sites, by inducing conformational changes,
or by tagging of TAP for proteasomal degradation(55)
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Several strategies of MHC retention are directly implemented
by adenoviruses and poxviruses that block transport of MHC-I out
of the ER by physical association.(56) Misfolded or incompletely
assembled MHC molecules are recognized within the ER and de-
graded by the ubiquitin-proteasome pathway through a process
denoted as ER-associated degradation (ERAD).(57) Herpesviruses
subvert these degradation mechanisms by encoding viral proteins
that bind directly to components of the MHC-I complex or by en-
forcing MHC ubiquitylation, thus inducing dislocation and degra-
dation of these molecules by ERAD.(58)
Although generally less well studied compared to MHC-I molecules,
MHC-II pathways are known to be also targeted by viral fac-
tors; herpesviruses, for instance, target both MHC-I and MHC-II
molecules by degradation and redirection.(59) Similarly, HPV as
well as HIV encode proteins that are assumed to inhibit endocytosis
and thus modulate trafficking of antigenic peptides.(60)
Presentation of MHC molecules is also a prime target for viruses.
Natural killer cells, usually considered to be part of the innate im-
mune system, recognize the absence of MHC-I molecules on cell
surfaces and mark these cells for destruction (’missing self hypothe-
sis’)(61) Since many pathogens subvert MHC expression by various
mechanisms, NK cells thus detect the pathogen by the absence of
immunocomplexes. Interestingly, viruses have evolved mechanisms
to also counter this second line of defense: poxviruses as well as
herpesviruses are known to encode nonfunctional MHC-I homologs
that may mask reduced cellular MHC-I surface expression.(62) Sim-
ilarly, other viruses such as HIV are suspected to actively regulate
cellular expression of specific HLA loci (the constituent parts of
MHC-I receptors) in order to increase the ratio of NK-protective
alleles while down-regulating immunogenic HLA variants.(63)
Viral use of molecular chaperones. Due to its important role in
MHC-I stabilization, tapasin is targeted by herpesvirus and ade-
novirus factors that inhibit peptide editing and thus facilitate re-
tainment of unstable MHC molecules in the ER(64) or that blocking
recruitment of other components of the peptide loading complex by
tapasin.(65) Indeed, tapasin is not the only chaperone that is subject
to viral inhibition; instead chaperones are believed to also buffer
pathogens against mutational effects(66) and are a common target
for a variety of viruses that have evolved mechanisms to utilize or
subvert the host protein quality control machinery at multiple steps
of the viral infection cycle, including endocytosis, early replication,
and assembly(67)
The dependencies of viruses on chaperones opens attractive
therapeutic possibilities for the development of broad-spectrum
antivirals which are currently pursued.(68)
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Viral modulation of apoptosis Cytotoxic cytokines secreted by NK
cells and cytolytic T cells as well cellularly delivered components
of the complement system are important mechanisms of apoptosis,
i.e., premature cell death of virally infected cells.(69) Since apoptosis
severely limits the replication window of the infecting virus and
would furthermore make viral latency impracticable, viruses have
evolved several ways to block initiation and execution of apoptotic
processes (cf. Tortorella et al. (2000) for a review).
A particularly attractive target for viral modulation in this con-
text are TNF receptors, a family of death receptors that initiate
apoptosis if activated by a suitable ligand such as tumor necrosis
factor (TNF), a cytotoxic cytokine.(70) Poxviruses and adenoviruses
disable TNF and related Fas receptors by direct binding to the re-
ceptor, antagonistic binding to the cytokine, or endocytosis.(71)
Similarly, many viruses also aim to gain control over components
of the NFkB pathways. These pathways may hinder apoptosis and
thus allow for prolonged viral replication. However, NFkB also
increases production of IFNb and chemokines which is detrimental
to long-term viral infection; therefore, precise timing of the viral
subversion processes is applied by viruses in order to maximize the
benefit of their manipulations.(72)
Antibody-mediated humoral immunity The humoral arms of the
immune response plays an important in preventing infections es-
pecially by pathogens that have been previously encountered by
the immune system. Antibodies, also denoted as immunoglobulins,
are host glycoproteins that bind to antigenic surface structures on
viral particles. By thus binding to the virus, these neutralizing anti-
bodies cause functional inactivation of the pathogen, for example
by inhibiting viral interactions with cellular receptors. In addition,
even non-neutralizing antibody binding can mark viral particles for
later ingestion by phagocytes or lysing by NK cells. Finally, bound
antibodies may coordinate a direct attack on antigenic membranes
via the complement-mediated membrane attack complex.
In order to elicit strong and long-lasting immunization, pathogens
have to sufficiently activate the immune system by presenting
danger signals to pathogen recognition patterns, thus inducing
the innate immune system produce chemokine and inflamma-
tory signals. These signals attract dendritic cells, leukocytes, and
monocytes to the site of injection, increasing antigen uptake and
MHC-based presentation by antigen processing cells, expression
of activation signatures, and cytokine production. Subsequently,
antigen-processing cells with MHC-I or MHC-II molecules loaded
with antigenic epitopes migrate towards the lymph nodes where
both T-cell (cellular immunity by differentiation of antigen-specific
CD4+ T-cells into effector cells and activation of CD8+ T-cells) and
B-cell (humoral immunity by CD4+-mediated differentiation of B-
cells into antibody-secreting plasma cells and long-lasting memory
cells) responses are activated.
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Viral subversion of humoral immunity An essential component of
the humoral immune system is presented by receptors located on
phagocytic cells, B-cells or other leukocytes as well as free protein
complexes of the complement system that bind to the invariable
Fc locus of bound antibodies. Upon binding, these receptors in-
duce effector immune responses, such as activation of complement
pathways, phagocytosis of opsonized antigens, or B-cell activation
resulting in virus-specific antibody production.(73)
Viruses commonly subvert antibody responses by either mod-
ulating Fc binding to effector complexes through endocytosis of
the bound complex, or by viral Fc receptor homologs that func-
tionally inactivate antibodies that are bound to viral antigens. The
latter strategy is particularly used by herpesviruses such as HSV-1;
this pathogen expresses glycoproteins that bind to antibodies, thus
masking virions and infected cells from immune recognition.(74)
This mechanism is of particular interest to herpesviruses since this
family of pathogens persistently infects its host by a strategy of
alternating latent and acute infections. Since this life cycle implies
previous immunization of the host, the virus requires antibody
masking to evade immune response at later stages of viral activa-
tions.(75)
Similarly to viral subversion of the chemokine system that is
employed to promote viral transmission (see above), viruses such
as HIV employ antibodies to facilitate uptake (but not ingestion)
of virions by dendritic cells. These dendritic cells then shuttle the
virus to new CD4+ T cells for infection, thus increasing transmissi-
bility of the pathogen.(76) In a related manner, viruses also employ
host regulatory pathways that prevent the complement system from
unrestrained over-activation. These regulators of complement ac-
tivation (RCA) are readily targeted by poxviruses, herpesviruses,
and retroviruses which encode RCA homologs or alter cellular ex-
pression of these factors, thus facilitating decay of the complement
system (cf. Tortorella et al. (2000)).
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15 An introduction to antivirals
As reviewed previously in chapter I of this thesis, infectious
diseases such as AIDS, malaria, and lower respiratory tract infections
are responsible for a significant portion of the global health burden.(1) In
2009, more than 30 million people were HIV-positive and an estimated
1.8 million deaths occurred as a result of this infection. Hepatitis viruses
may infect more than half a billion people worldwide and other highly
prevalent diseases such as influenza yearly kill on the order of 300,000
individuals, comparable to the inhabitants of Germany’s former capital
Bonn.(2) In addition, the increasing occurrence rates of zoonotic events
and the emergence of multi-drug resistant pathogens further aggravate the
situation. New medicines for combating viral diseases are urgently needed,
especially if faced with highly adaptive viral species such as HCV, HIV,
or influenza.(3) This section reviews the history of antivirals and presents
several drugs that are in common use today. In particular, four broad
classes of antiviral medicines and their relation to drug resistance are
discussed. It is the last of these classes, antivirals that target host factors
that is of special interest in the broader context of this chapter.
Drugs targeting viral factors
In general, antiviral medicines fall into four classes. Specific
inhibitors of viral targets such as small-molecule, high-affinity an-
tiviral drugs and RNAis are only efficacious against one or a few
closely related viral species, are vulnerable to the emergence of
drug resistance, and may exhibit off-target effects. Second, specific
inhibitors of host factors that are essential for viral replication may
be efficacious against broader classes of viruses that rely on the
same host pathway and are hypothesized to be less prone to the
emergence of viral drug resistance.(4) The third class of medicines,
vaccines, require specific development for each viral species or viral
genotype, are less efficacious against highly adaptive viral species
such as pandemic RNA viruses, must be administered preventively
before infection in most cases, and are nearly always biologicals(5)
and may therefore be difficult to mass-produce and to transport.
Finally, unspecific drugs such as ribavirin and interferon that mod-
ulate the host antiviral defense system, affect viral replication by
different means, or alter the host cell metabolism and are modestly
effective against a range of viruses at the cost of relatively high side
effects.
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Small-molecule inhibitors. Small molecule bacterial antibiotics,
commonly also denoted as antibiotics, belong to the most beneficial
medical compounds besides vaccines, antiseptics and anesthetics
and are currently available in broad-spectrum forms for all bacterial
diseases excluding multiple-drug-resistant strains. In contrast, the
high dependency of viruses on cellular host factors, their intracellu-
lar nature, high replication and mutation rates, and the absence of
a common drug target across viral species (as a result of the poly-
phyletic origin of viruses) require specialized antiviral compounds
for each viral species. The considerable research investment re-
quired for developing safe medicines for each these viral targets
as well the fact that drugs developed for one viral species are usu-
ally not applicable to related species result in considerable fewer
medicines available for treating viral infections than for treating
bacterial infections. Indeed, more than twenty classes of bacterial
antibiotics covering some 160 antibiotic compounds are known
today, most of which are applicable to several bacterial species.(6)
In contrast, only about 50 approved small-molecule antivirals are
currently available, most of which are applicable to only one viral
species.(7)
History of antivirals. Interestingly, it is this status of viruses as
obligate intracellular parasites that are depending on a tight inter-
play with host function that raised skepticism with regard to the
feasibility of developing specifically targeted antiviral compounds
in general. In particular, before the first antiviral was developed
it was unclear if components of the viral machinery could be tar-
geted at all by compounds without inhibiting essential host factors,
thereby eliciting considerable drug side effects. This skepticism was
only dissipated by the medical success of the first antiviral aciclovir,
an inhibitor of herpes simplex DNA replication.(8)
Due to pressing medical needs, subsequently developments
concentrated on finding effective anti-HIV compounds and devis-
ing therapy optimization techniques such as combination therapy
(highly active antiretroviral therapy, HAART) that aimed to increase
therapy response against drug-resistant viral strains.(9) Today, 51
FDA-approved small-molecule antivirals are in broad clinical use
and while most of these compound (29) are used in anti-HIV ther-
apy, targeted antiviral therapies against respiratory syncytial virus
(RSV), Influenza A/B, various Herpes viruses, HBV and HCV are
available.(10) These compounds are generally targeted against five
viral processes: viral fusion, entry and uncoating (entry and uncoating
inhibitors, 5 compounds), viral nucleotide replication (DNA and RNA
chain terminators, mutagens, and polymerase inhibitors, 25 com-
pounds), viral integration (integration inhibitors, one compound),
viral polypeptide processing (protease inhibitors, 12 compounds), and
viral capsid construction and release (capsid and release inhibitors, two
compounds).(11) In addition, drugs against other viral diseases with
major pathogenic impact (poxvirus, the hemorrhagic fever viruses
an introduction to antivirals 143
(12) McCormick et al. (1986)
(13) Exceptions exist; so for example the
use of antivirals for susceptible popula-
tions that cannot be immunized due to
missing vaccines (HIV) or contraindica-
tions (Influenza A)
(14) Subunit vaccines: components of the
pathogens such as proteins, toxins, or
polysaccharides with stable antigenic
epitopes.
(15) Also widely used as underarm deodor-
ant.
Ebola and Lassa, and several enteroviruses such as Coxsackie) are
currently under development. Due to the specific nature of viral
infections, no true broad-spectrum antivirals are currently available;
however, a small class of antiviral compounds that do not target
specific viral factors but activate the host immune system or in-
directly hamper viral replication such as interferon and ribavirin,
respectively, are in clinical use.(12)
Vaccines and antibody therapy
Vaccination has been of critical importance for efforts that
aim to significantly reduce or even eliminate the disease burden
of several infectious diseases such as diphtheria, pertussis, po-
liomyelitis, measles, smallpox, tetanus, and yellow fever. In ad-
dition, vaccines that are effective against meningitis, pneumonia,
and some forms of viral hepatitis are increasingly used and pre-
ventive medicines against dengue fever, respiratory infections,
and diarrhoeal diseases are currently in development. Today, vac-
cines are available as cheap, long-lasting, and specific protection
against many viral infections. While different kinds of vaccines
exist (see below), these medicines have in common that they stim-
ulate the host adaptive immune system in order to confer humoral
(antibody-mediated) or cellular (T-cell mediated) immunity against
three classes of pathogenic antigens: components of the whole
pathogen (such as proteins or polysaccharides located on the vi-
ral capsid), intracellularly expressed viral factors whose antigenic
epitopes are presented by infected cells, and pathogenic endo- and
exotoxins.
In contrast to antiviral drugs that are prescribed to patients in
order to counteract ongoing viral infections(13), immunization by
vaccines are today in broad use as preventive measures against vi-
ral infections. These preventive measures are especially relevant in
the light of populations of low-income countries that lack medical
infrastructure and funding for regularly providing antiviral drugs
against chronic infections. Offering immunization to these popu-
lations enables a logistically and commercially viable solution for
fighting infectious diseases while also removing a long-lasting
reservoir of (potentially evolving) pathogens that may quickly
spread to developed countries due to increased urbanization and
air traffic.
Due to safety considerations, modern vaccines less often rely on
whole live or attenuated pathogens but increasingly use subunit
vaccines(14) or recombinant vaccines consisting of pathogens ren-
dered non-pathogenic by genetic manipulation. Due to the lower
immunogenicity of these new compounds, the provided antigens
often do not induce strong neutralizing antibodies that are required
for a memory response. Consequently, immunologic adjuvants such
as potassium alum(15) or cytokines are often employed in order to
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stimulate immune response and illicit broader, cross-reactive an-
tibody neutralization.(16) These adjuvants are currently optimized
in order to further direct CD8+ and CD4+ T-cell response towards
increased specificity and differentiation of memory cells, respec-
tively.(17)
While the first vaccines targeted bacteria (pertussis and tuber-
culosis) or bacterial toxins (tetanus and diphtheria toxins) with
limited genetic diversity and practically invariant antigens, subse-
quently developed antiviral vaccines had to account for antigenic
variation in order to immunize against several (multivalent) viral
variants within a single dose.(18) Similarly, some viral pathogens
such as influenza A utilize several layers of antigenic variation and
recombination, thus requiring constant adaption of the correspond-
ing vaccine to the few viral variants that are in global circulation
each year.(19)
Today, several viruses exist that defy vaccination either due to
antigenic diversity (HIV, HCV, as well as parasites of the genera
Plasmodium, Trypanosoma, and Leishmania) or by resourceful (if
such an anthropomorphic term may be used) circumvention of the
adaptive immune response (in particular by large DNA viruses
such as the Herpesviridae). All these pathogens usually cause persis-
tent infections and offer significant challenges for vaccine design.
Consequently, no comprehensive and durable preventive medicine
is available for any of these pathogens as to date.(20)
In particular, pandemic HIV-1 is a highly relevant challenge for
vaccine development due to its high antigenic variation within
patients and also across different geographic locations that hin-
der identification of viral epitopes that induce cross-reactive and
protective antibodies.(21) These viral epitopes can undergo viral
mutations, or be affected by masking or structural burying of con-
served enzymatic sites.(22) While considerable scepticism remains
in the HIV community regarding the development of a vaccine any-
time soon, a certain cross-reactivity can remain even in modified
epitopes and broadly neutralizing antibodies are believed to ex-
ist, in principle.(23) This assumption has recently been supported
by trials of bioinformatically designed ‘mosaic‘ antigens that were
pieced together from multiple HIV epitopes and resulted in broad
protective efficacy in rhesus monkeys.(24)
Neutralizing antibodies are not only a product of the host im-
mune system but also experience increased use as antiviral drug
that are produced by recombinant techniques and administered to
the patient. However, only one antiviral antibody (Palivizumab, a
compound effective against the respiratory syncytial virus RSV) is
currently approved due to the high costs associated with the syn-
thesis of these biologicals.(25)
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Viral resistance and drugs targeting host factors
The emergence of resistant viral variants especially in high-
progeny, low-fidelity RNA viruses such as HIV and HCV have
resulted in the growing importance of resistance management in
antiviral therapy. Also, viral latency in cellular comportments or tis-
sues not reachable by antiviral drugs may lead to chronic infections
and residual viremia even if the virus is present at undetectably low
viral plasma loads.(26)
Three prominent strategies have been proposed for counteract-
ing the emergence of viral drug resistance: first, drug combination
therapies that increase the genetic barrier of the therapy against
upcoming drug resistance by requiring the virus to develop escape
mutations against two or more drugs with different mechanisms
of action.(27) Second, methodologies of personalized medicine that
afford insight in particularities of the viral and host genomes, re-
spectively, in order to select drugs that maximize therapy success
at any point in therapy.(28) Third, targeting host factors that are
essential for viral infection or replication and may be associated
with reduced emergence of resistance. The latter strategy will be
discussed here in detail while the other two approaches, combina-
tion therapies and personalized therapies, will be discussed at some
greater detail in Chapter IV.
Advantages of drugs targeting host factors. Basic research on essen-
tial host factors that are targeted by viral pathogens has lead to the
development of several new compounds especially against highly
diverse pathogens such as RNA viruses that rapidly acquire drug
resistance. In contrast to therapeutic compounds that target viral
factors and that may lose efficacy due to the emergence of resis-
tance mutations in the viral genome, host factors are typically well
conserved and can not be mutated by viral evolutionary processes.
In addition, targeting host factors significantly increases the viable
antiviral drug targets from about 10 proteins encoded in RNA-viral
proteins to the larger number of virally accessed host factors, some
of which may be relevant for other diseases and may thus have
known inhibitors.
An especially interesting class of host proteins in this regard are
bridge proteins, i.e., proteins that have a low number of binding
partners but act as a common component for many host pathways.
Such bridge proteins are selectively attacked by several classes
of viruses and may therefore constitute factors essential for viral
replication.(29) However, since these bridge proteins are also likely
to be important factors for the host cell, their inhibition may cause
unwanted side effects that may or may not surpass side effects of
existing antivirals that target viral factors.
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The search for druggable host factors has identified several
suitable targets with respect to HIV, HCV, and influenza infec-
tion.(30)Interestingly, up to 20% of all experimentally identified viral
host factors across experimental studies belong to a common set of
human pathways, a fact that may firstly allow for the development
of broad spectrum antivirals.(31) Only 10 of the more than 50 FDA-
approved antiviral compounds target host factors and none of these
compounds has been especially developed for broad efficacy;(32)
however, some of the most successful FDA approved inhibitors
such as the HIV antiviral Maraviroc exhibit favourable pharma-
cokinetic and safety profiles, indicating that host factor targeting
drugs are not necessarily paralleled by strong side effects.(33) In ad-
dition, supplementary approaches for using host factors to increase
therapeutic efficacy exist; as touched upon previously, at least two
indirect acting antiviral compounds, interferon and ribavirin, in-
crease the natural antiviral host response.
Limitations of host factor antivirals. Although host factor target-
ing medicines have been shown to be effective in many different
settings,(34) they may not be the golden bullet either. While viruses
cannot directly prevent antivirals from binding to host factors,
adaption of viral binding interfaces by mutation and selection may
result in differential usage of host factors and consequent loss of
drug efficacy. This is exemplified by recent results concerning HCV
that have demonstrated how alternative use of host factors may
result in resistance to the cyclophilin inhibitor SCY-635.(35)
Similarly, HIV-1 is also able to circumvent drugged host fac-
tors: immunodeficiency viruses employ host chemokine receptors
such as as CXCR4 or CCR5 as cofactors for viral entry that are tar-
geted by drugs in highly active antiretroviral therapy (HAART).(36)
Treatment with these drugs may result in mutations of viral glyco-
proteins that are associated with a shift in viral coreceptor usage or
by viral adaption to the inhibitor bound coreceptor, both of which
result in drug resistance.(37)
While this switch in coreceptor usage may partly reflect the
normal evolution of HIV-1,(38) and the reported levels of drug resis-
tance are comparably low and affect only a minority of patients,(39)
HIV resistance to host factor drugs is still considered an important
contributing factor to therapy failure.(40) As a result, determination
of viral host tropism profiles based on sequencing has significant
clinical consequences and is commonly used to inform therapy
decisions.(41)
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Future antivirals. Based on the successes of broadly acting drugs,
the drug-induced activation of host enzymes associated with the
innate immune systems such as APOBEC, TRIM, and toll-like re-
ceptors (TLRs) are considered to be an interesting approach to
broadly and indirectly acting antivirals.(42) Also, novel compounds
that do not target host factors but represent orthogonal approaches
to attacking viral factors are under active development. These ap-
proaches include broadly acting antibodies and RNAi technologies
whose therapeutic potential against HCV, HBV, HIV, and highly ag-
gressive viruses such as Marburg virus and Ebola virus is currently
explored.(43)
Current antiviral therapy is mainly aimed at lowering viral load
in order to limit symptoms of the disease and facilitate immune
clearance. In addition, low viral loads implicitly reduce the abun-
dance and thus the diversity of the viral infections, thus reducing
the viral adaptability to future interventions such as antiviral ther-
apy. As will be discussed in more detail in Chapter IV, combination
therapy is successful in increasing the overall genetic barrier of the
treatment especially if the drugs employed have orthogonal modes
of action and, as a consequence, feature differing pathways to re-
sistance. However, ongoing low-level replication, mutation, and
selection within highly adaptive viral species will commonly result
in development of multi-drug resistant variants and thus therapy
failure.
If antiviral compounds currently under development are a sign
of things to come, then the antiviral drugs of the next two decades
may increasingly focus on host factors instead of on viral factors
as drug targets. While the control of side effects of these drugs re-
mains an important goal, the potential for repurposing existing
drugs that already target host factors, the promise of reduced drug
resistance, and the potential of host factor targeting drugs to act as
broad-spectrum antivirals makes the development of these com-
pounds attractive endeavours.(44)
In addition, and in accordance with general trends in the phar-
maceutical industry, the importance of biologicals such as anti-
bodies, RNAi, vaccines, and synthetic interferons is also likely to
increase.(45) Although significantly more expensive to produce than
small molecule inhibitors and facing additional pharmacokinetic
constrains, biologicals often have proven effectiveness in the host as
confirmed by basic research, have high specificity towards one or
multiple closely related pathways, and have important competitive
advantages such as being harder to reproduce as generics. Exam-
ples for this development are early-stage broad-spectrum antivirals
that employ biologicals to emulate intracellular apoptotic control
circuits or inhibit viral maturation by blocking capsid assembly on
a broad range of viruses.(46)
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16 Measuring protein interactions
As discussed in the last section, virally targeted host factors
are of high medical relevance and their determination is crucial for the
development of novel antiviral drugs. Interactions between viral and host
proteins, arguably the most promising form of molecular virus-host inter-
action from the standpoint of drug development, can be inferred by high-
throughput experimental and computational protein interaction assays.
The measured or predicted interaction patterns can subsequently be visual-
ized in protein interaction networks (PINs). Within such networks, nodes
represent proteins and edges denote interactions that vary in directness
and directionality according to the network type. In contrast to detailed
analyses of single protein interactions, PINs are usually analyzed using
tools of interdisplinary disciplines such as network science or systems biol-
ogy. While PINs serve as useful abstraction of the protein interactome (i.e.,
the set of all protein interactions in a organism or host-pathogen system)
and are frequently used in systems biology, they also have been criticized
as hard to interpret and validate in a genome-wide manner, lacking struc-
tural annotations, and not sufficiently discerning between succinct kinds
of interactions and their associated experimental confidences.(1) Still, these
networks are widely employed as discovery tools for basic research as well
as for interrogating the molecular basis of disease.(2) In this section, we
will provide an introduction to protein interactions as well as the experi-
mental and computational methods that are commonly employed in their
investigation. In addition, we will also discuss protein purifications, a
specific form of protein interaction data that poses particular challenges in
term of interpretation and analysis.
Classes of protein interactions
Proteins are structurally and functionally diverse molecu-
lar entities that are responsible for the vast majority of mechanistic
(i.e., ordered and reproducible as far as conceivable within a highly
dynamic and stochastic environment) molecular manipulations
within the cell. As such, a protein specifies a discrete component of
cellular function that is embedded in a dynamic network of other
proteins with which it physically interacts.(3) Proteins perform their
functions by way of physical interactions with other proteins as
well as with other cellular components such as metabolites, nu-
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cleotides, and membranes. While some proteins form only transient
interactions (for example, most classes of enzymes and kinases),
many proteins co-complex and form longer lasting assemblies that
perform a concerted function and differ in size, heterogeneity, and
temporal dynamics.
Proteins may form both transient binary interactions form ho-
mogeneous or heterogeneous protein complexes which are longer
lasting (although not always permanent) and are also denoted as
protein assemblies. Examples for such assemblies range from dimers
consisting of only two polymers, over larger homo-multimers, up
to multi-component conglomerates such as ribosomal subunits,
the proteasome, and the gigantic nuclear pore complex.(4) Inter-
actions within these assemblies are inherently governed by both
thermodynamic principles,(5) as well as on the chemical and biolog-
ical characteristics of cell physiology, competitive binding to other
factors, and protein abundance.(6)
In the context of this chapter, experimentally derived protein in-
teractions can conceptually be separated by at least two dimensions;
one such dimension is the distinction between direct physical, indirect
physical, and non-physical associative interactions. Direct physical
protein interactions are interactions between peptides that are not
obligate (i.e., the peptides are modular entities that are not required
to bind and may exists separately) but either permanently or tran-
siently share a common binding interface where residues of both
peptides are in direct and non-covalent contact with each other.
Often, direct physical protein interactions are also shorthandedly
denoted as binary protein interactions, although these terms should
not be considered to be strictly identical.
Indirect physical protein interactions involve two peptides
that co-complex (i.e., are belonging to the same assembly of non-
covalently bound protein modules) but do not share a common in-
terface. Rather, these interactions are mediated by additional direct
physical protein interactions that may or may not be observed in a
given experimental procedure. Finally, non-physical associative in-
teractions denote pairs of proteins that co-occur in a common path-
way or sub-cellular compartment or are experimentally associated
(for example, by gene co-expression or synthetic lethality) without
any additional evidence of direct or indirect physical interactions
between the subunits.(7) As such, these associations often describe
metabolic or genetic correlations rather than co-localizations in time
and space.
The other classification of interest here is the distinction between
endogenous (i.e., interactions between proteins of the same species)
versus exogenous (interactions between proteins originating from
different species) protein interactions. While endogenous inter-
actions usually act cooperatively to implement a specific cellular
function, exogenous protein interactions are driven by a wider ar-
ray of mechanisms that range from from parasitic to symbiotic.(8)
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Experimental protein interaction assays
In order to investigate the precise function of a protein as-
sembly, it is crucial to infer the set of binding patterns between all
its members in a spatially and temporally highly resolved manner.
Several experimental protocols and technologies, in the following
denoted as assays or systems, have been developed in order to mea-
sure the transient and permanent features of protein interactions.
Today, protein interactions can be measured by several biophysi-
cal and genetic systems(9); while historically small-scale interaction
assays focused on structural methods such as X-ray crystallography
and NMR spectroscopy, modern genetic approaches neglect struc-
tural aspects of the measured interactions in favor of increased
experimental throughput. In particular, today binary interac-
tions assays and co-complex detecting methods such as Y2H and
(T)AP/MS, respectively, are considered to be premier approaches
for orthogonaly and complementarily masuring the interactome.(10)
Yeast Two-hybrid. Yeast Two-hybrid (Y2H) is an experimental
protein interaction assay that measures direct protein interactions
by means of transcriptional activity.(11) Yeast transcription factors
such as Gal4 that contain an activating (AD) and DNA binding
(BD) domain are fused to two open reading frames (ORFs), re-
spectively, that encode the pair of proteins under investigation,
functionally denoted as bait and prey. The fusion constructs are
transfected into yeast. Upon physical interaction of bird and prey
the transcription factor domains are brought into close proximity
and induce expression of a reporter gene that has phenotypic and
observable effects on the yeast cell. Due to the granularity and sen-
sitivity of this approach, large scale studies aided by robotics are
able to interrogate tens of thousands of individual interactions in
parallel.(12) However, the false positive rate of the Y2H system has
been reported to be high, mostly due to biases in the experimental
quantification of the interactions, artificial interactions between pro-
tein partners not co-located in the same sub-cellular compartments
under native conditions, and occasional indirect physical interac-
tions.(13) However, recent advancements of the original Y2H system
concerning the activation of reporter factors and the use of statisti-
cal scoring schemes have been employed to significantly lower the
error rate and Y2H is now the most widely used system to measure
protein interactions.(14)
Affinity purification. Affinity purification and mass spectrometry
(AP/MS) has been established as a more recent physical protein
interaction assay that is designed to detect co-complexing proteins
and thus measures both direct and indirect physical protein interac-
tions in a single assay.
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Similar to Y2H, affinity purification follows a bait/prey approach
that requires genetic tagging of the bait ORF with a known epitope
such as GFO, StrepII, or FLAG prior to transfection into a yeast
strain. The expressed protein complex is subsequently purified
from the cellular medium using antibody affinity to the genetic tag.
The components of the purified complex are then identified using
liquid chromatography and tandem mass spectrometry (LC-MS).
A prominent variant implementing this interaction detection sys-
tem is tandem affinity purification (TAP/MS) that allows for several
sequential purifications in order to reduce contaminating proteins
prior to identification.(15) In contrast to Y2H, affinity purification
systems are biased towards more stable interactions that survive
purification and are thus less likely to detect transient protein in-
teractions. Affinity purification systems have been employed in
large-scale studies interrogating the protein interactome of several
model organisms such as yeast, worm, fly, and also human.(16)
Due to their ability to measure larger protein assemblies that
may involve dynamic, i.e., functionally optional or temporally vari-
able interaction partners, (T)AP/MS approaches are also suited for
measuring protein complex dynamics using experimental perturba-
tion techniques where the same complex is assayed multiple times
in different states.(17)
Affinity purification exhibits significant false positive experimen-
tal errors due to its requirement to over-express bait proteins, as
well as due to off-target effects or reduced binding of antibodies,
nonspecific binding events, and missing cellular compartmentaliza-
tion of the tested proteins as a result of cell lyses.(18)
Refinements of the genetic protocols have been proposed that
allow for measurements in slightly more physiological environ-
ments but are still biased towards detecting highly stable interac-
tions.(19) Similarly, statistical approaches that better quantify the
uncertainty of MS protein identification have been utilized to re-
duce error rates.(20) For instance, while the raw false positive rate
of affinity purification systems is broadly comparable to that of
Y2H assays,(21) methodologies have been proposed that quantify
the abundance of the identified proteins by means of peptide spectra
or differential isotope labeling of test and control purifications in or-
der to identify contaminant proteins based on their abundance and
binding specificity.(22)
Similarly, false negative errors that may be incurred due to the
washing of physiologically relevant, transiently attached proteins
during purification or that may result from low abundance interac-
tions can partly be mitigated by specialized protocols.(23)
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Interpreting protein interaction assays
Apart from suffering from specific false positive and false
negative error profiles, purification data pose further challenges for
interpretation:(24) even after removal of contaminants, the retrieved
set of co-complexed proteins is stabilized by a mixture of direct and
indirect physical interactions. It is therefore not easily possible to
identify proteins that share a common binding interface, nor is it
straightforward to identify proteins that might by part of multiple
physiological protein complexes that are co-purified within one
single purification. Although additional techniques such as binary
protein interaction assays, perturbation protocols, and quantitative
MS approaches involving peptide counts or isotope labeling may
aid in answering these questions, no consensus on a method for the
integration of these approaches has yet been established. Instead,
ad-hoc methods for interpreting interactions within purifications
are commonly used when deposited these interactions in public
repositories.
These methods, termed spoke expansion (interactions between
bait protein and all its preys) and matrix expansion (interactions
between all proteins of a purification regardless of bait or prey sta-
tus), are prone to false negative and false positive errors: the spoke
expansion neglects possible interactions between prey proteins that
are physiologically likely to stabilize the complex and furthermore
assumes that all preys are in direct physical contact with the bait;
the latter fact is unlikely for larger purifications due to mutually
exclusive binding interfaces. For the same reason, the matrix model
of expansion leads to high rates of false positive interactions since
large complexes are unlikely to be fully connected. In addition,
both expansion models do not delineate multiple physiological
protein complexes that have been captured within the same purifi-
cation.
While additional experimental approaches like reciprocal pu-
rifications, multiple orthogonal purification steps, or perturbation
approaches may be conducted to obtain this missing information
from protein purifications,(25) for example by cross-linking experi-
ments,(26) these systems are cost-intensive and require specialized
training. In addition, all known experimental methods, both high-
throughput and low-throughput, influence cell physiology to dif-
ferent degrees and in different manners, resulting in experimental
results that are significantly biased by the assay being used. This
fact regularly results in low reproducibility between identical pro-
tein interaction assays run by different labs as well as low overlap
between the results of different experimental approaches, thereby
significantly complicating interpretation and comparison of protein
interaction screens on genomic scales.(27)
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Computational interpretation and scoring methods. Due to these
biases, even refined protein interaction protocols result in more
measured protein interactions than would be expected given exist-
ing biological knowledge and comparisons with orthogonal protein
interaction assays. Consequently, in silico methodologies have been
developed in order to aid in the interpretation of the measured data
and to support identification of false positive experimental results
by means of statistical models, additional experimental variables, or
external information such as known protein interactions, functional
annotations, and additional assays measuring protein-protein or
gene-gene associations as for example gene expression measure-
ments or synthetic lethality(28) experiments.
Many computational methods that classify or quantify protein
interactions with regard to their status as potential contaminants
make use of a background set of known, high-confidence protein
interactions deposited in public databases such as HPRD, DIP,
IntAct, BioGRID, MINT, and BIND.(29) However, analyses have re-
ported low levels of concordance between these databases, a fact
that is likely due to differing methods of data curation.(30) Recent
standards by the Proteomics Standard Initiative, data querying in-
terfaces that are able to contact multiple databases, as well as meta-
databases such as IRefIndex and IRefWeb have aimed to mitigate
these discrepancies.(31)
While a broad (perhaps overly broad) range of protein interac-
tion scoring schemes exists,(32) here we will concentrate on methods
that perform primary data analysis of purifications originating
from (T)AP/MS assays and do not utilize additional, external data
sources such as public databases. These primary data analysis
methods can be further subdivided into methods that only rely on
the list of proteins identified within each purification experiment
(frequency-based approaches) and methods that employ non-standard
experimental data from the (T)AP/MS workflow and thus require
special protocols (spectral count approaches).(33) Two computational
methods utilizing such additional (T)AP/MS data are ComPASS
and SAINT, both of which use spectral counts and experimental
replicates in combination with statistical models based on the Pois-
son distribution in order to detect false positive interactions within
the purification data.(34)
On the other hand, frequency-based socio-affinity approaches
apply statistical models directly to the purification data in order to
detect unreliable or promiscuous interactions based on experimen-
tal replicates.(35) This class of approaches has lately been supple-
mented by more elaborate methods by Collins et al., Guruharsha el
al., and Yu et al. that include clustering, supervised learning, and
permutation-based approaches in order to increase sensitivity.(36)
The last section of this chapter will discuss advantages and disad-
vantages of several of these methods in more detail.
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17 Detection of viral host factors
As discussed in previous sections, human pathogens in general and
viruses in particular are relying on host-pathogen molecular interac-
tions that are crucial for initiating and sustaining infection as well as for
evading host immune responses.(1) Successful establishment of infections
requires networks of molecular interactions of a pathogen with its host
that involve a variety of molecular agents such as proteins, nucleotides,
small ligands, sugars, and fatty acids.(2) Better characterization of these
networks may aid in identification of new targets for drugs or vaccines
and further has the potential of facilitating development of therapeutic
compounds that have higher genetic barriers to drug resistance or fewer
side effects than presently available medicines.(3) Of the interacting agents
mentioned, proteins have been identified as the factors of the highest med-
ical and pharmacological interest and therefore their interactions are of
primary importance for further investigation.(4)
Experimental determination of host factors
Viruses are especially amenable to genome-wide protein in-
teraction screens due to their relative small genome size; indeed,
many viral pathogens displaying drug resistance consist of RNA
viruses that encode only a limited number (on the order of 10) pro-
tein factors. Indeed, the smallest human infectious virus known,
Hepatitis D, encodes only two mature proteins. While DNA viruses
such as herpesviridae typically encode on the order of 200 proteins
and viruses with up to 1,200 genes have been identified, these num-
bers are still dramatically lower than the sizes of proteomes of
prokaryotes such as E. coli which contains more than 4,000 protein
coding genes and a pan-genome of more than 16,000 such genes,
similar in magnitude to the about 20,000 human protein-coding
genes.(5)
Intra-viral interaction networks. Consequently, experimental mea-
surements of host-pathogen PINs and subsequent analysis of their
functional and structural principles have first been undertaken
for viruses, followed by bacterial networks.(6) Following proof-of-
principle investigations on bacteriophages, several protein interac-
tion networks have been determined for HCV, herpesviruses such
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as HSHV and EBV, and SARS coronavirus using predominantly
Y2H assays.(7) Interactions thus identified have been deposited in
general protein interaction database as well as in a rising number of
more specialized repositories.(8)
Virus-host interaction networks. Due to the limited technology
available at the time, only intra-virus protein interactions (i.e.,
excluding host factors) were investigated in the aforementioned
studies. While this level of analysis allows for inference of basic
network properties as well as identification of essential protein
factors of a pathogen that may serve as therapeutic targets, only
very limited knowledge can be gained about the role of these fac-
tors within the larger host protein interaction network. Therefore,
and as a natural extension of these first intra-viral investigations,
combined host-pathogen interaction studies were later proposed
in order to interrogate the intricate interspecies interplay between
the pathogen and components of the host immune, signaling, and
nucleotide replication system.(9) While the first of these extensions
have focused on computational methods due to missing experi-
mental data,(10) more recent large-scale experimental setups target
important human pathogens such as HCV, Influenza A, HIV, and
EBV and include both human and viral protein factors.(11)
Structural approaches. In addition, structural studies have been
undertaken that interrogate structural properties of host-pathogen
interactions.(12) Using these structural data afforded a more de-
tailed look at the specific modes of experimentally derived and
predicted host-pathogen protein interactions by analyzing their
physical binding interfaces. Since only relatively few pathogen
protein structures are available at atomic resolution, these studies
commonly employ homology modeling(13) to increase coverage of the
host-pathogen PIN.(14)
Only few host-pathogen protein interactions with either atomic
or homology models exist: a recent study identified only 53 such
interactions.(15) While these numbers do not allow for high-coverage
annotation or prediction of host-pathogen PINs, the available data
are sufficient to derive general organizational principles of these
networks. It is estimated that more than half of all proteins without
known atomic structure share sufficient sequence similarity with a
structurally resolved template protein, allowing the construction of
at least partial homology models in most of these cases.(16) Struc-
tural coverage of endogenous protein interaction is significantly
lower (on the order of 20% of all known human protein interactions
are covered by at least partial models) and biased towards highly
stable interactions.(17) However, it was noted that structural cover-
age may be significantly increased by using either more advances
methods for homology modeling or by the additional use of tem-
plates with structural rather than sequence-based similarity to the
query.(18)
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Properties of host-pathogen interaction networks
Analyses of the topology of intra-virus interaction networks
have demonstrated that viral proteins are often multi-functional
and interact with a large number of distinct host factors, each of
which in turn is often targeted by more than one viral factor.(19)
Prior analyses of the about 144,000 known human endogenous
protein interactions(20) have shown that the human PIN is scale-
free and that its degree distribution (i.e., the distribution of the
number of connections of all nodes within the network) follows a
power law. This network contains only a limited number of highly
connected nodes (hubs) and is dominated by a vast majority of
nodes that have only few connections.(21) Scale-free topologies are
characterized by functionally separated protein modules that are
connected by a few hub proteins(22) As a consequence, the average
number of connections between nodes is low, i.e., the network ex-
hibits a high degree of signaling efficiency while still being very
robust with respect to random removal of nodes; however, networks
of this kind are highly sensitive to the removal of hubs.(23)
Properties of viral protein interaction networks. In contrast, topolog-
ical analysis of intra-virus protein interaction networks indicated
that viral proteins are highly coupled (i.e., are densely connected
with many other viral proteins), resulting in relatively many hubs
and only few peripheral nodes.(24) Detailed analyses of these vi-
ral network topologies showed that these networks are neither
scale-free nor do they exhibit small-world properties, thus indi-
cating their relatively high sensitivity to random perturbations
or deliberate attacks on the connectivity of the network.(25) This
apparent sensitivity of the viral protein interaction network is in
stark contrast with the observed persistence of infection; indeed,
even with an arsenal of only a few proteins, viruses regularly over-
come immune responses and control cellular networks of vast size
and complexity. It seems therefore likely that viral protein inter-
action networks obtain emergent properties within a native (i.e.,
host-embedded) context that provide them with robustness and
versatility not inferrable by intra-viral experiments.(26)
Virally targeted host factors. Later investigations of host-pathogen
interaction networks uncovered that viral proteins predominantly
target highly connected (topological hubs, i.e., having a high degree
within the interaction network) and bottleneck (topologically cen-
tral, i.e., being included in many shortest paths between random
proteins in the network) host proteins.(27) Host proteins thus tar-
geted are themselves densely clustered into protein complexes and
biological pathways that are essential to pathogen infection and
propagation and that further are in close network proximity with
each other.(28)
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Although experimental studies targeting host-pathogen interac-
tion networks investigated viruses with very different life cycles,
there is considerable overlap between the host factors identified
(5  20%). In particular, viruses seem to commonly utilize host pro-
teins and pathways concerning components of the innate immune
defence such as the Toll-like receptor network that is responsible
for eliciting interferon response or autophagy pathways which may
trigger degradation of foreign factors by the lysosomal machin-
ery.(29) While many of these host factors are under positive selec-
tion that may be evidence of pathogen-driven evolutionary selection
pressures, they also tend to be highly conserved across closely re-
lated species, possibly highlighting components of the host cell that
are especially vulnerable to viral perturbation.(30)
In order to further increase the power of host-pathogen inter-
action studies and allow for identification of driving principles of
viral infection, more comprehensive approaches were undertaken
that combined interaction data from several viral species. These
analyses further confirmed the importance of host hub and bottle-
neck proteins such as transcription factors and proteins involved in
cell cycle regulation, apoptosis, and cellular transport.(31) Interest-
ingly, while bacteria and viruses share common strategies, such as
attacking hub and bottleneck proteins and host factors involved in
metabolic processes, viruses seem to favor host proteins with higher
connectivity and centrality and tend to focus on cellular processes
to a larger degree than bacteria, which in turn predominantly ad-
dress the host immune system.(32)
Structural investigation of virus-host interactions. Structural investi-
gations led to the conclusion that viral proteins mimic endogenous
host protein interfaces, often without exhibiting any large-scale
structural homology to the host protein thus mimicked. This tac-
tic as well as observed overlaps of other existing endogenous host
interfaces with exogenous viral interfaces may be a common strat-
egy of viral proteins that facilitates accessing the host cell protein
network, competing with host factors, and evading immune recog-
nition. Host interfaces mimicked by viral factors are under positive
selection, possibly indicating an evolutionary arms race between
pathogen and host.(33) Reversely, viral interfaces are sometimes
acquired by the host cell and re-purposed.(34)
Interestingly, viral protein binding interfaces seem to be signifi-
cantly smaller than host interfaces, possibly indicating evolutionary
pressure on viral genome size. Indeed, since viruses are obligate
parasites that have to modulate or control the complex host en-
vironment in order to propagate, it is likely that most if not all
physical interactions of the few viral proteins that can be efficiently
encoded and replicated in the viral genome are also functionally
relevant.(35) Additionally, smaller viral binding interfaces may be
evidence for selection of less specific and more transient modes of
interaction of viral proteins.(36) The latter assumption is further
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supported by the fact that host proteins targeted by viral interfaces
are very often date-like, i.e., multiple binding interfaces of the same
protein are not used simultaneously to form larger complexes but
employed serially to bind to various partners across time. This fact
further supports prior findings that host proteins targeted by viral
factors are often hubs that mediate approximately twice as many
protein interactions as an average human protein.(37) Such ’serial’
hubs are often high-level regulatory host proteins that access and
regulate the host cell interaction network, indicating that viruses
specifically target these factors in order to efficiently control and
perturb host network functions.
Approaches to inferring host-pathogen interactions
Computational approaches play a two-fold role in processing
host-pathogen interaction data. First, since experimental data on
host-pathogen interactions are comparatively rare, these approaches
may predict high-confidence host-pathogen interactions based on
existing data and thus prioritize these interactions for experimental
investigation. Such predictive approaches can be roughly differen-
tiated into homology-based, structural, protein region-based, and
integrative methods.(38) Second, in silico methods can be utilized
for assessing experimentally derived and predicted host-pathogen
PINS based on reference protein interactions,(39) functional annota-
tion,(40) and secondary experimental evidence such as RNAi.(41)
In the following, classes of experimental data are discussed that
either may be utilized for directly validating host-pathogen pro-
tein interactions or that may serve as input for computational tools
aiming to predict or validate such interactions. Subsequently, com-
putational approaches that employ these data are discussed.
Approaches to validating physical interactions. Protein interactions
in general and host-pathogen protein interactions in particular can
be validated by several means. First and foremost is the assess-
ment of query interactions by gold standard experimentally derived
protein interactions. Such high-confidence interactions are only
available for a few, well studied pathogens such as HIV(42) and
are deposited in a range of specialized databases covering exper-
imentally conformed interactions (PHI-base), interactions cited in
literature (HIV-1, The Human Protein Interaction Database), Virus-
MINT, and interactions from mixed sources (VirHostNet).(43) All of
these database have significant overlap with more general protein
interaction database mentioned before and use the latter as sources
of newly deposited interactions. Furthermore, meta-databases such
as APID, iRefIndex, PHIDIAS, HPIDB, GPS-Prot, and PATRIC offer
unified access to their member databases and also allow for limited
data manipulation and visualization.(44)
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An interesting new alternative to traditional protein interaction
assays that is able to measure transient or dynamic interactions
is the use of molecular imaging techniques; in particular, live cell
imaging microscopy approaches afford detection of individual
molecules at high temporal resolution and have been employed for
studying host-pathogen interactions.(45)
Genetic and genomic approaches. Viral host factors can further be
identified by experimental RNA interference (RNAi), a protocol that
employs short interfering and short hairpin RNAs to inhibit gene
expression of specifically targeted factors. RNAi high-throughput
screening resulted in several human proteins that are not essential
to the host cell but whose inhibition proved lethal for viruses such
as HIV, indicating that these proteins may be involved in virus-host
protein interactions.(46) While the acceptance of RNAi is increasing,
developing RNAi libraries with high coverage over host factors is
still considered to be technically challenging and the relevant proto-
cols may suffer from technical errors that limit reproducibility.(47)
While purely concentrating on analyzing variants within the
host genome and correlating them with disease phenotypes using
genome-wide association (GWAS) methods enabled highlighting of
genomic loci that are predictive for the outcome of viral infections
by HCV and HIV, these methods require large sample sizes espe-
cially for rare variants and can suffer from sample-selection biases
and differences in population structures.(48)
Homology-based approaches to host-pathogen protein interac-
tion prediction rely on the assumption that interaction patterns are
conserved between protein homologs, in particular between or-
thologs.(49) This approach is often implemented by using template
protein interactions from several databases containing protein and
domain interactions and has predominantly been used to predict
human-bacterial protein interactions due to the higher coverage
of prokaryotic proteins and template protein interactions in public
databases compared to their viral counterparts.(50) Further refine-
ments of homology-based approaches that include additional filters
to reduce false-positive interactions (for example, from protein
homologs that are expressed in different cellular compartments
in the target species and are thus unlikely to interact) have been
proposed.(51)
Structural approaches. Analogous to the homology approach,
host-pathogen protein pairs that bind via an interface similar to
such already known to bind in other species are also suggested to
represent true interactions. This approach is followed by several
structural approaches using either protein sequences and corre-
sponding SCOP super-families with known binding interfaces(52)
or direct computation of structural similarity between atomic struc-
tures of pathogen and host proteins, assuming that pathogen pro-
teins structurally similar to host proteins share binding partners.(53)
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Proteins are composed of a finite set of protein structural do-
mains that fold independently and are covalently and non-covalently
bound to other domains within the same protein. Protein domains
are modules of protein function and exhibit various patterns of
well-defined activities, one of which being the stable binding of
other protein domains in the same or other proteins. Protein do-
main families and their binding interfaces thus mediate and im-
plement stable protein interactions in a regular and deterministic
fashion.
Protein-region based approaches to analyzing host-pathogen
protein interactions rely on obtaining patterns of domain interac-
tions from either known protein interactions or public reposito-
ries.(54) Putative host-pathogen protein interactions are then be-
lieved to be real if they are supported by one of the known domain-
domain interactions.(55) In principle, and due to the relatively low
coverage of known or high-confidence predicted domain interac-
tions, these methods currently have at most of 20% sensitivity.(56)
An extension of this approach consists of considering other pro-
tein regions, such as short linear motifs (SLiMs). SLiMs are short
sequence motifs located in disordered protein regions that are be-
lieved to mediate transient protein interactions. Viruses that, due
to their small proteomes, do not have physical space for as many
binding domains as there are observed protein interactions, are be-
lieved to make extensive use of short linear motifs for interacting
with host proteins.
This strategy is believed to be advantageous for viruses for sev-
eral reasons: first, the short length and location in disordered pro-
tein regions allows quick evolution of these motifs without being
limited by functional or structural constraints;
second, the broad specificity and transient interaction pattern of
SLiMs makes them particularly suited for signaling purposes, for
instance by modulating interaction patterns of cellular kinases;
third, the short length of linear motifs allows integration mul-
tiple such regions in a single viral protein chain, thus facilitating
multi-functionality.(57) Indeed, experimental evidence suggest that
viral proteins that target many host factors display a higher content
of intrinsically disordered regions that are likely locations for linear
motifs.(58) These locations seem to harbor clusters of short linear
motifs that may be important determinants of virulence.(59)
Functional and integrative approaches Physical interactions, genetic
attributes, and structural features of viral and host proteins often
result in specific functional annotation of these factors in the Gene
Ontology (GO). Analysis of GO terms in combination with scoring
methods and approaches to functional enrichment analysis may
thus serve as surrogates for experimental observables and can high-
light high-confidence interactions for experimental validation.(60)
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Similar to GO analysis, pathways annotations of genes or pro-
teins are employed to highlight which host functions are prefer-
entially targeted by pathogens; for instance, HIV alone is known
to directly or indirectly interact with the majority of known hu-
man cellular pathways and these annotation data may thus indicate
possible interactors.(61)
Finally, integrative approaches commonly use supervised or
semi-supervised machine learning methods in order to classify and
cluster protein interactions with regard to their similarity to known
host-pathogen protein interactions. These models are trained with
a wide array of proteomic, sequence-based, and functional fea-
tures.(62)
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Preliminary conclusion
In conclusion, this chapter has presented an overview of viral host
factors that are essential for viral entry, replication, and immune
evasion and that are cunningly subverted by all known viruses
pathogenic to humans. Several classes of antivirals are currently
employed to counteract viral disease, the use of many of which is
hindered by side effects and emergence of viral drug resistance.
Drugs targeting host factors promise to increase the repertoire of
available drug targets and may even yield one of the most coveted
results of antiviral research: a broad-spectrum antiviral. Identifi-
cation of drug targets for anti-host factor drugs is depending on
experimental assays that measure interactions between viral and
host proteins. These assays commonly produce results that contain
technical errors such as false positives that may suggest false drug
targets. In order to curb technical error rates, computational post-
processing schemes have been devised that increase the specificity
of the measured interactions and furthermore increase the inter-
pretability of one specific class of protein interaction assays. protein
purifications.

(1) Schelhorn et al. (2011)
18 Inferring physical protein contacts
As introduced earlier in this chapter, protein purification data
provide noisy representations of the dynamic protein complex landscape of
the cell. In contrast to binary interaction assays such as Y2H and PCA,
protein purification assays can capture complete protein complexes that
retain most of their functional components, in principle. It can therefore
be argued that the latter approch allows a more complete and naturalistic
view on the cellular machinery. As a consequence of their suitability for
high-throughput genome-wide applications, protein purification data
can inform the systematic search for novel drug targets, for instance by
determining the set of proteins that interact with viral peptides within
human cell lines.
This section presents a published manuscript of the author(1)
that pertains to the analysis of genome-wide protein interaction
assays. In particular, we introduce a novel approach for inferring
binary protein interactions from protein purification data that is
also well suited for detection of viral host factors. In particular, we
offer two novel contributions to the analysis of protein purification
data.
First, our approach focuses on inferring direct binary protein
interactions from purification data rather than aiming to predict the
full set of direct and indirect protein interactions existing within
physiological protein complexes. As a consequence, our approach
is better suited than comparable methods for inferring interacting
protein regions (as, for instance, protein domains) and the result
of our method are directly comparable to results of binary protein
interaction assays such as Y2H or PCA.
Second, we employ a statistical method that aims to better in-
corporate repeated protein purifications, i.e., technical replicates,
compared to related socio-affinity scores. This statistical approach
allows for increased specificity at detecting physical contacts in-
volving highly abundant or transiently interacting protein classes
such as kinases and molecular chaperones that are of high rele-
vance for antiviral research.
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Introduction
Abstract. Recent large-scale data sets of protein complex purifi-
cations have provided unprecedented insights into the organization
of cellular protein complexes. Several computational methods have
been developed to detect co-complexed proteins in these data sets.
Their common aim is the identification of biologically relevant pro-
tein complexes. However, much less is known about the network
of direct physical protein contacts within the detected protein com-
plexes. Therefore, our work investigates whether direct physical
contacts can be computationally derived by combining raw data
from large-scale protein complex purifications. We assess four es-
tablished scoring schemes and introduce a new scoring scheme that
is specifically devised to infer direct physical protein contacts from
protein complex purifications. The physical contacts identified by
the five methods are comprehensively benchmarked against differ-
ent reference sets that provide evidence for true physical contacts.
Our results show that raw purification data can indeed be ex-
ploited to determine high-confidence physical protein contacts
within protein complexes. In particular, our new method out-
performs competing approaches at discovering physical contacts
involving proteins that have been screened multiple times in purifi-
cation experiments. It also excels in the analysis of recent protein
purification screens of molecular chaperones and protein kinases.
In contrast to previous findings, we observe that physical contacts
inferred from purification experiments of protein complexes can be
qualitatively comparable to binary protein interactions measured
by experimental high-throughput assays such as yeast two-hybrid.
This suggests that computationally derived physical contacts might
complement binary protein interaction assays and guide large-scale
interactome mapping projects by prioritizing putative physical
contacts for further experimental screens.
Introduction. Proteins often do not act in isolation, but coop-
erate in larger assemblies to fulfill their functions. The resulting
protein complexes are essential in a variety of cellular processes.(2)
Thus, the identification and annotation of protein complexes is
currently the focus of both experimental and computational anal-
yses.(3) Recent advances in experimental technologies for protein
purification and identification,(4) such as tandem-affinity purifica-
tion techniques, enabled high-throughput purification screens for
protein complexes in several model organisms.(5) A typical high-
throughput screen entails hundreds of purification experiments,
where a single purification assays prey proteins that associate with a
given bait protein through multi-protein complex formation.
Due to a variety of reasons, such as experimental noise, pres-
ence of non-specific interactors, or participation of the bait protein
in multiple distinct protein complexes,(6) the experimentally ob-
tained purifications are not directly interpretable as biologically
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relevant protein complexes. Therefore, computational methods
are applied to infer these complexes from raw purification data by
scoring protein interactions within the purifications. Publication
of two independent large-scale screens of protein complexes in the
yeast Saccharomyces cerevisiae triggered development of several such
scoring schemes(7) and resulted in a revised catalog of manually
curated yeast complexes.(8)
Proteins within a complex are connected by protein interactions.
Here, protein interactions often refer to both direct physical con-
tacts, in which two proteins share a common binding interface, and
indirect, bridging interactions, in which the proteins do not contact
each other directly. Established purification scoring schemes have
been shown to perform well in determining the composition of pro-
tein complexes by identifying such protein interactions in the pu-
rification data. However, these scoring schemes do not discriminate
between direct physical contacts and indirect protein interactions.
Consequently, less is known about which proteins in large-scale
protein purifications form direct physical contacts although this in-
formation is crucial for a deeper understanding of protein complex
formation and organization.
Furthermore, the difficulty of identifying physical protein con-
tacts within protein complex purifications has hampered the com-
parison with results of binary protein interaction experiments such
as yeast two-hybrid assays. A recent comparison found substan-
tially more true physical contacts from binary assays than purifi-
cation experiments.(9) However, this analysis did not consider that
protein complex purifications contain both direct physical contacts
and indirect protein interactions in contrast to binary assays. Since
this results in a lower enrichment with physical contacts, a compar-
ison of the experimental assays that concentrates only on putative
physical protein contacts would provide deeper insights into the
relative merits of each experimental technology.
Even though several experimental and computational meth-
ods exist that produce structural models of protein complexes at
various levels of resolution,(10) structural data required by these
approaches is not readily available for the vast majority of com-
plexes detected by large-scale protein purifications. Thus, the main
objective of this work is to assess whether and how we can make
use of the available purification screens to computationally infer the
network of physical contacts within the assayed protein complexes.
Our guiding principle rests upon the observation that proteins
forming physical contacts within a complex exhibit stronger associ-
ations and thus are more likely to survive purification procedures
than proteins that do not form such contacts. A similar observa-
tion is central to a hybrid approach developed by the Robinson’s
lab in which individual protein complexes are perturbed by exper-
imental techniques to discover physical contacts between proteins
within these complexes.(11) We hypothesize that even though large-
scale purification screens do not directly measure physical contacts
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within complexes, the resulting experimental data does contain
sufficient information to reliably infer these interactions.The three
main contributions of our work are as follows.
First, we propose an elegant computational method for scor-
ing pairs of proteins based on their co-occurrence pattern within a
combined set of purifications originating from multiple large-scale
screens. In contrast to existing scoring schemes, which were origi-
nally developed and evaluated to detect co-complexed protein pairs
regardless of their mode of interaction, our approach is tuned to
detect protein pairs that form direct physical contacts and incorpo-
rates experimental replicates in a statistically sound fashion. As a
consequence, our method can reliably detect true physical contacts
even in the presence of many unspecific or highly transient protein
interactions and especially outperforms existing scoring schemes
if experimental replicates are available. These properties make our
approach particularly suited for the joint analysis of physical con-
tacts from multiple protein purification screens.
Second, we perform a comprehensive evaluation of our and four
other published scoring methods on the task of detecting physi-
cal contacts. Each method scores purification data from two recent
large-scale experiments in yeast.(12) The results of all scoring meth-
ods are benchmarked against several reference sets that represent
complementary evidence for physical contacts. The reference sets
are derived from experimentally determined physical interactions,
three-dimensional structures of protein complexes, manually cu-
rated catalogs of protein complexes, and genetic interaction profiles.
In particular, we assess the scoring methods by inferring specific
physical contacts in two challenging and biologically relevant pu-
rification data sets containing repeated purifications of molecular
chaperones or protein kinases.
Third, we compare top-ranking physical contacts inferred by
our method to two recent high-throughput interaction data sets
derived by the experimental techniques yeast two-hybrid (y2h)(13)
and protein fragment complementation assay (pca)(14) and address
intrinsic differences of high-throughput approaches to mapping
physical interactomes.
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Materials and methods
Large-scale yeast purification data. We utilized a combined set
of purifications from two large-scale screens in the yeast S. cere-
visiae.(15) Raw experimental data was obtained from the supporting
web-site (http://interactome-cmp.ucsf.edu) of one of the exist-
ing scoring methods included in our evaluation, the pe method.(16)
Purification data from the Gavin et al.(17) screen was taken as it is,
while purification data from the Krogan et al.(18) screen was fil-
tered as follows. The Krogan team used two different experimental
protocols, lcms and maldi, for prey identification. For each pu-
rification, we retained preys having maldi identification score of at
least 1.25 and/or lcms confidence score of at least 99%. We further
filtered out preys that were identical to baits in their respective pu-
rifications from both screens. Last, we combined purifications from
the two individual screens into one data set, which we denoted as
large-scale set of purifications. Table 18.1 summarizes purifica-
tion data from individual screens as well as from the large-scale
set.
gavin krogan large-scale
purifications 1,912 3,999 5,911
baits 1,754 2,178 2,830
preys 1,813 3,505 3,759
avg. # preys 10.56 10.31 10.39
protein interactions (bait-prey
pairs)
18,206 32,525 47,254
protein interactions (bait-prey
and prey-prey pairs)
82,202 182,134 238,154
Table 18.1: Summary of purification
data. Summary of purification data
from two independent large-scale
complex purification screens in yeast,
denoted here as gavin and krogan,
as well as for the combined
large-scale set. For each screen
the number of purifications, the
number of distinct bait proteins, the
number of distinct prey proteins, the
average number of preys per
purification, and the number of
distinct bait-prey and distinct
bait-prey and prey-prey pairs are
shown.
Large-scale host-pathogen purification data. In addition to the yeast
purification data employed in the main validation of this study, we
additional obtained large-scale host-pathogen protein purifications
of HIV proteins and HIV poly-proteins in combination with hu-
man host factors.(19) These purifications were performed on two
cell lines, HEK293 and Jurkat, and the resulting data sets are here
denoted as hek and jurkat, respectively.
Protein kinase and phosphatase purification data. In addition to the
large-scale data set, we utilized a specialized purification data
set focusing on kinase and phosphatase interactions in yeast from a
recent experimental study by Breitkreutz et al.(20) The bait proteins
in the Breitkreutz data were screened with three different tag sys-
tems (FLAG, HA, and TAP) and the purified prey proteins include
information about peptide (spectral) counts that can be used as
a semi-quantitative measure of absolute protein abundance. We
obtained raw purification data for all three tag systems from the
supporting website (http://www.yeastkinome.org). Subsequently,
the purifications were filtered to (i) exclude tag-specific contami-
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bk-flag bk-ha bk-tag
purifications 210 307 57
baits 129 207 48
avg. # preys 50.65 47.22 24.39
Table 18.2: Summary of purification
data from a recent purification screen.
Summary of purification data from
the recent breitkreutz (BK)
purification screen by Breitkreutz
et al. (2010) focusing on kinases and
phosphatases in yeast. The screen
was performed with three different
tag systems, FLAG, HA, and TAG.
For each tag system, the number of
purifications, the number of distinct
bait proteins, and the average
number of preys per purification are
shown.
(21) Yu et al. (2008)
(22) Tarassov et al. (2008)
(23) Hong et al. (2007)
(24) Kerrien et al. (2007)
(25) Jäger et al. (2012)
(26) Chatr-aryamontri et al. (2009)
(27) Guldener et al. (2006)
(28) Mulder et al. (2007)
(29) Aloy and Russell (2006)
(30) Berman et al. (2000)
(31) Stein et al. (2005)
nant proteins identified by control experiments in the original study
and to (ii) remove unreliably identified prey proteins with Mascot
scores 35. The resulting breitkreutz (BK) purification data set is
summarized in Table 18.2.
High-confidence physical contacts in yeast. Binary gold standard
(bgs) protein interactions used in a recent assessment of binary
experimental methods(21) as well as the experimental yeast two-
hybrid data (y2h) generated in the same study were obtained from
the CCSB interactome database. Note that, since no true gold stan-
dard for binary protein interactions is available, we decided to use
the bgs naming convention from Yu et al. (2008) to allow for better
comparability of our work. Further binary interactions measured
by a recent protein-fragment complementation assay (pca)(22) were
extracted from the Saccharomyces Genome Database (SGD).(23)
Binary interactions originating from experimental assays that
directly measure physical protein contacts were obtained from In-
tAct(24) and SGD. This set of interactions was filtered to exclude
physical contacts that solely rely on evidence from the y2h and
pca binary protein interaction data sets. The filtered data set was
utilized to (i) define two reference sets: a chaperone reference
set containing only interactions involving yeast molecular chaper-
ones and (ii) a kinase reference set including solely interactions
involving yeast kinases and phosphatases.
High-confidence host-pathogen physical contacts. Binary interactions
representing physical contacts between human and HIV proteins as
well as between pairs of HIV proteins were obtained from the pub-
lication of a recent large-scale purification screen involving these
factors.(25) Since these validation data originally originated from the
VirusMINT(26) database, we here denote the corresponding data set
as virusmint.
Protein complexes and domain interactions. Protein complexes de-
rived from Gene Ontology annotations as provided by SGD and
manually curated protein complexes from the Munich Informa-
tion Center for Protein Sequences (MIPS)(27) were imported from
the websites of the respective organizations and yielded the sgd
and mips reference sets, respectively. For the validation of inferred
physical contacts on the level of protein domain interactions, a
mapping table from SGD was obtained to assign UniProt acces-
sion numbers to all proteins in the large-scale purification data.
Subsequently, globular Pfam-A domain annotations for these pro-
teins were obtained from the InterPro database.(28) We restricted
the used annotations to globular domains since this type of protein
regions is especially well characterized and known to be involved in
stable protein interactions.(29) A list of Pfam-A domain interaction
partners derived from structures of interacting proteins in the Pro-
tein Data Bank (PDB)(30) was obtained from the 3DID database.(31)
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Genetic interaction profiles. Interaction confidence scores derived
from in-vivo synthetic genetic interactions (gi) were obtained from
the supplementary material of a recent large-scale functional study
in yeast.(32) Of the several available data sets containing genetic
interaction scores for pairs of proteins, we selected the lenient cut-
off interaction set that offered the highest coverage of yeast proteins
while, at the same time, including only statistically significant in-
teractions. This data was used to reconstruct genetic interaction
profiles for all proteins in the large-scale purification data set.
Consequently, genetic interaction profile similarities for pairs of
proteins were generated by computing Pearson’s correlation coef-
ficients between the genetic interaction profiles of all protein pairs.
Analogous to the original study, all protein pairs with a genetic in-
teraction profile similarity >= 0.2 were used to form a functional
map of the large-scale purification data. Protein pairs in this
map are denoted as the gi reference set.
Scoring methods. Let F = {f1, ..., fN} be a set of purifications
where each purification fk is composed of a bait protein baitk and
a set of prey proteins preysk. We will use nk to denote the number
of preys in fk and designate N = Âk nk as the size of the multi-set
of all preysk. For a pair of proteins, i and j, let Si!j be the number
of times j is observed among preys in purifications performed with
i as bait and Mi,j be the number of times i and j are observed as
preys in purifications performed with a third protein as a bait.
In what follows, the experimental observations S and M are also
denoted as spoke observations and matrix observations, respectively.
Some scoring schemes combine S and M into one number Oi,j =
Si!j + Sj!i + Mi,j. We will denote by Snulli!j , Mnulli,j , and Onulli,j random
variables representing these different types of observation counts
under appropriate null models. Next, we briefly introduce the
scoring methods that are assessed in this work.
Socio-affinity scores. The socio-affinity (sa) scoring scheme is
one of the first approaches for scoring purification data and was
developed by Gavin et al. to interpret the results of their large-scale
screen.(33) The score is based on three counts Si!j, Sj!i, and Mi,j
and is given by:
sa(i, j) = log
Si!j
E
h
Snulli!j
i + log Sj!i
E
h
Snullj!i
i + log M{i,j}
E
h
Mnull{i,j}
i (18.1)
The distributions of Snulli!j and Mnulli,j are modeled based on the
assumption that purifications are drawn uniformly at random from
the observed multi-set of preys. This means that fnullk is formed
through nk independent random selections of preys where the
probability of selecting protein the prey protein j is equal to its
relative frequency fj = |{fk | j 2 preysk}| · N 1. Under this null
model, the expected values of Snulli!j and Mnulli,j are given by:
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E
h
Snulli!j
i
= Â
k:i=baitk
f jnk (18.2)
E
h
Mnulli,j
i
= Â
k
fi f j
✓
nk
2
◆
(18.3)
Improved socio-affinity scores. In this work, we propose a modifi-
cation of the sa scoring scheme termed improved socio-affinity (isa)
score. It makes full use of repetitive purifications and concentrates
on spoke observations S to improve the detection of physical con-
tacts. In particular, we adopt the null model used for sa scores and
derive the isa score as follows:
isa(i, j) =   log Pr
⇣
Snulli!j   Si!j
⌘
  log Pr
⇣
Snullj!i   Sj!i
⌘
(18.4)
To compute Pr(Snulli!j   Si!j) and Pr(Snullj!i   Sj!i), we intro-
duce an indicator random variable Xj,k that corresponds to the
selection of protein j into the set of preys of fnullk , thus Pr(Xj,k) =
1   (1   f j)nk . We then note that Snulli!j is a sum of independent
binary random variables: Snulli!j = Âk:i=baitk Xj,k. Since Pr(Xj,k) de-
pends on the size of fk, it is, in general, not the same for different
purifications performed with bait protein i. As a result, the dis-
tribution of Snulli!j is not binomial. To alleviate this problem, we set
Pr(Xj,k) = 1  (1  f j)nˆ, where nˆ is the average size of purifications
performed with i, and use the binomial distribution to compute
Pr(Snulli!j   Si!j). To avoid a situation where a single observation
with a rare prey protein receives very high scores, we adjust back-
ground prey frequencies f j by adding a constant e fraction of each
prey to each purification. In this work we used e = 0.0025.
Purification enrichment scores. The purification enrichment (pe)
scoring scheme was proposed by Collins et al.(34) as an alternative
to the original sa scores to analyze the combined set of purifi-
cations from two recent large-scale screens in yeast. The authors
adopted a more sophisticated statistical model to score evidence for
each observation o separately:
pe(i, j) =Â
o
log
✓
Pr(o | i and j interact)
Pr(o | i and j do not interact)
◆
(18.5)
The detailed description of the statistical model used to derive
the probabilities above is beyond the scope of this paper and the
interested reader is referred to the original publication.(35) We just
note here that the estimation of parameters used by the model
is not straightforward and requires a representative set of gold
standard interactions.
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Hart scores. Another scoring scheme was proposed by Hart et
al.(36) with a particular emphasis on joint analysis of experimental
data from several large-scale purification screens of protein com-
plexes. In this approach, the scores are based on the combined
number of observations, Oi,j, and are computed as:
hart(i, j) =   log Pr
⇣
Onulli,j   Oi,j
⌘
(18.6)
The distribution of Onulli,j is modeled based on the assumption
that interactions of a protein are selected uniformly at random from
the multi-set of all observed interactions. More precisely, for a pair
of proteins i and j, Oi = Âj Oi,j interactions are selected uniformly
at random from the ground set of O = Âi,j Oi,j interactions that
contains Oj = Âi Oi,j “relevant” (involving j) interactions and
O   Oj “irrelevant” (not involving j) interactions. The statistical
significance of the observed Oi,j is then assessed by determining
the probability that at least Oi,j “relevant” interactions are selected.
Under this null model, Onulli,j has a hyper-geometric distribution and
Pr
⇣
Onulli,j   Oi,j
⌘
can be efficiently computed. We note that both the
sa and hart null models are simple and parameter free, resulting
in efficient computational procedures. However, the sa null model
takes the structure of original purifications into account while the
hart null model employs summary statistics of all pairwise inter-
actions in the purification data and thus disregards the structure of
the original purifications.
IDBOS scores. Recently, the idbos scoring scheme was proposed
for scoring purification data with an emphasis on the prediction of
direct physical protein interactions.(37) In this approach, the scores
are based on the combined number of observations, Oi,j, and are
computed as follows:
idbos(i, j) =
Oi,j   E
h
Onulli,j
i
S
h
Onulli,j
i (18.7)
The distribution of Onulli,j is modeled by assuming that the ob-
served purifications are randomly permuted. The resulting null
model is very similar to the one used by the sa and isa approaches.
The main difference is the accurate modeling of observed purifica-
tions – the idbos null model does not allow for random instances
where a prey appears multiple times in a single purification. How-
ever, this small gain in accuracy comes at a high computational
cost. Since the resulting distribution of Onulli,j is much more com-
plex, extensive numerical simulations are required to estimate its
properties. The authors perform 106 numerical randomization ex-
periments to estimate the expected value of Onulli,j , E
h
Onulli,j
i
, and its
standard deviation S
h
Onulli,j
i
.
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SAINT scores. The Significance Analysis of Interactome (saint)
scoring scheme was recently introduced to detect non-specifically
interacting proteins in the breitkreutz purification data.(38) The
method is depending on the use of peptide counts, an additional
type of experimental data that was generated during the peptide
identification phase of the breitkreutz screen and can be uti-
lized as a semi-quantitative measure of absolute protein abundance.
saint employs a mixture of Poisson distributions to heuristically
compute posterior probabilities of specific interactions between pro-
teins based on the peptide counts. Due to the high complexity of
the model, presentations of detailed theoretical underpinnings of
saint are beyond the scope of this work. However, we note here
that saint is a comparatively complex scoring method with many
free parameters and that it requires the availability of experimen-
tal peptide count data. Both properties hinder its applicability to
publicly available large-scale purification data.
Score implementations. sa, isa, and hart scores were computed
using in-house Python scripts on the large-scale set of purifica-
tions. Due to the computational complexity of idbos and pe scores,
these scores were obtained from the original publications. While
pe scores were computed on the large-scale set of purifications
by the authors, idbos does not support the computation of scores
based on multiple sources of purification data (personal commu-
nication with the first author of the Yu et al. (2009) publication).
Therefore, we used the idbos scores computed on the gavin data
since these showed the best performance among all scored data
sets in the original publication.(39) Due to its reliance on peptide
count data, saint is not applicable to the large-scale set of pu-
rifications. saint scores for the breitkreutz purification data
were obtained from the supplementary materials of the original
publication.(40)
Salama-Quade rank correlation. The Salama-Quade rank correla-
tion coefficient measures similarity between two different rankings
of a set of elements.(41) It was developed as an alternative to stan-
dard rank correlation measures, such as Spearman’s rho and Kendall’s
tau, for situations where agreement in low ranks is more important
than agreement in high ranks.
Let {1, ...,m} be a set of elements, R1(i) be the rank of element
i under the first method, and R2(i) be the rank of element i un-
der the second method. The Salama-Quade (SQ) coefficient mea-
sures the agreement between rankings R1 and R2 and is given by
sq(R1,R2) = ÂKk=1 Tk/k, where Tk is the number of elements hav-
ing rank less or equal to k under both R1 and R2. For similarity
values in Figure 18.1b we used K = 10, 000 and normalization
sq(R1,R2)/K in order to obtain rank similarities for the first 10,000
predicted interactions.
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Results and discussion
Scoring purification data. A purification represents the outcome
of an experiment in which a single bait protein is tagged and bio-
chemically co-purified with prey proteins that associate with the
bait by forming of one or several protein complexes. For exam-
ple, in the screen by Gavin et al.,(42) a specific purification using
the a-subunit of clathrin adaptor complex AP-2 as bait contained
22 prey proteins. Three of the co-purified preys correspond to the
other subunits of this hetero-tetrameric complex; the other preys
might be either unknown subunits of the AP-2 complex, subunits of
other complexes in which the a-subunit participates, or non-specific
interactors.
Even though the interpretation of a single purification is limited,
combined purifications from several large-scale screens contain re-
peated observations of associated proteins that may indicate true
protein-protein interactions. Over the years, several computational
approaches were developed to integrate experimental observations
across purifications in order to infer pairs of interacting proteins.
Four major approaches utilizing raw experimental data are socio-
affinity scores (sa),(43) purification enrichment scores (pe),(44) scores
developed by Hart et al.(45) (hart), and recently published id-
bos scores.(46) However, none of these methods is ideally suited
for identifying direct physical contacts between proteins within a
complex through the joint analysis of purifications from several
large-scale screens.
In this work we propose a novel scoring method specifically
tailored to using repeated purifications. In the following, we briefly
describe the main features of our new scoring method isa (improved
socio-affinity score).
A single purification provides two kinds of experimental evi-
dence for protein interactions: spoke observations supporting interac-
tions between the bait and each of the preys, and matrix observations
supporting interactions between every pair of preys. In some cases,
however, matrix observations are much less reliable than spoke
observations. In particular, a large fraction of matrix observations
from purifications containing several small complexes would sup-
port non-existing interactions between proteins in distinct com-
plexes.
The distribution of protein complex sizes in manually curated
catalogues of protein complexes in yeast suggests that the majority
of complexes are small; about 64% of complexes in the MIPS cat-
alogue, for example, have up to four subunits. In comparison, the
average number of preys in the purifications in our data set is about
10 (see Table 18.1). It appears therefore that the majority of purifica-
tions are indeed composed of several complexes and thus provide
many misleading matrix observations. While relying on potentially
misleading matrix observations does not adversely affect scoring of
co-complexed protein pairs, the task of identifying direct physical
contacts is more sensitive towards misleading observations.
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Consequently, isa is cautious and derives interaction confidence
scores solely from the more reliable spoke observations while com-
pletely discarding matrix observations. This is in stark contrast to
the other four methods sa, pe, hart, and idbos that derive their
scores from a mixture of both spoke and matrix observations.
Similar to related approaches, our method utilizes statistical
techniques to derive interaction confidence scores from spoke ob-
servations contained in the experimental purification data. Specifi-
cally, for each pair of proteins, the number of spoke observations in
the experimental data is compared to the number of such observa-
tions under an appropriate null model.
Our novel method isa adopts the null model of Gavin et al. in-
troduced in the context of the sa scoring method.(47) This null
model considers size and content of the original purifications dur-
ing computations, but selects prey proteins for each purification
uniformly at random from the multi-set of preys.
Even though more sophisticated null models were proposed in
the context of later scoring methods such as hart, we believe that
the sa null model is ideally suited for scoring complex purification
data. On the one hand, it is simple enough to allow for analytical
derivation of statistical significances. On the other hand, it realisti-
cally models the observed data by preserving much of the structure
of the original purifications such as the identity of bait proteins,
purifications sizes, and frequency of prey proteins.
However, one of the main problems with the sa approach is that
additional observations supporting a protein interaction result in
a disproportionally small increase of the sa score. This poses a
problem when purifications from several independent screens are
jointly analyzed. Therefore, as a major improvement over the sa
method, isa scores are derived through statistical p-value compu-
tations which allows for attributing higher confidence to putative
physical contacts with multiple supporting observations originating
from experimental replicates.
Scoring two large-scale purification experiments in S. cerevisiae. We
used the four established scoring schemes sa, hart, pe, and idbos
as well as our own approach to score a combined set of purifica-
tions from two recent large-scale screens of protein complexes in
S. cerevisiae.(48) In this section, we examine top-ranking inferred
physical contacts between proteins by our method and relate them
to results of the other four scoring methods.
Table 18.3 lists ten inferred physical contacts having the highest
isa scores. All but two interactions in the top-ten list are supported
by small-scale experiments reported in the literature. Four top-ten
physical contacts receive low scores under the sa method which
highlights one of the main differences between the sa and isa
approaches.
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Consider, for example, the interaction between HAT2 and HHT2
proteins, which is ranked third by the isa method and 56,934th by
the sa method. The HAT2 protein appears as prey in 23 out of 27
purifications performed with HHT2. Still, the sa method assigns
low weight to repeated observations of the kind ‘HAT2 purifies
HHT2’, resulting in a high rank number of the corresponding phys-
ical contact.
In general, top-ranking physical contacts inferred by our method
are expected to be enriched with interactions involving proteins
that were purified multiple times. Indeed, if a given bait protein
was purified repeatedly in multiple purifications, its interaction
partners can and should be determined with increased confidence.
For instance, our experimental data contains 27 purifications
performed with HHT2 as bait, which support a total of 124 protein
interactions. Out of these 124 interactions, 15 have sufficiently high
isa scores to be included in the top-3,000 inferred physical contacts.
Figure 18.1a depicts a network induced by the top-3,000 inferred
physical contacts inferred by isa. The network is sparse and mod-
ular, which agrees well with our intuition for the network of direct
physical interactions within stable multi-protein complexes.
i j Si!j Sj!i Mi,j sa pe hart idbos Ref.
UBP2 RUP1 11 7 0 1568 403 114 67 2
RFA1 RFA2 16 3 13 1131 256 91 2371 3
HAT2 HHT2 0 23 0 56934 7624 435 NA 1
HIF1 HHT2 0 22 0 53035 6250 444 NA 0
HIF1 HAT1 7 14 32 1857 70 5 321 2
HHT2 HAT1 22 0 0 58294 8010 622 NA 1
SRB4 SRB5 5 15 14 1322 44 170 264 12
SPT16 POB3 16 2 55 2705 791 4 2326 6
HHT2 PSH1 18 0 0 47045 6862 702 NA 0
UBA2 AOS1 6 5 0 899 1113 412 NA 1
Table 18.3: Top-10 physical contacts
inferred by isa. A list of top-10
physical contacts inferred by the isa
score. For each physical contact, the
number of supporting spoke
observations (Si!j and Sj!i), number
of supporting matrix observations
(Mi,j), rank under the other scoring
schemes, and number of distinct
supporting sgd literature references
(Ref.) are listed.
To assess the overall similarity among the five scoring methods
we utilized the Salama-Quade rank correlation coefficient. The
Salama-Quade coefficient belongs to a family of measures that
assign greater weight to agreement in top-ranked elements than
other correlations measures such as Spearman’s rho and Kendall’s
tau and is thus more suitable for our purpose (see Materials and
methods).
As we argue below, out of 238,154 possible physical contacts sup-
ported by raw purification data, only about 3,000 can be reliably
scored. Therefore, the relative ordering of inferred physical contacts
beyond this cutoff is less reliable and should affect the similarity
score to a lesser extent. Figure 18.1b shows Salama-Quade rank
correlation for every pair of methods. Ranking of inferred physi-
cal contacts induced by isa scores is quite distinct from rankings
induced by other scoring methods. Based on similarity scores, the
methods can be grouped into two clusters, one including hart,
pe, and idbos methods and another one containing sa and isa
methods.
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Figure 18.1: Top-ranking physical
contacts inferred by isa. Top-ranking
physical contacts inferred by the isa
method and their relation to physical
contacts inferred by other methods.
Figure 18.1a: A network induced by
the 3,000 protein interactions having
the top isa score ranks. Figure 18.1b:
Similarity of the inferred physical
contacts generated by the five scoring
methods. Nodes represent different
scoring schemes. Edges are labeled
with the Salama-Quade correlation
coefficient, which measures
agreement in the ranking of inferred
protein contacts induced by the
scores of the corresponding methods.
We hypothesize that this grouping reflects a major difference
among the scoring methods, namely, treatment of matrix obser-
vations. While the hart, pe, and idbos methods treat spoke and
matrix observations equally, the isa method completely ignores
matrix observations. sa implicitly downplays the contribution of
matrix observations by assigning low weight to repeated matrix
observations and, as a result, is grouped together with the isa
method.
Benchmarking against reference sets of physical contacts. In this sec-
tion, we assess the ability of the four established scoring schemes
and our new approach to detect physical contacts within protein
purifications. Since, to the best of our knowledge, there is no com-
prehensive gold standard set of protein interactions that form phys-
ical contacts within protein complexes, we approach the evaluation
task from four different directions. First, we compare top-ranked
inferred physical contacts between proteins to protein interactions
derived by experimental techniques that directly assay protein pairs
able to physically interact. However, as we argue later on, interac-
tions detected by these techniques represent only a small fraction of
physical contacts present in protein complexes. Therefore, we resort
to additional, albeit less direct, procedures to assess the perfor-
mance of the scoring methods by (i) relying on three-dimensional
structures of protein complexes, by (ii) utilizing manually curated
catalogs of protein complexes, and by (iii) employing synthetic
genetic interaction profiles.
Experimentally determined binary protein interactions. For the first
evaluation, we compiled three reference sets (y2h, pca, and bgs)
of experimentally validated binary protein interactions. The first
two data sets originate from recent high-throughput interactome
screens in yeast: one employing the yeast two-hybrid (y2h) tech-
nique and another utilizing protein-fragment complementation
assays (pca).(49) The third data set, bgs, contains manually curated
yeast interactions supported by literature and is taken from an ex-
tensive validation of the Y2H method.(50)
Figure 18.2 shows how well the scoring methods perform in
identifying true physical contacts from the reference sets. Note that
although all methods are able to infer a number of physical con-
tacts beyond the depicted 10,000 ranks, physical contacts at these
high cutoffs have only very low confidence and are thus omitted.
Notably, while sa and isa methods have comparable performance
across assessments, both of them outperform other approaches on
all three reference sets.
180 from basic research to clinical applications
0 2000 4000 6000 8000 10000
Rank cutoff of inferred physical contacts
0
100
200
300
400
500
In
fe
rre
d 
co
nt
ac
ts 
va
lid
at
ed
 b
y B
GS
 re
fe
re
nc
e 
se
t
Hart
IDBOS-Gavin
ISA
PE
SA
PCA
Y2H
(a) bgs reference set
0 2000 4000 6000 8000 10000
Rank cutoff of inferred physical contacts
0
50
100
150
200
In
fe
rre
d 
co
nt
ac
ts 
va
lid
at
ed
 b
y P
CA
 re
fe
re
nc
e 
se
t
(b) pca reference set
0 2000 4000 6000 8000 10000
Rank cutoff of inferred physical contacts
0
50
100
150
200
250
300
In
fe
rre
d 
co
nt
ac
ts 
va
lid
at
ed
 b
y Y
2H
 re
fe
re
nc
e 
se
t
(c) y2h reference set
Figure 18.2: Assessment by binary
reference sets. Assessment of inferred
physical protein contacts by five
scoring methods against binary
experimental reference sets that
provide direct evidence for physical
contacts.
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Moreover, the performance of all approaches starts to level off at
about 3,000 to 4,000 ranks. We hypothesize that this number con-
stitutes a reasonable limit on the number of physical contacts that
can be reliably inferred given the available experimental data. This
number of reliably inferable contacts also corresponds roughly
to the number of direct binary interactions measured by high-
throughput experimental techniques: the y2h data set and the
pca data contain 2,930 and 2,616 interactions, respectively.
As can be derived from Figure 18.2a, y2h and pca data sets are
less enriched in manually curated bgs interactions than an equiva-
lent number of top-scoring interactions extracted from purification
data. This suggests that physical contacts inferred by purification
scoring schemes are at least qualitatively comparable and often
superior to y2h and pca experimental data sets.
Three-dimensional structures of multi-protein complexes. In this as-
sessment of inferred physical contacts, we rely on experimentally
determined structures of protein complexes deposited in the Pro-
tein Data Bank (pdb).(51) Unfortunately, only crystal structures of
about 250 interactions between proteins in yeast are available.(52)
Therefore, the utilization of pdb structures for the assessment of
putative physical contacts is not possible due to the low coverage of
the validation set.
However, physical contacts in stable multi-protein complexes
are typically formed by pairs of structural protein domains,(53) and
members of an evolutionarily conserved domain family typically
share a common set of domain binding partners. Accordingly, a set
of protein interactions that correspond to physical contacts within
yeast protein complexes should be enriched in domain pairs that
are known to interact. Consequently, to achieve a higher coverage
of true physical contacts, we perform this evaluation at the level of
pdb-validated physical contacts between protein domains rather
than at the level of interacting proteins.
Several resources exist that derive pairs of interacting domains
from crystal structures of protein complexes in the PDB. In this
work, we use the latest release of the 3DID database(54) to obtain
interactions between domains that are annotated to at least one
yeast gene. These interactions are denoted as 3did reference set
and compared to a set of domains induced by top-ranking inferred
physical contacts. More specifically, for each method, all domain
pairs were ranked according to the best-ranking inferred physical
protein contact that could be formed by the domain pair.
The results of this evaluation are presented in Figure 18.3a.
Again, the sa and isa methods significantly outperform other ap-
proaches over the range of 3,000 to 4,000 inferred physical contacts
that are reliably supported by experimental data. At the same time,
both sa and isa perform comparably to the y2h binary experimen-
tal data set with about 240 true domain interactions at a rank cutoff
of 4,000 physical contacts.
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Functional similarity derived from genetic interaction profiles. To as-
sess the functional similarity of proteins inferred to form physical
contacts, we rely on in-vivo genetic interaction profiles measured
by a recent, functionally unbiased large-scale screen.(55) While the
results of this screen do not provide direct evidence for physical
contacts, physically interacting proteins that carry out similar func-
tions often exhibit strongly correlated genetic interaction profiles.
We employed these profile data to define a gi reference set contain-
ing protein pairs with high genetic interaction profile similarities.
This reference set was used to assess the functional similarity of
inferred physical contacts from all five methods (see Fig. 18.3b).
The assessment shows that the socio-affinity based methods sa
and isa significantly outperform other scoring methods as well
as the binary experimental data sets pca and y2h in enriching for
functionally similar protein pairs.
Manually curated catalogues of multi-protein complexes. Several
catalogues of manually curated protein assemblies in yeast are pub-
licly available, such as MIPS and SGD complexes. Unfortunately,
these high-quality data sets only provide information on the protein
composition of each assembly and do not include the network of
physical contacts present within the complex. Therefore, we rely
on the following assumption to assess the inferred physical con-
tacts with the mips and sgd data sets: physical contacts within a
complex connect all its member proteins. This means that, within
a given complex, every protein is connected to every other protein
through a network of physical contacts. Consequently, the quality
of a set of inferred physical contacts can be estimated by assessing
how well these physical contacts connect manually curated com-
plexes. Figures 18.3c–18.3d depict how well top-ranking inferred
physical contacts from different scoring methods connect com-
plexes in the two manually curated catalogs. It is noticeable that
the results generated by purification scoring schemes seem to be
significantly better suited to connect these complexes than data sets
originating from y2h and pca techniques, with the best perform-
ing scoring methods sa and isa connecting more than three times
as many complexes than the y2h data at a rank cutoff of approxi-
mately 3,000 physical contacts.
Inferring physical protein contacts from repeated purifications. The
use of experimental replicates in a statistically meaningful fashion
to account for experimental errors is a current theme in interac-
tomics research.(56) While the use of orthogonal assays is already
well established in experimental protocols for binary protein in-
teractions such as yeast two-hybrid,(57) it is less widespread in the
analysis of protein purification experiments. Our novel method isa
aims at being a generally applicable scoring scheme for inferring
physical protein contacts from repeated protein complex purifica-
tion experiments.
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Figure 18.3: Assessment by secondary reference sets. Assessment of inferred physical protein contacts by five scoring methods against reference sets that provide indirect
evidence for physical contacts. Inferred physical contacts are ranked by scores of the corresponding scoring method. Figure 18.3a: Physical contacts are evaluated by their
enrichment in protein domains that are known to interact in crystal structures of protein complexes. Figure 18.3b: Functional similarity of proteins involved in inferred
physical contacts is assessed by correlating genetic interaction profiles of these proteins. Figures 18.3c and 18.3d: Performance is measured by plotting the number of
complexes that are sufficiently connected by top-ranking inferred physical contacts for different rank cutoffs. We consider a complex sufficiently connected by a set of
inferred physical contacts if the physical contacts reduce the number of connected components within the complex to less than 50% compared to the unconnected
complex.
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Figure 18.4: Frequency distribution of
chaperone-proteins and assessment of
physical chaperone contacts. 18.4a: Box
plots showing the frequency
distribution of chaperone-proteins
and non-chaperone proteins in the
large-scale data set. Frequencies
on the abscissa are scaled
logarithmically. Boxes represent 50%
of the data of a given distribution,
while bold vertical lines denote the
median. 18.4b: Assessment of
inferred and experimentally obtained
physical contacts involving molecular
chaperones against the chaperone
reference set of experimentally
confirmed binary chaperone
interactions. The bgs reference set
does not contain a sufficient number
of chaperone interactions to allow
validation.
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While the isa method performs consistently well in the assess-
ment against experimentally determined physical contacts, its
performance difference to the original sa method appears to be
only minor. However, one of the main improvements of our novel
method isa is the enhanced null model that takes full advantage of
additional evidence contained in repeated observations, depends
on the presence of repeated purifications of the same bait protein
in the experimental data. A closer analysis of the purifications in
the large-scale data reveals that proteins were used as baits at
a median number of only one time (see bait frequency distribution
of non-chaperone proteins in Figure 18.4a). Additionally, although
both the gavin and the krogan experiments were performed on a
genomic scale, only 1,102 of the overall 2,830 distinct bait proteins
in the large-scale data set were used as baits in both experi-
ments. Therefore, the combination of the two experimental data
sets resulted in relatively few repeated purifications.
In order to demonstrate the ability of isa in utilizing repeated
purifications to infer physical protein contacts with high confi-
dence, we focused on two especially challenging purification data
sets with high biological relevance that contain repeated experi-
ments. The first analysis concentrates on inferring stable physical
contacts involving molecular chaperones from the large-scale data,
while the second analysis aims at identifying specific interactions
concerning protein kinases and phosphatases from a recently pub-
lished purification data set.
Detecting stable interaction partners of molecular chaperones. As
shown in the previous section, repeated purifications are not avail-
able for most bait proteins in the large-scale data. Fortunately,
however, a set of 63 known molecular chaperones in yeast were
screened intentionally multiple times by the Krogan group to pro-
vide experimental data for a later study.(58) Chaperones are a broad
class of heat shock proteins and protein-remodeling factors that
mediate non-covalent protein folding, assembly of macro-molecular
structures, protein transport, and degradation of misfolded pro-
teins, thereby maintaining protein homeostasis.(59) It has recently
become clear that membrane-associated chaperones are important
factors of inter-cellular signaling and may trigger both innate and
adaptive immune responses.(60) Misregulation of mutations within
host chaperone pathways have been associated with cancer as well
as with a number of human cardiovascular and neurodegenerative
diseases, as well as with certain cancers.(61) In addition, chaper-
one expression is correlated with viral infections, either as host
response to cellular stress or as a result of viral modulation.(62) In-
deed, viruses regularly encode chaperones or subvert cellular chap-
erone pathways in order to to assist folding of viral proteins(63): for
example, heat shock proteins hsp70 and hsp40 have been identified
as essential host factors for HCV replication.(64) Interestingly, drugs
that target these chaperones have been shown to exhibit broad
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efficacy against several RNA viruses and appeared to pose a suffi-
ciently high genetic barrier as to not elicit selection of drug-resistant
viral variants.(65) Consequently, chaperones may act as a prognostic
biomarkers for viral infections such as HBV(66) and both cellular
and viral chaperones are currently investigated as drug and vaccine
targets, respectively, against infections by a broad range of viruses
such as HCV, HSV-1, HBV, HIV, EBV, and Influenza.(67)
Due to their high prevalence and ability to assist in folding of
diverse classes of proteins, molecular chaperones are expected to
regularly appear in purifications with their substrate complexes.
Indeed, the high abundance of this functional class of proteins
results in their co-purification as preys at a median rate five times
higher than non-chaperone proteins. As a consequence of selective
screening in the large-scale purifications, chaperones were used
as baits twice as often as non-chaperone proteins, resulting in a
strong bias of repeatedly purified proteins in the large-scale
experimental data towards molecular chaperones. (Compare the
median number of bait and prey occurrences for chaperone and
non-chaperone proteins in Figure 18.4a).
Due to their high abundance, for some chaperones, numerous,
highly transient interactions with substrates obscure more perma-
nent interactions with co-chaperones and other regulatory proteins.
This makes detection of stable interactions a difficult task for any
scoring method. In fact, in order to succeed in this task, a scoring
method must take full advantage of repeated purifications with
chaperone bait proteins contained in the experimental data. As
such, the overrepresentation of molecular chaperones in the data
provides an ideal opportunity to examine the ability of scoring
methods to use repeated observations in the large-scale pu-
rification data. To this end, we assess the performance of scoring
methods in identifying stable physical contacts involving molecular
chaperones from two different perspectives. First, we assess how
the scoring methods perform in recovering direct physical contacts
involving molecular chaperones that are confirmed by binary ex-
perimental assays. Second, we present a high-confidence network
of inferred physical contacts involving molecular chaperones and
investigate how well stable contacts between chaperones and their
cofactors are recovered by the isa method.
We investigated the performance of the five scoring schemes in
recovering experimentally validated physical contacts involving
chaperones by comparing the inferred contacts of the scoring meth-
ods to the chaperone reference set (see Materials and methods
section for a description of the reference data). As can be seen in
Figure 18.4b, the isa method excels in this validation and recov-
ers 80% more physical contacts from the reference set than the sa
approach at the previously determined high-confidence rank cut-
off of 3,000 inferred physical contacts. isa is the only approach
that demonstrates a performance higher than the best-performing
binary experimental assay y2h at the same cutoff.
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Importantly, isa does not simply promote interaction partners
that have been screened repeatedly. Such an undifferentiated strat-
egy would lead to many falsely inferred physical contacts since the
highly abundant chaperones are involved in many interactions, of
which only very few are likely to be reliable physical contacts. On
the contrary, only 79 of the top 3,000 physical contacts inferred by
the isa method involve a molecular chaperone, much fewer than
the upper limit of 7,315 spoke observations that pertain to chap-
erones and are present in the large-scale experimental data. Of
these 79 physical contacts, more than 20 are validated by the refer-
ence set as shown in Figure 18.4b. This indicates that the ability of
the isa method to make use of repeated observations in the data
results in very selective promotion of true physical contacts that
cannot be discovered by established scoring methods such as sa.
Figure 18.5: Physical contacts involving
molecular chaperones ofyeast. All
physical contacts involving molecular
yeast chaperones extracted from the
overall top-3,000 physical contacts as
inferred by the isa score. Nodes and
edges denote proteins present in the
large-scale data set and their
inferred physical contacts,
respectively. The size of a node
corresponds to its degree, that is, the
number of physical contacts it is
involved with. Chaperones are
colored in white, while proteins with
known chaperone-related function,
such as co-chaperones, are colored in
grey. Black nodes denote putative
substrates of chaperones. Proteins
belonging to known families or
assemblies are grouped in grey
rectangles.
Analysis of inferred chaperone interactions. To obtain a more de-
tailed view on the relationships between molecular chaperones and
their cofactors, we generated an interaction network induced by
the top 3,000 physical contacts as inferred by the isa method (see
Figure 18.1a). From this network, we extracted all physical contacts
that involve at least one molecular chaperone. The resulting inter-
action network is displayed in Figure 18.5. It contains 79 inferred
physical contacts involving 31 of the 63 known yeast chaperones as
well as their cofactors and putative substrates.
As can be seen in Figure 18.5, physical contacts inferred by the
isa method form a sparse network. Additionally, known protein
assemblies, such as the RAC or Sec63 complexes, are connected by
patterns of physical contacts and several fine-grained biological
relationships between chaperone families are correctly recovered.
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Figure 18.6: Assessment of kinase
physical contacts. Assessment of
inferred and experimentally obtained
physical contacts involving protein
kinases and phosphatases against the
bgs and kinase reference set of
experimentally confirmed binary
kinase and phosphatase interactions.
Note that the saint scoring scheme
assigns identical score values for its
top-1, 262 inferred interactions.
Therefore, saint performance curve
seems to start at a later point than
the curves of other methods.
(70) Flores et al. (1999), Karlas et al. (2010),
König et al. (2010), Suratanee et al. (2010),
Zhou et al. (2008a)
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The Gimc complex, for instance, a hetero-oligomeric hexamer
stabilizing non-native proteins, consists of a dimeric core consisting
of a-subunits Gim2 and Gim5. The a-subunits form physical con-
tacts with each other as well as with two of four possible b-subunits
(Gim1,3,4 and 6) each.(68) While the isa score correctly identifies
the physical contact between the a-subunits by assigning it the top
rank among all inferred physical contacts of that complex, it also
infers contacts between the a-subunits and each of the four possible
b-subunits at a slightly lower confidence.
Additionally, more intricate relationships, such as patterns of
interactions between different families of chaperones, are correctly
formed by the inferred physical contacts. Hsp110 homologs Sse1
and Sse2, for instance, form mutually exclusive, hetero-dimeric
complexes with Hsp70 families SSA and SSB of the form SSA ·
SSE and SSB · SSE.(69) This relationship is correctly recovered by
inferred physical contacts as depicted in Figure 18.5, where SSA
· SSE and SSB · SSE interactions are partitioned and, correctly, no
physical contacts between SSA and SSB chaperones are inferred.
Importantly, the presented network of chaperone interactions is
unique among scoring methods. It is inherently difficult to infer
physical contacts involving chaperones from purification data. This
is due to the high abundance of this functional class of proteins
that leads to a low signal-to-noise ratio for physical contacts that in-
volve chaperones. As a result, established scoring schemes like the
sa method tend to uniformly rank down chaperone interactions.
Indeed, the sa method is unable to recover known biological rela-
tionships involving chaperones as shown in Figure 18.5 even among
its top-10,000 inferred physical contacts.
Identifying specific interactions of protein kinases and phosphatases.
The network of kinase and phosphatase interactions is an impor-
tant component of cellular regulation and messaging. Therefore,
these enzymes are highly relevant for understanding a wealth of
cellular processes that are influenced by kinase signaling. Protein
kinases are often targeted by infectious agents such as viruses due
to the central role of these proteins within the cellular signaling
network. Indeed, tumor viruses were instrumental for detection
and characterization of human kinases and highlight the intercon-
nection between cancer in viral infections in terms if subversion of
cellular control pathways. More recently and on a genome-wide
scale, genetic and phenotypic screens for viral factors targeting
cellular kinases have been undertaken for HCV, Influenza A, and
HIV.(70) While experimentally validated kinase and phosphatase
interactions have been available only sparsely in public databases,
a specialized large-scale purification screen of yeast kinases and
phosphatases has recently been published by Breitkreutz et al.(71)
Protein kinases are a challenging target for scoring schemes since
kinases have a propensity towards binding to a large number of
other proteins and it is therefore difficult to separate specific from
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non-specific interactions.(72) This is illustrated by the average pu-
rification size of the breitkreutz purification data: it is more than
twice as high as the corresponding sizes in the large-scale data
(compare Tables 18.1 and 18.2). One of the main contributions of
the Breitkreutz et al.study thus is the introduction of saint, a com-
putational method that identifies non-specific kinase interactors.
saint and closely related methods such as compass(73) primarily
rely on peptide (spectral) counts, which constitute additional types
of experimental data that can be interpreted as a semi-quantitative
measure of protein abundance. To further increase the coverage and
experimental confidence of their method, Breitkreutz et al. opted
to perform their screen with three different tag systems, yielding
multiple overlapping purifications with the same bait proteins. It
is due to this intentional application of repeated purifications that
we found the breitkreutz data set especially suited for our isa
method.
We assessed the performance of the scoring methods saint,
hart, isa, and sa in inferring experimentally known kinase inter-
actions from the bgs and kinase reference sets (see Materials and
methods section for a description of the reference data). Note that,
due to the involved computations or unavailable implementations
of the pe and idbos methods, these scores could not be evalu-
ated here. However, it has been reported elsewhere that pe was
not able to distinguish between true and false interactions in this
setting.(74) As displayed in Figure 18.6, the isa score outperforms
other general-purpose purification scoring schemes on both refer-
ence sets by a large margin. Only the highly specialized saint scor-
ing scheme can identify slightly more physical contacts in the data.
Importantly, however, the peptide counts employed as an integral
part of saint require additional processing during the experimen-
tal setup. Such counts are neither available for the large-scale
purifications nor for most other publicly available purification data.
In contrast, the isa scoring scheme is generally applicable to all
raw purification data without the need for additional peptide count
data.
Analysis of host-pathogen physical contacts. In order to demonstrate
the general applicability of our scoring method to model organisms
other than yeast, we utilize recently published large-scale purifica-
tion data of a host-pathogen system.(75) Within the experimental
setting that generated these data, genes corresponding to all HIV
proteins were expressed in two different human cell lines and as-
sayed using proteins purification methodology. Depending on the
cell line thus assayed, two purification data sets here denoted as
hek and jurkat were produced (see Materials and methods). In-
teractions within these purifications were scored by the authors of
the original publication using mist (mass spectrometry interaction
statistics), a novel scoring scheme especially optimized for detecting
host-pathogen interactions that employs both spectral counts and
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Figure 18.7: Assessment of
host-pathogen physical contacts.
Assessment of inferred physical
contacts involving human and HIV
proteins against the virusmint
reference set of experimentally
confirmed host-pathogen protein
interactions.
computationally costly permutation statistics. We compared the
mist predictions on the two separate purification data sets hek and
jurkat as well as sa, isa, and hart scores of the combined hek
and jurkat sets against validated physical contacts from Virus-
MINT(76) (see Figure 18.7). Similar to the previous validations, isa
performs significantly better than isa and hart scores at recov-
ering validated physical contacts. Indeed, isa performs similar or
better than mist scores without relying on spectral count data or
computationally costly permutation statistics.
Discussion. This work is first to investigate whether direct phys-
ical protein contacts can be extracted from raw purification data
contained in a combined set of large-scale protein complex purifi-
cations. We analyzed four established scoring schemes and one
new approach and assessed their ability to reliably detect physical
contacts within assayed complexes. Top ranking inferred physical
contacts from all five methods were benchmarked against refer-
ence sets based on binary experimental protein interactions, three-
dimensional structures of interacting proteins, manually curated
protein complexes, and genetic interaction profiles. Inclusion of
these four complementary sources of validated physical contacts
allowed us to investigate aspects of the scoring schemes that were
not examined before.
The results of our evaluation showed that raw purification data,
if scored correctly, can indeed be exploited to infer physical contacts
within protein complexes. While established methods devised for
inferring indirect protein interactions from purification data per-
form well in the task of identifying co-complexed protein pairs in
reference protein complexes (data not shown), the performance of
most of these methods in detecting direct physical protein contacts
is considerably diminished. Only the two socio-affinity based meth-
ods sa and isa consistently showed the best performance among
all evaluated methods in inferring physical contacts.
We attribute this difference of performance between the methods
to two facts. First, both sa and isa share the concept of a simple,
but elegant, null model to identify strongly associated proteins.
Second, both methods have a high propensity towards using only
direct, or spoke, associations between proteins as evidence for phys-
ical contacts, that is, they concentrate on interaction evidence be-
tween a bait protein and the prey proteins it purifies. This indicates
that, while indirect, or matrix, observations are useful for detecting
co-complexing protein pairs, direct observations are more informa-
tive for identifying physical contacts.
Besides intentionally concentrating on direct observations, the
main innovation of the isa method is an improved null model that
allows for integration of repeated purifications using the same set
of bait proteins in a statistically meaningful fashion. While im-
proving the predictive power of our method in the presence of any
repeated observations, this ability is especially relevant for inferring
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stable contacts involving highly abundant proteins, such as molec-
ular chaperones or protein kinases, whose specific interactions are
especially difficult to infer in the absence of repetitions. Intuitively,
the approach taken by our isa score is similar to strategies cur-
rently discussed for interactome mapping projects where repeated
experiments can allow for an increased sensitivity and specificity of
the resulting screens.(77)
Our analysis of the large-scale purification data found that
most proteins have been screened only once in experiments as baits.
Few proteins, such as the functional class of molecular chaperones,
have been used as baits multiple times. The assessment of chaper-
one interactions showed that the isa method improves upon other
scoring methods when repeated observations are available. Our
method recovered a range of biologically significant relationships
between chaperones and their cofactors that could not be detected
by the second best performing sa method. This highlights the im-
portance of correctly using repeated observations to gain statistical
confidence in the inferred physical contacts.
The use of repeated observations for gaining statistical confi-
dence in physical contacts is not limited to the general-purpose
large-scale purification experiments, but can also be applied to
specialized data sets aiming at specific biological targets as demon-
strated by our analysis of a recent purification study focussing
on protein kinases. Due to the intentional integration of repeated
purifications in that study, isa was available to infer significantly
more physical contacts from the raw purifications than any other
general-purpose scoring method.
Importantly, the mechanism of improved performance of isa
based on repeated observations is not depending on single purifi-
cation data sets that feature repeated purifications. Instead, isa is
able to exploit repetitions across several distinct data sets. There-
fore, we expect that physical contacts inferred by our method will
further improve in quality compared to established scoring schemes
once additional large-scale purification data sets become available.
Considering the experimental replicates within the Breitkreutz et
al.(78) data as well as current correspondences by experimentalists
about integrating multiple orthogonal assays to increase confidence
in the results,(79) there seem to be clear indications that repeated
purifications within one data set will become more widespread in
future.
An adequate comparison of interactions measured by high-
throughput binary experimental approaches to physical contacts
deduced from purification experiments has not been possible be-
fore. This is a result of the fact that binary experimental approaches
are more straightforward to interpret: each physical interaction is
measured directly, while in purification data only a small subset of
all interactions are likely to be physical contacts. As a consequence,
the whole set of interactions possible in purification data has previ-
ously been interpreted as putative physical contacts.
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Since this resulted in a low enrichment of true physical contacts
in the purification data, purification-based methodologies were de-
termined of being less useful for measuring true physical contacts
than high-throughput binary experimental techniques such as yeast
two-hybrid.(80)
However, a closer analysis of the performance of all five scoring
schemes and a comparative assessment of the inferred physical
contacts with the results of binary experimental assays such as y2h
or pca reveals several novel findings. First, the performance of all
scoring schemes in recovering physical contacts from the reference
sets levels off at about 3, 000 top-ranking physical contacts, indicat-
ing that this number constitutes a limit on the number of interac-
tions that can be reliably scored given current experimental data.
Second, our results surprisingly suggest that, once correctly scored
and ranked, physical protein contacts derived from complex pu-
rification experiments are qualitatively comparable to interactions
measured by state-of-the-art y2h and pca techniques. Additionally,
the purification scoring schemes perform significantly better than
the y2h and pca data sets in connecting manually curated pro-
tein complexes. This suggests that physical contacts derived from
purification data might be more relevant for interpreting protein
complexes than interactions measured by these binary experimental
techniques.
Besides offering new opportunities for the interpretation of pu-
rification data and the understanding of protein complexes, there
are additional application scenarios of our scoring method. Since
the isa method is optimized to make best use of repeated obser-
vations in the data, experimental research groups can repeatedly
perform small-scale purifications for proteins of interest, possi-
bly involving perturbation experiments(81) or novel purification
methodologies applicable to human cells.(82) These purifications
can then be added to the large-scale experimental data. Subse-
quently, the isa method can be re-applied on this newly enlarged
data set. The additional information contained in the repeated pu-
rifications will then allow for reliable inference of physical contacts
involving the proteins of interest.
We further propose that physical contacts derived from purifica-
tion data are applicable to large-scale interactome mapping projects.
Several interactome screens are currently underway for model
species such as S. cerevisiae or D. melanogaster. Meta-strategies for
cost-effective mapping have been developed involving schemes for
pooling, prioritization, and repetition of experiments to increase
overall coverage and accuracy of the combined screens.(83) We sug-
gest that physical contacts derived from purification data may be
used complementary to binary interaction data sets by prioritizing
high-confidence physical contacts for experimental validation by
y2h or pca techniques. Such a prioritization strategy seems espe-
cially valuable as part of high-throughput large-scale interactome
screening projects such as recently proposed by Schwartz et al.(84)
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Addendum. Since publication of the preceding manuscript in
2011, several additional purification data sets and computational
filtering schemes have been introduced.(85) Although the isa score
continues to offer specific and unique advantages compared to
other affinity-based approaches such as sa and hart scores while
also delivering on par performance with more involved spectral
counting approaches such as mist and saint, affinity-based ap-
proaches in general and isa in particular have not seen increased
adoption by the proteomics community.
This is likely due to three reasons: first, isa has been developed
for (and excels in) deriving physical protein contacts from protein
purification data. While we could demonstrate that the quality of
the interactions inferred by isa are of similar or better quality than
interactions measured by binary experimental methods such as y2h
and pca, binary interactions are not a current focus of attention of
biologists undertaking protein complex purification experiments.
Instead, these experimentalists are more interested in recovering
complete functional complexes, as demonstrated by the themes of
several recent publications.(86)
Second, the application and validation of scoring schemes is not
well standardized in the community. Rather, each publication of a
novel purification data set is usually paralleled by a new scoring
scheme and the choice of validation sets and the depth of validation
of these novel schemes vary widely. While this development is
partly justified by the high variability of data sets and biological
targets under investigation that result in experimental setups of
disparate sizes, coverages, target organisms, purification methods,
and quantification schemes, it also results in low re-use of scoring
schemes in general.
Third, and most importantly, all ’first line’ affinity-based ap-
proaches (i.e., sa and hart) have been proposed by research
groups that undertook genome-wide purification screens that in-
cluded a large fraction of reciprocal experiments (i.e., the role of
baits and preys was reversed in technical replicates). Results have
indicated that affinity-based approaches excel under these condi-
tions and produce results superior to spectral counting and cluster-
ing approaches if high (i.e., approaching genome-wide) coverage
and reciprocal interactions are given; conversely, the performance of
affinity-based methods suffers dramatically if these conditions are
not met.(87) While our ISA score is able to incorporate incomplete
purification sets and score repeated experiments in a statistically
sound fashion, it is nevertheless bound by the same limitations as
other socio-affinity approaches.
Generation of genome-wide purification of data is not a current
focus of experimentalists who instead concentrate on small or mid-
size subnetworks of particular interest for reasons of both better
interpretability and increased cost-effectiveness. As a consequence,
only one such genome-wide set is currently available for human(88)
and the completion of the human protein complex interactome is
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expected to rely on integration of these incomplete data sets rather
than on concerted, genome-wide efforts.(89) Similarly, available
host-pathogen interaction networks also tend to be of limited size
and the availability of the high-coverage human-viral (Jäger et al.,
2012) data set that was utilized in our study is the exception rather
than the norm.
As a result of the lack of genome-wide data sets, socio-affinity
based scoring schemes are currently less applicable on current
data and alternative methods that are specialized towards incom-
plete purification screens are required. One way to control false
positive rates and achieve sufficient specificity given these incom-
plete data is the use of additional data sources such as spectral
counts and negative control experiments. Since publication of our
manuscript in 2011, the necessary primary data analysis methods
(i.e., the spectral counting) have been further refined and can now
be generated in an automatized fashion. Consequently, spectral-
count approaches such as ComPASS, saint and mist that support
this line of analysis and perform well with small or mid-size data
sets currently dominate the landscape of protein complex purifica-
tion analyses.
However, there is justified hope for a renewed focus on genome-
wide approaches in future studies. As recently pointed out by
Ideker and Krogan (2012), the high availability of genotypic data
(e.g., originating from second generation sequencing approaches)
has highlighted both the lack of correlated phenotypic data and the
importance of differential approaches (i.e., comparison of samples
given different biological conditions such as disease vs. normal or
drug-treated vs. untreated). Almost all protein interaction networks
examined to date, however, have been examined under static condi-
tions that do not well reflect the dynamics of biological systems and
thus limit the depth of scientific inquiry.
In order to gain deeper insights into biological properties of pro-
tein interaction networks, Ideker and Krogan argue that differential
approaches for measuring physical protein interactions have to be
undertaken. Besides aiming to investigate network changes given
disease states such as cancerous transformation, host-pathogen
interaction networks are of particular interest in this regard, as
characterizing the viral subversion of host signalling pathways may
be a particularly insightful application of differential methods.(90)
Importantly, these approaches again necessity genome-wide screens
in order to curb the rate of false-negatives that otherwise may con-
found differential approaches. It is due to these reasons that both
socio-affinity approaches and the analysis of genome-wide host-
pathogen interaction networks may well see a revival in the coming
years.
IV
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The last chapter of is concerned with real-world viral disease and
closes with the description of a major antagonist of clinical treat-
ment: the viral quasispecies. The existence of viral quasispecies
populations, the recognition of their concerted evolution, and their
role in antiviral therapy are the main points of interest in this chap-
ter. Sections 19 to 22 introduce the concept of viral quasispecies,
discuss the most important parameter governing its evolution, and
exemplify these aspects in the HCV quasispecies. Subsequently,
sections 23 to 23 review approaches to treating viral quasispecies
by manipulating aspects of its evolution using antiviral drugs. The
effects that these manipulations have on the genetic composition of
the quasispecies are then quantified using sensitive deep sequenc-
ing technologies. Finally, all these aspects are combined in Section
24, where the first experimental study using in vivo deep sequenc-
ing data is introduced that investigates quasispecies behavior under
monotherapy with ribavirin, the most important broad-spectrum
antiviral and essential component of anti-HCV therapy.
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(3) Margeridon-Thermet and Shafer (2010)
An IU corresponds to about 1-5 RNA
copies depending on the method of
quantification, cf. Pawlotsky (2002).
(4) Within the following sections, we will
denote as viral variants specific genome
positions that differentiate viral geno-
types from each other. These variants
are commonly defined with respect to an
external reference genome, the consensus
sequence, or the master sequence of the
quasispecies, i.e., the genome that is most
abundant (has the highest frequency) in
the genotype distribution. While the dom-
inant genome is distinct from the consen-
sus sequence, i.e., the average genome of
the quasispecies, both of these sequences
are often identical (are always identical if
the frequency of the master sequence is
above 50%). Since each genotype within a
quasispecies is fully defined by the total
of its variations from reference sequence,
genotypes are often also simply denoted
as variants. However, the latter choice of
terminology predominantly applies to
virology while in genomics and bioin-
formatics the term variant denotes the
smallest unit of difference, in principle,
such as single nucleotide variants (SNV,
also termed SNP if the variant is common,
e.g., has a frequency of > 1% within the
population in case of the human genome)
and indels, or structural variants such
as copy number variations, duplications,
recombinations, reassortments, and large
insertions.
19 Viral quasispecies
Among the epidemiologically most relevant RNA viruses are
highly divergent viral species such as HIV-1 and HCV, and Influenza-
A, as well causative agents of the emerging viral diseases Ebola hemor-
rhagic fever, Dengue fever, and West Nile fever.(1) In particular, three viral
species that cause chronic infections are associated with the highest disease
burdens: HIV, HCV, and HBV. By conservative estimates, infections with
these three viruses are afflicting 40 million, 400 million, and 200 million
individuals worldwide, respectively, and may be collectively responsible for
more than 3 million deaths per year.(2)
Although these pathogens belong to different groups of the
Baltimore classification and consequently have very different life
cycles, they have at least three characteristics in common: these
viruses employ RNA genomes for replication, display high rates of
mutation of about 10-5 substitutions/site/copy, and chronically per-
sist at very high abundances in patients (HIV: 103-106 copies/mL,
HBV: 105-109 copies/mL, HCV: 104-107 copies/mL, all in untreated
hosts).(3) As a consequence of this high abundance and divergence,
these viruses are believed to exist as a distribution of genetically
distinct but closely related genotypes that are present at varying
frequencies within the host.
This genotype distribution, also denoted as mutant distribution,
mutant spectrum, or viral quasispecies, is induced by the lack of
proofreading activity in viral RNA-dependent RNA polymerase
(RdRp) and is results in high rates of mutations, or variants(4)
within the viral progeny.
A short history of quasispecies theory
Phenotypic traits of viruses are a product of evolution, i.e., the
consequence of genetic variation, reproduction, and subsequent
selection of neutral or beneficial traits by the environment of the
pathogen. In particular, traits that confer advantages with respect
to the viral micro-environment, for instance with respect to the
host immune response or tissue tropism, are rapidly selected for in
viruses due to their short generation times and compact genomes.
This micro-evolution is of particular clinical importance due to
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Figure 19.1: Principle equations of
quasispecies theory according to
Domingo et al. (2012), Eigen and
Schuster (1977). The first equation
models the concentration of
genotypes i and k as functions of
time xi(t) and xk(t). In particular,
this formula describes the generation
of a mutant i from a template
population k due to erroneous
replication. Ai and Di are the rate
parameters for the replication and
degradation of i, respectively. Qi is
the fraction of faithful replicates that
are produced from i during
replication. Wik is the rate for
erroneous generation of i based on
the template genotype k. Fi is a flux
parameter that models the physical
movement of molecules within the
quasispecies environment. Equations
19.2 and 19.3 describe the error
threshold relationship where vmax is
the maximum genetic complexity
maintainable through replication, s0
is the fitness advantage of the master
sequence relative to minority
genotypes, q is the average copying
fidelity, and 1  q = p represents the
average error rate during replication.
Based on quasispecies theory,
replicative accuracy can only be
maintained for sequences shorter
than a maximal sequence length vmax
for constant replication accuracy, or
given a maximal error rate pmax
provided a constant sequence length.
the selection of traits of therapeutic relevance, such as resistance
to antiviral drugs, both within a single patient and across a whole
multi-host population of pathogens.(5)
As a consequence of the close genetic relatedness of the quasis-
pecies population, the whole quasispecies rather than the single
virus is often considered to be the unit of natural selection (6) and
traditional population genetics may not be well suited to model the
behavior of RNA viruses.(7) Instead, the evolutionary dynamics of
these pathogens is commonly described by what has been termed
quasispecies theory.
Quasispecies theory has first been proposed by Manfred Eigen
in 1971 as a purely mathematically concept describing an infinite
number of replicons that regularly produce erroneous copies of a
template molecule. Reportedly, the original research project that
later culminated in this model was suggested to Eigen by Nobel
laureate Francis Crick over breakfast.(8)
The model built on experimental work concerning the phage Qb,
an organism that displayed Darwinian behavior (i.e., mutation and
selection) in serial transfer experiments.(9) By utilizing information
theory as theoretical foundation, Eigen proposed the quasispecies
theory as a model of the origin of life within a hypothetical, primi-
tive RNA-world of self-organizing macromolecules (see Figure 19.1
for an introduction to the basic variables of this model).(10) Only
later were these concepts extended to RNA viruses.(11)
Application of quasispecies theory to viral populations. Viruses play
a two-fold role in quasispecies theory: first, as direct subjects of
enquiry that may divulge biologically and medically relevant mech-
anisms of viral replication and adaption; second, as explanatory
devices for experimentally testing theories of population genetics.
Within the original theory of Eigen and Schuster, quasispecies
describe replicon populations of infinite size within a mutation-
selection equilibrium, also denoted as mutation-selection balance. At
these equilibria, frequencies of replicon genotypes are balanced
between production of new genotypes by mutation and pruning
of unfit genotypes by selection; in particular, quasispecies the-
ory predicts the existence of a well-adapted master sequence with
high fitness and a distribution of mutated genotypes that display
lower fitness, densely fill the genotypic space around the master
sequence, and are constantly replenished by mutated progeny of
the master sequence and of each other.
As a result of this mutational coupling, the quasispecies distribu-
tion as a whole rather than the individual genotype is believed to
be the unit of selection.(12)
Theoretical considerations have demonstrated that quasispecies
theory is generally compatible with the more traditional concept
of selection-mutation (or Wright-Fisher) equilibrium known from
classical population genetics, indicating the broad applicability of
the quasispecies concept.(13) By utilizing models of population ge-
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(18) Competetive exclusion principle: A
principle of population genetics that states
that, if no niche specialization is possible,
less fit genotypes or genotype populations
will be supplanted (or excluded from
replication) by fitter genotypes that
compete for the same resources. Note
that, due to the continuous generation of
distinct genotypes by mutation and the
high abundance of the quasispecies in
general, individual genotypes are unlikely
to be replaced entirely. Rather, they are
suppressed and maintained at very low
frequencies.
(19) Evolutionary arms race and Red Queen dy-
namics: genotype populations within viral
quasispecies are believed to be involved
in a process of continuous maintenance or
increase of fitness relative to co-evolving
systems such as the host immune system,
drug pressure, or viral genotypes compet-
ing for the same resources. As a net effect,
viral quasispecies are believed to con-
tinuously increase their absolute fitness
if measured in isolation; however, since
the co-evolving systems also increase
their respective fitness, the relative fitness
of each system remains constant. These
phenomena are reminiscent of the nuclear
arms race of the superpowers during the
cold war as well as of statements of the
Red Queen in Lewis Carroll’s "Through
the Looking Glass" stating that "... it takes
all the running you can do to keep in the same
place".
(20) Jiang et al. (2010)
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netics, quasispecies theory has been extended to better encompass
features of experimental RNA virus populations that operate as
finite populations and within dynamic fitness landscapes that pre-
vent the population from achieving a permanent mutation-selection
equilibrium.(14) These extensions granted the quasispecies model
additional attributes that allowed it to explain medically relevant
behaviors of viral populations, such as the emergence of resistance
variants in drug-treated viral populations.(15)
Current state of viral quasispecies theory. Today, the term qua-
sispecies commonly includes the aforementioned extensions and
refers to
(...) distributions of non-identical but related genomes subjected to a
continuous process of genetic variation, competition, and selection,
and which act as a unit of selection.(16)
More mechanistically, a viral quasispecies can be defined as popula-
tions of genetically diverse but related genotypes that are subjected
to both internal (i.e., competition for resources between genotypes)
and external (i.e., competition between genotypes and their envi-
ronment) pressures that influence variation, replicative fitness, and
selection within the genotype population.(17)
The experimental validity of these definitions is supported by
several in vitro and in vivo experiments that relate antigenic hetero-
geneity to genetic variation (reviewed in Domingo et al. 2003), and
identified mechanisms in viral quasispecies that are reminiscent
of classical population genetics such as the competitive exclusion
principle,(18) replicative fitness, and an evolutionary arms race(19)
(reviewed in Novella (2003), see later sections for a more detailed
description of these mechanisms).
Basic tenets of viral quasispecies.
Replication fidelity and mutation rates. Organisms existing in a
static environment that is not dominated by changing selective
forces are expected to evolve towards a global fitness optimum
and low mutation rates in order to maximize the number of viable
progeny(20) Conversely, genotypes within viral quasispecies exists
in a constantly changing environment resulting comprising drug
and immune pressure as well as competing genotypes. In order
to uphold replicative fitness, it is assumed that quasispecies adapt
to these conditions by modifying the phenotypic characteristics
of their constituting genotypes.(21) This is enabled by inducing
high rates of randomly mutated viral variants; although most of
these variants are unlikely to be viable, a minority may, by chance,
display higher replicative fitness than existing variants especially in
adverse environmental conditions.
High rates of genetic variation, commonly quantified as the error
rate (also termed mutation rate)(22) are be believed to significantly
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error-prone replication that induces ran-
dom mutations. The rate by which these
mutations are introduced by the replica-
tive molecule, generally a polymerase,
is termed mutation rate, or error rate. It
is often determined by sequencing the
viral quasispecies and is quantified as
the estimated rate at which an individual
genomic site is expected to mutate either
at a single replicative event or across a
timespan of a year of continuous repli-
cation. Mutation frequency then is the
average rate at which a single genomic
site differs from the consensus sequence
of the viral quasispecies after selective
events of the environment have removed
genomes with lethal mutations. Impor-
tantly, therefore, mutation rate does not
generally equal mutation frequency: the
latter takes environmental factors into
account while the former does not; on
the other hand, mutation frequency is
considerably simpler to measure experi-
mentally because it can be determined by
the present state of the quasispecies.
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increase the chances for generating beneficial mutations and may
thus be maintained by RNA viruses in order to confer adaptability
to rapidly changing environments.(23)
Indeed, RNA viruses display high mutation rates of about one
mutation per genome and replication, values that are significantly
increased compared to DNA viruses.(24) Due the compactness of
viral genomes, however, most random variation is expected do
be deleterious and thus decrease fitness.(25) RNA viruses utilize
their high abundances and replication rates in order to increase
the likelihood that progeny with higher replicative fitness will
eventually be generated and evolutionary selected due to their
replicative advantage.(26)
Optimal mutation rates. As a result of their importance for viral
quasispecies, mutation rates themselves are believed to be a subject
of selection, as for example demonstrated by the emergence of
mutator and anti-mutator phenotypes in the HIV-1 quasispecies.(27)
This evolutionary optimal mutation rate is believed to be specific
to the selective and replicative context of the quasispecies and is
determined by at least three factors:(28)
(1) Since most random mutations in RNA viruses are deleteri-
ous, selective pressure exists for reducing mutation rates in order to
uphold replicative fitness; indeed, overly increased error rates may
result in accumulation of deleterious mutations and irreversible
loss of genetic information, a process also denoted as genetic melt-
down.(29)
(2) Increased replication fidelity comes at an increased kinetic or
energetic cost, thus limiting replication capacity; this fact is espe-
cially relevant for RNA viruses that rely on rapid infection cycles
in order achieve high abundances before the host immune reaction
sets in.(30)
(3) As noted before, elevated mutation rates confer increased
adaptability, as has been demonstrated for poliovirus where in-
creased replicative fidelity (and thus lower error rates) lead to a
reduction in pathogenicity and tissue tropism of the virus, thus
indicating a diminished ability to adapt to new cellular micro-
environments.(31)
As a result of these conflicting factors influencing selective ad-
vantages of elevated mutation rates, a trade-off between mutation
rates is assumed to exist that prevents that ensures sufficient adap-
tive variability to ensure survival of the viral quasispecies in the
host microenvironment while also preventing the accumulation of
deleterious mutations.(32)
The molecular basis of this trade-off may be implemented by
selectively adapting the fidelity of viral polymerases to error rates
just below a critical error threshold; this line of reasoning is sup-
ported by experimental evidence that relies on artificially increased
mutation rates (reviewed in Anderson et al. 2004, Domingo et al.
2005) as well as by more recent theoretical models.(33) Indeed, ex-
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(38) While a complete description of the
Kamp et al. model is omitted here for
sake of brevity, we will briefly discuss
one of the major results: given that the
host immune system adapts to a new
viral subpopulation with in a time-span
ti and the virus replicates within a time
1/sv, the optimal genomic mutation rate
µv ⇡ 1/(svti) can be derived by approxi-
mation from the model. The ratio between
these time scales represents the duration
of one generation of virus in units of the
response time of the immune system;
consequently, the the optimal (i.e., mini-
mal) viral error rate sufficient for immune
escape is one mutation per genome within
the time the immune system requires for
adaption. Intuitively, this result that every
viral genome produced within that time
frame is different from the viral subpop-
ulation that the immune system adapted.
Assuming adaption times of the immune
system of 7-14 days, the predicted error
rates are well within the range of experi-
mentally measured generation times and
mutation rates for several RNA viruses,
including HIV.
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perimental data indicate that mutation rates of RNA viruses can
only be increased slightly: 2 to 3-fold increases of mutation rates for
non-retroviral RNA viruses and about 13-fold increased rates for
retroviruses are sufficient for viral fitness to degrade significantly;
in contrast, bacteria are able to cope with more than 1,000-fold
higher increases or error rates.(34)
Characteristic mutation rates. This balancing tradeoff between
increasing adaptability on the one hand and reducing the number
of inviable progeny on the other hand is theorized to lead to spe-
cific error rates characteristic for each RNA virus species.(35) Such
optimal rates were determined for several special cases using mod-
eling approaches; for instance (Kamp et al., 2003) have undertaken
to derive optimal viral error rates required for escaping the host
immune answer, arguably one of the major determinants of viral
fitness. Similar to viral quasispecies, B-cell receptor sequences are
associated with closely related receptors that result from somatic
hypermutation of B-cells.(36) Consequently, the virus is believed
to evade immune response by mutating antigenic epitopes and
avoid eliciting proliferation processes of the corresponding immune
receptor.
Within the Kamp et al. model, competition between viral qua-
sispecies and the adaptive immune response features an asym-
metric coupling where the immune response is attracted by (i.e.,
proliferates in the presence of) matching viral epitopes while viral
quasispecies populations are selected that are different from the
high-profile master sequence and thus provide increased means of
immune escape. This process resembles a predator-prey dynamic as
demonstrated for HIV.(37) Modeling can be utilized to derive opti-
mal mutation rates of immune receptors and the viral quasispecies,
respectively.(38)
Error threshold and error catastrophe. One of the most interesting
and controversial implications of this theory is the existence of a
phase transition that be triggered at relatively trivial increases in
mutation rates and that causes dramatic changes in the genotype
distribution of the quasispecies. The critical mutation rate is also
denoted as error threshold below which
"populations equilibrate in a traditional mutation–selection balance and
above which the population experiences an error catastrophe, that is, the
loss of the favored genotype through frequent deleterious mutations."(39)
The concept of an error catastrophe is one of the main features of
quasispecies theory and is of considerable importance for antiviral
treatments.(40) In this context, mutagenic drugs may be employed
to destabilize the viral quasispecies by elevating mutation rates,
a process that may result in the quasispecies undergoing genetic
meltdown, i.e., the irrecoverable loss of genetic information, and
extinction by lethal mutagenesis.
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While it is commonly stated that lethal mutagenesis is identical
to (or an an instance of) an error catastrophe,(41) newer theoretical
results argue differently.(42) However, a detailed discussion of these
arguments require prior knowledge of additional fundamental prin-
ciples such as genotypic spaces and viral fitness and is therefore
postponed until later in this chapter.
Challenges of quasispecies theory
While quasispecies theory is conceptually appealing and seems to
be well in accordance with experimentally observable attributes of
RNA viruses, there are controversies concerning its applicability to
several viral systems that are currently proposed to exhibit quasis-
pecies properties. Specifically, critics raise concerns about overusing
the quasispecies concept and point out that the original theory was
developed by Eigen at al. to define primordial RNA replicators and
not to describe features of viral pathogens. Quasispecies theory
may therefore not generally provide more explanatory power to
describe clinical phenomena than existing models of population
genetics.(43) In particular, well-understood concepts of mutation,
genetic drift, and natural selection as represented in classical pop-
ulation genetics may serve to describe many phenomena of viral
populations without making explicit use of quasispecies theory.(44)
Population geneticists further point out that at its core, quasis-
pecies theory diverges from classical population genetics in only
two ways: first, in contrast to the species concept in population
genetics, quasispecies genotypes are not independent but tightly
coupled in genotype-phenotype space; thus, the "entire population
forms a cooperative structure that evolves as a single unit" upon which
selection acts.(45) Second, due to large effective viral population
sizes, small genomes, and high mutation rates, the genotypic space
around viral genotypes with high fitness is assumed to be com-
pletely explored by viral genotypes, hence preventing genetic drift
(see later sections of this chapter for a detailed discussion of geno-
typic spaces and mutational coupling).(46)
Both of these defining features are imparted by quasispecies
theorists to real-world viral populations while being contested by
population geneticists; in particular, population geneticists raise
the point that viral populations are subjected to immune selection
that results in many genotypes being inviable; as a consequence,
tight genetic coupling between all genotypes (as in a continuous
genetic distribution of viral genotypes) is impossible, thus ques-
tioning the concept of combined selection as the defining attribute
of viral quasispecies(47) If, however, combined selection is indeed
not a property of real-world ensembles of viruses, then observed
features of RNA-viral populations are purported to be equally well
explainable by classical population genetics and random drift, thus
possibly making quasispecies theory unnecessary to explain the
experimental data.(48)
(1) Ruiz-Jarabo et al. (2000)
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Genotypes of viral quasispecies are constantly undergoing neg-
ative and positive selection based on the characteristics of their environ-
ment. Positive selection rewards phenotypic traits that confer replicative
advantages and typically results in increased abundances of the selected
genotype. However, positive selection does not automatically result in
the selected genotypes becoming the dominant subpopulation (or master
sequence) of the viral quasispecies since multiple genotypes with distinct
genetic makeup may share the trait that is selected for. Instead, these geno-
types compete based on their relative fitness and the resulting frequency
distribution of the viral quasispecies can be interpreted as a steady-state
of these competing fluxes and environmental constraints. This section
introduces the concept of viral fitness and discusses particular aspects of
fitness that relate to viral quasispecies such as bottleneck events and fitness
landscapes.
Viral fitness and selection
Commonly, viral variants are associated with an ability to survive
and replicate in a given environment. These phenotypic charac-
teristics are often summarized in terms of fitness (literally derived
from "fitting into the environment") that denote the ability of viral
quasispecies genotypes or the whole quasispecies to survive and
procreate.
While absolute fitness may be defined by the number of repli-
cates a viral genotype produces in a given unit of time in isolation,
the concept of fitness is highly relative. For instance, modest posi-
tive selection of a genotype (or, more precisely, of a genetic variant
encoded by a genotype that results in an advantageous phenotypic
trait) in absolute terms may be regarded as negative selection in rel-
ative terms if another genotype population is undergoing extremely
strong positive selection.
By the same token, selective pressures in quasispecies almost
never result in absolute dominance or absolute extinction of qua-
sispecies genotypes, even if fitness is low; instead, selection is con-
sidered to work in a ’soft’ rather than in a ’hard’ manner and low-
fitness genotypes may be maintained indefinitely as low-frequency
minority genotypes (see later sections for a discussion of viral mi-
norities).(1)
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As a result of the relativity of the concept, viral fitness can be re-
garded as a complex parameter that is often quantified in absolute
by surrogate variables such as the number of the copy number of
viral genomes within a given volume of tissue. This viral load,(2) is
often correlated with the severity of disease and is thus commonly
employed to quantify viral fitness in clinical settings.(3)
Alternatively, relative measures of viral fitness may be conducted
based on the replication capacity of a virus relative to a reference
virus using competitive growth assays.(4)
Finally, sequence analysis of viral quasispecies is often employed
to determine fitness by measuring the frequencies of genotype
populations within the viral quasispecies. This method is motivated
by the fact that higher frequencies of viral genotypes typically are
associated with increased replication rates, thus implicitly entailing
fitness gains.(5)
It is important to note the differences between these three ap-
proaches: while competitive growth experiments allow for quan-
tification of relative fitness but include only a limited number of
reference strains and are undertaken in vitro in a controlled and
observable environment, viral load is directly based on patient
samples but only reports the absolute fitness of a whole viral qua-
sispecies; however, viral load measurements produce clinically
actionable results and are well suited for comparisons between dif-
ferent patients. Sequence analysis of viral genomes may report the
full genotype distribution of a quasispecies based on either patient
samples or in vitro samples and allows for deduction of relative
fitness based on the relative frequencies of genotypes; however, it
does not yield an absolute quantification of viral fitness.
Bottleneck events. Fitness is often investigated with respect to
bottleneck events, i.e., rapid changes in the quasispecies environment
that reduce the effective population size of the quasispecies due to
strong selective forces that spare only few genotypes of the viral
quasispecies that are adapted to the new environment, for example,
by virtue of enabling immune escape or conferring drug resistance.
Bottlenecks regularly occur during initial transmission of viruses
between hosts and are correlated with significant changes in the vi-
ral quasispecies(6) that can have dramatic consequences for clinical
outcomes.(7)
Since only few viral variants are expected to encode pheno-
typic features compatible with surviving the bottleneck event, the
surviving part of the viral quasispecies typically features lower
abundance and reduced variability compared to the pre-bottleneck
viral population.(8) This is due to the fact that quasispecies geno-
types with high fitness are likely to be removed by the bottleneck
due to sampling effects; since fitness of a viral population is largely
determined by its fittest genotype, the replicative capacity of the
post-bottleneck population is decreased, as has been demonstrated
experimentally(9) as well as by stochastic simulations.(10)
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Sequence spaces. The viral quasispecies is often conceptual-
ized dynamically as a swarm of genotype populations that moves
through an abstract, high-dimensional sequence space, also termed
genotypic space. This representation serves as a means for concep-
tualizing the the interactive and interdependent processes of viral
variability, fitness, and selective pressures. Coordinates within se-
quence spaces represent specific viral genotypes as determined by
genomic nucleotide sequences. Thus, geometric distances within
sequence space represent sequence dissimilarity between viral
genotypes.
Since phenotypic characteristics of a virus are highly dependent
on its genotypic identity, each coordinate in sequence space is com-
monly associated with a specific fitness value. These fitness values
represent the ability of a specific viral phenotype to procreate in
the current environment. Since higher fitness of a viral genotypes
typically also entails higher frequencies of this genotype within
the viral quasispecies, the density of genotypes at a given coordi-
nate is assumed to be directly correlated with relative fitness of the
corresponding viral phenotype.
Fitness values are commonly depicted as elevations of the se-
quence space; if represented in a simplified 3-space that allows for
two genotypic dimensions and one fitness dimension, the result-
ing manifold bears similarity to natural landscape with riffs and
valleys, plateaus and peaks. As a consequence, sequence spaces
are termed to induce fitness landscapes. Within these landscapes,
genotype populations (as identified by their sequence and fitness
coordinates) form a spatially connected swarm that clusters near
peaks of the fitness landscape.(11)
Fitness landscapes are believed to be rough (i.e., non-continuous)
due to the deleterious effects of most mutations and may display
considerable dynamics, both in terms of changing fitness values
associated with specific genotypes, and in terms of which parts of
the fitness landscape are currently occupied by viral quasispecies
genotypes(12)
Exploration of fitness landscapes. The adaptive capacity of viruses
is mediated by several parameters of the viral quasispecies. Among
these are the mutation rate and associated genetic divergence of the
viral quasispecies that facilitate rapid exploration of sequence space
and are believed to be important determinants of viral adaptability.
Replication-competent viruses will constantly generate offspring
that differ from the parent by a number of nucleotide positions
according to the mutation rate. As a consequence, viral progeny
will slightly deviate from the ancestral genotypic coordinates in
sequence space.
The continuous generation of viral progeny can be represented
by discrete movements of viral genotypes in sequence space. As a
result, viral genotypes are constantly "on the move": while advan-
tageous movements in sequence space may lead to the occupation
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cording to the advance that they bring in
overcoming the barrier.
of new "peaks" on the fitness landscape and thus in increased num-
bers of progeny, disadvantageous movements may lead into fitness
valleys and thus to loss of replicative ability.
Sequence spaces of viral quasispecies are tremendously large;
for a viruses such as HCV with a genome length of approximately
10 kbp, 410,000 (⇡ 106,020) sequence states are possible, significantly
more than the number of atoms in the observable universe (esti-
mated to be on the order of 1082 atoms, based on combined stellar
mass of the observable universe.(13)
In order to enable highly parallel exploration of the sequence
space, large viral population sizes are required; these high abun-
dances are supported by the short genome lengths of RNA viruses
that allow for efficient replication and decrease the probability of
accumulating several deleterious mutations within an individual
replicate. In addition, high rates of replication also entail advan-
tages with respect to the host: since the immune system cannot
clear viral genomes at a sufficiently high rate to overcome new
infections of host cells, large viral population sizes also promote
chronicity of infection.
Mutational pathways and genetic barriers. Acquiring new phe-
notypes that are advantageous for replicating within new host
micro-environments requires following a number of discrete steps
(i.e., mutations) in sequence space. These mutational pathways are
believed to be guided by fitness gradients that facilitate evolution
towards advantageous phenotypes. Mutational pathways may
require a large number of steps or the traversal of low-fitness "val-
leys" in the rough fitness landscape. The set of limitations a viral
genome has to overcome in order to overcome a selective constraint
such as an antiviral drug by a mutational pathway is often denoted
as the genetic barrier of the selective constraint.
The "height" of the genetic barrier is generally quantified as the
length of the mutational pathways that has to be traversed.(14) In
principle, each pair of coordinates in sequence space is connected
by a mutational pathway that is shorter than the viral genome
length. In practice, however, much shorter distances consisting
of only a few mutations may already have high genetic barriers,
likely due to the roughness of the fitness landscape that results in
intermediate steps exhibiting only low fitness. For instance, while
single nucleotide transitions are associated with low barriers in
viral quasispecies since they are readily reached by only one ran-
dom mutation, nucleotide transversions that are less likely to occur
randomly as well as pathways requiring two or three mutations
in order to elicit changes on the protein sequence level are already
considered to have comparatively high genetic barriers.
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Error threshold and catastrophe
Since, by definition, viral quasispecies arise from a background of
high mutation rates, regions in sequence space that confer high
fitness are densely occupied by viral genotypes while genotypes
that are distant from high-fitness regions are pruned by negative
selection. However, as a consequent of the geometric properties of
the sequence space and the inherent dynamics of fitness landscape,
genotypes with lower fitness can be maintained if they are near in
sequence space to high-fitness peaks. Since the progeny of high-
fitness genotypes will commonly be distributed across a domain of
sequence space that includes regions with lower fitness, the high-
fitness genotype continuously replenishes surrounding low-fitness
genotypes.
Similarly, low-fitness genotypes also replenish the high-fitness
genotype as well as each other with their mutated progeny, al-
though at a decreased rate due to their lower replicative fitness.
This effect is termed genotypic coupling and can be generalized as
to include all genotypes within connected and viable regions of
the fitness landscape. The domain that encompasses all genotypes
benefiting from such a shared region of high fitness is denoted as a
neutral network or contingent neutrality.(15)
Advantages of genotypic coupling. It is in this context that broad
exploration of a sequence space by viral quasispecies has important
advantages: due to the high dimensionality of the space and the
associated close connectivity, each genotype inhabiting a particular
coordinate is connected to many other genotypes by just a single
mutation. As a consequence of this tight coupling, a large hyper-
sphere around a central master sequence with the currently highest
fitness can be densely occupied by viral genotypes. This allows for
continuous dissemination of new variants by the master sequence
while also providing protection from rapid environmental changes:
if a fitness peak shifts within the hypersphere due to environmental
changes, the quasispecies already has established genotypes that
encode many adapted phenotypes, one of which may be selected to
become the new master sequence.
Occupying such a large sequence space with sufficient coupling,
however, requires high population sizes; indeed, given the HCV
example, 3 ⇥ 104 viral genotypes are within distances of a single
mutation with respect to the master sequence. This number is well
below the population size of RNA viruses inhabiting a single in-
fected host, thus ensuring dense coupling and consequently high
adaptability of the quasispecies. In contrast, larger mammalian
genomes may generate many more variants (on the order of 1010),
in principle, thus seemingly offering more potential for variabil-
ity and adaptability. However, this is offset by the considerably
smaller population sizes of mammals which usually is well below
the 1-step hypersphere around the master sequence.
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(17) for example, by introducing a param-
eter µ0 that represents the base mutation
rate of the quasispecies and setting
µa = kµ0 and µb = µ0, with k > 1
(18) Notably, error thresholds are further
modulated by finite population sizes and
the frequency of back mutations, the latter
of which we disregarded in the model;
while finite population sizes are likely
to increase the conversion of A to B due
to the accumulation of deleterious muta-
tions (Nowak and Schuster, 1989), back
mutations can retain A at infinitesimal
population sizes; however, given ana-
lytical results, back mutations are only
relevant if occurring at large frequencies
(Bull et al., 2005). Also, in real-world
settings A may not necessarily become
extinct but may be maintained as a low-
frequency minority genotype (Ruiz-Jarabo
et al., 2000).
Error catastrophe, revisited. Based on the previously introduced
concepts pertaining to viral sequence spaces and genotypic cou-
pling, we are now in a position to better appreciate recent finding
on the distinctiveness of error catastrophe and lethal mutagenesis.
Bull et al. was one of the first to argue, based on both theoretical
models and experimental data, that lethal mutagenesis and error
catastrophe are not equivalent, i.e., that error catastrophe is not a
particular form of lethal mutagenesis and that the prior may even
impede the latter.(16)
Bull et al. employed a minimal theoretical model of viral quasis-
pecies theory as proposed by Eigen consisting of a two-genotype
quasispecies population. The model assumes a population A and a
mutant population B, the latter of which is constantly replenished
by mutated progeny of A at a mutation rate µa. B also creates mu-
tated progeny at a mutation rate µb, but all of its descendants are
assumed to be inviable. The directionality of mutation is assumed
to be asymmetric, i.e., descendants of A can mutate to B but not
vice versa. Both populations A and B have their own relative fitness
values wa and wb, respectively, and wa > wb.
It follows from quasispecies theory that both populations will
achieve a mutation-selection equilibrium where mutations continu-
ously create B from A and natural selection purges B by removing
inviable descendants, thus decreasing the relative abundance of B
in favor of A.
An explanatory model for the error catastrophe. This equilibrium
between A and B is subject to change if mutation rates or relative
fitness values are altered; in particular, lowering the fitness of A
(wa) or increasing the mutation rate of A progeny (µa) will lead to
a constant decrease of A abundance in the quasispecies. Let wx(1 
µx) be the number of unaltered X progeny originating from the X
population. We will denote this value as the replacement rate of X
and assume that it has a value greater one. Since, by definition, the
fitness of A is higher than the fitness of B, the replacement rate of A
is greater than that of B at µa = µb. This relation maintains both A
and B at an equilibrium: A because of the higher replacement rate,
and B due to mutation of A progeny to B.
If however, µa unilaterally increases (17) until wb(1   µb) >
wa(1  µa), A has a lower replacement rate than B and thus is grad-
ually replaced by B. The µa at which wb(1  µb) = wa(1  µa) is
the error threshold associated with that particular error catastrophe.
Since A is not supported by mutated progeny of B, the frequency
of A is reduced to 0 in this model. This elimination of A is termed
an error catastrophe and is the endpoint of a gradual decrease of the
frequency of A compared to B.(18)
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Quasispecies interactions and mutational robustness.
As noted upon in previous sections, viral mutation rates them-
selves are subject to selection.(19) Quasispecies theory adds to these
propositions by further suggesting that mode selection optimizes
the mutation rate of quasispecies in order to confer robustness with
respect to mutation and thus allow for the quasispecies to exist at
relatively high mutation rates.(20)
In combination with high rates of genetic coupling that is charac-
teristic for viral quasispecies, it follows that (1) selection acts upon
population of genotypes within the quasispecies that are close in
sequence space and (2) that the selective process maximizes the
average fitness of these groups rather than the fitness of single
genotypes. As a result, less fit genotypes that occupy theoretical,
elevated regions in the fitness landscape that provide moderate fit-
ness can, as a connected population, generate more progeny than
other viral populations that occupy narrow, high-fitness peaks(21)
and whose progeny is more likely to be deleterious given even
slight changes in the fitness landscape.(22)
This hypothetical phenomenon is denoted as "survival of the
flattest" and can well be illustrated with the minimal quasispecies
model introduced earlier. As can be derived from the previous def-
initions, an error catastrophe of A can only take place if A suffers a
stronger mutational loss of its progeny than B. While the differing
sensitivity to mutations may seem contrived in this model setting,
the phenomenon is well in accordance with supplementary evi-
dence indicating that error thresholds are believed to exist due to
deleterious mutations may vary between populations (c.f. Wilke
2005). Importantly, after crossing of the error threshold of A and
its extinction due to error catastrophe, further deleterious impact
on the remaining population B is impeded: since B is more robust
against mutations in the model (due to lower µb), the replacement
rate of B is less affected than the replacement rate of A was prior to
its error catastrophe.
Interestingly, this varying robustness is not necessarily a result
of differing fidelities of the replication processes of genotype popu-
lations; instead, robustness may also depend on the particularities
of the fitness landscape that is populated by a given genotypic
population. In particular, high genotypic coupling of quasispecies
populations can convey additional robustness to genotypic popu-
lations that can support each other by mutated progeny (as B was
produced by A in the model presented). Such relations between
subpopulations are denoted as neutral networks. Large neutral net-
works are assumed to pose additional robustness towards elevated
mutation rates since neighboring positions in sequence space are
more likely to be viable and populations within these network are
constantly supplemented by mutated progeny of related geno-
types.(23)
210 from basic research to clinical applications
(24) Burch and Chao (2000)
(25) Wilke et al. (2001)
Two model of mutational robustness. These robustness theories,
while notoriously difficult to prove experimentally due to the com-
plexity of finding suitable model systems, have been supported by
tentative experimental results demonstrating the selective advan-
tages of interacting subpopulations.(24) In addition, simulation
studies have beed devised in which simulated, asexual organ-
isms compete for resources within a computational model envi-
ronment.(25)
The simulation extends the previously introduced, minimal
quasispecies model (A/B) and consists of two populations of or-
ganisms that originate from the same common ancestor but were
evolved at differing mutation rates. While population L adapted to
low rates of mutations, achieved high absolute fitness (in terms of
simulated replication rates), and tended to populate small, high-
fitness regions of the fitness landscape, population H was evolved
at (and thus adapted to) higher mutation rates, displayed lower ab-
solute fitness, and occupied elevated plateaus ("flat peaks") of the
fitness landscape. L and H were then mixed in equal proportions
and competed for resources across a ranges of mutation rates.
As could be expected, L replaced H at low mutation rates while
H excluded L at higher rates of mutation within the simulation.
Interestingly, this ability of a low-fitness population to replace a
high-fitness population is neither due to absolute fitness increases
of the H population in high-mutation environments (for instance,
by increasing replication fidelity), nor due to absolute fitness de-
crease of the L population in the same, high-mutation environment;
rather, the absolute fitness of H as measured in replicates per sim-
ulated organism per time unit is constant and remains below the
fitness of L also in the high mutation environment. Similarly, L is
well able to replicate indefinitely also in presence of high mutation
rates if H is not present.
The shape of fitness peaks occupied by the respective popula-
tions was quantitatively confirmed. The relative fitness of a pop-
ulation and its relation to mutation rate and peak shape can be
approximated by a realized growth rate (i.e., the relative fitness un-
der different loads of mutations) w(µ) = w0 exp( aµ   bµ2) that
depends on the genomic mutation rate µ, and the absolute repli-
cation rate w0 of the populations in their original, non-competitive
environment. a and b correspond to mutational robustness param-
eters that are fit to each population based on characteristics of the
model environment, in particular the peak regions occupied by a
population.
Based on these approximations, the reason for the success of
H could be determined to be based on the shape of the fitness
peaks that were occupied: while L occupied narrow peak regions
of high absolute fitness that could no support a neutral network,
H evolved towards occupying flatter peak and thus gained support
from a neutral network, resulting in increased protection from high
mutation rates.
quasispecies dynamics 211
(26) Bull et al. (2005)
(27) Tannenbaum and Shakhnovich (2004)
(28) Bull et al. (2005)
(29) Holmes (2003)
Interpretation of minimal quasispecies models. The two models de-
scribed (mutational robustness and error catastrophe: A/B, shape
of the fitness landscape: H/L), while simple, are well in accordance
with quasispecies theory and convey several messages of practical
importance.
First, the A/B model can be extended to arbitrarily many geno-
types that are connected by mutations. Multiple error thresholds
are therefore possible if subpopulations have increasing error
thresholds due to increasing robustness against mutations.(26) Such
error thresholds could be arranged sequentially in a way that the
highest-fitness, lowest-robustness error threshold is lowest and is
succeeded by increasingly higher thresholds of more robust geno-
typic populations; as a consequence, increased error rates would
be elicit continuous replacement of less robust genotypes with
more robust genotypes.(27) In addition to being well covered by
quasispecies theory, this sequential structure results in increasing
resistance (or adaptation) to rising mutation rates, a phenomenon
that may explain the therapeutic failure of monotherapies with
mutagens against RNA virus populations (see below).
Second, from existence of multiple error thresholds becomes
clear that an error catastrophe do not necessarily imply lethal mu-
tagenesis and extinction of the complete population: only if the
mutation rate exceeds the error thresholds specific to all genotypic
populations, mutagenesis is truly lethal and the total quasispecies
become extinct. Therefore, the concepts of error catastrophe and
lethal mutagenesis are distinct; the error threshold only refers to
"the loss of the highest fitness genotype in favor of other geno-
types with lower fitness but greater mutational robustness"(28) and
takes place when one population’s replacement rate exceeds that
of another population. In contrast, lethal mutagenesis and extinc-
tion occurs if no population can maintain a replacement rate of at
least one (wi(1  µi) < 1 for all populations i). The smallest µi for
which this is true can then be considered the last error threshold or
extinction threshold.
Finally, the emergence of neutral networks at elevated mutation
rates ("survival of the flattest") is likely to play an important role
for robustness of the viral quasispecies. The phenomenon is espe-
cially relevant in the context of the use of mutagenic drugs against
infections with RNA viruses. Intuitively, a modest increase of the
mutation rate of the quasispecies that does not immediately lead to
lethal mutagenesis as may be considered to be detrimental to the
host since it will increase the viral adaptability.
However, assuming the existence of successive error thresholds
and of neutral networks, an increased mutation rate may result
in error catastrophes that is paralleled by a shift to more robust
and less fit viral subpopulations. While the viral infection may not
be cleared in this manner, treatment may still result in decreased
fitness and constrained adaption, thus representing a viable therapy
option, in principle.(29).
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21 Quasispecies and antiviral therapy
The genetic variability and the population mechanics of viral qua-
sispecies enable it to undergo rapid cycles of mutation and selection in
order to adapt to novel environmental conditions. As a result, the qua-
sispecies nature of many human pathogens constitutes a major hindrance
to antiviral therapy.(1) The association of viral sequence variation with
therapy success as an intensively studied field of current research(2) and
detection of viral minorities, here exemplified by tracking the subclonal
evolution of viral quasispecies with regard to drug resistance(3) and im-
mune escape(4) has important consequences for developing and implement-
ing rational drug treatment regimes.(5) This section discusses the role of
genetic variants within the viral quasispecies and their relation to drug
resistance and immune escape. In addition, effects of increasing mutation
rates on the quasispecies are reviewed in a context of mutagenic drugs.
Resistance and compensation
As noted in the previous section, it follows from quasispecies
theory that individual viral genotypes within a quasispecies are
not the units of selection; rather, populations of these genotypes
are subjected to group selection under consideration of inter-
population relations such as neutral networks. It has therefore
become clear that antiviral therapies should not target individual
genotypes of the quasispecies but specific populations in the quasis-
pecies.
Resistance-associated variants. Strong selective constraints such
as immune pressure or antiviral drugs may have significant effects
on genotype distributions within the quasispecies, for instance by
drastically reducing the fitness of the current master sequence. In
such cases, minority genotypes that previously had low replica-
tive fitness or were suppressed by the highly competitive master
sequence may display high relative fitness under the new selective
constraints. These minority genotypes are commonly termed escape
mutants(6) or, in the context of antiviral therapy, resistance-associated
variants (RAVs).
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RAVs are mutations within the viral genome that confer resis-
tance to specific or groups of closely related antiviral drugs, usually
by altering viral protein binding interfaces that these drugs target
to inhibit pathways of the viral replicative cycle. As a result of their
protective effect against antivirals, RAVs confer additional pheno-
typic advantages to viral populations that evolve under pressure of
these drugs. Viral genomes containing RAVs therefore often evolve
according to a selection of mutational pathways that are character-
ized by serial and interdependent accumulation of RAVs.(7) The
time a viral population requires to traverse such pathways to drug
resistance is often also conceptualized as genetic barrier with re-
spect to the development of resistance.
Importantly, viral genotypes are not limited to acquire resistance
to only one antiviral at a time; instead, cross-resistance, i.e. resistance
against several drugs, may be achieved my serially acquiring mul-
tiple RAVs and is especially pronounced with regard to drugs that
employ identical modes of action.(8)
Compensatory mutations. Often, mutations such as RAVs with re-
spect to the viral wild type entail additional fitness costs that limit
either reproducibility or infectability of the affected viral species.
This phenomenon is due to the fact that large structural changes in
the viral proteins that confer high levels of resistance also inhibit
normal functions of these proteins, for example by altering catalytic
centers or binding interfaces, resulting in deleterious effects on viral
replicative ability. Still, RAVs observed in clinical settings are gen-
erally advantageous for the viral quasispecies in spite of reduced
fitness simply because they prevent extinction of the quasispecies
by the antiviral.
Often, genotypes encoding RAVs that directly confer drug resis-
tance evolve additional RAVs that restore viral fitness. These sup-
porting RAVs are denoted compensatory mutations and do not them-
selves confer drug resistance. Rather, they induce compensatory
structural changes in viral proteins, thus rescuing viral replicative
ability in the presence of high-level drug-resistance RAVs. Com-
monly, these compensatory mutations are located in viral proteins
targeted by directly acting antivirals, such as viral proteases or
polymerases.(9) are are evolved subsequently to drug resistance
mutations.
The concept of rapidly acquiring protective phenotypes is not
limited to drug resistance: similar mechanisms are also active in
viral evasion of antibody recognition. Therapies with neutralizing
antibodies that target conserved viral epitopes are an active field of
pharmacological research; however, similar to emerging drug resis-
tance, viral genotypes encoding variants in epitope regions that do
not encode antigenic epitopes are quickly selected for. These escape
mechanisms are complemented by convergence towards epitopes
that emulate sequence motifs of host factors and are therefore not
readily targetable by antibodies due to immune tolerance.(10)
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population: T-memory cells of the adap-
tive immune system that confer enduring
immunity against certain antigen patterns
and are maintained by the host long after
initial infection Ahmed and Gray (1996),
Fazilleau et al. (2007)
Mutational pathways to drug resistance. As a consequence of the
complex networks of escape variants and compensatory mutations
as well as the various structural mechanism that may confer drug
resistance on the protein level, often multiple mutational pathways
exist that confer resistance to a single drug.(11) Each of these path-
ways may be associated with different levels of drug resistance,
fitness costs, and compensatory mutations.(12)
RAVs induced within the HCV genome, for instance, are as-
sociated with various levels of resistance as quantified by IC50
assays(13) and corresponding losses of fitness as determined by
growth competition and colony formation assays.(14)
The role of minority variants. Genotypes within viral quasispecies
that occur at frequencies of lower than 20% (for Sanger sequencing)
or lower than single-digit percentages (for NGS sequencing) are de-
noted as viral minorities and sequence variants that distinguish them
from genotypes with higher frequencies are termed minority vari-
ants. Based on quasispecies theory of population equilibria, these
genotypes are likely to display lower fitness if compared to the
high-frequency genotypes such as the dominant species within the
viral quasispecies (i.e., the master sequence). Minorities are of high
clinical importance due to their crucial role in the development of
drug resistance and immune escape variants by (1) providing high
sequence diversity to the viral quasispecies that encode beneficial
phenotypes for yet-to-be encountered selective constraints, and (2)
by allowing for storage of formerly high-fitness genotypes for later
use, for instance by encoding resistance-associated variants from
prior drug treatment episodes.(15) This phenomena will be briefly
discussed here.
The first feature has gained considerable clinical importance:
due to the high variability of viral quasispecies, all possible single-
mutations genotypes (compared to the master sequence) are likely
to exist within a viral quasispecies at any given time. Some of these
genotypes may encode for drug resistant phenotypes that exist
at low frequencies of 10-3 to 10-5 even prior to therapy.(16) Upon
antiviral therapy, these resistant genotypes are selected for and
rapidly increase in frequency within the viral quasispecies. This
phenomenon may result in rapid treatment failure during early
phases of therapy and the characterization of the baseline genotype
population prior to therapy has therefore gained considerably in
clinical importance.
Even after treatment with an antiviral inhibitor has ended, vi-
ral minorities encoding resistance-associated variants may persist
within the quasispecies. These "stored" genotypes are hypothesized
to implement a molecular memory of formerly highly fit variants
that may reemerge once selective pressures change again in their
favor.(17) These memory mechanisms are associated with specific
clinical phenomena such as resistant viral phenotypes that are
present either before therapy (and possibly originate from infection
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(18) Briones et al. (2006)
(19) Arias et al. (2004), Ruiz-Jarabo et al.
(2000)
(20) Clay et al. (2011), Harki et al. (2006)
(21) Anderson et al. (2004)
1990 Error catastrophe firstly investigated in
experimental settings; Poliovirus has
been shown to be affected by mutagen-
esis Holland et al. (1990).
1999 Mutagens are shown to impair HIV-1
replication in vitro; first use of the term
"lethal mutagenesis" Loeb et al. (1999)
2000 First evidence that RNA viruses can
indeed be extinguished by mutagenic
drugs if viral load and viral fitness is
low Sierra et al. (2000).
2000 The mutagen Ribavirin is shown to
be effective against poliovirus in a
clinically relevant setting Crotty et al.
(2000).
2005 Experimental evidence for the lethal
defection activity of mutagenic drugs,
i.e., clinically relevant impairment of
viral replication even at low concentra-
tions of mutagenic drugs by generation
of "interfering" genomes that can repli-
cate but actively inhibit formation of
infectious particles Grande-Pérez et al.
(2005).
2009 First studies on therapy optimiza-
tion and drug interactions involving
mutagenic drugs; sequential and com-
bination therapies are shown to a have
relative advantages depending on the
distribution of the viral quasispecies
Perales et al. (2009a).
Table 21.1: Timeline of viral
mytagenesis. Derived from Moreno
et al. (2012).
(22) Anderson et al. (2004), Domingo et al.
(2005), Graci and Cameron (2008), Perales
et al. (2011a)
by another treatment-experienced host) or re-emergence of highly
fit viral genomes after successful therapy.(18) This process may be
further aided by viral compartmentalization, i.e., low-level repli-
cation or maintenance of these memory quasispecies in cell types
not readily available to immune clearance. Memory genomes are
under constant competitive pressure by other genotypes of the viral
quasispecies and have been shown to be eliminated by bottleneck
events,(19) indicating that antiviral treatment targeting viral replica-
tion may also be successful in counteracting memory mechanisms.
Mutagenesis and error catastrophe
As touched upon earlier, a high rate of genomic variation is a cru-
cial factor for the evolution of viral quasispecies. It serves as a
bedrock for high adaptability and fitness in of the viral population,
especially in environments that are dominated by strong selective
forces as for example induced by the host immune system or by
antiviral therapy. The high rate of variability in RNA viruses is
believed to be a consequence of the lack of error-correcting proof-
reading activity in viral RNA-dependent RNA polymerases, as well
as due to missing mechanism of post-transcriptional repair of viral
genomes.
Mutagenic drugs, especially nucleoside analogs such as rib-
avirin,(20) have been employed as antivirals since the 1970’s and
their effect on viral quasispecies is an active field of current re-
search (see Table 21.1). Mutagenesis may be achieved by mutagenic
drugs by several means, for example directly by genetic damage
to viral genomes, or indirectly by either biasing intracellular nu-
cleotide concentrations or by incorporation of non-complementary
nucleotides, terminating nucleotides, or nucleotide analogs with
incorrect base-pairing during viral genome synthesis.(21)
Nucleoside analogs. Of the known mutagenic compounds, nu-
cleoside analogs are the most well studied mutagens of RNA
viruses. These compounds are often intracellularly metabolized
into nucleoside-triphosphates, which are incorporated into viral
genomes during polymerase-mediated nucleotide elongation. In
contrast to antagonistic nucleoside/nucleotide inhibitors as used
for example in anti-HIV therapy, nucleoside analogs do not result in
chain termination as their main mode of action.
Instead, these compounds are incorporated into the nascent
nucleotide chain and allow, due to their ambiguous molecular
structure, allow for pairings with complementary purines and
pyrimidines upon later use of the modified nucleotide chain as
either substrate or template of the viral replication machinery. This
unspecific pairing results in nucleotide substitution patterns that
increase the viral mutation rate.(22)
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(23) Interestingly, the proposed induction of
error catastrophes by mutagens parallels
the action of components of the innate
immune system: specific host factors
of the APOBEC (apolipoprotein B mRNA
editing complex) family are known to also
have antiviral functions by deaminating
viral RNA, a process denoted as hyper-
mutagenesis. In particular, the human
cytidine deaminase APOBEC3G was
shown to target HIV and HBV ribonu-
cleotides (Holmes et al., 2007, Mangeat
et al., 2003). The fact that components of
the immune system employ such strate-
gies suggest that mutagenic therapies may
indeed be based on sensible foundations
(24) Grande-Pérez et al. (2002), Ojosnegros
et al. (2008)
(25) Anderson et al. (2004)
(26) Muller’s ratchet: hypothetical genetic
process that describes the accumulation
of harmful mutations and the loss of
genetic diversity in asexual populations
due to the higher likelihood of harmful
rather than beneficial mutations (Haigh,
1978). Especially relevant in populations
with small effective population size such
as post-treatment viral quasispecies.
(Domingo et al., 1996, Duarte et al., 1992,
1993, Loeb et al., 1999, Yuste et al., 1999)
(27) Bull et al. (2007)
(28) Bull et al. (2007)
(29) Crotty et al. (2001), Grande-Pérez et al.
(2005, 2002), Loeb et al. (1999)
Mutagens and error catastrophe. As a consequence of the increased
mutation rate, random mutations are believed to be accumulated
within viral genomes until the error threshold of the viral quasis-
pecies is exceeded. This loss of genetic information may lead the
quasispecies into one or more error catastrophes, a process that can
theoretically lead to the extinction of the viral population by lethal
mutagenesis (see previous sections).(23)
Importantly, the mutation frequency is not required to increase
linearly during successful mutagenic treatments and elimination of
the virus by mutagenic drugs is not required to be associated with
large increases of mutational complexity within the viral quasis-
pecies; instead, several error thresholds may be exceeded during
treatment and the viral quasispecies may undergo multiple rounds
of adaption towards more robust populations and decreased fitness
without showing signs of large-scale deterioration.(24)
Indicators for mutagenesis. Interestingly, the main mode of action
of widely used mutagens such as ribavirin is not well understood.
As later sections of this chapter will discuss in detail, mutagenesis
is a complex process that may involve indirect means of actions
such as effects of mutagenic compounds on the intracellular nucle-
oside metabolism and on immune pathways. In general, however, a
few direct indicators for the effectiveness of mutagenic drugs can be
formulated:(25)
(1) mutagenic drugs should increase the mutation frequency
in the viral progeny, (2) the mutagen or its metabolite should be
incorporated into viral genomes by the viral polymerase, (3) mu-
tation rates in vitro should depend on the concentration of the
mutagen, (4) mutagenesis can be experimentally facilitated by
increasing incorporation of the mutagen or by decreasing proof
reading/genomic repair, and last (5), reduction of viral load should
increase effectiveness of the mutagen due to proposed effects of
Muller’s ratchet.(26)
Since several modes of action may be causal for the observed
efficacy of mutagens, the ability of mutagenesis to independently
cause viral extinction is currently contested.(27) Partly, this circum-
stance is due to the fact that lethal mutagenesis is hard to prove
experimentally, especially since current experiments cannot differ-
entiate ongoing lethal mutagenesis from a sequence of nonlethal
error catastrophes.(28) Because both mechanisms follow the same
evolutionary pathways, only the total extinction of a viral quasis-
pecies can provide conclusive evidence for lethal mutagenesis.(29)
However, since viral clearance may also be a result of an immune
response becoming more effective due to lower viral fitness, the
distinction is very hard to make in vivo.
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(34) Gerrish and García-Lerma (2003)
(35) Handel et al. (2006)
(36) Gerrish and García-Lerma (2003),
Grande-Pérez et al. (2002), Nowak and
Schuster (1989)
Therapy optimization using mutagens
Monotherapy with mutagens often has only limited effects on viral
quasispecies and generally does not result in viral extinction at
non-toxic concentrations of the mutagen. One avenue for explaining
this phenomenon is the great abundance of the viral quasispecies
that allows for adaptation to increased mutation rates as discussed
previously in the context of error catastrophes and mutational
robustness. As a consequence, mutagens are likely not useful in
monotherapy but should be administered in combination with
other antivirals such as directly acting antivirals that drastically
reduce viral population size and thus induce a bottleneck event.(30)
While not effective in monotherapy, mutagenic drugs are in-
teresting candidates for combination therapy with directly acting
antivirals. Directly acting antivirals induce strong population bot-
tlenecks and abundance and fitness of the post-bottleneck viral
population is predictive for therapy success.(31) As we we will ar-
gue in the following, the lower abundance and replicative fitness of
the persisting, drug-resistant viral population offers an opportunity
for treatment with mutagenic drug in order to further destabilize
the viral quasispecies and increase treatment efficacy.
The efficacy of combination therapy with mutagens and directly
acting antivirals is assumed to depend on the specific sequence of
the treatment.(32) Parallel combination therapy involving a specifi-
cally acting drug and a mutagenic antiviral may not always be opti-
mal for supporting viral extinction: while administering both drugs
simultaneously is indicated in settings of high viral fitness in order
to maximally constrain viral replication,(33) sequential dosage of
first the specifically acting inhibitor followed by the mutagen may
be advantageous in order to increase the effects of each individual
drug.
In particular, administration of the mutagen prior to treat-
ment with directly acting antivirals may increase the frequency
of resistance-conferring viral variants, thus increasing surviving
population size. On the other hand, the persistent population may
also carry additional harmful mutations in addition to resistance
mutations, thus resulting in lower numbers of viable genotypes
after treatment. Stochastic simulations that model the effects of
bottleneck events and acquired drug resistance on viral population
dynamics indicate that the latter effect prevails at high mutation
rates and especially with smaller persistent population sizes.(34)
Similarly, mutagens may be discontinued after directly antiviral
treatment, thus slowing the development of compensatory muta-
tions,(35) or be continued in order to further destabilize the viral
population by enhancing the effect of Muller’s ratchet. Tentative
experimental results and simulations indicate, that continuing the
mutagen may make sense if the persistent population is sufficiently
small.(36)
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(37) Pariente et al. (2001, 2003), Perales
et al. (2009b)
(38) Iranzo et al. (2011b)
The applicability of treatment serialization strategies involving
mutagens is currently explored experimentally in combination ther-
apies against foot-and-mouth disease virus.(37) Results of these
studies indicate that the use of a mutagen and a directly acting
inhibitor increased treatment efficacy compared to the mutagenic
agent alone and that sequential treatment protocols of first the
directly acting inhibitor followed by the mutagen were more suc-
cessful than combination treatments. These findings were further
corroborated by models of viral dynamics at different doses of
inhibitor and mutagen that stressed the importance of the inhibitor-
induced bottleneck event for success of the mutagen.(38)
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(2006), Pokrovskii et al. (2011)
(4) Laskus et al. (2004), Quer et al. (2005)
(5) Farci (2011), Simmonds (2004)
(6) Farci (2011), Martell et al. (1992)
(7) Lutchman et al. (2007)
(8) Transgenic mouse models have recently
been developed but require expression of
viral entry factors in mouse hepatocytes,
cf. Dorner et al. (2011)
22 The HCV quasispecies
Of the approximately 170 million infected individuals that are
chronically infected with HCV, twenty percent will develop liver cirrhosis
of which up to 2.5% will progress to hepatocellular carcinoma (HCC).(1)
Apart from displaying a wide range of side effects, the efficacy of the cur-
rent standard of care (SOC) therapy is highly dependent on viral genotype
and may result in viral clearance in only 50-60% of all patients in large
subgroups of the patient population.(2) Several indicators of highly adap-
tive quasispecies as discussed previously are present in HCV mutants,
such as the rapid emergence of drug resistance and compensatory muta-
tions,(3) the shaping of viral populations by epidemiological bottleneck
events,(4) as well as increased variability of viral genes that are associ-
ated with immune escape.(5) This section discusses several aspects of viral
quasispecies at the example of HCV. In particular, the high diversity and
abundance of this virus as well as modes of disease progression and im-
mune evasion are reviewed in detail. Finally, antiviral treatment options
are reviewed, both in relation to the current standard of care therapy as
well as in a context of recently approved directly acting inhibitors.
Diversity and abundance
The existence of viral quasispecies in HCV was proposed almost
immediately after the discovery of the pathogen and is now an in-
tegral part of anti-HCV treatment.(6) Based on experimental data
originating from both Sanger and deep sequencing techniques, the
normal mutation rate of HCV can be estimated at about 10-2 sub-
stitutions per site and year,(7) a relatively high value compared to
other RNA viruses. HCV features a very narrow host cell tropism
as well as a limited host range and almost exclusively infects liver
cells of humans and chimpanzees.(8) Due to its reliance on RNA
genomes with short half-lifes and the lack of latency mechanisms
such as proviral integration, HCV is depending on continuous
replication for persistence.
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HCV variability. Similar to other RNA viruses, HCV features
high replication kinetics of up to 1012 virions per day in untreated
patients.(9) Since both humoral and cellular arms of the immune
system exert selection pressure on the quasispecies,(10) deleterious
variants are constantly pruned from the population. Still, the re-
maining diversity of the quasispecies quantified as average genetic
distances between genomes regularly exceeds 10%.(11)
RNA copies produced by the HCV RNA-dependent RNA-
polymerase NS5B have an estimated error rate of approximately
10-5 per genomic site and copy, a rate typical for non-retroviral
RNA viruses.(12) Given a genomic length of approximately 9.6 kbp,
experimental data suggest that about 0.096 mutations are intro-
duced per replicated viral genome, on average.(13),(14) While these
rates do not incorporate additional effects that influence genomic
variation such as recombination by polymerase template switching,
the latter is believed to be a low-frequency process in HCV and is
therefore neglected here.(15)
Given these estimates and assuming a binomial model of muta-
tions(16) within copied viral genomes, each new virion has a prob-
ability of 0.91 to be free of mutations and probabilities of 0.087,
0.0042, and 0.00013 to harbor one, two, or three substitutions, re-
spectively. Based on the large number of virions that are produced
each day, on the order of 1010 and 109 single- and double mutants,
respectively, are generated daily, effectively covering the space of
theoretically possible single and double mutants more than 10-
fold, even given the low average life span of the virus of about 4
hours.(17)
As a consequence of this dense coverage of genotypic space, it
is statistically likely that all viable single and double mutations
that confer drug resistance already exist within the HCV quasis-
pecies prior to antiviral treatment.(18) While only a small fraction
(on the order of 10-5) of the space of all possible triple mutants is
explored by the HCV quasispecies each day, resistance-conferring
triple mutations can be acquired by the virus through sequential
accumulation of single mutants. Even given the most potent anti-
HCV therapeutics that decrease HCV RNA to 10-5 and thus reduce
the number of virions produced per day to 107, a sufficiently high
number of single mutants remain to achieve resistance phenotypes
within days.
Resistance-associated variants. Indeed, resistance-associated vari-
ants can be detected rapidly after HCV monotherapy with directly
acting antivirals (DAA) as part of specifically acting antiviral therapy
for hepatitis C (STAT-C).(19) As a consequence, the clinical outcome
of disease treatment can be significantly impaired if no alterna-
tive therapy options are available. The early detection of RAVs is
therefore a critical component of rational therapy optimization.(20)
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Importantly, however, RAVs are not only a product of evolution
of the viral quasispecies within the host; instead, due to the high
variability of the viral quasispecies as well as a result of possible
infections with viral strains originating from pretreated hosts (see
previous sections on molecular memory), viral genomes infecting
treatment-naive patients may already contain minority RAVs.(21)
These baseline escape mutations have been experimentally mea-
sured at minority frequencies of about 1-2% in in vitro fluorescence
experiments involving replicon assays as well as by direct sequenc-
ing.(22)
Disease progression and immune evasion
HCV infection is diagnosed by the detection of HCV RNA as well
as anti-HCV antibody sero-conversion, both of which are detectable
4–10 weeks after exposure to the virus, in principle. HCV acutely
infects humans within the first six months after transmission and a
minority of 20% of patients is able to clear the virus spontaneously.
Since infection is mostly asymptomatic at the acute state, patients
frequently remain undiagnosed and clinical progression at this
stage is severely understudied.(23) The remaining 80% of infected
individuals develops chronic liver diseases such as cirrhosis as
indicated by increased levels of serum alanine aminotransferase
(ALT), an enzyme used as a surrogate for liver damage.
HCV is the dominant factor for both the development of virally
induced liver carcinoma, which occurs in about 1-2% of chronic
patients, and the main cause of liver transplantations. While there
is evidence for extra-hepaticular compartmentalization of HCV
by low replication in immuno-privileged brain cells, the relevance
of these data is currently contested.(24) Possibly as a result of this
compartmentalization, liver grafts are recurrently infected by HCV,
often leading to highly progressive liver disease in organ accep-
tors.(25)
Complexity of viral quasispecies has been correlated with ther-
apy response and clinical progression of HCV.(26) The HVR-1 region
in particular is a common surrogate marker for HCV quasispecies
heterogeneity. As it is located within the viral envelope protein,
HVR-1 may be relevant for both cellular entry and evasion from
antibody recognition.(27)
Fittingly, while newly infected HCV patients tend to have low
HVR-1 variability, possibly as a result of bottleneck events associ-
ated with transmission,(28) chronic HCV patients usually feature
high variability and differences in mutant frequencies in this re-
gion, possibly indicating complex interactions of the quasispecies
genotypes with the immune system. By way of supporting this as-
sumption, quasispecies complexity in the HVR-1 has been shown
to be low in individuals with suppressed immune system, possibly
indicating low selective pressure.(29)
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Humoral immunity and HCV infection. Similar to other viral in-
fections, both humoral and cellular components of the adaptive
immune system play important roles in modulating the pathogen-
esis of HCV infections and are inhibited by different viral mech-
anisms.(30) Successful clearance of initial infection is associated
with an increased production of CD8+ and CD4+ T cells as well as
with the initiation of immunologic memory that confers modest
protection upon reinfection.(31)
HCV is very apt at evading adaptive immune response both
in the initial acute phase of infection as well as during chronic
persistence. Interestingly, HCV immune evasion is highly spe-
cific and does not seem to affect host immune responses to other
pathogens. While HCV-specific antibodies are detectable soon af-
ter infection,(32) it is still unclear if these immunoglobulins are
indeed neutralizing as the occurrence of HVR-1 escape mutations
in the HCV E2 proteins of chronically infected individuals may
suggest.(33) If the latter is the case, then these mutations are likely
evidence for viral quasispecies adaption to humoral and cellular
(CD8+) immune responses by antigenic variation and epitope loss.
While epitope loss seems to be a primary mechanism of escape
from neutralizing antibodies,(34) a more active role of the viral hy-
pervariable regions has been proposed that may serve as decoy for
neutralizing antibodies or physical hindrance to antibody binding,
thus protecting conserved viral epitopes.(35) Similarly, lipoproteins
and glycans of the HCV virion may have additional roles concern-
ing antibody masking, for instance by inducing conformational
changes in neutralizing antibodies or by preferably binding to non-
neutralizing antibodies that may mask epitopes.(36)
Loss of viral epitopes by hypermutation during the acute phase
of infection in dependence on the host HLA type seems to deter-
mine immune failure and disease chronicity.(37) These mutations
predominantly occur at the HLA binding anchors of the epitope
peptide as well as in the centr of the epitope and may inhibit HLA
binding and T-cell recognition, respectively. Their frequency and
highly clustered nature on the genome seems to represent a trade-
off between maintaining replicative fitness on the one hand and
disabling broad cross-recognition of the epitope by T-cells on the
other hand.(38)
Cellular immunity and HCV infection. In contrast to humoral
responses, cellular immune response to HCV is currently better
understood and the initial delay of T-cell response as well as the
failure of chronic patients to generate adequate immune answers is
an active field of research.(39) Experimental results have indicated
that both CD8+ and CD4+ T cells of successful therapy responders
target several MHC-I and MHC-II epitopes within HCV proteins(40)
while patients with progressive disease express lower numbers of
T-cells that target significantly fewer epitopes.(41)
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Proposed explanations for this inability of the adaptive immune
system to generate adequate responses include impairment of anti-
gen presentation dendritic cells (DC) by viral modulation of the
innate immune response or inhibition of DC maturation, as well as
antigenic variation and functional impairment of CD8+ T cells.(42)
In particular, HCV may modulate T-cell response by up-regulating
inhibitory receptors such as PD-1 and Tim-3 on HCV-specific CD8+
T-cells, thereby inhibiting proliferation and predisposing these cells
to apoptosis.(43) While these pathways may indicate promising
new drug targets for host-factor based anti-HCV medicines, the
precise molecular mechanisms of active HCV immune evasion are
currently unknown.(44)
Anti-HCV therapy
The current standard of care (SOC) therapy against HCV is based
on a combination treatment of the immunoregulatory cytokine
interferon-a (IFN-a), an important modulator of the host immune
system, and the antiviral prodrug ribavirin (RBV). The latter com-
pound is known to display several modes of action against other
RNA viruses, including interference with RNA metabolism and
mutagenic activity. However, its effective mechanism against HCV
is presently unknown.(45)
Both the effects of host genotype and of viral genotype have been
associated with the mode of action of interferon-a. Viral determi-
nants of interferon response are probably multi-factorial and may
include the multifunctional HCV NS5A protein as well as structural
E2 (envelope) and core (capsid) HCV factors.(46) Of these proteins,
especially the aptly named interferon sensitivity-determining region
(ISDR) of NS5A and the hypervariable region (HVR-1) of the E2-
coding region may be involved in inhibition of interferon-inducible
protein kinase R (PKR) and immune escape by antigenic variabil-
ity,(47) respectively.
In addition to viral determinants of interferon response, the
detection of host genes that significantly effect anti-HCV treat-
ment response has permanently shaped HCV therapy towards a
personalized (or precision) paradigm of medicine. A number of
polymorphisms within the IL28B gene on human chromosome 19
that are associated with interferon secretion and were shown to be
predictive for SVR.(48),(49) Similarly, IP-10, a host factor involved
in chemo-attraction that may by at variation in non-responding
patients compared to responding patients, has been demonstrated
to be a promising new factor in HCV pharmacogenomics.(50) Fi-
nally, the human inosine triphosphatase (ITPA) gene, a relative of
IMDPH, as well as the ENT1 nucleoside transporter are correlated
with therapy response.(51)
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Treatment efficacy. While the SOC interferon-a plus ribavirin
therapy achieves a SVR against most the viral genotypes, it is not
effective against all patients infected with HCV genotype 1, the
most frequent genotype in western countries. In particular, treat-
ment of HCV genotype 1 patients results in SVR of only about 50%
of patients (in contrast to more than 80% of patients for genotypes 2
and 3).(52) As a consequence, novel, directly acting anti-HCV com-
pounds have recently been approved or are currently in late stages
of development.
While the combination therapy of pegylated interferon-a and rib-
avirin is still considered to be the standard of care therapy against
HCV, these recommendations are in the process of being changed
as DAAs are introduced in clinical therapy. Two protease inhibitors,
telaprevir and boceprevir, are currently FDA approved and at least
20 additional compounds including nucleoside (chain-terminating)
and non-nucleoside (allosterically functioning) inhibitors of the
polymerase, an inhibitor of the membrane-associated HCV phos-
phoprotein NS5A, and a cyclophilin inhibitor are in current test-
ing.(53) Peptidomimetic protease inhibitors constituted the first line
of DAAs that underwent development,(54) and have been shown
to dramatically increase SVR rates especially for genotype 1 pa-
tients.(55)
However, due to their direct mode of action, these new antivirals
are prone to the development of viral resistance and several RAVs
are currently known for all inhibitors currently used in clinical
settings.(56) Since one to two mutations are required to acquire
the resistance phenotype for the currently used DAAs,(57) these
estimates suggest that treatment failure for HCV monotherapy is
inevitable. While some classes of drugs, such as HCV polymerase
inhibitors may feature a higher genetic barrier against evolving
drug resistance, combination therapy may still be required in order
to raise the genetic barrier of therapy to at least three and better
four mutations.(58)
HCV therapy optimization. Monotherapy with currently approved
DAAs leads to development of resistance-associated variants within
the inhibited viral proteins, resulting in viral breakthrough and
drastically reduced efficacy of therapy.(59) Subsequent analysis of
the viral genotypes confirmed the existence of RAVs at frequencies
of 4-20% in the viral quasispecies within just days of therapy, signif-
icantly more rapid than observed in monotherapy against HIV and
HBV.(60) This rapid emergence of resistance can be explained by the
high variation and large numbers of progeny of HCV that allow for
efficient exploration of genotypic space in search for beneficial mu-
tations.(61) HCV replication requires multiple rounds of low-fidelity
RNA copying, a process that increases error rates in comparison to
other positive-sense single-stranded RNA viruses.
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In addition, the HCV genome does not face an important func-
tional constraints to evolvability: while genomes of other RNA
viruses such as HIV and HBV feature overlapping reading frames
and mutations are thus likely to have functional impact on multiple
viral genes, the HCV has only a single reading frame (possible ex-
ceptions exist in specific viral genotypes)(62) and should therefore
be able to accumulate mutations with less deleterious effects, in
principle.(63)
In order to avoid or postpone eventual treatment failure, an-
tiviral approaches that counteract the selection of both RAVs and
compensatory mutations while also hindering the viral population
at overcoming the genetic barrier of resistance are of crucial clin-
ical importance. Several classes of strategies for modulating the
accumulation of RAVs are currently in clinical use. Among these
are drug combination therapies that increase the genetic barrier by
requiring a viral population to evolve RAVs and compensatory mu-
tations against several, orthogonally acting drugs in parallel, a pro-
cess that is statistically less likely the more drugs are involved.(64)
Similarly, the use of drugs that target host factors instead of
viral factors is also believed to increase the genetic barrier against
HCV drug resistance. In order to gain resistance against host-factor
targeting drugs, the virus has to acquire mutations that makes it
less dependent on a host factor that is essential for viral replication.
This feat may necessitate interactions with alternative host factors
featuring distinct binding interfaces and thus require considerable
more changes to viral proteins than evolving resistance mutations
against DAA binding viral proteins would require.(65)
Clinical studies have demonstrated that anti-HCV treatment
should start early and with maximal effectiveness in order to inhibit
the recovery of intra-host fitness from bottleneck events induced by
transmission and initial adaption to the the immune system.(66) Ide-
ally, such protocols should be highly personalized and the choice
of drugs as well as the timing of the intervention should take into
account viral genotype, the composition of the viral quasispecies,
as well as genetic host genotypic factors that may influence im-
mune response or pharmacokinetics. Future anti-HCV therapies
will thus likely exclude interferon due to its intravenous applica-
tion and high side effects and will instead consists of an all-oral
therapy of combinations of three or four direct acting anti-HCV
agents.(67) These therapies may optionally be followed up with with
mutagenic drugs that further reduce the fitness of the viral qua-
sispecies and thus increase the likelihood of immune clearance (cf.
next section). However, while promising, none of these approaches
is currently considered to result in unsurmountable genetic barriers
against antiviral resistance.(68)
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Ribavirin (1-b-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide or
C8H12N4O5) is a guanosine analogue with antiviral activity against many
RNA viruses.(1) In addition to its mutagenic effects, the compound is di-
rectly modulating different aspects of nucleotide synthesis and metabolism
while also indirectly supporting proliferation of T-helper cells towards im-
mune response profiles beneficial for viral clearance. At its conception in
1972,(2) ribavirin was the first synthetic nucleoside that exhibited broad-
spectrum antiviral activity. It is currently used in monotherapy against
highly aggressive zoonotic Arenaviruses such as Lassa virus(3) and is also
being indicated against mild infections of viruses that lack other antivi-
ral such as caused by the respiratory syncytial virus.(4) While mutagenic
activity of ribavirin is experimentally supported in several viral species,
evidence in that regard concerning HCV is conflicted. This section aims
to review the proposed modes of action of ribavirin both in HCV and in
other viral species with a particular focus on mutagenesis. Finally, this
section discusses ways of experimentally quantifying mutagenesis in viral
quasispecies.
Ribavirin monotherapy. Ribavirin monotherapy of HCV is asso-
ciated with mildly beneficial effects on treatment progress such as
transiently lowered aminotransferase levels and modest improve-
ment in hepatic histology.(5) Ribavirin induces a modest direct
antiviral effect mainly in the first weeks of treatment,(6) and a tran-
sient decrease in viral load associated with ribavirin monotherapy
in patients by the end of 8-48 weeks of treatment has been con-
firmed by a Cochrane meta analysis of 11 randomized trials.(7)
However, the drug causes no lasting decrease of HCV viral load,
the most important indicator for sustained treatment success.(8) The
drug is therefore not used in HCV monotherapies but in combi-
nation with pegylated interferon-a, where by reasons that are still
not completely clear it significantly improves sustained virological
response, primarily by reduced relapse rates.(9)
Significant long-term beneficial effects of ribavirin in combi-
nation therapy with interferon have also been confirmed by meta
analyses.(10) Interestingly, the synergistic effect of ribavirin with
other antivirals is not limited to interferon; instead, ribavirin combi-
nation therapy with several novel specifically acting antivirals have
resulted in dramatically improved sustained virological response
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rates (SVRs) compared to using the direct inhibitor in monother-
apy(11) possibly due to ribavirin-mediated inhibition of resistance
mutations.(12)
While in principle RAVs against mutagenic drugs seem to pose
a viable escape strategy for various viral species confronted with
mutagens, for example by increasing the fidelity or selectivity of
the viral polymerase in order to reject or compensate for mutagenic
drugs,(13) it is presently unknown if such mutagen-resistant viruses
are indeed evolving in clinical settings.(14) Although indicators
for ribavirin-induced RAVs have been observed in cell culture and
monotherapy,(15) these mutations are associated with multiple viral
genes and their precise effects on therapy success are currently
debated.
Ribavirin side effects. However, treatment of Ribavirin induces
significant dose-limiting side effects as for example haemolytic
anaemia in patients due to accumulation of ribavirin metabolites
in erythrocytes, thus limiting dosage and broad applicability of
the drug.(16) Indeed, 10-22% of treated patients develop significant
anaemia of which up to 52% experience a decrease in quality of
life.(17) In addition, ribavrin has been shown to act as teratogen
and carcinogen animal models, highlighting its toxicity in certain
circumstances.(18) As a consequences of these side effects, other
ribavirin-like molecules are in development that promise to display
better metabolic properties or increased specificity of targeting
liver compartments, thus facilitating tolerance.(19) In particular,
these compounds are aimed at combination therapies involving a
variety of novel anti-HCV drugs including protease, helicase, and
polymerase inhibitors, antagonists of the internal ribosome entry
site and of Ithenosine-5’-monophosphate dehydrogenase (IMPDH),
as well as small interfering RNAs, ribozymes, and new interferons
that are currently under development.(20)
Overview of proposed modes of action
The mode of action of ribavirin within anti-HCV therapy is cur-
rently now well understood.(21) However, several possibilities have
been proposed, most of which are supported by evidence from the
use of ribavirin in other RNA-viral diseases such as polio or foot-
and-mouth disease. Among these proposed modes of action are the
ability of ribavirin to influence metabolic pathways within the cell,
immune-related modes of action, antagonistic inhibition of the viral
polymerase, directly mutagenic activity, modulation of guanylyl-
and methyltransferase activity, interference with viral transcript
capping, inhibition of the viral polymerase by binding close to the
active site and interfering with elongation reaction.(22) Several of
these modes of action alone may serve to explain the antiviral ac-
tivity of ribavirin in HCV. Interestingly, however, these modes of
action may also have mutually supportive roles.(23)
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Metabolic mode of action. Due to the rapid replication kinetics of
HCV, de novo nucleotide synthesis rather than salvage of cellular
nucleosides is the predominant source for viral RNAs in HCV
infected cells. During de novo synthesis, Inosine-5’-monophosphate
dehydrogenase (IMPDH) catalyses of ionosine monophosphate into
xanthine monophosphate has been shown to be the rate-delimiting
step in the production of guanine nucleotides, especially for rapid
viral replication.(24)
Ribavirin in its native form is a prodrug that is metabolized into
ribavirin 5’-mono-, di-, and triphosphates (RMP, RDP, and RTP,
respectively) by cellular kinases within erythrocytes.(25) RMP is
a competitive inhibitor of both isoforms of IMPDH and thus de-
creases cellular levels of guanosine triphosphate (GTP) by about
50%.(26) Nucleoside triphosphates are important precursors for
RNA synthesis. In theory, the perturbation of their intracellular
concentrations may negatively affect the fidelity of the RNA poly-
merase by increasing the probability of misinsertions, primarily by
suppression of proofreading mechanisms (c.f. Kumar et al. (2011a)
for an investigation of the proposed mechanisms in the DNA poly-
merase). IMPDH inhibition results in negatively effecting rapid
viral replication as shown for yellow fever virus and human parain-
fluenza virus,(27) while being of lesser but still sufficient effective-
ness in HCV.(28)
Immune-related mode of action. Successful immune control of HCV
infection is associated with strong intrahepatic T-helper cell re-
sponse, in particular with Th1 proliferation and the corresponding
cytokine profile.(29) Chronicity, on the other hand, is often paral-
leled with insufficient Th1 activation, possibly due to HCV-core
dependent subversion of the interleukin system.(30) Ribavirin is
assumed to shape the adaptive immune response against HCV
infected cells by enhancing the effect CD4+ T-helper cells Th1 cy-
tokine profiles, resulting in increased production of tumor necrosis
factor-a, interleukin-2, g-interferon and IFN-a.(31) In addition to T-
helper mediated effects, ribavirin may also potentiate inflammatory
defenses through specific activation of IFN stimulated genes (ISGs),
thus modulating the expression of host Toll-like receptor 7 (TLR7)
and ISG15, the latter of which is implied in HCV immune evasion
(c.f. Paeshuyse et al. (2011) for a review).
Mutagenic mode of action. While modulation of intracellular nu-
cleotide pools by competitive interaction with IMPDH remains the
experimentally most well supported means of action of ribavirin, it
is notable that not all IMPDH inhibitors have antiviral activity(32)
and it is thus likely that ribavirin and related compounds also have
other antiviral activities. The monophosphate form of ribavirin
(RMP) can be phosphorylated to form ribavirin triphosphate (RTP),
which inhibits viral polymerase(33) and may be non-specifically
incorporated into viral RNA during replication opposite to either
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cytidine (in place of guanine, by Watson-Crick pairing) or uridine (in
place of adenosine, by wobble pairing) at roughly one copy per HCV
genome. This non-specific incorporation is due to the two different
possible configurations of the carboxamide moiety of the ribavirin
pseudobase(34) and results in increased rates of C* U and G*
A and, to a lesser extent, U* C and A* G transitions.(35) This
erroneous incorporation causes viral genome mutations at subse-
quent cycles of replication of the erroneous template, resulting in
increased mutation rate of the viral quasispecies.(36)
Experimental evidence for mutagenesis. Although first experiments
employing radio-labeled ribavirin have indicated only low rates of
incorporation,(37) later studies that compared mutation frequencies
in test and control samples as a surrogate variable for ribavirin in-
corporation could determine significant substitution rates of about
0.015 substitutions per base in in vitro experiments. These substi-
tutions resulted in about three ribavirin molecules per poliovirus
genome per replication cycle, causing more than three times as
many mutations per genome under high doses of ribavirin of 400
µM than without medication.(38) Due to the promiscuous base pair-
ing of ribavirin (both cytidine and uridin are templated with about
equal efficiency), incorporation was shown to particularly increase
the frequency of transition mutations in viral replicates.(39) The ob-
served increases in mutation rates were associated with reductions
of viral infectivity and fitness to about 30% of the untreated pop-
ulation when the mutation frequency exceeded two mutations per
genome, and to about 4% at more than 6 mutations per genome.(40)
These results parallel similar investigations pertaining to HIV
and vesicular stomatitis virus that also reported about threefold
increases in mutation rates drastically reducing viral viability.(41)
Interestingly, however, mutagen monotherapy did not result in viral
extinction and could only be achieved by additional measures that
reduce the fitness of the viral quasispecies, for instance by serial
passaging or addition of specifically acting antivirals.(42)
Anti-ribavirin drug resistance. Another type of evidence for the
efficacy of ribavirin in HCV is the emergence of drug resistance
agains ribavirin. Of particular interest in this regard is the iden-
tity of viral genes that are associated with the emergence of anti-
ribavirin RAVs. Since HCV genes are specialized towards one or
more, non-overlapping functions, the predominant mode of action
of ribavirin in HCV should be associated with the effected genes, in
principle.
anti-hcv efficacy of ribavirin 233
(43) Lesburg et al. (1999), Lutchman et al.
(2007)
(44) Cao et al. (2011), Young et al. (2003)
(45) Hmwe et al. (2010)
(46) Nakamura et al. (2008)
(47) Pfeiffer and Kirkegaard (2005b)
(48) Feigelstock et al. (2011), Pfeiffer and
Kirkegaard (2005b), Young et al. (2003)
(49) Domingo et al. (2012)
(50) Pfeiffer and Kirkegaard (2005a), Vi-
gnuzzi et al. (2006)
(51) Agudo et al. (2010), Arias et al. (2008),
Sierra et al. (2007)
(52) Iranzo et al. (2011a)
(53) Contreras et al. (2002), Hofmann et al.
(2007), Maag et al. (2001), Vallejo et al.
(2004), Zhou et al. (2003)
(54) Asahina et al. (2005), Chevaliez et al.
(2007), Schinkel et al. (2003)
(55) Cuevas et al. (2009), Hofmann et al.
(2007), Lutchman et al. (2007), Young et al.
(2003)
The HCV NS5B RNA-dependent RNA polymerase is similar to
other viral polymerase in that is contains finger, palm, and thumb
domains with 7 conserved domains, including a unique 12-amino
acid b-hairpin in the thumb domain.(43) A resistance mutation
(F415Y) within the b-hairpin against ribavirin in the HCV poly-
merase that could narrow the putative RNA-binding pocket (and
thus disable ribavirin incorporation) was reported based on in
vivo data of non-responders. This finding is generally interpreted
as supporting a direct inhibitory effect of ribavirin on the poly-
merase.(44) These results were confirmed in in vitro experiments(45)
and additional mutations were proposed that possibly are induced
by ribavirin resistance (V85I, K124E, and V85I/K124E).(46) In addi-
tion, low level resistance to ribavirin has also been associated with
NS5A mutations G404S and E442G.(47)
However, while the aforementioned results as well as research
concerning other viruses indeed indicate the emergence of anti-
ribavirin drug resistance,(48) it remains unclear to which precise
mode of action of ribavirin this resistance relates. In particular, it
is still open if the resistance refers to the mutagenic activity rather
than the inhibitory activity of the compound.(49) The matter is fur-
ther complicated by the fact that viruses may implement several
mechanisms of ribavirin resistance: while picornaviruses employ
RAVs in order to increase the fidelity of the polymerase,(50) ex-
perimental evidence on other viral families suggests that ribavirin
resistance is implemented by restricting ribavirin incorporation.(51)
As discussed previously, the question whether a mutagen has
predominantly inhibitory or mutagenic properties is highly relevant
for therapy optimization: while a dominantly inhibitory component
would suggest combination therapy with other specifically acting
antivirals, a mutagenic components is an indicator for sequential
administration of specific antiviral and mutagen. The question of
therapy serialization in the context of highly adaptive viral quasis-
pecies is an active field of research; while this research currently
focuses on non-retroviruses due to their simpler replication dynam-
ics, extensions to other viral species are also investigated.(52)
Evidence for ribavirin-induced mutagenesis in HCV
In HCV, the mutagenic mode of action of ribavirin has been exten-
sively investigated using both in vitro and in vivo experiments.(53)
However, these results were not conclusive especially for in vivo ex-
periments,(54) only some of which reported increased mutation
rates in HCV NS5A/B genes. Especially analyses of ribavirin-
monotherapy in comparison to an untreated placebo group, ar-
guably the most meaningful way of isolating ribavirin activity,
have resulted in conflicting results ranging from low or transient
increases in mutation rates to more than two-fold increases.(55)
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In vitro studies. Experiments employing in vitro technology are
commonly based on the ribavirin-treated HCV replicon assays or,
more recently, cell assays or cultures, followed by Sanger sequenc-
ing. While some studies support increases in mutation frequencies
in these systems after ribavirin treatment,(56) other studies resulted
in ambiguous or negative results.(57)
In all cases where evidence for ribavirin-associated increases in
mutation rates could be identified in vitro, the corresponding fold
increases were roughly comparable (2 to 3.5-fold) to related exper-
iments on poliovirus. Critics of in vitro approaches to measuring
the mutagenic effect of ribavirin in HCV point out that the transfer-
ability of in vitro results to in vivo conditions is severely limited;(58)
in addition, the in vitro mutagenic effect of ribavirin was only ob-
served at high concentrations between 400 and 1000 µM, far above
the tolerable plasma concentration in patients of about 9 µM.(59)
In vivo studies. However, in-vivo studies for determining muta-
genic effects of ribavirin on HCV are similarly conflicting:(60) while
some investigations reported an increased mutation rate in indi-
vidual viral genes,(61) other studies found only insignificant or no
measured increases of mutations rates.(62) All studies presented
here are inherently limited due to their restriction to only parts of
the viral genome due to artifacts induced by the replicon system or
the cost-aware use of sequencing technology that lead researchers
to prioritize only few HCV genes such as NS3, NS5A, and NS5B.
Although even modest increases of mutation rates of about 5% as
identified by Hofmann et al. (2007), Young et al. (2003) may be suf-
ficient to trigger viral error catastrophes,(63) depth of sequencing in
experimental setups is often restricted to 20-80 clones per sample,
thus severely limiting the ability to detect minority variants.
Shortcomings of present studies. All relevant in vivo studies on the
mutagenic effect of ribavirin on the HCV quasispecies known to
the author have significant flaws that limit the informative value of
the results. A highly cited study(64) that aims to disprove ribavirin-
induced mutagenesis in HCV may serve as illustration. This study
investigated only four patients under ribavirin monotherapy and
did not employ an untreated control group for comparison. The
sequencing approach utilized 20 clones of the HCV NS3 and NS5A
genes per sample. As a result of the low sequencing depth, the
study is severely limited in resolution, especially with respect to
the detection of minority variants. As a consequence of the few pa-
tients that were participating in the study, the results feature large
within-sample variances of mutation frequencies, a fact that may
be indicative of insufficient statistical power. Many or all of these
flaws, most prominently the limitation to only about 10 sequence
clones per sample, are also recurring in other studies that did find
no or only weak evidence for ribavirin-mediated mutagenesis.(65)
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(66) Within both methods, absolute
counts of sequence reads are con-
verted to frequencies of nucleotides
at each viral genome position i. This
results in a discrete distribution F of
frequencies f for the four nucleotides
n 2 {A,C,G, T}  for instance,
Fi = {A : 0.1,C : 0.4,G : 0.3, T : 0.2} .
Using the within-sample method, this
nucleotide distribution is employed to
estimate the mutation frequency min
for each nucleotide based on a single
sequence sample by first determining the
frequency of the consensus nucleotide vi , i.e.,
the mode of Fi , and then determining
the partial mutation frequencies for each
nucleotide min = vi   f in|n 2 {A,C,G, T}
as well the overall mutation frequency
Mi = Ân2{A,C,G,T} min. Intuitively, the
overall mutation frequency is zero at a
position if the nucleotide distribution is
clonal and only contains the consensus
nucleotide; conversely, the maximal
overall mutation frequency is 0.75.
This approach can be directly ex-
tended to compute the error rate ei by
the between-sample method; computa-
tions are analogous to the within-sample
method but includes sequence data of two
sampling time points t1 and t2, where t1
is prior to treatment with the mutagen
(baseline) while t2 is after (or during)
treatment (treatment). The error rate is
then computed based on the nucleotide
distribution Fit2 (i.e., at the time of ther-
apy) while the frequency of the consensus
nucleotide is derived from the frequency
distribution of the baseline data, i.e., vit1 .
From this follow the partial error rates
ei = vit1   f in|n 2 {A,C,G, T} as well
as the overall error rate Ei , again as a sum
of the partials over all nucleotides (see
above).
In order to confirm specific nucleotide
substitution patterns for mutagens (e.g.,
C to T and G to A for ribavirin (Crotty
et al., 2000, Vo et al., 2003)), sin and ein
are only evaluated at positions where
the consensus nucleotide corresponds
to C or G and n corresponds to T or A,
respectively. While in fact it is not clear if
any shift in frequencies is indeed a result
of nucleotide substitutions from the the
consensus nucleotide to one of the target
nucleotides T and A, this simplifying
assumption is regularly made in related
work (Chevaliez et al., 2007, Lutchman
et al., 2007, Mori et al., 2011, Young et al.,
2003)
Quantification of mutagenic effects
These varying outcomes of experimental studies aiming to inves-
tigate the mutagenic effect of ribavirin reflect the large difficulties
that are associated with the detection of minute changes in muta-
tion frequencies in sequencing data.
Since the true mutation rate of the viral polymerase cannot be
conveniently observed, surrogate measures are employed that aim
to quantify increased mutation frequencies of the viral quasispecies
in drug-treated versus control subjects based on sequencing data.
Several of these quantization methods are in current use.
Means of quantization. Mutation frequency is estimated in differ-
ent ways from the sequencing data. In general, both within-sample
methods, i.e., the the characterization of sequence diversity within
a single sequence sample, and between-sample method, i.e., the com-
putation of changes of sequence diversity between time points are
employed to derive estimates for viral mutation frequencies at each
viral genome position such as overall mutation frequencies or over-
all error rates (see side note for a more detailed description of these
methods).(66)
Subsequently to averaging across all genome positions and nor-
malization by the time difference between sampling points, the
fold-changes of these estimates can be compared between mutagen-
treated and control groups by means of inferential statistics such as
c2 in order to determine the effects of ribavirin treatment.
Increasing the resolution of quantization. While the within-sample
and between-sample methods are simple to compute and interpret,
they either are not well suited for comparing mutation frequencies
between time points (within-sample method) or are disregarding
the nucleotide frequency distribution at the baseline time point
(between-sample method). Both of these drawbacks have conse-
quences on the qualities of the estimates that can be derived.
Omitting the comparison of nucleotide frequencies between time
points (as the within-sample method does) can be considered to
be a flawed approach for determining the effects of mutagens in-
sofar as the mutation rates of viral quasispecies can differ between
subjects and thus confound further analyses. As a consequence, nu-
cleotide frequencies should be normalized by differential analysis
of pre-treatment and post-treatment samples of the same subject.
Similarly, relying only on the consensus nucleotide of the base-
line time point and disregarding the full nucleotide frequency dis-
tribution at this time point (the strategy of the between-sample
method) is perilous since a shift in consensus sequence is not a
good indicator for changes in sequence diversity, in general (see
previous sections). In addition, this approach does not into consid-
eration presence of minority genotypes at the baseline time point,
thus hindering an unbiased estimation of mutation frequencies.
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The author and colleagues therefore recently proposed an alter-
native approach that employs the full nucleotide frequency distri-
butions at both time points in order to quantify minute frequency
changes with less dependence on the consensus nucleotide (see
Section 24) We denote a substitution of a source nucleotide k with a
target nucleotide l with (k, l)|k 2 {A,C,G, T}, l 2 {A,C,G, T}, k 6= l.
In case of ribavirin, the substitutions of interest are (C, T) and
(G, A).(67) By denoting two subsequent sampling time points as
t1 and t2 where t1 corresponds to pre-treatment sequence data and
t2 corresponds to post-treatment sequence data, the observed fre-
quencies of a nucleotide n at a time point t and genome position i
can be denoted by f tn,t. We define a quantifier d for the change in
relative frequencies of these substitutions as follows:
di(k,l) =
 
f il,t2   f ik,t2
     f il,t1   f ik,t1  (23.1)
Intuitively, d ranges from 0 to 1 its value increases if the fre-
quency of the target nucleotide in relation to the frequency of the
source nucleotide increases at the second time point compared to
the first time point. In order to consider multiple substitution pat-
terns, we average di(k,l) across all such substitution patterns ((C, T)
and (G, A) in the case of ribavirin, see Equation 24.2 in the next
section for an example). This averaged value can then interpreted
as an estimate of the mutagen-induced mutation frequency of the
viral quasispecies. This estimate can further be aggregated across
genome positions and subsequently compared between mutagen-
treated and control groups using inferential statistics in order to
statistically infer mutagenic effects of a purported mutagen.
Confounding effects of selection. Viral genotypes that are heavily
mutated due to mutagenic action have a higher likelihood of being
deleterious and are thus preferably removed from the population
by selective forces. The observable rates of mutation frequencies are
therefore bound to be significantly lower than the original mutation
rate and thus do not accurately reflect the effect of the mutagen.
At first sight, a viable strategy for dealing with these purify-
ing effects of natural selection may be based on determining fre-
quencies of functionally neutral mutations, e.g., mutations that
are synonymous at the amino-acid level.(68) Since the amino-acid
sequences viral proteins remain constant even if synonymous po-
sitions mutate, these positions may exhibit fewer effects on fitness
(and, therefore, less selection bias) than using non-synonymous
positions.
However, since genomes of RNA viruses are densely packed
with functional elements and often possess multiple reading frames
or noncoding regions that determine properties of RNA secondary
structure, even synonymously coding sites in these viruses are not
truly neutral. In addition, the accumulation of neutral mutations is
also depending on replication cycles, a number that is expected to
be dependent on treatment response.(69)
anti-hcv efficacy of ribavirin 237
(70) Cuevas et al. (2009)
(71) González-López et al. (2005), Grande-
Pérez et al. (2005), Iranzo and Manrubia
(2008)
(72) Palmer et al. (2004), Salazar-Gonzalez
et al. (2008), Zhang et al. (1991), Zhu et al.
(1993)
(73) Zeuzem et al. (1998)
(74) Gerstung et al. (2012)
Importance of minority variants. Quantification of mutagenic ef-
fects based on sequencing if further complicated by the fact that
population sequencing, i.e., determination of the average genotype
of a viral quasispecies as still commonly done on viral diagnostics,
is not informative for quantification of viral mutation frequencies.
For instance, high rates of nucleotide substitutions within the
consensus sequence do not necessarily imply increased mutation
rates of the underlying quasispecies; instead, they may merely in-
dicate an increased fixation of selectively advantageous variants in
the consensus sequence.(70) This phenomenon is a consequence of
the fact that changes observable on the level of the consensus se-
quence are a product of not only mutation but more importantly of
competition and selection within the quasispecies population: since
deleterious variants are regularly removed from the population, the
true viral mutation rate is likely to be significantly higher than the
mutation frequency or the consensus sequence may indicate.
Conversely, low rates of observed change of the consensus se-
quence at rates of 10-1 substitutions per site and year (common
values for well adapted viral quasispecies) are not a sign of re-
duced mutation rates. This has been demonstrated in the context
of of mutagenic drugs where invariant consensus sequences where
measured in spite of significant changes in viral mutation rates.(71)
These phenomena generally confound approaches to quantify-
ing mutation rates that employ low-sensitivity Sanger technology.
Instead, a deeper look at the viral population structure is required
in order to measure minute mutagenic effects. This is currently
only possible if low-frequency minority variants of the viral qua-
sispecies, as, for example, determined by deep sequencing, are
considered during the analysis.
Difficulty of estimating minority variants. Increases in low-frequency
mutation frequencies are notoriously hard to measure precisely
with limited-dilution Sanger sequencing, a method which exhibits
limited sensitivity at the numbers of clones that are usually ana-
lyzed.(72) Next-generation or deep sequencing offers significantly
higher sensitivity than Sanger approaches but displays high techni-
cal error rates that may mask ribavirin activity (cf. Chapter II).
The background mutation rate of the HCV quasispecies is about
10-5 substitutions per site and copy.(73) Experimental evidence from
other organisms such as polio report clinically relevant ribavirin-
induced increases of mutation frequencies of about 3-fold. A simi-
lar analysis of the HCV quasispecies would require detection sen-
sitivities about equal to the mutation rate of 10-5. However, even
advanced statistical approaches that aim to detect increases of mi-
nority frequencies based on comparative approaches and model
sequencing error require sequencing depths of more than the in-
verse of the expected frequency for successful detection.(74) Con-
sequently, sequencing depths of about 10,000 fold are required to
reliably detect ribavirin-induced mutations in HCV.
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Differential analysis of minority variants. In order to quantify
changes in mutation frequencies as a function of ribavirin admin-
istration, the viral quasispecies of multiple patient groups (treated
versus placebo) and time points (prior to administration versus at
end of therapy) are commonly sequenced and mutation frequencies
are quantified.
Importantly, sequencing data may include technical errors that
may mask true signatures of ribavirin incorporation (see follow-
ing section for a more detailled discussion of error modes). Con-
sequently, downstream analysis should utilize statistical models
that consider the error rates of the sequencing process in order to
(1) detect minority variants within the quasispecies and delineate
these variants from technical errors, and to (2) statistically compare
subsequent time points within each patient in order to decide if
a observed increase in frequency is due to technical noise or true
biological variation.
Finally, these estimates of increased frequencies and their sta-
tistical confidences have to be employed to statistically compare
ribavirin-treated groups from placebo-treated groups in order to
associate the mutagenic effect with the treatment.
Determination of minority variants. Viral minority variants are
usually determined by deep sequencing,(75) a technology enables
the parallel measurement of billions of nucleotide bases at low
cost.(76) In contrast to vanilla Sanger technologies, deep sequencing
does not result in an average genotype of a given heterogeneous
population of genomes. Instead, it affords the determination of
the identity of individual DNA fragments, thus providing a dig-
ital view on a large portion of that population. However, due to
the elevated error rates of current, second-generation sequencing
technology on the order of 1%, statistical and algorithmically ap-
proaches that differentiate technical sequencing error from true
minority variants are required.(77)
In particular, the study of subclonal human cancers has high-
lighted the importance of minority variants for clinically relevant
phenotypes associated with growth, resistance, and proliferation of
cancer.(78) Novel mutations that occurred during tumorgenesis and
proliferation, so called somatic mutations, are of interest for tumor
subtyping and the estimation of its probably evolutionary trajectory
– information highly important for precise diagnostics and therapy
optimization.(79) As a consequence of this interest in heterogeneous
cancers, a variety of computational approaches have been devel-
oped for identifying minority variants in mixed samples. Many of
these approaches are also applicable to viral quasispecies and are
thus discussed briefly here.
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Sequencing errors. Deep sequencing approaches afford high
throughput and theoretically also high sensitivity; the latter, how-
ever, is confounded by the relatively high error rate resulting from
library preparation and sequencing artifacts.(80) In combination,
these error sources result in per-base error rates of the whole se-
quencing process of about 1%.(81)
Interestingly, local characteristics of genome sequences induce
errors also in multiple experimental replicates that have been
processed independently.(82) These sequence-specific and strand-
specific errors have been identified, for instance around G-rich
motifs. While greater sequencing depth may facilitate detection
of many errors due to the associated increased power of statisti-
cal approaches, in principle, sequence-specific errors tend to occur
consistently at any depth and are therefore difficult to remove by
any approach.(83) In addition to considering platform-specific er-
rors, modeling these local sequence characteristics has especially
important consequences for successful identification of genetic vari-
ation.(84) In particular, variants predominantly occurring on one
strand have been shown to more often correspond to sequencing
errors than equally distributed SNVs.(85)
Use of specialized sequencing libraries. Microbiological and chem-
ical techniques(86) may be employed to reduce the error rate of the
library generation and sequencing process. Artifacts such as PCR
duplicates can be addressed by random tagging approaches that
discriminate between multiple copies of the same molecule, thus
allowing for the correction of errors and better identification of mi-
nority variants, in principle.(87) As a result, considerably reduced
error rates of about 0.001% are achievable in special cases.(88) Still,
this error rate is at least 1,000-fold higher than the mutation rates
of human cells,(89) the latter being only recently approximated by
independently tagging and sequencing each of the two strands of
a DNA duplex.(90) However, these approaches require skilled per-
sonnel and may exhibit reduced scalability compared to established
high-throughput library preparation techniques. As a consequence,
identification of tumor minority variants is commonly undertaken
on standard deep sequencing sequencing libraries.
Minority variant calling In order to reliably estimate minority
variants from noisy second-generation deep sequencing data, ap-
proaches towards modeling intratumor heterogeneity as resulting
from sample impurity and genomic subclonality have been pro-
posed.(91) These comparative, subclonal, or somatic variant callers
employ more sensitive statistical models than standard variation
callers that are limited to differentiating homozygous variants from
heterozygous variants in diploid genomes.
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Interestingly, even in relatively simple scenarios that exclusively
involve sequence data of diploid organisms and that lacksubclonal
variation, concordance between diploid variant callers is low (about
60%). This indicates the inherent difficulty of distinguishing se-
quencing errors from true variation in general.(92)
Deducing minority variants occurring at frequencies comparable
to technical error rates of the library generation and sequencing
process seems to be daunting and indeed has been denoted as im-
practical in the general sense.(93) These error rates differ not only
between sequencing platforms but also between sequencing runs.
Furthermore, physical placement of the sequencing product on
the machine (lanes or flowcells), multiplexing technology, prop-
erties of the sequenced genomes, genomic location of a read, and
error type.(94) Due to this variety of factors involved, error rates are
highly non-uniform with respect to their location on sequencing
reads and genomic positions.
Approaches to variant calling. By exploiting this non-uniformity,
approaches that employ high sequencing coverage and adapt error
models to the sequencing data may resolve many minority variants
at frequencies lower that the average error rate.(95) In addition to
error modeling and employing more sensitive statistical models
compared to diploid variant callers, comparative variant callers
employ a third trick to increase sensitivity: the combined sequenc-
ing and analysis of a test sample and a control sample of the same
patient. This analysis affords both the determination of local error
rates of the sequencing process and the identification of variants
that are unique to the test sample.(96)
While in cancer sequences test and control samples correspond
to tumor tissue and healthy tissue, respectively, virological appli-
cations often employ viral samples from two different time points
or with different degrees of subclonality. Estimated error rates are
then compared with the frequencies of putative minority variants
by binomial(97) and Bayesian likelihood models.
Comparative variant calling tools. In the last three years, several
comparative variant callers have been proposed for estimating
minority variants at low frequencies of about 1% from sequencing
data of subclonal cancers(98) that employ related analysis principles
and provide increased sensitivity with regard to variant callers
designed for diploid genomes.(99) These comparative variation
callers claim accurate calls of minority variants of frequencies less
than 0.05%,(100) significantly less than the average error rate of
sequencing.
A particularly interesting comparative variant caller that displays
best-in-class performance at recovering minority variants based on
deep sequencing data is DeepSNV.(101) As it is one of the few tools
specifically designed for inferring SNVs in subclonal populations
with an unknown number of clones, the software is also applicable
to viral quasispecies, in principle.
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Similar to related methods, DeepSNV relies on a control, for in-
stance originating from pre-treatment samples or a clonal aliquot
of the same virus, in order to infer change rates of nucleotide fre-
quencies at each genomic position. Utilization of a clonal control
sample is desirable in cases where the existence of minority variants
in the test sample is the target of inquiry. However, the statistical
approach in general also allows for selection of non-clonal samples
if changes in clonality at specific sequence positions are investi-
gated with respect to a combined background of technical errors
and variation in the control sample. Indeed, similar approaches are
suggested by the authors for the use on whole exome sequencing
data.
DeepSNV models nucleotide counts based on deep sequencing
read data of test and control samples at each genomic position us-
ing a betabinomial model. This betabinomial model is parametrized
by an overdispersion factor that is derived from the control data
using a maximum likelihood approach. SNV frequencies in the
test data that differ significantly from corresponding frequencies in
the control set are determined based on binomial models of each
sequence strand by a likelihood ratio test statistic.
Since the test statistic is c2 distributed, P-values can be com-
puted for nucleotide frequencies of both nucleotide strands and
for data of both samples. For each nucleotide but the consensus
nucleotide, P-values of each strand and sample are then combined
into a single P value using Fisher’s method followed by correction
for multiple testing. The combined P-value reflects the uncertainty
of an increased variant frequency at a specific genomic position.
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Preliminary conclusion
In conclusion, this chapter has presented a view on the viral quasis-
pecies as highly adaptable and robust system that is evolutionary
optimized to withstand antiviral treatment. However, by combining
drugs with different modes of action that influence the structure
of the quasispecies population, novel therapy options seem possi-
ble that may increase viral response rates. Optimization of these
combination treatments requires a detailed characterization of the
molecular modes of action of the drugs employed. One class of
drugs whose mode of action presently is not well understood are
antiviral mutagens such as ribavirin. Evaluation of the proposed
mutagenic effect of ribavirin on the HCV quasispecies requires ul-
tradeep sequencing, a technology that exhibits error rates of the
same order of magnitude as the purported mutagenic effects of the
drug. These error rates can be significantly lowered by bioinformat-
ics analyses that employ sensitive statistical models and suitable
control samples.
(1) Dietz et al. (2013)
24 HCV and mode of action of ribavirin
This last section synthesizes much of the content of this chapter
in order to best introduce an investigation for detecting minute changes
of population structures of HCV viral genomes upon treatment with the
therapeutic mutagen ribavirin. Ribavirin displays several modes of action
in other highly divergent viral species, including mutagenic activity.
As discussed previously, the mutagenic effect of antivirals is important
for informing therapy decisions and coordinating the administration of
drug combinations involving directly acting antivirals in order to limit
emergence of drug resistance and maximize therapy efficacy. However, a
possible mutagenic effect of ribavirin on the HCV quasispecies is contested
and rational therapy optimization involving ribavirin is therefore impeded.
We undertook the first deep-sequencing analyses of HCV sam-
ples in order to detect mutagenic activity based on time-series data
of patients under ribavirin monotherapy. In contrast to related stud-
ies, we firstly sequenced the HCV quasispecies of patients under
ribavirin monotherapy at sufficient depth in order to detect minor-
ity variants at significantly lower frequencies than was previously
possible using clonal Sanger sequencing. In addition, we employed
amplicon sequencing of the full HCV genome at multiple time
points and using two different sequencing platforms in order to
obtain a broad overview on mutation rates across genomic sites.
Finally, we performed a statistical filtering procedure that com-
pares quasispecies distributions across time points in a statistically
meaningful fashion and takes sequencing errors into account.
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Introduction
Abstract. The preeminent mode of action of the broad-
spectrum antiviral nucleoside ribavirin in the therapy of chronic
hepatitis C is currently unresolved. Particularly under contest are
possible mutagenic effects of ribavirin that may lead to viral extinc-
tion by lethal mutagenesis of the hepatitis C virus (HCV) genome.
We applied ultradeep sequencing to determine ribavirin-induced
sequence changes in the HCV coding region (nucleotides [nt] 330
to 9351) of patients treated with 6-week ribavirin monotherapy
(n = 6) in comparison to placebo (n = 6). Baseline HCV RNA lev-
els maximally declined on average by -0.8 or -0.1 log10 IU/ml in
ribavirin- versus placebo-treated patients. No general increase in
rates of nucleotide substitutions in ribavirin-treated patients was
observed. However, more HCV genome positions with high G-to-
A and C-to-U transition rates were detected between baseline and
treatment week 6 in ribavirin-treated patients in comparison to
placebo-treated patients (rate of 0.0041 transitions per base pair ver-
sus rate of 0.0022 transitions per base pair; p = 0.049). Similarly, the
sensitive detection of low-frequency minority variants by statistical
filtering indicated significantly more positions with G-to-A and C-
to-U transitions in ribavirin-treated patients than in placebo-treated
patients (rate of 0.0331 transitions versus rate of 0.0186 transitions
per G/C-containing position at baseline; p = 0.018). In contrast,
non-ribavirin-associated A-to-G and U-to-C transitions were not en-
riched in the ribavirin group (p = 0.152). We conclude that ribavirin
exerts a mutagenic effect on the virus in patients with chronic hep-
atitis C by facilitating G-to-A and C-to-U nucleotide transitions.
Introduction. The guanosine analogue ribavirin (1-b-D-ribofuranosyl-
1,2,4-triazole-3-carboxamide) displays broad antiviral activity
against RNA and DNA viruses in vitro and is used for the treat-
ment of hepatitis C virus (HCV), respiratory syncytial virus (RSV),
and Lassa fever virus infections.(2) Monotherapy of patients with
chronic HCV infection with ribavirin causes declining serum
aminotransferase levels but leads to only a moderate and tran-
sient reduction of HCV RNA levels.(3) In spite of the inefficacy of
ribavirin monotherapy, the drug acts synergistically with (pegy-
lated) alpha interferon (IFN-a) during anti-HCV therapy, resulting
in roughly 3-fold-enhanced sustained virologic response (SVR) rates
compared to those resulting from interferon monotherapy.(4) Sim-
ilar effects of ribavirin were observed for triple therapies of HCV
genotype 1-infected patients that included direct antiviral agents.
Here the addition of ribavirin to a NS3/4A protease inhibitor and
pegylated IFN-a (PEG-IFN-a) resulted in increased antiviral ef-
ficacy and reduced viral breakthroughs associated with resistant
viral variants.(5) Furthermore, even in the context of a combination
of two direct antiviral agents in patients with chronic hepatitis C
which led to frequent treatment failure, the addition of ribavirin
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without PEG-IFN-a enhanced the initial virus decline and reduced
the number of viral breakthrough events.(6)
The preeminent mode of action of ribavirin in the therapy of
chronic hepatitis C is unresolved. It was recently shown that rib-
avirin in conjunction with IFN-a/PEG-IFN-a induces the expression
of specific interferon-stimulated genes (ISGs) in vitro and in vivo,
thereby potentiating the anti-HCV effect of interferon.(7) Other pos-
sible mechanisms of ribavirin action include the following models:
strengthening of the adaptive antiviral immune response, impair-
ment of the cellular enzyme IMP dehydrogenase (IMPDH), direct
inhibition of the HCV nonstructural 5B (NS5B) RNA-dependent
RNA polymerase, and exertion of a mutagenic effect on RNA
viruses and the resulting error catastrophe.(8) The lack of proof-
reading activity of the HCV polymerase results in a population of
divergent but closely related viruses, termed viral quasispecies,
that optimizes viral evolutionary fitness by maximizing genetic
variation. Quasispecies are assumed to exist at the edge of a ge-
nomic error threshold.(9) Exceeding this error threshold may lead
the quasispecies into a sequence of error catastrophes, termed lethal
mutagenesis, that results in viral extinction.(10) The application of
a model poliovirus polymerase showed that the incorporation of
ribavirin templates the incorporation of cytidine and uridine, lead-
ing to a mutagenic effect which coincided with reduced poliovirus
infectivity as well as with the observation of G-to-A and C-to-U
transitions in mutagenized genomes.(11)
Ribavirin-induced mutagenesis of the HCV genome has been
demonstrated in vitro based on sequenced isolates from ribavirin-
treated HCV cell culture systems.(12) Furthermore, HCV cell culture
experiments revealed the selection of several HCV mutations(13) as
well as changes in the cell line,(14) both conferring ribavirin resis-
tance. In vivo analyses of ribavirin-induced mutations in the HCV
genome, on the other hand, remain inconclusive. Several stud-
ies reported selective mutations in NS5A/B as well as increased
nucleotide substitution rates consistent with G-to-A and C-to-U
nucleotide transitions in NS3/NS5B in patients under ribavirin
monotherapy.(15) Also, in patients undergoing therapy with IFN-a
plus ribavirin, an increased mutation rate and a mutational spec-
trum with increased G-to-A and C-to-U transitions were detected
during treatment based on E1/E2 and NS5A sequencing studies.(16)
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A greater nucleotide sequence variation with an increase in C-to-
U transitions within NS3 and NS5B was also observed for patients
treated with a NS3 inhibitor and a NS5B inhibitor in combination
with ribavirin-containing regimens.(17) In contrast, other results
showed only transient(18) or no(19) increases in substitution rates in
NS5B and NS3/4A, respectively. Selection for a ribavirin-associated
resistance mutation in NS5B that is suggestive of a mutagenic ef-
fect of ribavirin(20) was not verified in nonresponder patients who
were treated with ribavirin in combination with IFN-a or PEG-IFN-
a.(21) In this study, we employed ultradeep sequencing of the HCV
coding region (nucleotides [nt] 330 to 9351) in order to investigate
the ribavirin-induced mutagenesis of the viral quasispecies in de-
tail over time in 12 patients under ribavirin monotherapy versus
placebo.
Materials and methods
Patients. In a prospective, randomized, placebo-controlled study,
68 patients with chronic HCV genotype 1 infection were random-
ized and treated at the University Hospitals in Frankfurt, Berlin,
Hannover, and Homburg/Saar, Germany, as well as at an Indepen-
dent Medical Center in Frankfurt between 2007 and 2010. Initially,
for 6 weeks, patients received either placebo or ribavirin at 1,000 to
1,200 mg per day according to body weight or 180 µg PEG-IFN-a2a
per week. Subsequently, all patients received antiviral treatment ac-
cording to the standard of care (180 µg PEG-IFN-a-2a once weekly
plus 1, 000 to 1, 200 mg ribavirin daily, body weight adapted).(22)
For deep-sequencing analysis of HCV quasispecies, serum samples
during monotherapy were selected from 12 patients (HCV subtype
1b [n = 6], ribavirin [n = 6], and placebo) at baseline (before treat-
ment) and at treatment day 42. Enrollment in the clinical study as
well as the usage of patient serum samples for HCV sequencing
studies were approved by the local ethics committee, and written
informed consent was obtained from all patients. Quantitative HCV
RNA measurement was performed by using a commercially avail-
able assay (COBAS AmpliPrep/COBAS TaqMan HCV test; Roche
Diagnostics).
HCV RNA extraction, reverse transcription, and PCR. For HCV
RNA extraction, 140 µ L of serum was used (QIAamp viral RNA
minikit; Qiagen, Hilden, Germany). cDNA synthesis was per-
formed in triplicates by using SuperScript III reverse transcriptase
(Invitrogen) with random or specific primers and 8µ L of viral RNA
corresponding to 0.5 µ g of viral RNA on average. Amplification
of the HCV genome from the 5’ N-terminal region (NTR) to NS5B
(nt 145 to 9351) occurred in 5’ overlapping PCR amplicons with
gene-specific primers for outer and inner nested PCRs. Patient-
specific primers were designed after sequencing and alignment of
the primer binding regions of all patients. Nested PCRs were con-
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ducted with 1/20 of cDNA or outer PCR product, using the Expand
High FidelityPlus PCR system (Roche Applied Science) containing
a DNA polymerase and a proofreading protein. The resulting am-
plicons were analyzed for correct size and purity on 0.8% agarose
gels stained with ethidium bromide.
Deep sequencing. For a first analysis, four patients (ribavirin-
treated patients 1 and 2 and placebo-treated patients 7 and 8) were
selected for 454 deep sequencing. Based on the results for the com-
parison of mutational frequencies among baseline, day 7, day 21,
and day 42 of treatment with ribavirin versus placebo, eight addi-
tional patients (ribavirin-treated patients 3 to 6 and placebo-treated
patients 9 to 12) were subsequently enrolled for deep sequencing
analysis (Illumina technology) at baseline and day 42. Per patient
and time point, five HCV amplicons were generated for deep se-
quencing analysis. All amplicons were purified by using Agencourt
CleanSeq beads on a BioMek NX workstation (Beckman Coulter),
quantified fluorometrically on a FluoStar Optima instrument (BMG
Labtech) by using Quant-iT Picogreen double-stranded DNA (ds-
DNA) reagent (Invitrogen), and sample-specific amplicons were
pooled equimolarly for library preparation.
For 454 deep sequencing, amplicons were fragmented by nebu-
lization. Next, a sizing solution was applied to remove fragments
shorter than 400 bp on a BioMek NX workstation, and the size dis-
tribution of the DNA was confirmed by a 2100 Bioanalyzer (Agilent
Technologies). DNA adaptors containing primer binding sites for
deep sequencing as well as multiplex identifiers (MIDs) for sam-
ple bar coding were ligated into the purified DNA fragments by
using a GS FLX Titanium Rapid Library Preparation kit (Roche
Applied Science). The library was subjected to emulsion PCR for
clonal amplification of DNA fragments on water-in-oil emulsion
microreactors followed by enrichment and counting of DNA con-
taining beads (GS FLX Titanium LV emPCR kit [Lib-L] and GS FLX
Titanium emPCR breaking kit LV/MV 12pc; Roche Applied Sci-
ence). Subsequently, microbeads were collected and loaded onto
the PicoTiter plate of the FLX Genome Sequencer (Roche Applied
Science). 454 FLX second-generation sequencing technology with
an average read length of 400 bp was performed according to the
manufacturer’s protocols by using the GS FLX Titanium sequencing
kit (Roche Applied Science).
For the preparation of libraries for Illumina deep sequencing,
equimolarly pooled amplicons were "tagmentated" (fragmented
and tagged) by using a Nextera DNA sample preparation and
index kit (Illumina) according to the manufacturer’s manual. DNA
fragments shorter than 400 bp were removed as described above.
Resulting libraries were quantified on a 2100 Bioanalyzer (Agilent
Technologies) and diluted to 10 pM for cluster generation and
subsequent sequencing on an Illumina MiSeq platform using the
paired-end sequencing protocol for 2 ⇥ 250 bp runs.
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The theoretical mean coverages were calculated to be approxi-
mately 4,900 reads by using the 454 platform and 8,200 reads by
using Illumina deep sequencing technology, assuming optimal
quantity and length of generated reads (see Tables 24.1 and 24.2
for the actual coverages). To compare 454 and Illumina deep se-
quencing, one patient sample was sequenced at baseline and at day
42 with both platforms, and the generated reads were compared.
Although variants determined by the 454 and Illumina platforms
were highly correlated, we computed substitution and nucleotide
transition rates exclusively on pairs of samples that underwent
identical library preparation and that were sequenced on the same
platform and the same sequencing run. After nucleotide transition
and substitution rates were thus generated in a platform-dependent
manner, these quantities were combined and subjected to further
statistical analysis.
Patient Time Core E1 E2 P7 NS2 NS3 NS4A NS4B NS5A NS5B all regions
Rbv Pat1 bl 7.883 4.792 4.189 4.416 4.582 6.285 2.743 7.849 4.643 6.722 5.410
Rbv Pat1 d42 5.321 3.533 4.542 6.245 5.762 7.562 6.154 11.095 6.336 9.365 6.592
Rbv Pat2 bl 3.972 2.944 3.554 4.636 4.310 4.720 1.866 5.567 3.988 4.883 4.044
Rbv Pat2 d42 4.571 3.560 5.171 7.536 6.679 6.425 2.510 8.563 6.595 9.506 6.112
Rbv total 5.437 3.707 4.364 5.708 5.334 6.248 3.318 8.268 5.390 7.619 5.539
Plac Pat7 bl 4.411 2.905 2.662 2.841 3.350 3.041 1.131 4.917 3.504 3.690 3.245
Plac Pat7 d42 6.249 3.892 3.579 4.279 4.552 5.342 1.932 7.846 5.708 6.155 4.953
Plac Pat8 bl 4.618 3.246 3.500 4.756 4.726 5.370 2.157 6.654 4.593 5.389 4.501
Plac Pat8 d42 4.412 3.519 3.577 4.330 4.110 4.306 1.657 5.271 4.080 5.390 4.065
Plac total 4.923 3.390 3.329 4.051 4.184 4.515 1.719 6.172 4.471 5.156 4.191
total total 5.180 3.549 3.847 4.880 4.759 5.381 2.519 7.220 4.931 6.388 4.865
Table 24.1: Average nucleotide depths
after 454 deep sequencing according to
HCV regions.
Mapping of deep sequencing data. A standard flowgram format
(SFF) file containing the nucleotide sequence reads was generated
for each sequenced sample by the 454 sequencing software (GS Run
Processor; Roche Applied Sciences) provided with the instrument.
Reads produced by Illumina software were provided in FASTQ
format. Subsequently, Phred quality scores were extracted from
the reads, and primer sequences were removed from the start of
the reads. For 454 reads, bases succeeding the first base call with a
Phred quality score below 10 were trimmed, as reported in previ-
ous studies,(23) and reads produced by the Illumina platform were
trimmed to a Phred quality score of 20. We note that Phred scores
have a slightly different interpretation on both platforms, denot-
ing the probability of a miscalled base and incorrect read length
for Illumina and 454 technologies, respectively. Reads with no "N"
base calls and a length of more than 25 bases were retained, and
quality control metrics were computed for the trimmed reads to en-
sure consistent high quality across all samples. The resulting high-
quality reads were mapped to the HCV-J reference genome(24) with
the gapped read mapper SMALT (Wellcome Trust Sanger Center),
the successor of the popular long-read mapper SSAHA2(25) that
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displays increased specificity and sensitivity according to both the
original authors and external validations.(26) Base insertions and
deletions, both common errors in deep sequencing, were detected
and marked in the alignment and were not included in subsequent
evaluations. Subsequently, nucleotide variant distributions were
called for each variant position in the alignment (nt 330 to 9351) by
the SAMtools suite.(27) The uniformity of the base distribution at
each alignment position was quantified with an entropy measure.
HCV sequences from patient samples taken at baseline and during
ribavirin monotherapy and placebo treatment, respectively, were
compared.
Patient Time Core E1 E2 P7 NS2 NS3 NS4A NS4B NS5A NS5B all regions
Rbv Pat3 bl 3.002 8.074 12.337 19.464 12.725 6.413 5.423 9.409 13.625 8.631 9.910
Rbv Pat3 d42 880 1.911 7.055 20.546 14.905 9.164 9.558 5.323 4.088 385 7.382
Rbv Pat4 bl 3.297 3.266 8.126 19.160 14.929 7.437 5.275 3.326 1.241 6.049 7.211
Rbv Pat4 d42 4.271 4.814 11.583 27.182 18.961 10.082 7.321 9.476 13.450 2.679 10.982
Rbv Pat5 bl 4.694 5.648 11.416 35.134 24.446 6.857 3.722 5.319 6.643 6.082 10.996
Rbv Pat5 d42 6.744 7.835 9.763 21.851 14.837 3.761 1.449 2.162 3.120 19.824 9.135
Rbv Pat6 bl 3.418 4.434 5.725 6.721 5.354 4.522 4.402 3.252 3.573 11.733 5.313
Rbv Pat6 d42 798 929 2.070 4.860 3.924 1.483 1.172 1.191 1.872 4.678 2.298
Rbv total 3.388 4.614 8.509 19.365 13.760 6.215 4.790 4.932 5.951 7.508 7.903
Plac Pat9 bl 12.861 21.154 22.951 16.042 12.538 5.619 4.530 6.145 8.555 8.967 11.936
Plac Pat9 d42 6.295 9.426 11.272 11.607 8.896 7.683 8.200 8.190 8.157 7.131 8.686
Plac Pat10 bl 2.177 2.816 3.297 5.927 4.545 1.594 1.312 2.210 3.093 6.871 3.384
Plac Pat10 d42 1.663 2.422 3.507 6.820 5.499 3.286 3.532 2.827 2.247 2.712 3.452
Plac Pat11 bl 3.975 5.496 5.208 5.586 4.747 3.375 3.678 4.153 4.677 1.746 4.264
Plac Pat11 d42 10.822 15.457 12.204 4.172 3.259 3.740 3.615 8.037 10.592 5.842 7.774
Plac Pat12 bl 5.380 6.708 5.942 3.426 3.654 3.374 3.170 4.218 4.726 11.623 5.222
Plac Pat12 d42 1.475 1.807 4.499 10.077 8.968 4.735 3.687 4.351 5.219 23.974 6.879
Plac total 5.581 8.161 8.610 7.957 6.513 4.176 3.966 5.017 5.908 8.608 6.450
total total 4.484 6.387 8.560 13.661 10.137 5.195 4.378 4.974 5.930 8.058 7.176
Table 24.2: Average nucleotide depths
after Illumina deep sequencing according
to HCV regions.Variant calling. For each base position of an aligned read set
(HCV coding region at nt 330 to 9351) at two time points, t1 and t2
(baseline and day 42, respectively), we consider the frequencies of
the individual bases A, C, G, and T. The predominant substitution
rate, S, at a specific position describes the dominant base mutation
comparing time points t1 and t2:
S(t1, t2) = max
⇣
|Freqt1(B)  Freqt2(B)|
⌘
(24.1)
(where B is A, C, G, or U).
Based on previous approaches,(28) at each position, an indicator,
T, of ribavirin-supported transition rates comparing time points t1
and t2 is defined as follows:
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T(t1, t2) =
1
2
⇣ ⇥
Freqt2(A)  Freqt2(G)
⇤
  ⇥Freqt1(A)  Freqt1(G)⇤
+
⇥
Freqt2(U)  Freqt2(C)
⇤
  ⇥Freqt1(U)  Freqt1(C)⇤⌘ (24.2)
Transitions from G to A and C to U are considered to be facil-
itated by ribavirin.(29) A cutoff value of 0.4 for the evaluation of
substitution rates and transition rates was chosen from a first eval-
uation of a first patient treated with ribavirin compared with a
patient treated with placebo by comparing several possible values.
Unfortunately, the limited number of patients in this study does not
allow for a refined optimization of the cutoff levels.
Investigation of deep sequencing error rates. In order to determine
the technical error rates of library preparation and deep sequenc-
ing using 454 and Illumina platforms, amplicon 3 (2,228 bp frag-
ment ranging from NS3 to NS4B) of one patient and time point
was cloned into a pSC-A-amp/kan vector and transformed into
Escherichia coli competent cells (StrataClone PCR cloning kit; Agi-
lent Technologies). The plasmid DNA was purified (QIAprep Spin
miniprep kit; Qiagen) and Sanger sequenced with M13 forward
and reverse as well as internal template-specific primers accord-
ing to the manufacturer’s protocol (BigDye Terminator v1.1 cycle
sequencing kit; Applied Biosystems), on an ABI Prism 3130xl ge-
netic analyzer (Applied Biosystems). The insert of one sequenced
plasmid clone was excised from the vector with the restriction en-
zyme EcoRI and was deep sequenced in parallel with the other PCR
amplicon samples. In accordance with other studies,(30) the tech-
nical error rate was calculated by counting all nucleotide variants
of the plasmid reads in the alignment that did not correspond to
the sequence of the clone determined by Sanger sequencing. While
insertion errors were subject to automatic removal during the map-
ping of the sequencing reads to the HCV-J reference genome,(31)
deletions with respect to the reference sequence were detected dur-
ing the mapping and quantified as errors but excluded from all
further analyses.
Minority variant calling based on a statistical filtering procedure.
Low-frequency nucleotide variants were distinguished from tech-
nical errors by utilizing the statistical filtering procedure deepSNV
(where SNV is single-nucleotide variants).(32) The filtering pro-
cedure estimates sequence-specific and strand-specific error rates
to derive a position-wise test statistic for reliably identifying low-
frequency minority variants that display increased frequencies
in a test sample compared to a given control. Using this method,
we computed FDR (false discovery rate)-corrected p-values for all
nucleotide variants. To calculate ribavirin-supported G-to-A and C-
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to-U nucleotide transitions between two time points, only positions
within the HCV coding region (nt 330 to 9351) containing a G or C
in the consensus baseline sequence were considered. At these posi-
tions, variants were considered for further analysis if they showed a
significant increase of A or U frequencies, respectively, between two
time points, as characterized by a position-wise p-value of the sta-
tistical filtering procedure below a cutoff of 0.001. The computation
of non-ribavirin-associated A-to-G and U-to-C transitions occurred
analogously to the calculation described above. Thereby, variants
with a significant increase of G or C between both time points were
considered at positions with an A or U in the consensus baseline
sequence.
Statistical analysis. The predominant substitution rate, S, and
the nucleotide transition rate, T, of ribavirin- and placebo-treated
patients were compared by random-effect models for these rates
and testing for group effects. Statistical analysis was conducted
based on the metaprop procedure of the meta package by Guido
Schwarzer for R software (R Foundation for Statistical Comput-
ing, Vienna, Austria). p-values of less than 0.05 were considered
significant.
Deep sequencing data access. The deep sequencing data from this
study have been deposited in the Sequence Read Archive (SRA)
under accession number ERP001566.
Results and discussion
HCV RNA kinetics and analysis of deep sequencing. For the inves-
tigation of ribavirin-induced mutations, we used clinical serum
samples from HCV genotype 1-infected patients (see Materials and
Methods). We selected an overall number of 12 patients (n = 6 for
ribavirin; n = 6 for placebo) with the same HCV genotype (GT1b)
and similar HCV RNA concentrations (between around 1⇥ 106 and
1.5 ⇥ 107 IU/ml) before initiation of therapy (baseline) for deep
sequencing analysis of the HCV quasispecies. As it is not known
whether a mutagenic effect of ribavirin would be reflected by a
decline of the HCV RNA concentration, we chose patients under
ribavirin monotherapy or placebo treatment who displayed various
HCV kinetics (Fig. 24.1A).
On average, baseline HCV RNA levels maximally decreased by
 0.8 or  0.1 log10 IU/ml in ribavirin- versus placebo-treated pa-
tients. 454 deep sequencing of the HCV quasispecies from four pa-
tients (see Materials and Methods) during the 6-week monotherapy
resulted in an average of 160, 250 sequenced reads per sample, with
a mean read length of 316.6 bp after removing low-quality bases.
A total of 99.1% of high-quality reads could be unambiguously
aligned to the HCV-J reference genome, resulting in a mean mini-
mum coverage (averaged over all patients and positions) of 4, 394.3
252 from basic research to clinical applications
(33) Kato et al. (1990)
(34) Quail et al. (2012)
(35) Kato et al. (1990)
(range, 597 to 17, 542) reads per position for the 454 platform (Fig.
24.1B).
Samples from further patients included in the study (ribavirin-
treated patients 3 to 6 and placebo-treated patients 9 to 12) were
sequenced by using the Illumina platform, which produced an
average of 527,968 high-quality reads per sample, with a mean
read length of 133.4 bp after clipping of bases with low quality.
The alignment of 94.9% of high-quality reads to the HCV-J refer-
ence genome(33) gave rise to a mean minimum coverage of 4,649.2
(range, 0 to 27,033) reads per position (Fig. 24.1C). We observed a
decreased coverage of the Illumina sequencing reads between posi-
tions 1500 and 1550 (E2) and at position 8627 (NS5B). The reduced
coverage within E2 is attributed mainly to hypervariable region 1
(HVR-1), which is known to produce difficulties during the align-
ment process due to its high variability. Furthermore, the Nextera
method used for library preparation for Illumina deep sequencing
was shown to produce biased data sets.(34) As position 8627 is lo-
cated before a large G/C stretch, this may influence the recovery
of these sequences during library preparation. Nonetheless, during
statistical filtering, positions with low coverages are rejected from
further analyses.
To compare the sequencing results produced by 454 and Illu-
mina deep sequencing, two samples (baseline and day 42) from one
patient were each processed with both platforms. The nucleotide
ratios of these samples were compared between the 454 and the
Illumina data, and an R2 correlation resulted in a correlation of
>0.995 for the ratios of all four nucleotides (A, C, G, and T). Align-
ment of the deep sequencing reads produced nucleotide counts of
the four possible bases (A, C, G, and U) at every position of the
HCV-J reference genome.(35) These nucleotide counts were ana-
lyzed for each sample and compared between baseline and day 42
in order to investigate a potential ribavirin-induced increase in the
number of nucleotide substitutions.
Ribavirin does not generally induce mutations in the HCV genome.
To determine whether ribavirin treatment is associated with the
fixation of mutations in the HCV genome, we estimated S, the
change rate of the predominant substitution between two consec-
utive sampling time points (see Materials and Methods). S values
exceeding a 40% threshold, indicating large changes of the HCV
quasispecies, were observed at slightly more HCV genome posi-
tions in patients undergoing ribavirin monotherapy than in patients
receiving placebo between baseline and day 42 (rate of 0.0085 sub-
stitutions per base pair versus rate of 0.0052 substitutions per base
pair) (Table 24.3 and Fig. 24.2). However, no significant differences
between the ribavirin group and the placebo group were detected
(p = 0.230), and no local clustering of S values within the HCV
genome of patients treated with ribavirin was detected (Fig. 24.2).
This indicates that ribavirin does not lead to a generally increased
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Figure 24.1: Deep sequencing of HCV quasispecies. Deep sequencing of HCV quasispecies of 12 patients during the
6-week monotherapy phase (n = 6 for ribavirin; n = 6 for placebo). For each patient, samples were sequenced at
two time points (baseline and day 42) during monotherapy. (A) HCV RNA kinetics for selected patients during
monotherapy. (B) Minimal coverage of the HCV genome (nt 330 to 9351) after 454 deep sequencing of PCR ampli-
cons (A1 to A5) averaged over two patients who received ribavirin monotherapy and two patients who received
placebo. (C) Minimal coverage of the HCV genome (nt 330 to 9351) after Illumina deep sequencing of PCR ampli-
cons (A1 to A5) of ribavirin-treated (n = 4) and placebo-treated (n = 4) patients.
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mutation rate.
Patienta S (per 9,022 nt)b T (per 9,022 nt)b
Rbv Pat1 98 47
Rbv Pat2 143 72
Rbv Pat3 94 42
Rbv Pat4 18 4
Rbv Pat5 134 62
Rbv Pat6 48 24
Plac Pat7 57 24
Plac Pat8 39 14
Plac Pat9 21 10
Plac Pat10 156 44
Plac Pat11 41 19
Plac Pat12 35 18
Statistical measure Groupa Value
Avg. rate of S (per bp) Rbv 0.0085
Avg. rate of T (per bp) Rbv 0.0041
95% confidence interval for S Rbv 0.0056-0.0127
95% confidence interval for T Rbv 0.0027-0.0063
Avg. rate of S (per bp) Plac 0.0052
Avg. rate of T (per bp) Plac 0.0022
95% confidence interval for S Plac 0.0027-0.0102
95% confidence interval for T Plac 0.0014-0.0034
p-value for S Rbv vs. Plac 0.230
p-value for T Rbv vs. Plac 0.049
Table 24.3: Comparison of predominant
substitution rates and transition rates of
HCV quasispecies. Comparison of
predominant substitution rates and
transition rates of HCV quasispecies
between patients treated with
ribavirin and those treated with
placebo between baseline and day 42
of the study. S, substitution rate; T,
transition rate. a Rbv Pat, patient
given ribavirin; Plac Pat, patient
given placebo. b Indicated is the
number of HCV genome positions
with changes in the respective
parameter exceeding a 0.4 cutoff
threshold referring to the entire
analyzed HCV coding region (nt 330
to 9351).
Figure 24.2: HCV genome positions for
ribavirin- versus placebo-treated patients.
HCV genome positions for ribavirin-
versus placebo-treated patients with
changes in predominant substitution
rates. The horizontal line at the 0.4
level represents the cutoff used for
the evaluation of the predominant
substitution rate, S, between baseline
and day 42.
Accumulation of ribavirin-induced nucleotide transitions. Misin-
corporation of the guanosine analogue ribavirin in the viral RNA
results in mutation of the viral genome by acting as a nonspecific
nucleotide template for the incorporation of both cytidine and uri-
dine. This mutagenic effect may lead the viral quasispecies into
error catastrophe and lethal mutagenesis.(36) Increased nucleotide
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substitution rates and accumulation of G-to-A and C-to-U transi-
tions within NS3 and NS5B of patients with chronic HCV infection
receiving ribavirin monotherapy support this hypothesis.(37) We
computed the change in substitution rates of ribavirin-associated
transitions, T (G to A and C to U), between baseline and day 42 by
expanding on approaches introduced in previous work(38) (see Ma-
terials and Methods). Patients under ribavirin monotherapy exhib-
ited significantly more HCV genome positions with large (T > 40%)
increases in rates of ribavirin-associated transitions than the placebo
group (rate of 0.0041 transitions per base pair versus rate of 0.0022
transitions per base pair; p = 0.049) (Table 24.3 and Fig. 24.3) be-
tween baseline and day 42. An enhancement of ribavirin-associated
transitions in ribavirin-treated patients was still observable after
small alterations of the 0.4 cutoff level. To characterize the mutation
spectrum at baseline, quasispecies entropy was calculated for all
samples at baseline. Entropy was determined to be highly similar
for the ribavirin and placebo groups, indicating similar mutation
spectra at baseline. Furthermore, the frequency of positions with a
C/G in the baseline consensus sequences was comparable between
ribavirin- and placebo-treated patients (data not shown). Moreover,
we did not observe any favored localization of ribavirin-associated
transitions within the HCV genome of ribavirin-treated patients
(Fig. 24.3).
Figure 24.3: Comparison of HCV
genome positions with changes in
nucleotide transition rates. Comparison
of HCV genome positions with
changes in nucleotide transition
rates, T, comprising G-to-A and
C-to-U transitions between patients
receiving ribavirin and those
receiving placebo, respectively. The
cutoff used for the assessment of the
nucleotide transition rate, T, between
baseline and day 42 is depicted by
the horizontal line at the 0.4 level.
Analysis after statistical filtering procedure. In order to differen-
tiate low-frequency nucleotide variants from technical errors, we
applied an involved statistical filtering procedure that allows for the
identification of such minority variants with high sensitivity and
specificity.(39) Using this method, p-values were computed for each
HCV genome position, quantifying the significance of occurring nu-
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cleotide substitutions between two time points. Ribavirin-supported
G-to-A and C-to-U nucleotide transitions were calculated by con-
sidering only positions which exhibited a G or a C in the consensus
sequence at baseline and displayed a significant (a = 0.001) in-
crease in A and U frequencies, respectively, between baseline and
day 42. Based on the application of this strategy for filtering of
deep sequencing data, we confirmed that patients under ribavirin
monotherapy display significantly more HCV genome positions
with significant G-to-A and C-to-U transitions than patients treated
with placebo (rate of 0.0331 transitions versus rate of 0.0186 tran-
sitions per G/C-containing position at baseline; p = 0.018) (Table
24.4). Furthermore, ribavirin-induced transitions did not display a
preferred nucleotide signature in ribavirin-treated patients in com-
parison to placebo-treated patients, indicating that these transitions
do not occur in a certain context of surrounding nucleotides (data
not shown).
Patienta Rbv transitionsb
Rbv Pat1 148/5,307
Rbv Pat2 105/5,319
Rbv Pat3 339/5,307
Rbv Pat4 111/5,334
Rbv Pat5 209/5,360
Rbv Pat6 234/5,292
Plac Pat7 60/5,271
Plac Pat8 91/5,267
Plac Pat9 106/5,289
Plac Pat10 87/5,273
Plac Pat11 174/5,255
Plac Pat12 96/5,276
Statistical measure Groupa Value
Avg. rate of Rbv transitions (per bp)c Rbv 0.0331
Avg. rate of Rbv transitions (per bp)c Plac 0.0186
95% confidence interval for rate Rbv 0.0228-0.0479
95% confidence interval for rate Plac 0.0138-0.0250
p-value Rbv vs. Plac 0.018
Table 24.4: Number of HCV genome
positions from patients treated with
ribavirin and placebo after the
application of statistical filtering.
Statistical filtering considers positions
with a significant increase (a = 0.001)
in A and U frequencies between
baseline and day 42 related to the
number of positions showing a G or
C, respectively, in the baseline
consensus sequence. a Rbv Pat,
patient given ribavirin; Plac Pat,
patient given placebo. b Number of
ribavirin- associated transitions per
G/C-containing position. c Rate of
ribavirin-associated transitions per
G/C-containing bp.
We intended to determine whether differences from ribavirin-
supported transitions originate from many small or from large tran-
sitions. Therefore, we analyzed the magnitude and the correspond-
ing frequencies of G-to-A and C-to-U transitions and compared
the results before and after application of the data-filtering strat-
egy (Fig. 24.4A and 24.4B). Both before and after filtering of deep
sequencing data, ribavirin-treated patients displayed an overall
increase in the number of G-to-A and C-to-U transitions in com-
parison to placebo-treated patients between baseline and day 42
that encompassed small, medium, and large changes in ribavirin-
associated transitions, T. Application of the statistical filtering
procedure especially eliminated variants with nonsignificant small
changes, affirming the importance of this method for differentiat-
ing genuine variants from technical errors. However, when small
nucleotide transition changes (including changes of <40%) were
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included in the analysis without statistical filtering, we observed
no significant differences between the ribavirin and the placebo
groups, indicating that ribavirin-associated transitions are gener-
ated predominantly via medium and large nucleotide changes.
Transitions in the reverse direction (A-to-G and U-to-C) were not
significantly enhanced in ribavirin-treated patients in comparison
to placebo-treated patients (rate of 0.0184 transitions versus rate
of 0.0128 transitions per A/U-containing position at baseline; p =
0.152) (Table 24.5) between baseline and day 42. Therefore, the mu-
tagenic effect of ribavirin is attributed mainly to the generation of
G-to-A and C-to-U transitions.
Patienta Rbv transitionsb
Rbv Pat1 85/3,712
Rbv Pat2 48/3,698
Rbv Pat3 98/3,711
Rbv Pat4 25/3,684
Rbv Pat5 108/3,656
Rbv Pat6 76/3,725
Plac Pat7 19/3,748
Plac Pat8 56/3,753
Plac Pat9 48/3,732
Plac Pat10 82/3,686
Plac Pat11 71/3,766
Plac Pat12 34/3,744
Statistical measure Groupa Value
Avg. rate of Rbv transitions (per bp)c Rbv 0.0184
Avg. rate of Rbv transitions (per bp)c Plac 0.0128
95% confidence interval for rate Rbv 0.0131-0.0256
95% confidence interval for rate Plac 0.0090-0.0183
p-value Rbv vs. Plac 0.152
Table 24.5: Number of HCV genome
positions from patients treated with
ribavirin and placebo after application of
statistical filtering. Statistical filtering
considers positions with a significant
increase (a = 0.001) in G and C
frequencies between baseline and day
42 related to the number of positions
showing an A or U, respectively, in
the baseline consensus sequence.
a Rbv Pat, patient given ribavirin;
Plac Pat, patient given placebo.
b Number of ribavirin- associated
transitions per A/U-containing
position. c Rate of
ribavirin-associated transitions per
A/U-containing bp.
Determination of deep sequencing error rates. In order to estimate
the technical error rate of our sequencing approach, a plasmid-
amplified clonal sample of a fragment ranging from NS3 to NS4B
was sequenced by using 454 and Illumina technologies with the
same parameters as those used for samples from the main study.
Sequencing reads and nucleotide distributions from this positive
control were compared with the Sanger sequence corresponding to
the clone, which also matched the consensus sequences generated
from the 454 and Illumina reads. Sanger sequencing is commonly
used as a comparator for the determination of deep sequencing
errors(40) and is expected to have an error rate of 0.01% to 1%, de-
pending on the software applied.(41) All sequenced nucleotides
differing from the Sanger sequence were considered technical errors
attributable to library preparation and the sequencing process. Fol-
lowing this protocol, we estimated a technical error rate of 0.507%
erroneous substitutions per sequenced nucleotide for 454 deep se-
quencing and an error rate of 0.036% erroneous substitutions per
sequenced nucleotide for Illumina deep sequencing. These rates
include mismatches (454, 0.158%; Illumina, 0.035%) and deletions
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Figure 24.4: Occurrence of
ribavirin-associated G-to-A and C-to-U
transitions. Occurrence of
ribavirin-associated G-to-A and
C-to-U transitions between baseline
and day 42 in the HCV genome of
ribavirin- and placebo-treated
patients. The vertical dashed line at
the 0.4 level displays the cutoff,
which was applied to differentiate
small versus medium/large changes
in ribavirin-associated transitions.
(A) Frequency of HCV genome
positions with changes in
ribavirin-associated transitions before
statistical filtering of deep sequencing
data. All HCV genome positions
with transition changes are shown.
(B) Frequency of HCV genome
positions with changes in
ribavirin-associated transitions after
application of statistical filtering.
HCV genome positions with
significant transition changes are
represented.
(42) Chung et al. (2007), Crotty et al. (2001,
2000), Lanford et al. (2001), Pfeiffer and
Kirkegaard (2005b), Sierra et al. (2007)
(43) Asahina et al. (2005), Chevaliez et al.
(2007), Hofmann et al. (2007), Lutchman
et al. (2007), Young et al. (2003)
(44) Dixit and Perelson (2006)
(45) Dixit et al. (2004)
(454, 0.349%; Illumina, 0.001%) while excluding insertion errors due
to the particularities of the alignment process (see Materials and
Methods).
Discussion. Existing studies on the preeminent mode of action
of ribavirin in HCV therapy and particularly the significance of
ribavirin-induced mutagenesis remained inconclusive. Several in
vitro analyses of poliovirus, GB virus B, hantaan virus, and foot-
and-mouth disease virus(42) showed that ribavirin exhibits muta-
genic properties. In contrast, studies investigating ribavirin-induced
HCV mutagenesis in patients receiving ribavirin monotherapy
concentrated mainly on the analysis of small regions of the HCV
genome (NS3, NS5A, and NS5B) via standard clonal sequencing or
direct sequencing of PCR products at a depth of about 30 clones per
time point, which yielded contradictory results.(43) We performed
deep sequencing of the complete HCV coding region of patients
with chronic hepatitis C undergoing ribavirin monotherapy in or-
der to analyze systematically and with high sensitivity whether
ribavirin induces nucleotide substitutions. An increased mutation
rate may indicate an error catastrophe, which is followed by viral
extinction. Alternatively, it is also conceivable that viruses which
are generated in the presence of ribavirin display decreased infec-
tivity and reduced replication capacities,(44) which could lead, in
combination with interferon, to the antiviral effect against HCV.(45)
Our results do not reveal significantly higher frequencies of pre-
dominant substitutions in ribavirin-treated patients, indicating that
the number of mutations is not generally increased. As during
ribavirin monotherapy, only a slight reduction of the HCV load is
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detectable, a continuous accumulation of mutations with a consec-
utive increasing probability for the generation of defective viruses
is presumably not taking place. The mutagenic effect of ribavirin
seems to lead rather to the continuous production of new viruses
with increased numbers of ribavirin-induced mutations incorpo-
rated, which exhibit slightly reduced replication capacity and/or
infectivity, thereby explaining the weak HCV load reduction. This
may result in a continuous process with a constant exchange of vi-
ral variants. In the present study, we demonstrate that during the
6-week ribavirin monotherapy, the rate of G-to-A and C-to-U tran-
sitions, which are specifically induced by the guanosine analogue
ribavirin, is enhanced within the HCV genome of ribavirin-treated
patients in comparison to placebo-treated patients. In a subgroup
of four patients, additional time points between baseline and day
42 (day 7 and day 21) were investigated. In line with our hypoth-
esis, here we observed significant mutational differences between
each time point without an overall constant increase in the rate of
mutations from baseline to day 42 (data not shown).
The observed transitions were not limited to NS3 and NS5B,
as reported previously,(46) but occurred throughout the full HCV
genome, with no preferential location of transitions in certain HCV
genome regions.
In principle, ultradeep sequencing allows for the sensitive de-
tection of HCV variants. Nevertheless, it is critical to differenti-
ate minor variants from technical errors associated with library
preparation and the sequencing process. By sequencing a clonal
fragment, we determined for the 454 platform and the Illumina
platform error rates in good accordance with data from previous
studies.(47) Although specialized software for additional error cor-
rection exists,(48) we refrained from employing it in this setting due
to the risk of discarding genuine minority variants. Instead, we
applied an alternative approach that explicitly incorporates error
modeling into the calculation of changes in variant frequencies be-
tween two time points (see below). Furthermore, a quality control
of deep sequencing reads ensured that only reads with high-quality
scores and sufficient read length were used for mapping and down-
stream analyses (see Materials and Methods). In order to discrim-
inate low-frequency nucleotide variants from technical errors, we
employed deepSNV, a statistical filtering procedure that calculates
the significance of changes in variant frequencies between two
time points for each HCV genome position. Although this method
was validated on virus data generated by the Illumina platform,
the underlying mathematical model of deepSNV does not make
assumptions about the sequencing platform or platform-specific
error patterns and is thus also generally applicable to 454 data
(N. Beerenwinkel, personal communication). To estimate the gen-
uine number of ribavirin-supported G-to-A and C-to-U transitions,
only positions with significant increases in these transitions were
considered. This additional analysis confirms our results, further
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supporting the conclusion that patients under ribavirin monother-
apy exhibit significantly more HCV genome positions with G-to-A
and C-to-U transitions than do placebo-treated patients. Moreover,
non-ribavirin-associated A-to-G and U-to-C transitions were not
significantly enriched in ribavirin-treated patients, indicating that
ribavirin specifically induces G-to-A and C-to-U transitions.
Both analyses (with and without statistical filtering) show that
ribavirin-supported transitions occur as small, medium, and large
changes in nucleotide substitutions between two time points. Dif-
ferences in medium- and high-frequency transitions (>40% change)
between both patient groups could readily be detected without sta-
tistical filtering of the deep sequencing data. In ribavirin-treated
patients, small transition changes (including changes of <40%)
were not significantly enriched, suggesting that ribavirin-associated
transitions originate mainly from medium and large nucleotide
changes. However, statistical filtering was essential for distin-
guishing low-level transitions from technical errors in both pa-
tient groups, underlining the importance of the statistical filtering
method, particularly for the sensitive detection of minority variants.
Nevertheless, our study has several limitations. Due to difficul-
ties of full-length HCV genome amplification and the high costs
of deep sequencing of the entire HCV genome, we were able to
sequence the HCV genomes of only a limited number of patients.
Therefore, our results do not allow for a direct conclusion on the
extent of the effect of ribavirin-induced mutagenesis on virologic
response. The clinical results of the study in which the patients
analyzed here were included are reported elsewhere.(49) Further-
more, we have not yet performed functional analyses to clarify the
potential mechanism of action of ribavirin-induced mutagenesis.
Finally, our findings do not readily explain the enhanced vi-
rological response rates for treatment with IFN-a in combination
with ribavirin. It is conceivable that the clinical effect of ribavirin
may be at least partially mediated by resetting the IFN respon-
siveness in the liver.(50) In conclusion, this explorative study an-
alyzed ribavirin-induced mutations with high sensitivity and
demonstrated that ribavirin induces nucleotide transitions dur-
ing monotherapy. This effect seems to be a relevant factor for the
antiviral activity of ribavirin, which is independent of the addi-
tional application of PEG-IFN-a and may explain the efficiency of
ribavirin in combination with other direct-acting antivirals. The
observed mutagenesis of the HCV genome in patients undergoing
ribavirin monotherapy is based on the generation of G-to-A and
C-to-U transitions. Ribavirin-induced mutagenesis does not explain
the normalization of serum aminotransferase levels observed in pa-
tients undergoing ribavirin monotherapy, which we also detected in
the patients analyzed here. Therefore, other mechanisms of action
are likely also involved in the antiviral activity of ribavirin.
V
Conclusions

25 Summary
This thesis presented an integrated view on the analysis of virolog-
ical data that spans (1) early detection of emergent viral pathogens, (2)
antiviral drug target discovery, and (3) the clinical treatment of genet-
ically complex viral disease. Three organizing principles were proposed
by the author to structure this work. First among these themes was the
aforementioned integrated view on antiviral data analysis. Second was the
introduction of particularly sensitive methods for the detection of faint bio-
logical signatures such as viral nucleotide sequences, human-viral protein
interactions, or low-frequency mutations in viral genomes amidst exper-
imental noise. The last and most speculative theme concerned subtle but
reoccurring similarities of viral infections to another heterogeneous and
adaptable disorder: cancer. After summarizing the main contributions of
this thesis in the context of the first two themes, we will discuss the third
theme in more detail before providing an outlook of the field as the author
perceives it.
Introduction to viruses and viral disease
In the beginning of this thesis in Chapter I, characteristics of viruses
and their life cycles were introduced and the changing definition of
these entities was discussed. We learned that viruses are taxonomi-
cally ill-defined and that their status of living entities is sometimes
affirmed but more often denied. Several schemes to classify viruses
were put forward, the importance of the Baltimore scheme was
highlighted, and an overview of the known numbers of viral fami-
lies and viral species was provided.
Next, the evolutionary origins of viruses were detailed and sev-
eral interesting hypotheses regarding the association between the
respective origins of viral and cellular organisms were proposed.
One of these hypotheses argued that viruses were essential for the
origin of DNA-based cellular life. The importance of viruses for
the human species was further highlighted by results on ancient
proviral integration events, some of which may have had beneficial
effects for the human species. Subsequently, the detrimental effects
of viral infection, in particular in the context of public health, were
estimated and current trends of infectious disease burdens were
analyzed.
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Finally, an outlook on viral diversity and zoonotic emergence
was provided and estimates for the number of novel human pathogenic
viruses, most of which originate from animal hosts, were presented.
At the end of the first chapter, a picture of viruses emerged as
complex, highly diverse, and abundant entities that are intricately
linked to cellular and human life.
Detecting tumor viruses in human cancers
Chapter II introduced a burgeoning field of current research: micro-
bial metagenomics. By way of continuing the theme of viral variety
and zoonotic emergence of the introductory chapter, an initial in-
troduction to the basic tenets of metagenomics and an exposition
of the astonishingly high abundance of microbial organisms in gen-
eral and viruses in particular was provided. Next, deep sequencing
approaches and associated error sources were introduced, both of
which serve as major methodological backdrops for the remainder
of the thesis. Within the context of these methods, recent results of
human and viral metagenomics as well as computational aspects of
metagenomic analyses were discussed, highlighting the difficulty of
taxonomic annotation based on short read data.
Subsequently, the focus of the chapter shifted towards biology
and tumor viruses and their molecular mechanisms of cellular
transformation were introduced. Tumor viruses inadvertently act
as cofactors of cancers either due to their manipulations of cellular
environments and signaling networks or by integration into the
host genome. Epidemiological indicators of likely cancer-virus asso-
ciations as well as the difficulty of establishing causal relationships
between pathogens and delayed oncogenesis were discussed and
systematic metagenomics approaches for the detection of novel
cancer causing viruses were proposed.
Finally, the chapter introduced a novel computational method for
inferring known and novel viruses in deep sequencing data of hu-
man cancers that offered increased sensitivity and interpretability
compared to related approaches. These advantages were realized
by adapting a strategy of mapping reads to viral and human refer-
ences in a parallel fashion and using sensitive read mapping and
taxonomic annotation procedures. As a result, viruses with high
sequence divergence from known references or close homology
to human factors could be reliably detected, in principle. In addi-
tion, this study is the first to suggest that oncogenic viruses are not
causative for metastatic neuroblastoma, a common tumor of infants.
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Inferring viral host factors from protein purifications
Chapter III focused on approaches for inferring the phenotypic in-
teraction patterns of viral and host proteins in order to inform the
search for antiviral drug targets. After introducing the concept of
viral host factors and their importance as targets of viral manipu-
lation, a variety of human-viral interaction patterns involving viral
entry factors and components of the human immune system were
discussed.
After elucidating how measurement of host-pathogen protein
interaction patterns may aid in the discovery of novel antivirals,
the history and current state of development of several classes
of antivirals was presented and experimental approaches for the
measurement of protein interactions were introduced.
Finally, a method for the statistical inference of physical protein
interactions from protein purification assays was presented that
makes better use of technical replicates than related approaches.
This feature enables the method to detect reliable interaction pat-
terns involving transient interactions or highly abundant protein
classes such as molecular chaperones and protein kinases, both of
which are frequent viral host factors.
Treatment of divergent viral quasispecies
The last core chapter of this thesis, Chapter IV, presented a clini-
cally relevant topic with additional merits for basic research: the
characterization and treatment of highly diverse and adaptable
viral populations. After a short introduction to the history of qua-
sispecies theory and its basic tenets abundance, mutation, fitness,
and selection, a particular focus was directed at factors that influ-
ence the dynamics and robustness of viral genotype populations.
Subsequently, approaches for reducing the fitness of viral pop-
ulations by mutagenesis were discussed and related to techniques
of therapy optimization such as drug combination therapy. Qua-
sispecies attributes and treatment options of a specific, highly di-
vergent virus, HCV, were introduced and the proposed mode of
action of a specific mutagenic drug, ribavirin, against HCV was
introduced. In order to quantify the faint mutagenic action of rib-
avirin based on in vivo sequencing data, we introduced methods for
genotyping, quantification, and statistical comparison of minority
variants that can serve as indicators for ongoing mutagenesis.
Finally, these methods were applied in the first deep sequencing
study on HCV patients under ribavirin monotherapy in order to
demonstrate the mutagenic effect of ribavirin on the HCV quasis-
pecies.
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26 Viral infection and malignant
disease
Viral infectious disease and cancer share several subtle sim-
ilarities that are of theoretical and practical interest for virology and on-
cology. Both maladies are essentially genetic diseases, in which "selfish"
genetic elements manipulate cellular pathways for their unique evolution-
ary purposes. This relatedness spans a range of concepts such as common
molecular mechanisms, evolutionary behavior, treatment targets, and
therepeutic strategies.
As discussed at some length in Chapter II, viruses are masterful
manipulators of cellular growth control as well as of innate and
adaptive immunity. Many molecular mechanisms leading to cel-
lular transformation by tumor viruses, such as perturbation of the
genomic environment of oncogenes, misregulation of cell cycle con-
trol, and subversion of host immune and apoptosis pathways, are
also implicated in spontaneous (i.e., non-viral) oncogenesis. The
investigation of transforming RNA and DNA viruses in particular
served as a Rosetta stone unlocking the secrets of the mitogenic
pathway and thus provided the conceptual basis for understanding
the molecular mechanisms of cancer.(1) As a consequence, the study
of tumor viruses may suggest drug targets such as kinases that are
commonly targeted by anti-cancer drugs and also play a major role
as viral host factors (cf. Chapter III). Also, viruses may act directly
as therapeutics against cancer, as exemplified by oncolytic viruses
that specifically infect cancer cells or induce anti-tumor immune
responses.(2)
Cancer, as we now understand it, represents a diverse family
of genetic diseases that is characterized by a loss of the usual co-
operativity between cells in exchange for the gain of proliferative
attributes that confer selective growth advantages to the individ-
ual cancer cell.(3) Similar to viral infection, cancer may arise from
a low number of founder cells (tumor stem cells) whose progeny
follows an evolutionary trajectory that maximizes replicative fitness
by clonal expansion, progressive accumulation of mutations, and
selection of genotypes with advantageous phenotypes.(4) These
mechanisms lead the cancer cell population to diversification into
heterogeneous genotypes that follow separate mutational pathways
within the host.(5)
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While high genomic mutation rates of viral quasispecies are
probably unparalleled among other biological systems and the
abundance and mutational coupling of cancer cells is dramatically
lower than that of a viral population, eukaryotic cancer cells are
also known to generate considerable genetic heterogeneity and
may exist as a population distribution within the patient.(6) Efforts
concerning the characterization of cancer variability and evolution
are currently undertaken and seem to qualitatively confirm pre-
vious assumptions of cancers as evolving Darwinian systems that
are similar to viral quasispecies in many regards.(7) Analogous to
the master sequence of viral quasispecies, tumor stem cells have
been proposed to act as stabilizing elements in the cancer genotype
distribution from which highly adaptive mutant genotypes arise.(8)
Similar to the diversity of RNA virus populations, genetic het-
erogeneity of cancer has been linked to escape mechanisms against
host immune answer and targeted anti-cancers drugs.(9) Also, both
cancer cells and virus populations employ latency mechanisms
in which the pathogen either lies dormant or withdraws to reser-
voirs that lack efficient immune surveillance in order to persist in
the host. These insights have led to the development of predictive
models for cancer progression(10) and the design of anti-cancer
treatments based on highly active antiretroviral therapy (HAART),
both of the latter propose combination treatment in order to over-
come drug resistance.(11) In the same context, the concept of error
catastrophe has also been formulated for cancer and the use of
mutagenic drugs for the treatment of cancer is an ongoing field of
research.(12)
27 Outlook
All of the research topics discussed in this thesis are currently
being inovated to different degrees by technical advancements. This section
aims, based on the limited perspective of the author, to predict development
of the next five years in the respective fields.
The use of metagenomics techniques (Chapter II) is likely to
expand in the near future and may soon represent a general and
cost-effective approach for clinical diagnostics of infectious dis-
eases as well as for disease surveillance in tropic regions in order
to identify zoonotic or pre-zoonotic pathogens. In line with results
of this treatise, metagenomics will furthermore be useful for iden-
tifying viral cofactors of certain cancers as well as of metabolic and
gastroenterological diseases with unknown etiology.
In addition, metagenomics analyses of highly abundant micro-
bial habitats like sea water and soil may significantly extend our
knowledge of functional genetic elements, a fact that may have in-
teresting consequences for industrial biotechnology applications.
While presently the assembly of metagenomes and their taxonomic
annotation present significant hurdles for interpreting metagenomic
data, long-read deep sequencing technologies and more efficient
algorithmic approaches will soon allow near complete characteriza-
tion of highly abundant microbial habitats.
Advances in studying host-pathogen protein interactions (Chap-
ter III) are presently still limited by available technology to measure
protein interactions on a large scale; even given automatized ap-
proaches, the high error rates of presently available methodologies
make determining the set of all human protein interactions ex-
tremely challenging.
If the inherent dynamics of protein interaction networks given
different cell types and disease conditions are added to the picture,
it becomes clear that the complete characterization of the protein
interaction phenotype of a cell is considerably more challenging
than determining its genotype. However, these phenotypic char-
acterizations are urgently needed in order to understand and treat
genetically (and thus phenotypically) divergent diseases such as
cancer and viral infection.
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While protein arrays and molecular imaging techniques are in-
teresting technologies that can measure physical interactions of
cellular components in a high-throughput and high-accuracy man-
ner, in principle, both technologies are not sufficiently matured to
provide viable solutions to the problem. Also, it seems unlikely
at present that a concerted effort like the Human Genome Project
is conducted for determination of the cellular interaction pheno-
type. Instead, only incremental advances in both experimental and
computational methodologies can be expected.
Still, the availability of genome-wide protein interaction screens
will likely increase as technologies mature and differential network
analyses gain in interest. These screens as well as host-pathogen
protein interaction studies of smaller scale will continue to identify
new drug targets for antivirals and antibiotics and it is likely that
drugs targeting host factors as well as biologicals such as recom-
binant vaccines and monoclonal antibodies will be of particular
interest in this regard.
Finally, developments in treating highly divergent viruses (Chap-
ter IV) are likely to be significantly influenced by advances in se-
quencing technology. While it is currently difficult or impossible
to genetically characterize a viral quasispecies in its entirety due
to the comparably short read lengths and high error rates of sec-
ond generation sequencing approaches, upcoming third genera-
tion sequencing platforms such as the Pacific Biosciences RS offer
read lengths spanning complete viral genomes at very high accu-
racy. Provided that these technologies further increase sequencing
throughput, the identification and evolution of minority variants as
well as characterization of genetic interactions within viral genomes
will simplify dramatically.
In addition, further advances to clinical virology will probably
originate from metagenomics and oncology. These fields currently
attract considerable attention and are likely to yield novel experi-
mental and computational methods that will also be applicable to
measuring viral diversity and optimizing antiviral therapies.
(1) Shared first authorship.
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